
<html lang="en"     class="pb-page"  data-request-id="3b9770b3-e8a5-498a-a41b-1065337647bc"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2020.63.issue-15;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c00408;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer" /></meta><meta name="dc.Creator" content="Hong  Yao" /></meta><meta name="dc.Creator" content="Shaowen  Xie" /></meta><meta name="dc.Creator" content="Xiaoqian  Ma" /></meta><meta name="dc.Creator" content="Junkai  Liu" /></meta><meta name="dc.Creator" content="Hongyu  Wu" /></meta><meta name="dc.Creator" content="Aijun  Lin" /></meta><meta name="dc.Creator" content="Hequan  Yao" /></meta><meta name="dc.Creator" content="Dahong  Li" /></meta><meta name="dc.Creator" content="Shengtao  Xu" /></meta><meta name="dc.Creator" content="Dong-Hua  Yang" /></meta><meta name="dc.Creator" content="Zhe-Sheng  Chen" /></meta><meta name="dc.Creator" content="Jinyi  Xu" /></meta><meta name="dc.Description" content="Triple-negative breast cancer (TNBC) is one of the most highly invasive and metastatic breast cancers without safe and effective therapeutic drugs. The natural product oridonin is reported to be a ..." /></meta><meta name="Description" content="Triple-negative breast cancer (TNBC) is one of the most highly invasive and metastatic breast cancers without safe and effective therapeutic drugs. The natural product oridonin is reported to be a ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 2, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00408" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00408" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00408" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00408" /></link>
        
    
    

<title>Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00408" /></meta><meta property="og:title" content="Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0017.jpeg" /></meta><meta property="og:description" content="Triple-negative breast cancer (TNBC) is one of the most highly invasive and metastatic breast cancers without safe and effective therapeutic drugs. The natural product oridonin is reported to be a potential anti-TNBC agent. However, its moderate activity and complex structure hampered its clinical application. In this study, the novel oridonin analogues were first identified by removal of multiple hydroxyl groups and structural simplification of oridonin. The representative analogue 20 exhibited potent anticancer effects. Further structural modification on 20 generated the most potent derivative 56, which possessed 120-fold more potent antiproliferative activity than oridonin in the TNBC cell line HCC1806. Importantly, compound 56 exhibited more potent anticancer activity than paclitaxel in TNBC xenograft nude mice. Moreover, 56 could attenuate the expression of MMP-2, MMP-9, p-FAK, and integrin β1 to inhibit TNBC cell metastasis. All results suggest that compound 56 may warrant further investigation as a promising candidate agent for the treatment of TNBC." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00408"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00408">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00408&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00408&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00408&amp;href=/doi/10.1021/acs.jmedchem.0c00408" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 8157-8178</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00377" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00413" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Hong Yao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong Yao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Yao">Hong Yao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shaowen Xie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shaowen Xie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shaowen++Xie">Shaowen Xie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaoqian Ma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoqian Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoqian++Ma">Xiaoqian Ma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Junkai Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Junkai Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Junkai++Liu">Junkai Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hongyu Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hongyu Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hongyu++Wu">Hongyu Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aijun Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aijun Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aijun++Lin">Aijun Lin</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5786-4537" title="Orcid link">http://orcid.org/0000-0001-5786-4537</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hequan Yao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hequan Yao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hequan++Yao">Hequan Yao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dahong Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dahong Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dahong++Li">Dahong Li</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6964-4619" title="Orcid link">http://orcid.org/0000-0002-6964-4619</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shengtao Xu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shengtao Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#2f4c5f5a575c5b6f1e191c014c4042"><span class="__cf_email__" data-cfemail="056675707d7671453433362b666a68">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shengtao++Xu">Shengtao Xu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5705-6377" title="Orcid link">http://orcid.org/0000-0002-5705-6377</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dong-Hua Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dong-Hua Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy and Health Sciences, St. John’s University, 8000 Utopia Parkway, Queens, New York 11439, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dong-Hua++Yang">Dong-Hua Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhe-Sheng Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhe-Sheng Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy and Health Sciences, St. John’s University, 8000 Utopia Parkway, Queens, New York 11439, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhe-Sheng++Chen">Zhe-Sheng Chen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8289-097X" title="Orcid link">http://orcid.org/0000-0002-8289-097X</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jinyi Xu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jinyi Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#1f7576716676676a5f7c7776717e317c7072"><span class="__cf_email__" data-cfemail="d5bfbcbbacbcada095b6bdbcbbb4fbb6bab8">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jinyi++Xu">Jinyi Xu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1961-0402" title="Orcid link">http://orcid.org/0000-0002-1961-0402</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00408&amp;href=/doi/10.1021%2Facs.jmedchem.0c00408" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 8157–8178</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 2, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 March 2020</li><li><span class="item_label"><b>Published</b> online</span>2 July 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 August 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00408" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00408</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8157%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHong%2BYao%252C%2BShaowen%2BXie%252C%2BXiaoqian%2BMa%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D15%26contentID%3Dacs.jmedchem.0c00408%26title%3DIdentification%2Bof%2Ba%2BPotent%2BOridonin%2BAnalogue%2Bfor%2BTreatment%2Bof%2BTriple-Negative%2BBreast%2BCancer%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8178%26publicationDate%3DAugust%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00408"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1801</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00408" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Yao&quot;},{&quot;first_name&quot;:&quot;Shaowen&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;Xiaoqian&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Junkai&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Hongyu&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Aijun&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Hequan&quot;,&quot;last_name&quot;:&quot;Yao&quot;},{&quot;first_name&quot;:&quot;Dahong&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Shengtao&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Dong-Hua&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Zhe-Sheng&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Jinyi&quot;,&quot;last_name&quot;:&quot;Xu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;8157-8178&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00408&quot;},&quot;abstract&quot;:&quot;Triple-negative breast cancer (TNBC) is one of the most highly invasive and metastatic breast cancers without safe and effective therapeutic drugs. The natural product oridonin is reported to be a potential anti-TNBC agent. However, its moderate activity and complex structure hampered its clinical application. In this study, the novel oridonin analogues were first identified by removal of multiple hydroxyl groups and structural simplification of oridonin. The representative analogue 20 exhibited potent anticancer effects. Further structural modification on 20 generated the most potent derivative 56, which possessed 120-fold more potent antiproliferative activity than oridonin in the TNBC cell line HCC1806. Importantly, compound 56 exhibited more potent anticancer activity than paclitaxel in TNBC xenograft nude mice. Moreover, 56 could attenuate the expression of MMP-2, MMP-9, p-FAK, and integrin β1 to inhibit TNBC cell metastasis. All results suggest that compound 56 may warrant further investigation as a pro&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00408&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00408" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00408&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00408" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00408&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00408" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00408&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00408&amp;href=/doi/10.1021/acs.jmedchem.0c00408" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00408" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00408" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (12 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00408%26sid%3Dliteratum%253Aachs%26pmid%3D32610904%26genre%3Darticle%26aulast%3DYao%26date%3D2020%26atitle%3DIdentification%2Bof%2Ba%2BPotent%2BOridonin%2BAnalogue%2Bfor%2BTreatment%2Bof%2BTriple-Negative%2BBreast%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D15%26spage%3D8157%26epage%3D8178%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291750" title="Hydroxyls">Hydroxyls</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291149" title="Apoptosis">Apoptosis</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291376" title="Free radicals">Free radicals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/jmcmar.2020.63.issue-15/20200813/jmcmar.2020.63.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Triple-negative breast cancer (TNBC) is one of the most highly invasive and metastatic breast cancers without safe and effective therapeutic drugs. The natural product oridonin is reported to be a potential anti-TNBC agent. However, its moderate activity and complex structure hampered its clinical application. In this study, the novel oridonin analogues were first identified by removal of multiple hydroxyl groups and structural simplification of oridonin. The representative analogue <b>20</b> exhibited potent anticancer effects. Further structural modification on <b>20</b> generated the most potent derivative <b>56</b>, which possessed 120-fold more potent antiproliferative activity than oridonin in the TNBC cell line HCC1806. Importantly, compound <b>56</b> exhibited more potent anticancer activity than paclitaxel in TNBC xenograft nude mice. Moreover, <b>56</b> could attenuate the expression of MMP-2, MMP-9, p-FAK, and integrin β1 to inhibit TNBC cell metastasis. All results suggest that compound <b>56</b> may warrant further investigation as a promising candidate agent for the treatment of TNBC.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24450" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24450" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Breast cancer is the most frequently diagnosed cancer in women and remains the second most common cause of cancer death after lung cancer.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Although the mortality rate for breast cancer is declining because of the improvement of both early detection and available therapies, only limited success has been achieved in cases of triple-negative breast cancer (TNBC).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> TNBC is the term used to describe 10–20% of breast tumors that are negative in the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It is one of the most highly aggressive forms of invasive and metastatic breast cancer with a worse prognosis than other breast cancers.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Routine treatments for breast cancer that target hormone receptors (ER, PR, and HER2) are barely effective for TNBC.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Thus far, estimates of the median overall survival of TNBC vary but remain at approximately 18 months or less because of a lack of satisfactory therapeutic agents.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Therefore, new approaches for the treatment of TNBC are urgently needed to improve patient survival.</div><div class="NLM_p">Historically, research and development of natural products has played a promising role in the discovery of innovative drugs.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Reverting to nature for answers is a viable means of finding drugs that can treat refractory diseases, such as artemisinin (malaria), vancomycin (methicillin-resistant <i>Staphylococcus aureus</i> infections), and cabazitaxel (hormone-refractory metastatic prostate cancer).<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a> Oridonin (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, <b>1</b>), a natural diterpenoid compound isolated from the medicinal herb <i>Rabdosia rubescens</i>, and its derivatives have been widely investigated for the treatment of diverse human cancers.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20">(10−20)</a> In recent years, multiple studies have demonstrated that oridonin is effective in inhibiting tumor proliferation, suppressing metastasis, and inducing cell apoptosis and autophagy in breast cancer.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> Although oridonin was determined to be safe and effective for breast cancer therapy, its moderate to poor effects against highly aggressive breast cancer (e.g., TNBC) and its complex oxygenated diterpenoid scaffold have hampered its preclinical development. Therefore, researchers have sought to modify the structure of oridonin to develop a more simple structure with more potent activities for the oridonin-derived compounds. For example, Zhou et al. revealed that modification of the A-ring of oridonin to furnish dienone <b>2</b>,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> thiazole analogues <b>3</b>,<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> and triazole <b>4</b><a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> could markedly enhance the antiproliferative efficacy against breast cancer. Very recently, they have disclosed that aziridination of the D-ring (compounds <b>5</b> and <b>6</b>) could significantly inhibit the growth and metastasis of TNBC cells <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> Despite the fact that several oridonin analogues were obtained in these studies, the modifications generally focused on the A-ring (compounds <b>2–4</b>) or D-ring (compounds <b>5</b> and <b>6</b>) of oridonin to afford more complex core structures. Therefore, the research for more potent oridonin analogues with a concise framework could be more interesting work.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of oridonin and some representative oridonin analogues reported to be effective against breast cancer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Our previous work demonstrated that modifications of the A-ring and 14-hydroxyl of oridonin (compound <b>7</b>) could generate potent derivative compounds that significantly inhibit the growth of breast cancer cells and xenograft tumors.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> It should be noted that oridonin possesses multiple hydroxyl groups, including 1-hydroxyl (A-ring), 6-hydroxyl (B-ring), 7-hydroxyl (B-ring), and 14-hydroxyl groups (C-ring). In previous study, we found that analogues with the 1-hydroxyl group eliminated could inhibit the growth of breast cancer cells and xenograft tumors even more effectively than oridonin itself. We envisioned that not all the hydroxyl groups were necessary, and they would increase the desolvation penalty of oridonin, which would equally reduce the anticancer efficacy of oridonin.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Moreover, complex natural products often possess high molecular weights, resulting in low bioactivity contributed from each atom. Therefore, removing unnecessary hydroxyl groups might provide structurally simpler core structures of oridonin which retain or even have better bioactivities.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> To date, despite much structure–activity relationship (SAR) being developed, the systematic SAR of the hydroxyl groups of oridonin is still insufficient. Based on our ongoing pursuit on the investigation of oridonin,<a onclick="showRef(event, 'ref10 ref29 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref10 ref29 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41">(10,29,33−41)</a> in the present study, we aimed to remove unnecessary hydroxyl groups to simplify the core framework of oridonin for the detailed information of SAR and further to modify the 14-hydroxyl group to obtain a more potent derivative as the candidate for metastatic TNBC therapy.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73524" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73524" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemical Synthesis</h3><div class="NLM_p">To explore the meaningful SAR of multiple hydroxyl groups of oridonin, a series of novel oridonin analogues (<b>14</b>, <b>15</b>, <b>18–20</b>, <b>25</b>, <b>26</b>, and <b>29</b>) were designed by removing or blocking the hydroxyl groups of oridonin. The derivatives (<b>30–64</b>) were obtained by introducing different types of substituents to the 14-hydroxyl of compound <b>20</b>.</div><div class="NLM_p"><a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> outlines the synthesis of target compounds <b>14</b> and <b>15</b>. Diprotection of the 7- and 14-hydroxyl groups of oridonin with 2,2-dimethoxypropane under a catalytic amount of <i>p</i>-toluenesulfonic acid was performed to provide <b>8</b> in 95% yield. The olefin of the α,β-unsaturated ketone was then protected by epoxidation with 30% H<sub>2</sub>O<sub>2</sub> and 6 N NaOH to afford <b>9</b> in 88% yield (a mixture of diastereoisomers with 2:1 dr). Reaction of <b>9</b> with PhOC(S)Cl in the presence of 4-dimethylaminopyridine (DMAP) and pyridine produced <b>10</b> in 75% yield. Treatment of <b>10</b> with <i>n</i>-Bu<sub>3</sub>SnH and azodiisobutyronitrile (AIBN) in refluxing toluene provided hydroxyl <b>11</b> in 85% yield. Hydroxyl <b>11</b> was then activated by mesyl chloride, which subsequently underwent an elimination reaction using Li<sub>2</sub>CO<sub>3</sub> and LiBr in <i>N</i>,<i>N</i>-dimethylformamide (DMF) to give compound <b>13</b>. Compound <b>13</b> was then subjected to deprotection of acetonide with 10% HCl aqueous solution in tetrahydrofuran (THF) to produce compound <b>14</b>. Reaction of <b>13</b> with diethylaminosulfur trifluoride (DAST) at −20 °C provided compound <b>15</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>14</b> and <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TsOH, MeCH(OMe)<sub>2</sub>, dry acetone, reflux, 10 min, 95%; (b) 30% H<sub>2</sub>O<sub>2</sub> (water solution), 6 N NaOH, MeOH, 0 °C, 88%; (c) pyridine, DMAP, PhOC(S)Cl, dichloromethane, 0 °C-rt, 75%; (d) AIBN, <i>n</i>-Bu<sub>3</sub>SnH, toluene, reflux, 85%; (e) MsCl, Et<sub>3</sub>N, dichloromethane, rt, overnight; (f) LiBr, Li<sub>2</sub>CO<sub>3</sub>, DMF, 110 °C, 2 h; (g) 10% HCl, THF (v/v, 1:1), rt, 0.5 h, 55% from <b>11</b>; and (h) DAST, dichloromethane, −20 °C, 41% from <b>11</b>.</p></p></figure><div class="NLM_p">The synthesis of analogues <b>18</b>, <b>19</b>, and <b>20</b> followed the procedures shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The 1-hydroxyl of compound <b>8</b> was activated by mesyl chloride, and then, compound <b>16</b> was treated with Li<sub>2</sub>CO<sub>3</sub> and LiBr to produce <b>17</b>, which underwent deprotection to provide <b>18</b>. Hydrolysis of the hemiketal of <b>18</b> afforded compound <b>19</b> in 84% yield. Reaction of <b>17</b> with DAST at −20 °C produced compound <b>20</b> in 75% yield.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>18</b>, <b>19</b>, and <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) MsCl, TEA, 0 °C, 2 h; (b) LiBr, Li<sub>2</sub>CO<sub>3</sub>, DMF, 110 °C, 0.5 h; (c) 10% HCl, THF (v/v, 1:1), rt, 0.5 h, 54% from <b>8</b>; (d) acetic anhydride, TsOH, 40 °C, 84%; and (e) DAST, dichloromethane, −20 °C, 75%.</p></p></figure><div class="NLM_p">Treatment of diastereoisomers of <b>9</b> with CS<sub>2</sub> and MeI in the presence of NaH and imidazole in THF provided thiocarbamate <b>21</b> in 81% yield, which further underwent reaction with <i>n</i>-Bu<sub>3</sub>SnH and AIBN to readily access <b>22</b> in 69% yield. Similar to the synthesis procedure of <b>14</b>, <b>22</b> underwent a three-step synthesis to give compound <b>25</b>. Hydrolysis of the hemiketal of <b>25</b> with acetic anhydride in the presence of <i>p</i>-toluenesulfonic acid afforded compound <b>26</b> in 83% yield (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>25</b> and <b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, CS<sub>2</sub>, MeI, imidazole, THF, 0 °C-rt, 88%; (b) AIBN, <i>n</i>-Bu<sub>3</sub>SnH, toluene, reflux, 85%; (c) MsCl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight; (d) LiBr, Li<sub>2</sub>CO<sub>3</sub>, DMF, 110 °C, 2 h; (e) 10% HCl, THF (v/v, 1:1), rt, 0.5 h, 58% from <b>22</b>; and (f) acetic anhydride, TsOH, 40 °C, 83%.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> details the synthesis of compound <b>29</b>. Compound <b>8</b> was trifluoroacetylated with trifluoroacetic anhydride in the presence of DMAP to give <b>27</b>; then, compound <b>27</b> reacted with DAST to afford <b>28</b> in 70% yield. Compound <b>28</b> was further treated with 0.5 N NaOH solution to give <b>29</b> in 75% yield.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) trifluoroacetic anhydride, DMAP, rt, 2 h, 90%; (b) DAST, dichloromethane, −20 °C, 70%; and (c) 0.5 N NaOH, TBAB, 75%.</p></p></figure><div class="NLM_p">Compound <b>20</b> was then coupled with acyl moieties to its 14-hydroxyl position to afford a series of new derivatives <b>30–64</b> in 35–89% yields (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>30–64</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) corresponding acids, DMAP, EDCI, dichloromethane, rt, 2–72 h, 35–89%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Effects of the Oridonin Analogues on TNBC Cell Growth</h3><div class="NLM_p">The <i>in vitro</i> antiproliferative efficacy of the newly synthesized oridonin analogues was determined by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2<i>H</i>-tetrazolium bromide (MTT) assay using the human TNBC cell lines DU4475 (immunomodulatory subtype), HCC1806 (basal-like-1 subtype), MDA-MB-468 (basal-like-2 subtype), and MDA-MB-231 (mesenchymal-like subtype).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The abilities of these new analogues to inhibit the growth of these cancer cells are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Oridonin (<b>1</b>) was used as the baseline control. The results showed that all of the newly synthesized analogues were significantly more potent than oridonin. Compounds <b>14</b> and <b>18</b> exerted 6–12-fold increased anticancer activity than oridonin against all tested cancer cells, indicating that eliminating the C-1 hydroxyl group of oridonin is beneficial. Analogue <b>25</b> showed better anticancer efficacy than compounds <b>14</b> and <b>18</b>, suggesting that the removal of the hydroxyl group at C-6 could improve anticancer activity. Interestingly, the antiproliferative activities of compounds <b>19</b> and <b>26</b> were slightly lower than or comparable to those of compounds <b>18</b> and <b>25</b>, suggesting that breaking the oxygen bridge might not be beneficial for anticancer activity. The hydrolysis of the hemiacetal at C-7 and transfer of the oxygen bridge from C-7 to C-6 (compounds <b>15</b>, <b>20</b>, and <b>29</b>) displayed excellent antiproliferative activity against the cell lines tested, with IC<sub>50</sub> values ranging from 0.92 to 2.42 μM. The abovementioned results suggested that compound <b>20</b> could be a potential lead compound for further optimization. Because the topological polar surface area (tPSA) and log <i>P</i> values have potential impact on the ability of cell penetration, we calculated these values of oridonin analogues. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, except for compound <b>29</b>, analogues with larger log <i>P</i> would have better anticancer activities than oridonin. It seemed that analogues with a log <i>P</i> value of 1.5 would have better activities. For example, compounds <b>15–20</b> with log <i>P</i> values ranging from 1.43 to 1.75 would possess more potent activities than compounds <b>14</b>, <b>25</b>, and <b>26</b>, which had larger log <i>P</i> values (1.98–2.70). As for tPSA, apart from compound <b>19</b>, the anticancer activities were almost inversely correlated with tPSA values. When the values of log <i>P</i> and tPSA combined, the exceptions of compounds <b>29</b> and <b>19</b> could obtain a good explanation for their activities, they either had better log <i>P</i> or tPSA than oridonin.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Effects of Oridonin (1) and Its Representative Analogues on the Proliferation of Four Human TNBC Cell Lines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0014.gif" alt="" id="GRAPHIC-d7e958-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char="±">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">comp.</th><th class="colsep0 rowsep0" align="center" char="±">DU4475</th><th class="colsep0 rowsep0" align="center" char="±">HCC1806</th><th class="colsep0 rowsep0" align="center" char="±">MDA-MB-468</th><th class="colsep0 rowsep0" align="center" char="±">MDA-MB-231</th><th class="colsep0 rowsep0" align="center" char=".">log <i>P</i><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">tPSA<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char="±">16.95 ± 1.05</td><td class="colsep0 rowsep0" align="char" char="±">21.74 ± 1.82</td><td class="colsep0 rowsep0" align="char" char="±">17.28 ± 1.57</td><td class="colsep0 rowsep0" align="char" char="±">17.92 ± 0.16</td><td class="colsep0 rowsep0" align="char" char=".">0.89</td><td class="colsep0 rowsep0" align="char" char=".">107.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="char" char="±">2.36 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">2.39 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±">2.24 ± 0.14</td><td class="colsep0 rowsep0" align="char" char="±">2.96 ± 0.21</td><td class="colsep0 rowsep0" align="char" char=".">1.98</td><td class="colsep0 rowsep0" align="char" char=".">86.99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="char" char="±">1.56 ± 0.10</td><td class="colsep0 rowsep0" align="char" char="±">2.05 ± 0.18</td><td class="colsep0 rowsep0" align="char" char="±">2.29 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±">1.74 ± 0.09</td><td class="colsep0 rowsep0" align="char" char=".">1.75</td><td class="colsep0 rowsep0" align="char" char=".">63.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="char" char="±">1.61 ± 0.12</td><td class="colsep0 rowsep0" align="char" char="±">2.35 ± 0.16</td><td class="colsep0 rowsep0" align="char" char="±">1.44 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">2.33 ± 0.19</td><td class="colsep0 rowsep0" align="char" char=".">1.67</td><td class="colsep0 rowsep0" align="char" char=".">86.99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="char" char="±">1.90 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">2.42 ± 0.18</td><td class="colsep0 rowsep0" align="char" char="±">1.66 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">3.71 ± 0.28</td><td class="colsep0 rowsep0" align="char" char=".">1.48</td><td class="colsep0 rowsep0" align="char" char=".">113.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="char" char="±">0.92 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">0.97 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.99 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">1.30 ± 0.12</td><td class="colsep0 rowsep0" align="char" char=".">1.43</td><td class="colsep0 rowsep0" align="char" char=".">63.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="char" char="±">1.88 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">2.92 ± 0.20</td><td class="colsep0 rowsep0" align="char" char="±">2.45 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±">3.44 ± 0.25</td><td class="colsep0 rowsep0" align="char" char=".">2.70</td><td class="colsep0 rowsep0" align="char" char=".">66.76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="char" char="±">1.81 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">2.87 ± 0.13</td><td class="colsep0 rowsep0" align="char" char="±">2.49 ± 0.21</td><td class="colsep0 rowsep0" align="char" char="±">3.66 ± 0.32</td><td class="colsep0 rowsep0" align="char" char=".">2.30</td><td class="colsep0 rowsep0" align="char" char=".">86.74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="char" char="±">1.37 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">2.42 ± 0.22</td><td class="colsep0 rowsep0" align="char" char="±">2.40 ± 0.16</td><td class="colsep0 rowsep0" align="char" char="±">1.68 ± 0.13</td><td class="colsep0 rowsep0" align="char" char=".">0.66</td><td class="colsep0 rowsep0" align="char" char=".">83.83</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Cells were treated with the indicated compounds for 72 h, and cell viability was determined by MTT methods (means ± SD, <i>n</i> = 3).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Calculated using ChemBioDraw Ultra 14.0.</p></div></div></div><div class="NLM_p">Previously, we reported that the 14-<i>O</i>-derivatives of oridonin had significant efficacy against several human cancer cell lines both <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Based on the abovementioned preliminary results, we continued to modify the potent analogue <b>20</b> by introducing different types of substituents to the 14-hydroxyl position, including alkyl-, aryl-, and heterocycle-substituted esters. Therefore, compounds <b>30–56</b> were synthesized and subsequently evaluated against the four human cancer cell lines, and the results are shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Compounds <b>30</b> and <b>31</b> bearing small alkyl groups had potencies comparable to <b>20</b> with IC<sub>50</sub> values ranging from 0.75 to 1.73 μM, indicating that modification of the 14-hydroxyl of <b>20</b> was tolerable. The introduction of a large group, such as cyclohexyl, isobutenyl, and phenyl (<b>32–34</b>), led to a twofold to ninefold decrease in antiproliferative activity. Fortunately, derivatives with aromatic substitutions (<b>35–38</b>) exhibited fourfold to sixfold greater potencies than that of <b>34</b>. Furthermore, derivatives with an <i>N</i>-heterocycle (<b>39–44</b>) had potencies comparable to or even greater than <b>20</b>, with IC<sub>50</sub> values ranging from 0.53 to 2.73 μM. Because compound <b>30</b>, bearing an acetyl moiety, could maintain the antiproliferative activity, compounds <b>45</b> and <b>46</b> were prepared by the insertion of two carbon atoms between the phenyl ring and carbonyl group of compound <b>34</b>. Notably, compound <b>46</b> was slightly more potent than <b>45</b>, indicating that the double bond was more suitable for biological activity. Cis substitution (methyl) on the double bond (compound <b>47</b>) resulted in a slight decrease in activity, with IC<sub>50</sub> values ranging from 1.48 to 2.44 μM. A phenyl substituent on the cinnamic acid moiety of compound <b>46</b> (compounds <b>48–50</b>) led to a slight decrease in activity. Furthermore, replacing the phenyl group of the cinnamic acid moiety with a five-membered ring or aryl-fused phenyl group also resulted in a slight decrease in activity (compounds <b>51–55</b>). To our surprise, replacing the phenyl group with 4-pyridine (compound <b>56</b>) resulted in dramatically increased efficacy against the DU4475, HCC1806, MDA-MB-468, and MDA-MB-231 cancer cell lines, with IC<sub>50</sub> values of 0.21, 0.18, 0.45, and 0.63 μM, respectively.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Effects of the Ester Derivatives (<b>30–56</b>) on Proliferation of Four Human TNBC Cell Lines<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0015.gif" alt="" id="GRAPHIC-d7e1307-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char="±">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">comp.</th><th class="colsep0 rowsep0" align="center" char="±">DU4475</th><th class="colsep0 rowsep0" align="center" char="±">HCC1806</th><th class="colsep0 rowsep0" align="center" char="±">MDA-MB-468</th><th class="colsep0 rowsep0" align="center" char="±">MDA-MB-231</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="char" char="±">0.92 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">0.97 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.99 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">1.30 ± 0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="char" char="±">0.75 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">1.00 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">0.79 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.96 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char="±">1.06 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">1.73 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">0.99 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">0.76 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="char" char="±">2.14 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±">2.58 ± 0.20</td><td class="colsep0 rowsep0" align="char" char="±">2.40 ± 0.23</td><td class="colsep0 rowsep0" align="char" char="±">1.60 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="char" char="±">2.72 ± 0.23</td><td class="colsep0 rowsep0" align="char" char="±">3.06 ± 0.26</td><td class="colsep0 rowsep0" align="char" char="±">2.81 ± 0.14</td><td class="colsep0 rowsep0" align="char" char="±">2.09 ± 0.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char="±">8.50 ± 0.69</td><td class="colsep0 rowsep0" align="char" char="±">7.12 ± 0.53</td><td class="colsep0 rowsep0" align="char" char="±">8.96 ± 0.77</td><td class="colsep0 rowsep0" align="char" char="±">7.45 ± 0.62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="char" char="±">2.05 ± 0.13</td><td class="colsep0 rowsep0" align="char" char="±">1.65 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">2.05 ± 0.14</td><td class="colsep0 rowsep0" align="char" char="±">1.41 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="char" char="±">1.95 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±">1.93 ± 0.12</td><td class="colsep0 rowsep0" align="char" char="±">1.88 ± 0.19</td><td class="colsep0 rowsep0" align="char" char="±">1.39 ± 0.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="char" char="±">1.89 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">1.71 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">2.02 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±">1.30 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="char" char="±">1.28 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">1.17 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">1.38 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">1.13 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="char" char="±">1.42 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">1.39 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">1.32 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">1.08 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="char" char="±">2.62 ± 0.23</td><td class="colsep0 rowsep0" align="char" char="±">2.73 ± 0.21</td><td class="colsep0 rowsep0" align="char" char="±">1.37 ± 0.10</td><td class="colsep0 rowsep0" align="char" char="±">1.07 ± 0.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="char" char="±">0.78 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.71 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">1.47 ± 0.12</td><td class="colsep0 rowsep0" align="char" char="±">1.12 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="char" char="±">0.71 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.73 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">0.76 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">0.53 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="char" char="±">0.85 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">0.74 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.85 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">0.64 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="char" char="±">2.59 ± 0.16</td><td class="colsep0 rowsep0" align="char" char="±">2.67 ± 0.23</td><td class="colsep0 rowsep0" align="char" char="±">2.56 ± 0.19</td><td class="colsep0 rowsep0" align="char" char="±">2.11 ± 0.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="char" char="±">1.74 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">1.62 ± 0.13</td><td class="colsep0 rowsep0" align="char" char="±">1.94 ± 0.16</td><td class="colsep0 rowsep0" align="char" char="±">1.42 ± 0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="char" char="±">1.64 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">1.55 ± 0.12</td><td class="colsep0 rowsep0" align="char" char="±">1.63 ± 0.14</td><td class="colsep0 rowsep0" align="char" char="±">1.37 ± 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="char" char="±">2.44 ± 0.21</td><td class="colsep0 rowsep0" align="char" char="±">1.85 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±">1.99 ± 0.19</td><td class="colsep0 rowsep0" align="char" char="±">1.48 ± 0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="char" char="±">1.75 ± 0.14</td><td class="colsep0 rowsep0" align="char" char="±">1.63 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">1.60 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">1.18 ± 0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="char" char="±">2.15 ± 0.20</td><td class="colsep0 rowsep0" align="char" char="±">1.97 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±">2.34 ± 0.23</td><td class="colsep0 rowsep0" align="char" char="±">1.62 ± 0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="char" char="±">2.32 ± 0.22</td><td class="colsep0 rowsep0" align="char" char="±">1.96 ± 0.16</td><td class="colsep0 rowsep0" align="char" char="±">2.29 ± 0.19</td><td class="colsep0 rowsep0" align="char" char="±">1.31 ± 0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="char" char="±">1.38 ± 0.10</td><td class="colsep0 rowsep0" align="char" char="±">1.22 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">1.34 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">1.28 ± 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="char" char="±">2.82 ± 0.26</td><td class="colsep0 rowsep0" align="char" char="±">2.74 ± 0.24</td><td class="colsep0 rowsep0" align="char" char="±">3.07 ± 0.28</td><td class="colsep0 rowsep0" align="char" char="±">2.18 ± 0.19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="char" char="±">2.00 ± 0.16</td><td class="colsep0 rowsep0" align="char" char="±">1.78 ± 0.12</td><td class="colsep0 rowsep0" align="char" char="±">2.25 ± 0.21</td><td class="colsep0 rowsep0" align="char" char="±">1.47 ± 0.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="char" char="±">2.48 ± 0.23</td><td class="colsep0 rowsep0" align="char" char="±">3.02 ± 0.27</td><td class="colsep0 rowsep0" align="char" char="±">2.65 ± 0.24</td><td class="colsep0 rowsep0" align="char" char="±">2.23 ± 0.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="char" char="±">2.40 ± 0.23</td><td class="colsep0 rowsep0" align="char" char="±">2.05 ± 0.21</td><td class="colsep0 rowsep0" align="char" char="±">2.44 ± 0.20</td><td class="colsep0 rowsep0" align="char" char="±">2.16 ± 0.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="char" char="±">0.21 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.18 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.45 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">0.63 ± 0.03</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Cells were treated with the indicated compounds for 72 h, and cell viability was determined by MTT methods (means ± SD, <i>n</i> = 3).</p></div></div></div><div class="NLM_p">We then investigated the influence of the position and number of nitrogen atoms on the phenyl group (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Rerouting the nitrogen atom from the 4-position to the 3-position of the phenyl group (compound <b>57</b>) led to a slight decrease in antiproliferative efficacy, with IC<sub>50</sub> values ranging from 0.34 to 0.68 μM. Rerouting this nitrogen to the 2-position (compound <b>58</b>) resulted in a significant decline in anticancer activity, with IC<sub>50</sub> values ranging from 0.47 to 1.45 μM. Changing the pyridine to a pyrimidine group (compound <b>59</b>) also led to a slight decrease in antiproliferative efficacy, with IC<sub>50</sub> values ranging from 0.47 to 1.45 μM. Further substitution at the 4-pyridine moiety with fluoro, chloro, or methoxyl groups (compounds <b>60–64</b>) led to a decrease in antiproliferative efficacy against all cancer cell lines, suggesting that substitutions at the 4-pyridine moiety were not tolerable. Taken together, compound <b>56</b> was the most potent compound, which was approximately 120-fold more potent than oridonin (<b>1</b>) against HCC1806 cells (IC<sub>50</sub> values of 0.18 and 21.74 μM, respectively), and deserved further investigation.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Effects of Ester Derivatives (<b>57–64</b>) on the Proliferation of Four Human TNBC Cell Lines<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0016.gif" alt="" id="GRAPHIC-d7e1843-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char="±">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">comp.</th><th class="colsep0 rowsep0" align="center" char="±">DU4475</th><th class="colsep0 rowsep0" align="center" char="±">HCC1806</th><th class="colsep0 rowsep0" align="center" char="±">MDA-MB-468</th><th class="colsep0 rowsep0" align="center" char="±">MDA-MB-231</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="char" char="±">0.21 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.18 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.45 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">0.63 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="char" char="±">0.34 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.31 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.53 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">0.68 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="char" char="±">0.47 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">0.60 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">1.08 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">1.45 ± 0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="char" char="±">0.62 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">0.77 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.84 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">1.08 ± 0.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b></td><td class="colsep0 rowsep0" align="char" char="±">0.94 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">1.12 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">1.03 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">0.70 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="char" char="±">1.10 ± 0.10</td><td class="colsep0 rowsep0" align="char" char="±">1.14 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">1.04 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">0.85 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62</b></td><td class="colsep0 rowsep0" align="char" char="±">1.71 ± 0.14</td><td class="colsep0 rowsep0" align="char" char="±">2.09 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±">1.60 ± 0.12</td><td class="colsep0 rowsep0" align="char" char="±">1.35 ± 0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="char" char="±">1.63 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">1.93 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±">1.75 ± 0.13</td><td class="colsep0 rowsep0" align="char" char="±">1.42 ± 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="char" char="±">0.86 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">0.82 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.85 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.64 ± 0.02</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Cells were treated with the indicated compounds for 72 h, and then, cell viability was determined by MTT methods (means ± SD, <i>n</i> = 3).</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Evaluation of Compound <b>56</b> on a Wide Range of Breast Cancer Cells</h3><div class="NLM_p">To investigate whether the representative oridonin analogue <b>56</b> was efficacious against a wide range of breast cancer cells, compound <b>56</b> was tested against a panel of highly aggressive and metastatic breast cancer cells (HCC1937, T47D, MDA-MB-453, SK-BR-3, and drug-resistant MCF-7/ADR cell lines) using the MTT assay. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, oridonin had moderate antiproliferative efficacy against these breast cancer cell lines, while compound <b>56</b> exhibited potent activity with IC<sub>50</sub> values ranging from the low micromolar to sub-micromolar range. In particular, it should be noted that compound <b>56</b> possessed potent antiproliferative efficacy against MCF-7/ADR cells as well, with an IC<sub>50</sub> value of 1.383 μM, which is approximately 20-fold more potent than oridonin (26.18 μM).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Effects of <b>56</b> on the Proliferation of a Wide Range of Breast Cancer Cell Lines<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char="±">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">comp.</th><th class="colsep0 rowsep0" align="center" char="±">HCC1937</th><th class="colsep0 rowsep0" align="center" char="±">T47D</th><th class="colsep0 rowsep0" align="center" char="±">MDA-MB-453</th><th class="colsep0 rowsep0" align="center" char="±">SK-BR-3</th><th class="colsep0 rowsep0" align="center" char="±">MCF-7/ADR<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="char" char="±">0.28 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.56 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">0.33 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">0.22 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">1.38 ± 0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">oridonin</td><td class="colsep0 rowsep0" align="char" char="±">8.27 ± 0.63</td><td class="colsep0 rowsep0" align="char" char="±">7.56 ± 0.71</td><td class="colsep0 rowsep0" align="char" char="±">6.67 ± 0.57</td><td class="colsep0 rowsep0" align="char" char="±">8.49 ± 0.61</td><td class="colsep0 rowsep0" align="char" char="±">26.18 ± 2.16</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Cells were treated with the indicated compounds for 72 h, and cell viability was determined by MTT methods (means ± SD, <i>n</i> = 3).</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">MCF-7/ADR/adriamycin-resistant human breast carcinoma.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Compound <b>56</b> Induced Cell Cycle G2/M Phase Arrest with Corresponding Changes in G2/M-Related Protein Expression</h3><div class="NLM_p">Because HCC1806 was the most sensitive cell line to compound <b>56</b> among the abovementioned TNBC cells, it was selected for further studies. The cell cycle arrest effects of compound <b>56</b> on HCC1806 cells were determined by flow cytometry analysis. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a, the cell cycle was blocked at the G2/M phase in a dose-dependent manner in <b>56</b>-treated HCC1806 cells. With increasing concentrations of compound <b>56</b> from 0 to 200 nM, the percent of cells in the G2/M phase varied from 10.38 to 24.28%, while the percent of cells in the S and G1 phases decreased concomitantly (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b). In eukaryotic cells, it has been reported that mitosis could be inhibited by the decreased expression of cdc2 kinase, which is controlled by several steps, including cyclin B1 binding and cdc25c phosphorylation.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Western blotting assays showed that compound <b>56</b> upregulated the expression of phosphorylated cdc25c (at residue Ser216) and downregulated cdc2 and cyclin B1 expression in a concentration-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>c,d). These results indicated that compound <b>56</b> induced G2/M phase arrest in HCC1806 cells that might be achieved through the regulation of the expression of cdc2, cyclin B1, and p-cdc25c.</div><figure id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>56</b>-induced G2/M arrest in HCC1806 cancer cells. HCC1806 cells were incubated with different concentrations of <b>56</b> (0, 50, 100, and 200 nM) for 48 h. (a) Cells were harvested and stained with PI and then analyzed by flow cytometry. (b) Histograms display the cell cycle distribution percentages. (c) Western blot analysis of the G2/M-related protein. Cells were harvested and lysed for the detection of p-cdc25c, cdc2, and cyclin B1. (d) Histograms display the density ratios of cdc2, cdc25c, and cyclin B1 to GAPDH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Compound <b>56</b>-Induced Apoptosis in HCC1806 Cells</h3><div class="NLM_p">To investigate whether the growth inhibition of <b>56</b> on breast cancer cells was through the induction of apoptosis, vehicle- or <b>56</b>-incubated HCC1806 cells were stained with Annexin V-FITC and propidium iodide (PI). Treatment with <b>56</b> induced a dose-dependent (50, 100, and 200 nM) increase in both the early- and late-stage apoptosis of HCC1806 cells (17.3, 30.39, and 45.3%, respectively, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a,b).</div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>56</b>-induced apoptosis in HCC1806 cancer cells. (a) Flow cytometry analysis of apoptotic HCC1806 breast cancer cells induced by <b>56</b> at different concentrations (48 h). (b) Apoptotic ratio of different concentrations of <b>56</b> in HCC1806 breast cancer cells. The values are the means ± SD of at least three independent experiments. ***<i>p</i> < 0.001 compared to the vehicle control group (DMSO, vehicle control). (c) Western blot analysis of biomarkers for apoptosis induced by <b>56</b> in HCC1806 cells at different concentrations (48 h). (d,e) Histograms display the density ratios of Bad, Bax, Bcl-2, PI3K, p-PI3K, Akt, p-Akt, mTOR, and p-mTOR to GAPDH. Data are represented as the mean ± SD of three independent experiments. ***<i>p</i> < 0.001 compared to control cells. (f) Protective effects of necrostatin-1 and z-VAD in HCC1806 cells. HCC1806 cells were pretreated with vehicle or 50 μM z-VAD or/and necrostatin-1 for 2 h and then was incubated with 200 nM compound <b>56</b> for 72 h. The values are the means ± SD of at least three independent experiments. ***<i>p</i> < 0.001 vs the control group; <sup>###</sup><i>p</i> < 0.001 vs the compound <b>56</b>-treated group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Previous studies have shown that oridonin induces the apoptosis of cancer cells by regulating a series of proteins in the Bcl-2 family, including proapoptotic proteins (e.g., Bad and Bax) and antiapoptotic proteins (e.g., Bcl-2).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Moreover, evidence has indicated that oridonin also affects the PI3K-Akt-mTOR signaling pathway, which is aberrantly activated in various cancers and leads to uncontrolled growth. To confirm whether such a mechanism is involved in apoptosis induced by compound <b>56</b>, the expression levels of Bax, Bad, Bcl-2, PI3K, phosphorylated PI3K (at residue Tyr458), Akt, phosphorylated Akt (at residue Ser473), mTOR, and phosphorylated mTOR (at residue Ser2448) were determined by western blot analysis. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>c, the expression of Bax and Bad began to increase after incubation with <b>56</b> for 48 h, while Bcl-2 expression significantly decreased at concentrations of <b>56</b> ≥50 nM (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>d). In addition, compound <b>56</b> dose-dependently led to decreases in p-PI3K, p-mTOR, and p-Akt, which indicated that compound <b>56</b> could suppress proliferation and induce apoptosis of HCC1806 cells through regulation of the PI3K-Akt-mTOR signaling pathway (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>e). To determine which type of cell death was involved in the process, we evaluated cell viability by treating the cells with compound <b>56</b> in combination with either the caspase inhibitor z-VAD or necroptosis inhibitor necrostatin-1 (Nec-1).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>f, there was no significant difference between the compound <b>56</b>-treated group and Nec-1 + compound <b>56</b> group, indicating that Nec-1 had no effect on compound <b>56</b>-induced cell death. By the comparison between the compound <b>56</b> group and z-VAD + compound <b>56</b> group, it was shown that z-VAD could significantly decrease cell death, suggesting that caspase-dependent apoptosis was involved in compound <b>56</b>-induced cell death.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Compound <b>56</b>-Induced Reactive Oxygen Species Generation</h3><div class="NLM_p">Intracellular reactive oxygen species (ROS) generation is considered an important factor in inducing apoptosis in various types of cells. To investigate whether compound <b>56</b> could change intracellular ROS levels, the fluorogenic ROS probe 2′,7′-dichlorodihydrofluorescein diacetate (DCFH<sub>2</sub>-DA) was used to monitor ROS levels in the presence and absence of compound <b>56</b>. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, treatment with compound <b>56</b> increased intracellular ROS levels in HCC1806 cells in a dose-dependent manner. The ratio of DCFH<sub>2</sub>-DA positive cells increased from 3.53% in cells incubated with dimethyl sulfoxide (DMSO) to 45.87% in cells incubated with 200 nM compound <b>56</b>. Moreover, preincubation with 2.5 mM <i>N</i>-acetyl cysteine (NAC), a ROS scavenger, significantly inhibited <b>56</b>-induced ROS generation.</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Accumulation of ROS production in HCC1806 cells induced by <b>56</b> (48 h). (a) Generation of ROS was measured using the ROS-detecting fluorescent dye DCFH<sub>2</sub>-DA in combination with FACScan flow cytometry. (b) Corresponding histograms of FACScan flow cytometry are shown. ***<i>p</i> < 0.001 compared to control cells. <sup>###</sup><i>p</i> < 0.001, 200 nM <b>56</b>-treated cells compared with NAC and 200 nM <b>56</b>-treated cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Compound <b>56</b> Inhibited the Metastasis, Invasion, and Adhesion of HCC1806 Cells</h3><div class="NLM_p">TNBC is one of the most lethal cancers because of its highly metastatic and invasive characteristics. To confirm whether compound <b>56</b> could inhibit cancer metastasis, wound healing and transwell assays were conducted. The results of the wound healing assay are shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a,b. Untreated cells obviously minimized the gap that was initially scraped after 24 and 48 h, while treatment of HCC1806 cells with compound <b>56</b> significantly inhibited migration in a dose-dependent manner. The results of the transwell assay are shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>c,d. Treatment with compound <b>56</b> markedly suppressed HCC1806 cell invasion at sub-micromolar concentrations (100–200 nM). Further adhesion assays (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>e,f) demonstrated that compound <b>56</b> dose-dependently inhibited HCC1806 cell adhesion. Therefore, compound <b>56</b> had potent activity against the migration, invasion, and adhesion of HCC-1806 cells <i>in vitro</i>.</div><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of <b>56</b> on metastasis, invasion, and adhesion of HCC1806 cells. (a,b) Scratches of HCC1806 cell colonies were generated with pipette tips (200 μL). After 24 or 48 h of incubation with 0, 50, 100, and 200 nM compound <b>56</b>, representative images were captured using phase contrast microscopy. *<i>p</i> < 0.05 and ***<i>p</i> < 0.001 vs the control group. (c,d) HCC1806 cells were seeded onto chambers and incubated with <b>56</b> (0, 50, 100, and 200 nM) for 24 h. Cells that migrated through the chambers were stained with crystal violet, and representative images were captured. ***<i>p</i> < 0.001 vs the control group. (e,f) HCC1806 cells were incubated with <b>56</b> (0, 50, 100, and 200 nM) in 96-well plates for 24 h, and the nonadherent cells were washed away with phosphate-buffered saline, while the adhesive cells were counted using phase contrast microscopy. ***<i>p</i> < 0.001 vs the control group. (g) Western blot analysis of biomarkers for migration in HCC1806 cells treated with different concentrations of <b>56</b> (48 h). (h) Histograms display the density ratios of MMP-2, MMP-9, integrin β1, FAK, p-FAK, and EGFR to GAPDH. Data are represented as the mean ± SD of three independent experiments. ***<i>p</i> < 0.001; control compared with <b>56</b>-treated cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To illustrate the potential mechanisms contributing to the inhibition of metastasis, invasion, and adhesion by compound <b>56</b>, several related proteins were determined by western blotting. MMP-2 and MMP-9 have been reported to be key biomarkers for the prognosis of breast cancer metastasis. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>g, compound <b>56</b> could decrease the expression of MMP-2 and MMP-9, indicating the antimetastatic potential of compound <b>56</b>, which was consistent with the results of wound healing and transwell assays. FAK plays an important role in the early stages of cell migration and adhesion, and integrin β1 is tightly associated with motility and radio resistance in breast cancer cells.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> From the results shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>h, we found that treatment of HCC1806 cells with <b>56</b> did not change the expression of the FAK protein but suppressed the level of FAK phosphorylation (at residue Tyr397). Moreover, the level of integrin β1 dramatically decreased after treatment with <b>56</b> in a dose-dependent manner. Moreover, <b>56</b> downregulated the expression level of the epidermal growth factor receptor (EGFR), which induces tumor cell growth, migration, and adhesion. These results suggest that <b>56</b> can inhibit metastasis in HCC1806 cells and has the potential to be an antimetastatic agent for TNBC.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Compound <b>56</b> Suppressed Tumor Growth <i>In Vivo</i></h3><div class="NLM_p">Because compound <b>56</b> significantly inhibited the proliferation of TNBC cells, we performed a preliminary experiment to assess its antitumor activity <i>in vivo</i> utilizing a mouse breast cancer xenograft model established by the subcutaneous inoculation of luciferase-based HCC1806 cells (<i>n</i> = 2). Mice were randomly assigned to four groups: the negative control group, the positive control group (i.v., paclitaxel, 6 mg/kg per 2 days), and the <b>56</b>-treated groups (i.v., 12.5 and 25 mg/kg per day). The tumor tissue significantly shrank in the <b>56</b>-treated groups compared with the vehicle group (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a). Moreover, the tumor volumes in the 25 mg/kg <b>56</b>-treated group were dramatically smaller than those in the paclitaxel-treated group. Based on these results, we further conducted an <i>in vivo</i> experiment utilizing a mouse breast cancer xenograft model established by subcutaneous inoculation of normal HCC1806 cells into nude mice (<i>n</i> = 6). The tumor sizes and body weights of the mice were monitored and recorded every 2 days. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b, compound <b>56</b> dose-dependently inhibited tumor volume with superior antiproliferative activity compared to the positive control. After 23 days of treatment, compound <b>56</b> reduced the tumor weight by 67.3% at a dose of 12.5 mg/kg, which was comparable to the paclitaxel group with a reduction of 66.0%, and when the dose of <b>56</b> increased to 25 mg/kg, the rate of reduction of tumor weight reached 74.1% (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>c,d). Moreover, paclitaxel-treated mice showed a significant loss in body weight, while the mice treated with compound <b>56</b> displayed no significant loss in body weight (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>e).</div><figure id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>56</b> suppressed TNBC cell xenograft growth <i>in vivo</i>. (a) Bioluminescence images of tumor growth in luciferase-based HCC1806 xenograft nude mice from day 0 to day 21. (b) Normal HCC1806 cell xenograft tumor volume changes during treatment. ***<i>p</i> < 0.001 vs the control group. (c) Images of normal HCC1806 tumors from mice 23 days after initiation of treatment. After administering vehicle, paclitaxel (6 mg/kg per 2 days), <b>56</b> (12.5 mg/kg per day), and <b>56</b> (25 mg/kg per day) for 23 days, the mice were sacrificed, and the tumors were weighed. (d) Weight of the excised tumors of each group. ***<i>p</i> < 0.001 vs the control group; <sup>#</sup><i>p</i> < 0.05 vs the paclitaxel group. (e) Body weight changes of mice during treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Histological analysis and immunohistochemical labeling of tumor tissue were performed using hematoxylin and eosin (H&E) and antibodies for cell proliferation marker (Ki67) and apoptotic cell death (TUNEL). Treatment with paclitaxel or <b>56</b> significantly induced tumor shrinkage and cancer cell apoptosis (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), and this result was consistent with the abovementioned results that compound <b>56</b> inhibited cancer cell growth in a dose-dependent manner, and the high-dose <b>56</b>-treated group exhibited greater efficacy than the paclitaxel control group.</div><figure id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. H&E, Ki67, and TUNEL immunohistochemical staining of tumors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To investigate the effect of paclitaxel and compound <b>56</b> on organ damage, the H&E staining of the heart, liver, spleen, lung, and kidney of mice from the control, paclitaxel (6 mg/kg) group, and compound <b>56</b> (25 mg/kg) group was analyzed. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, the morphology of cells and tissues in the compound <b>56</b>-treated group was very similar to that of the control group, suggesting that there was no overt toxicity under the current treatment paradigm.</div><figure id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. H&E staining of the heart, liver, spleen, lung, and kidney of mice. No abnormalities in these organs were observed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Taken together, these data indicate that compound <b>56</b> possesses potent antiproliferative activities <i>in vivo</i> and deserves further investigation.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03611" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03611" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">On the basis of our previous work, we continued studying the SAR of the hydroxyl groups of oridonin. The removal of multiple hydroxyl groups of oridonin led to the discovery of a series of novel oridonin analogues with a simplified scaffold. SAR analysis suggested that the fewer the remaining hydroxyl groups of the oridonin analogues, the better the antiproliferative efficacy they possess. Potent oridonin-based core compound <b>20</b> was generated by eliminating the hydroxyl group at the C-1 position, removing the hydroxyl group at the C-6 position and hydrolyzing the hemiketal at the C-7 position. The anticancer activity of compound <b>20</b> could be improved by structural modifications at the C-14 position. Among the derivatives of compound <b>20</b>, compound <b>56</b>, bearing a <i>trans</i>-4-pyridineacrylic acid moiety, was the most potent compound with a 120-fold improvement in potency compared with parent compound oridonin against HCC1806 cancer cells.</div><div class="NLM_p">A mechanistic study showed that compound <b>56</b> might exert on multiple cell-signaling networks, especially those concerning cell apoptosis, DNA replication, cell cycle, endocytosis, MAPK signaling pathway, and protein processing in the endoplasmic reticulum (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00408/suppl_file/jm0c00408_si_001.pdf" class="ext-link">Figure S1</a>). Cell apoptosis study revealed that compound <b>56</b> could induce both the early- and late-stage apoptosis of HCC1806 cells through regulation of a series of Bcl-2 family proteins (Bcl-2, Bad, and Bax) and the PI3K-Akt-mTOR signaling pathway. Furthermore, compound <b>56</b> inhibited the metastasis, invasion, and adhesion of HCC1806 cells. A potential mechanistic study showed that compound <b>56</b> could decrease the expression levels of MMP-2, MMP-9, p-FAK, integrin β1, and EGFR, indicating that compound <b>56</b> might be a potential antimetastatic agent for TNBC.</div><div class="NLM_p">More importantly, compound <b>56</b> displayed potent anticancer efficacy in HCC1806 TNBC xenograft nude mice. Compound <b>56</b> effectively suppressed the tumor volume and reduced the tumor weight by 74.1% at a dose of 25 mg/kg/day (i.v.), which was better than that of the positive control, paclitaxel (66.0% at 6 mg/kg/day). Moreover, compound <b>56</b> showed no significant toxicity.</div><div class="NLM_p last">Collectively, the newly developed oridonin derivative <b>56</b> possessed significant anticancer activities both <i>in vitro</i> and <i>in vivo</i>. Thus, compound <b>56</b> has the potential to be further developed as a promising therapeutic agent for TNBC.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73705" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73705" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Methods</h3><div class="NLM_p">All commercially available reagents were used without further purification. Solvents were dried through routine protocols. Flash column chromatography was carried out on 200–300 mesh silica gel (Qingdao Haiyang Chemical, China). Reactions were monitored by thin-layer chromatography (TLC) on 0.25 mm silica gel plates (GF254) and visualized under UV light. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded with a Bruker AV-300 spectrometer (Bruker Company, Germany) in the indicated solvents (CDCl<sub>3</sub> or DMSO-<i>d</i><sub>6</sub> and tetramethylsilane as the internal standard): the values of the chemical shifts are expressed in δ values (ppm) and the coupling constants (<i>J</i>) are expressed in Hertz. Low- and high-resolution mass spectra (LRMS and HRMS) were measured on a Finnigan MAT 95 spectrometer (Finnigan, Germany). Purity of all tested compounds was ≥95%, as estimated by high-performance liquid chromatography (HPLC; SHIMADZU LabSolutions; UV detection at λ = 254 nm) analysis on an Agilent C18 column (4.6 × 150 mm, 5 μm) eluting at 1 mL/min of menthol and water (80:20).</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (3<i>S</i>,3<i>aR</i>,3<i>a</i>1<i>R</i>,6<i>aR</i>,7<i>S</i>,11<i>S</i>,11<i>aS</i>)-7,11-Dihydroxy-5,5,8,8-tetramethyl-15-methylenedecahydro-2<i>H</i>-6<i>a</i>,11<i>a</i>-(epoxymethano)-3,3<i>a</i>1-ethanophenanthro[1,10-<i>de</i>][1,3]dioxin-14-one (<b>8</b>)</h4><div class="NLM_p last">Compound <b>8</b> was prepared as previously described for compound <b>10</b> in our prior work.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (2<i>S</i>,3′<i>R</i>,3<i>a</i>′<i>R</i>,3<i>a</i>1′<i>R</i>,6<i>a</i>′<i>R</i>,7′<i>S</i>,11′<i>S</i>,11<i>a</i>′<i>S</i>)-7′,11′-Dihydroxy-5′,5′,8′,8′-tetramethyldecahydro-2′<i>H</i>-spiro[oxirane-2,15′-[6<i>a</i>,11<i>a</i>](epoxymethano)[3,3<i>a</i>1]ethanophenanthro[1,10-<i>de</i>][1,3]dioxin]-14′-one (<b>9</b>)</h4><div class="NLM_p last">Compound <b>8</b> (2.81 g, 7.0 mmol) was dissolved in MeOH (40 mL) and then cooled to 0 °C; 30% H<sub>2</sub>O<sub>2</sub> (2.5 mL, 40.8 mmol) and 6 N NaOH (5.0 mL, 3 mmol) were added to the solution. The mixture was stirred at 0 °C for 2 h. Water was added to the reaction solution and it was evaporated to remove methanol and then extracted with EtOAc three times. The extract was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give diastereoisomer mixtures of compound <b>9</b> (2.75 g, <b>9a</b>/<b>9b</b> = 2:1, 88% overall yield).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a><b>9a</b>: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 5.34 (d, <i>J</i> = 11.8 Hz, 1H), 4.93 (d, <i>J</i> = 1.9 Hz, 1H), 4.27 (d, <i>J</i> = 9.9 Hz, 1H), 4.09 (dd, <i>J</i> = 16.7, 8.6 Hz, 1H), 3.89 (dd, <i>J</i> = 11.7, 7.6 Hz, 1H), 3.48 (dd, <i>J</i> = 11.2, 5.5 Hz, 1H), 3.16 (d, <i>J</i> = 5.9 Hz, 1H), 2.97 (d, <i>J</i> = 5.9 Hz, 1H), 2.60–2.39 (m, 1H), 2.28 (d, <i>J</i> = 9.8 Hz, 1H), 1.97–1.59 (m, 10H), 1.39–1.04 (m, 12H).</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>O</i>-((3<i>S</i>,3<i>aR</i>,3<i>a</i>1<i>R</i>,6<i>aR</i>,7<i>S</i>,7<i>aR</i>,11<i>S</i>,11<i>aS</i>,11<i>bS</i>,15<i>R</i>)-7-Hydroxy-15-(hydroxymethyl)-5,5,8,8-tetramethyl-14-oxodecahydro-2<i>H</i>-6<i>a</i>,11<i>a</i>-(epoxymethano)-3,3<i>a</i>1-ethanophenanthro[1,10-<i>de</i>][1,3]dioxin-11-yl) <i>O</i>-Phenyl Carbonothioate (<b>10</b>)</h4><div class="NLM_p last">To a solution of diastereoisomer mixtures of <b>9</b> (3.00 g, 7.13 mmol) in anhydrous dichloromethane were added PhOC(S)Cl (2.6 mL, 18.8 mmol), pyridine (0.98 μL, 32.3 mmol), and DMAP (1.31 g, 10.7 mmol). Upon completion (TLC analysis), the reaction solution was quenched with MeOH, diluted with water, and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (silica gel, EtOAc/petroleum ether, 1:10 to 1:4) to give compound <b>10</b> as a mixture of diastereoisomers with 2:1 dr (2.98 g, 75% overall yield). <b>10a</b>: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.43 (dd, <i>J</i> = 10.5, 4.9 Hz, 2H), 7.31 (t, <i>J</i> = 7.4 Hz, 1H), 7.06–6.98 (m, 2H), 5.23 (d, <i>J</i> = 12.2 Hz, 1H), 5.07 (dd, <i>J</i> = 11.4, 5.5 Hz, 1H), 4.94 (d, <i>J</i> = 2.0 Hz, 1H), 4.24 (s, 2H), 4.00–3.84 (m, 1H), 3.29 (d, <i>J</i> = 6.4 Hz, 1H), 3.07 (d, <i>J</i> = 6.4 Hz, 1H), 2.47 (d, <i>J</i> = 9.0 Hz, 1H), 2.24–1.91 (m, 5H), 1.69 (d, <i>J</i> = 13.9 Hz, 4H), 1.48 (dd, <i>J</i> = 41.1, 10.5 Hz, 5H), 1.35 (s, 4H), 1.20 (d, <i>J</i> = 6.0 Hz, 6H).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (3<i>S</i>,3<i>aR</i>,3<i>a</i>1<i>R</i>,6<i>aR</i>,7<i>S</i>,11<i>aR</i>,15<i>R</i>)-7-Hydroxy-15-(hydroxymethyl)-5,5,8,8-tetramethyldecahydro-2<i>H</i>-6<i>a</i>,11<i>a</i>-(epoxymethano)-3,3<i>a</i>1-ethanophenanthro[1,10-<i>de</i>][1,3]dioxin-14-one (<b>11</b>)</h4><div class="NLM_p last">To a solution of the mixture of diastereoisomers of <b>10</b> (2 g, 3.6 mmol) in anhydrous toluene (50 mL) were added AIBN (200 mg, 1.4 mmol) and <i>n</i>Bu<sub>3</sub>SnH (3.8 mL, 14.3 mmol). The solution was stirred at 110 °C for 2 h under argon. Then, the reaction solution was evaporated <i>in vacuo</i> and purified by silica gel column chromatography (EtOAc/petroleum ether, 1:6 to 1:2) to afford a mixture of diastereoisomers of <b>11</b> (1.46 g, <b>11a</b>/<b>11b</b> 2:1, 85% overall yield).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a><b>11a</b>: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 6.17 (s, 1H), 5.83 (d, <i>J</i> = 11.7 Hz, 1H), 5.56 (s, 1H), 4.74 (s, 1H), 4.11 (t, <i>J</i> = 10.3 Hz, 1H), 3.98–3.83 (m, 1H), 3.76 (d, <i>J</i> = 9.7 Hz, 1H), 3.06 (d, <i>J</i> = 8.6 Hz, 1H), 2.59–2.44 (m, 1H), 1.46–1.32 (m, 8H), 1.31–1.21 (m, 12H), 1.15 (d, <i>J</i> = 9.8 Hz, 4H).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> ((3<i>S</i>,3<i>aR</i>,3<i>a</i>1<i>R</i>,6<i>aR</i>,7<i>S</i>,11<i>aR</i>,15<i>R</i>)-7-Hydroxy-5,5,8,8-tetramethyl-14-oxodecahydro-2<i>H</i>-6<i>a</i>,11<i>a</i>-(epoxymethano)-3,3<i>a</i>1-ethanophenanthro[1,10-<i>de</i>][1,3]dioxin-15-yl)methyl Methanesulfonate (<b>12</b>)</h4><div class="NLM_p last">To a solution of <b>11</b> (1.75 g, 4.3 mmol) in 40 mL of anhydrous dichloromethane, tetraethylammonium (TEA; 1.2 mL, 5.2 mmol) was added, and then, methylsulfonyl chloride (0.4 mL, 5.17 mmol) was added dropwise to the solution at 0 °C, and the resulting solution was stirred for 30 min. Then, the reaction was quenched with water and extracted with dichloromethane. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i> to yield crude yellow oil without any further purification.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (3<i>S</i>,3<i>aR</i>,3<i>a</i>1<i>R</i>,6<i>aR</i>,7<i>S</i>,11<i>aR</i>)-7-Hydroxy-5,5,8,8-tetramethyl-15-methylenedecahydro-2<i>H</i>-6<i>a</i>,11<i>a</i>-(epoxymethano)-3,3<i>a</i>1-ethanophenanthro[1,10-<i>de</i>][1,3]dioxin-14-one (<b>13</b>)</h4><div class="NLM_p last">A mixture of compound <b>12</b> (650 mg, 1.4 mmol), lithium carbonate (1 g, 14 mmol), and lithium bromide (1.17 g, 14 mmol) in 25 mL of DMF was heated below 110 °C for 2 h. Then, we filtered off the inorganic precipitate, washed the precipitate with EtOAc, and collected the filtrate. The filtrate was diluted with 400 mL of water and extracted with EtOAc (25 mL × 5) and then washed with brine. The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated <i>in vacuo</i> to yield crude yellow oil without any further purification.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (5<i>S</i>,6<i>S</i>,6<i>aR</i>,9<i>S</i>,11<i>bR</i>,14<i>R</i>)-5,6,14-Trihydroxy-4,4-dimethyl-8-methylenedecahydro-1<i>H</i>-6,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-7(8<i>H</i>)-one (<b>14</b>)</h4><div class="NLM_p last">Compound <b>13</b> (430 mg, 2.1 mmol) was dissolved in 10 mL of THF, and 6 mL of 10% HCl was added and stirred at room temperature for 30 min. Then, the mixture was diluted with water and extracted with dichloromethane. The extract was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was subjected to column chromatography (silica gel, EtOAc/petroleum ether, 1:4 to 1:2) to give compound <b>14</b> (212 mg, 55% yield from <b>11</b>) as a white powder. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 6.82 (s, 1H), 6.07–5.92 (m, 3H), 5.59 (s, 1H), 4.69 (s, 1H), 3.88 (d, <i>J</i> = 9.8 Hz, 1H), 3.77 (d, <i>J</i> = 9.8 Hz, 1H), 3.50 (dd, <i>J</i> = 9.9, 6.1 Hz, 1H), 2.92 (d, <i>J</i> = 9.6 Hz, 1H), 2.38 (s, 1H), 1.63 (s, 2H), 1.30 (ddd, <i>J</i> = 19.5, 13.8, 10.6 Hz, 7H), 1.11 (d, <i>J</i> = 5.9 Hz, 2H), 0.99 (d, <i>J</i> = 5.6 Hz, 6H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 208.8, 152.1, 120.2, 97.5, 73.1, 73.1, 65.5, 61.9, 60.4, 52.1, 43.2, 41.2, 36.2, 33.8, 33.6, 30.0, 29.9, 22.4, 18.6, 16.3; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>20</sub>H<sub>28</sub>NaO<sub>5</sub> [M + Na]<sup>+</sup>, 371.1829; found, 371.1828.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>bR</i>,14<i>R</i>)-14-Hydroxy-4,4-dimethyl-8-methylenedecahydro-6<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalene-6,7(8<i>H</i>)-dione (<b>15</b>)</h4><div class="NLM_p last">Compound <b>13</b> (255 mg, 0.51 mmol) was dissolved in 5 mL of anhydrous dichloromethane and degassed with argon three times; then, the solution was cooled to −20 °C. DAST (171 μL, 1.3 mmol) was dissolved in 200 μL of anhydrous dichloromethane and added dropwise into the solution, and the mixture solution was stirred for 10 min and then was quenched by dropping ice water. The resulting solution was extracted with dichloromethane and concentrated. The residue was subjected to column chromatography (silica gel, EtOAc/petroleum ether, 1:4) to give compound <b>15</b> (yield 41% from compound <b>11</b>) as a white powder.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 6.11 (s, 1H), 5.49 (s, 1H), 4.56 (s, 1H), 4.17 (s, 1H), 3.96 (d, <i>J</i> = 9.2 Hz, 1H), 3.79 (d, <i>J</i> = 9.7 Hz, 2H), 3.10 (d, <i>J</i> = 8.0 Hz, 1H), 2.38 (tt, <i>J</i> = 8.5, 4.8 Hz, 1H), 2.00 (dd, <i>J</i> = 14.6, 7.0 Hz, 1H), 1.81 (d, <i>J</i> = 13.5 Hz, 1H), 1.71–1.61 (m, 3H), 1.61–1.47 (m, 4H), 1.24–1.12 (m, 2H), 1.00 (t, <i>J</i> = 5.4 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 205.3, 203.4, 148.9, 119.7, 82.9, 74.1, 69.4, 66.0, 54.4, 52.9, 48.2, 44.0, 39.5, 33.1, 31.1, 29.6, 29.53, 22.9, 18.2, 17.4; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>20</sub>H<sub>27</sub>O<sub>4</sub> [M + Na]<sup>+</sup>, 371.1829; found, 371.1828.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (3<i>S</i>,3<i>aR</i>,3<i>a</i>1<i>R</i>,6<i>aR</i>,7<i>S</i>,7<i>aR</i>,11<i>S</i>,11<i>aS</i>,11<i>bS</i>)-7-Hydroxy-5,5,8,8-tetramethyl-15-methylene-14-oxodecahydro-2<i>H</i>-6<i>a</i>,11<i>a</i>-(epoxymethano)-3,3<i>a</i>1-ethanophenanthro[1,10-<i>de</i>][1,3]dioxin-11-yl Methanesulfonate (<b>16</b>)</h4><div class="NLM_p last">Compound <b>16</b> was prepared as previously described for compound <b>11</b> in our prior work.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (3<i>S</i>,3<i>aR</i>,3<i>a</i>1<i>R</i>,6<i>aR</i>,7<i>S</i>,7<i>aR</i>,11<i>aR</i>,11<i>bS</i>)-7-Hydroxy-5,5,8,8-tetramethyl-15-methylene-1,3,3<i>a</i>,7,7<i>a</i>,8,9,11<i>b</i>-octahydro-2<i>H</i>-6<i>a</i>,11<i>a</i>-(epoxymethano)-3,3<i>a</i>1-ethanophenanthro[1,10-<i>de</i>][1,3]dioxin-14-one (<b>17</b>)</h4><div class="NLM_p last">Compound <b>17</b> was prepared as previously described for compound <b>12</b> in our prior work.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (4<i>aR</i>,5<i>S</i>,6<i>S</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-5,6,14-Trihydroxy-4,4-dimethyl-8-methylene-4,4<i>a</i>,5,6,9,10,11,11<i>a</i>-octahydro-3<i>H</i>-6,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-7(8<i>H</i>)-one (<b>18</b>)</h4><div class="NLM_p last">Compound 1<b>8</b> was prepared as previously described for compound <b>13</b> in our prior work.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (4<i>aR</i>,5<i>S</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,12<i>R</i>)-11<i>b</i>-(Acetoxymethyl)-4,4-dimethyl-8-methylene-6,7-dioxo-3,4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>,11<i>b</i>-dodecahydro-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalene-5,12-diyl Diacetate (<b>19</b>)</h4><div class="NLM_p last">Compound <b>18</b> (180 mg, 0.5 mmol) and <i>p</i>-toluenesulfonic acid (110 mg, 0.6 mmol) were dissolved in 5 mL of acetic anhydride; then, the solution was heated below 40 °C and stirred for 2 h. The reaction solution was diluted with saturated sodium bicarbonate solution and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (silica gel, EtOAc/petroleum ether, 1:4) to give compound <b>19</b> (231 mg, 84%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 6.22 (s, 1H), 6.02 (s, 1H), 5.95–5.81 (m, 1H), 5.74 (d, <i>J</i> = 13.7 Hz, 1H), 5.61 (d, <i>J</i> = 9.8 Hz, 1H), 5.50 (s, 1H), 4.44 (d, <i>J</i> = 12.9 Hz, 1H), 4.28 (d, <i>J</i> = 12.9 Hz, 1H), 3.13 (s, 1H), 2.26 (d, <i>J</i> = 4.2 Hz, 1H), 2.15 (t, <i>J</i> = 6.4 Hz, 8H), 2.02 (d, <i>J</i> = 11.1 Hz, 4H), 1.85 (s, 1H), 1.68 (s, 1H), 1.07 (d, <i>J</i> = 20.9 Hz, 6H), 0.86 (d, <i>J</i> = 6.6 Hz, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 199.1, 198.1, 170.2, 170.0, 169.2, 145.6, 130.7, 129.4, 119.2, 114.5, 74.6, 73.3, 65.2, 62.2, 52.6, 50.5, 43.6, 42.2, 41.2, 34.4, 32.6, 30.1, 26.4, 24.3, 20.6, 17.4; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>32</sub>NaO<sub>8</sub> [M + Na]<sup>+</sup>, 495.1989; found, 495.1991.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-14-Hydroxy-4,4-dimethyl-8-methylene-3,4,4<i>a</i>,5,9,10,11,11<i>a</i>-octahydro-6<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalene-6,7(8<i>H</i>)-dione (<b>20</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>15</b>. Compound <b>17</b> (0.51 mmol) was dissolved in 5 mL of anhydrous dichloromethane and degassed with argon three times; then, the solution was cooled to −20 °C. DAST (1.3 mmol) was dissolved in 200 μL of anhydrous dichloromethane and added dropwise into the solution, and the mixture solution was stirred for 10 min and then was quenched by dropping ice water. The resulting solution was extracted with dichloromethane and concentrated. The residue was subjected to column chromatography (silica gel, EtOAc/petroleum ether, 1:4). Compound <b>20</b> was synthesized as a white powder (yield 75%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 6.13 (s, 1H), 5.90–5.72 (m, 1H), 5.65 (d, <i>J</i> = 10.1 Hz, 1H), 5.53 (s, 1H), 4.63 (s, 1H), 4.31 (s, 1H), 4.13 (d, <i>J</i> = 9.0 Hz, 1H), 4.01 (s, 1H), 3.72 (d, <i>J</i> = 9.0 Hz, 1H), 3.12 (d, <i>J</i> = 8.9 Hz, 1H), 2.47 (dd, <i>J</i> = 20.3, 8.1 Hz, 1H), 2.14–2.04 (m, 1H), 1.94 (dd, <i>J</i> = 23.5, 8.2 Hz, 2H), 1.86–1.61 (m, 4H), 1.06 (d, <i>J</i> = 13.6 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 205.6, 203.2, 149.2, 128.2, 124.1, 120.1, 81.8, 73.7, 71.6, 65.4, 54.0, 50.0, 49.3, 43.9, 39.5, 30.4, 29.4, 23.1, 18.2; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>20</sub>H<sub>25</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 329.1747; found, 329.1746.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>O</i>,<i>O</i>′-((2<i>S</i>,3′<i>R</i>,3<i>a</i>′<i>R</i>,3<i>a</i>1′<i>R</i>,6<i>a</i>′<i>R</i>,7′<i>S</i>,11′<i>S</i>,11<i>a</i>′<i>S</i>)-5′,5′,8′,8′-Tetramethyl-14′-oxodecahydro-2′<i>H</i>-spiro[oxirane-2,15′-[6<i>a</i>,11<i>a</i>](epoxymethano)[3,3<i>a</i>1]ethanophenanthro[1,10-<i>de</i>][1,3]dioxine]-7′,11′-diyl) Diethanethioate (<b>21</b>)</h4><div class="NLM_p last">To a solution of <b>9</b> (4.17 g, 9.9 mmol) in anhydrous THF were added NaH (60% in oil, 3.17 g, 79.3 mmol), CS<sub>2</sub> (2.46 mL, 40.7 mmol), imidazole (0.42 g, 5.95 mmol), and MeI (2.02 mL, 21.8 mmol). Upon completion (TLC analysis), the reaction solution was quenched with MeOH, diluted with water, and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (silica gel, EtOAc/petroleum ether, 1:10 to 1:6) to give compound <b>21</b> as a mixture of diastereoisomers with 2:1 dr (5.24 g, <b>21a</b>/<b>21b</b> 2:1, 88% overall yield).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a><b>21a</b>: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 6.46 (d, <i>J</i> = 8.3 Hz, 1H), 5.47 (dd, <i>J</i> = 10.8, 5.1 Hz, 1H), 4.95 (s, 1H), 4.36 (s, 2H), 3.25 (d, <i>J</i> = 6.4 Hz, 1H), 2.99 (d, <i>J</i> = 6.4 Hz, 1H), 2.60 (d, <i>J</i> = 15.0 Hz, 6H), 2.37 (t, <i>J</i> = 8.0 Hz, 1H), 2.19–1.92 (m, 5H), 1.85–1.69 (m, 1H), 1.63 (s, 3H), 1.58–1.38 (m, 3H), 1.32 (d, <i>J</i> = 7.3 Hz, 4H), 1.21 (s, 3H), 0.98 (s, 3H).</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (3<i>S</i>,3<i>aR</i>,3<i>a</i>1<i>R</i>,6<i>aS</i>,11<i>aS</i>,15<i>R</i>)-15-(Hydroxymethyl)-5,5,8,8-tetramethyldecahydro-2<i>H</i>-6<i>a</i>,11<i>a</i>-(epoxymethano)-3,3<i>a</i>1-ethanophenanthro[1,10-<i>de</i>][1,3]dioxin-14-one (<b>22</b>)</h4><div class="NLM_p last">To a solution of the mixture of diastereoisomers of <b>21</b> (1.8 g, 3.2 mmol) in anhydrous toluene (30 mL) were added AIBN (203 mg, 1.2 mmol) and <i>n</i>Bu<sub>3</sub>SnH (4.8 mL, 17.9 mmol). The solution was stirred at 110 °C for 2 h under argon. Then, the reaction solution was evaporated <i>in vacuo</i> and purified by silica gel column chromatography (EtOAc/petroleum ether, 1:6 to 1:2) to afford a mixture of diastereoisomers of <b>22</b> (1.10 g overall, 85%, <b>22a</b>/<b>22b</b> 2:1).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a><b>22a</b>: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 4.65 (s, 1H), 4.24–4.15 (m, 1H), 3.87 (m, 2H), 3.75 (d, <i>J</i> = 9.6 Hz, 1H), 3.09–2.92 (m, 1H), 2.79 (q, <i>J</i> = 12.1 Hz, 1H), 2.67 (s, 1H), 2.58 (t, <i>J</i> = 8.1 Hz, 1H), 2.36 (dt, <i>J</i> = 30.3, 8.5 Hz, 1H), 2.11–1.93 (m, 1H), 1.86 (d, <i>J</i> = 8.1 Hz, 1H), 1.72–1.53 (m, 5H), 1.39 (d, <i>J</i> = 13.6 Hz, 3H), 1.24 (d, <i>J</i> = 8.1 Hz, 5H), 1.14–0.75 (m, 9H).</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> ((3<i>S</i>,3<i>aR</i>,3<i>a</i>1<i>R</i>,6<i>aS</i>,11<i>aS</i>,15<i>R</i>)-5,5,8,8-Tetramethyl-14-oxodecahydro-2<i>H</i>-6<i>a</i>,11<i>a</i>-(epoxymethano)-3,3<i>a</i>1-ethanophenanthro[1,10-<i>de</i>][1,3]dioxin-15-yl)methyl Methanesulfonate (<b>23</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>12</b>. To a solution of <b>22</b> (4.3 mmol) in 40 mL of anhydrous dichloromethane, TEA (5.2 mmol) was added, and then, methylsulfonyl chloride (5.17 mmol) was added dropwise to the solution at 0 °C, and the resulting solution was stirred for 30 min. Then, the reaction was quenched with water and extracted with dichloromethane. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. Compound <b>23</b> was synthesized as a crude yellow oil without any further purification.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (3<i>S</i>,3<i>aR</i>,3<i>a</i>1<i>R</i>,6<i>aS</i>,11<i>aS</i>)-5,5,8,8-Tetramethyl-15-methylenedecahydro-2<i>H</i>-6<i>a</i>,11<i>a</i>-(epoxymethano)-3,3<i>a</i>1-ethanophenanthro[1,10-<i>de</i>][1,3]dioxin-14-one (<b>24</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>13</b>. A mixture of compound <b>23</b> (1.4 mmol), lithium carbonate (14 mmol), and lithium bromide (14 mmol) in 25 mL of DMF was heated below 110 °C for 2 h. Then, we filtered off the inorganic precipitate, washed the precipitate with EtOAc, and collected the filtrate. The filtrate was diluted with 400 mL of water, extracted with EtOAc (25 mL × 5), and then washed with brine. The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated <i>in vacuo</i>. Compound <b>24</b> was synthesized as a colorless oil without any further purification.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (6<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>bS</i>,14<i>R</i>)-6,14-Dihydroxy-4,4-dimethyl-8-methylenedecahydro-1<i>H</i>-6,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-7(8<i>H</i>)-one (<b>25</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>14</b>. Compound <b>24</b> (2.1 mmol) was dissolved in 10 mL of THF, and 6 mL of 10% HCl was added and stirred at room temperature for 30 min. Then, the mixture was diluted with water and extracted with dichloromethane. The extract was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was subjected to column chromatography (silica gel, EtOAc/petroleum ether, 1:4 to 1:2).Compound <b>25</b> was synthesized as a white powder (yield 58% from <b>22</b>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 6.43 (s, 1H), 5.99 (d, <i>J</i> = 1.5 Hz, 1H), 5.86 (s, 1H), 5.44 (s, 1H), 4.70 (s, 1H), 4.06–4.01 (m, 1H), 3.81 (d, <i>J</i> = 9.3 Hz, 1H), 2.83 (dd, <i>J</i> = 16.3, 8.8 Hz, 2H), 2.45–2.31 (m, 1H), 1.62 (dd, <i>J</i> = 20.5, 12.1 Hz, 1H), 1.47 (dd, <i>J</i> = 13.2, 6.7 Hz, 3H), 1.41–1.29 (m, 3H), 1.28–1.09 (m, 4H), 1.02 (s, 3H), 0.96–0.85 (m, 1H), 0.81 (s, 3H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 202.9, 152.3, 117.0, 96.9, 72.3, 65.3, 58.3, 51.7, 47.9, 41.9, 40.3, 35.2, 33.4, 32.1, 31.0, 29.8, 20.4, 18.2, 15.6; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>20</sub>H<sub>29</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 333.2060; found, 333.2060.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (4<i>aR</i>,5<i>S</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,12<i>R</i>)-11<i>b</i>-(Acetoxymethyl)-4,4-dimethyl-8-methylene-6,7-dioxotetradecahydro-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalene-5,12-diyl Diacetate (<b>26</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>19</b>. Compound <b>25</b> (0.5 mmol) and <i>p</i>-toluenesulfonic acid (0.6 mmol) were dissolved in 5 mL of acetic anhydride; then, the solution was heated below 40 °C and stirred for 2 h. The reaction solution was diluted with saturated sodium bicarbonate solution and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (silica gel, EtOAc/petroleum ether, 1:4). Compound <b>26</b> was synthesized as a white powder (yield 83%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 6.13 (s, 1H), 5.54 (s, 1H), 5.42 (s, 1H), 4.64 (d, <i>J</i> = 12.7 Hz, 1H), 4.47 (d, <i>J</i> = 12.6 Hz, 1H), 3.01 (s, 1H), 2.61–2.36 (m, 2H), 2.24 (s, 1H), 2.14–1.97 (m, 4H), 1.92 (s, 4H), 1.73 (s, 2H), 1.47 (dd, <i>J</i> = 40.7, 17.5 Hz, 5H), 1.17 (d, <i>J</i> = 11.7 Hz, 2H), 0.84 (d, <i>J</i> = 10.6 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 205.7, 201.5, 171.0, 170.7, 146.6, 119.0, 75.7, 68.1, 63.2, 55.4, 51.0, 43.0, 41.4, 40.7, 38.3, 35.5, 33.2, 32.8, 30.9, 29.7, 21.2, 21.1, 18.4, 17.4; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>32</sub>NaO<sub>6</sub> [M + Na]<sup>+</sup>, 439.2091; found, 439.2090.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (3<i>S</i>,3<i>aR</i>,3<i>a</i>1<i>R</i>,6<i>aR</i>,7<i>S</i>,7<i>aR</i>,11<i>S</i>,11<i>aS</i>,11<i>bS</i>)-7-Hydroxy-5,5,8,8-tetramethyl-15-methylene-14-oxodecahydro-2<i>H</i>-6<i>a</i>,11<i>a</i>-(epoxymethano)-3,3<i>a</i>1-ethanophenanthro[1,10-<i>de</i>][1,3]dioxin-11-yl 2,2,2-Trifluoroacetate (<b>27</b>)</h4><div class="NLM_p last">To a solution of <b>8</b> (383 mg, 0.9 mmol) in anhydrous dichloromethane (12 mL) were added TEA (197 μL, 1.4 mmol) and trifluoroacetic anhydride (200 μL, 1.4 mmol). The solution was stirred at room temperature for 5 h. Then, the reaction solution was quenched with saturated NaHCO<sub>3</sub>, extracted with EtOAc, evaporated <i>in vacuo</i>, and purified by silica gel column chromatography (EtOAc/petroleum ether, 1:6) to afford <b>27</b> (426 mg, 90%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 6.21 (s, 1H), 5.86 (d, <i>J</i> = 11.8 Hz, 1H), 5.62 (s, 1H), 4.92–4.76 (m, 2H), 4.24 (s, 2H), 3.98 (dd, <i>J</i> = 11.8, 7.4 Hz, 1H), 3.11 (d, <i>J</i> = 9.2 Hz, 1H), 2.54 (ddd, <i>J</i> = 14.6, 7.7, 5.0 Hz, 1H), 1.88 (dt, <i>J</i> = 6.3, 5.9 Hz, 3H), 1.76–1.54 (m, 6H), 1.45–1.36 (m, 5H), 1.29 (s, 1H), 1.24 (d, <i>J</i> = 3.1 Hz, 6H).</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (1<i>S</i>,4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bS</i>,14<i>R</i>)-14-Hydroxy-4,4-dimethyl-8-methylene-6,7-dioxododecahydro-1<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-1-yl 2,2,2-Trifluoroacetate (<b>28</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>15</b>. Compound <b>27</b> (0.51 mmol) was dissolved in 5 mL of anhydrous dichloromethane and degassed with argon three times; then, the solution was cooled to −20 °C. DAST (1.3 mmol) was dissolved in 200 μL of anhydrous dichloromethane and added dropwise into the solution, and the mixture solution was stirred for 10 min and then was quenched by dropping ice water. The resulting solution was extracted with dichloromethane and concentrated. The residue was subjected to column chromatography (silica gel, EtOAc/petroleum ether, 1:2). Compound <b>28</b> was synthesized as a white powder (yield 70%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 6.18 (s, 1H), 5.58 (s, 1H), 5.12 (dd, <i>J</i> = 11.0, 6.2 Hz, 1H), 4.63 (s, 1H), 4.32–4.11 (m, 3H), 3.17 (d, <i>J</i> = 8.7 Hz, 1H), 2.54–2.37 (m, 1H), 2.26 (dd, <i>J</i> = 11.7, 6.3 Hz, 1H), 2.11 (ddt, <i>J</i> = 12.9, 6.3, 3.3 Hz, 1H), 1.98 (s, 1H), 1.89–1.73 (m, 2H), 1.72–1.57 (m, 2H), 1.49 (dd, <i>J</i> = 14.1, 2.3 Hz, 1H), 1.39–1.24 (m, 2H), 1.10 (d, <i>J</i> = 9.7 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 204.4, 203.2, 148.8, 120.4, 82.6, 82.3, 73.5, 67.9, 65.1, 55.5, 52.7, 51.1, 43.7, 36.7, 32.1, 30.8, 29.1, 24.1, 22.3, 18.9.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (1<i>S</i>,4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bS</i>,14<i>R</i>)-1,14-Dihydroxy-4,4-dimethyl-8-methylenedecahydro-6<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalene-6,7(8<i>H</i>)-dione (<b>29</b>)</h4><div class="NLM_p last">To a solution of <b>28</b> (300 mg, 0.68 mmol) in dichloromethane (12 mL) were added NaOH (0.5 N, 1.76 mL, 0.88 mmol) and tetrabutylammonium bromide (TBAB; 30 mg). The solution was stirred at room temperature for 15 min. Then, the reaction solution was extracted with EtOAc, evaporated <i>in vacuo</i>, and purified by silica gel column chromatography (EtOAc/petroleum ether, 1:6) to afford <b>29</b> (176 mg, 75%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 5.91 (s, 1H), 5.44 (s, 1H), 5.23 (d, <i>J</i> = 3.0 Hz, 1H), 4.79 (d, <i>J</i> = 4.6 Hz, 1H), 4.57 (s, 1H), 4.15–3.95 (m, 3H), 3.72–3.59 (m, 1H), 2.98 (s, 1H), 2.14 (dd, <i>J</i> = 13.7, 6.9 Hz, 1H), 2.02–1.95 (m, 1H), 1.62 (dd, <i>J</i> = 12.4, 7.9 Hz, 3H), 1.50–1.22 (m, 5H), 0.97 (s, 3H), 0.89 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 203.5, 202.3, 149.3, 117.2, 84.7, 74.4, 72.3, 69.9, 68.5, 59.0, 54.7, 54.2, 45.3, 37.2, 32.6, 31.6, 30.6, 29.1, 22.2, 18.9; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>20</sub>H<sub>26</sub>NaO<sub>5</sub> [M + Na]<sup>+</sup>, 369.1672; found, 369.1676.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl acetate (<b>30</b>)</h4><div class="NLM_p last">To a solution of compound <b>20</b> (50 mg, 0.15 mmol) in 10 mL of anhydrous dichloromethane were added DMAP (catalytic amount), acetic anhydride (0.03 mL), and TEA (0.1 mL). The resulting solution was stirred at room temperature for 3 h. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i> to yield crude colorless oil. The residue was subjected to column chromatography (petroleum ether/EtOAc 8:1, v/v) to obtain compound <b>30</b> (44.5 mg, 78%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.20 (s, 1H), 6.05 (s, 1H), 5.78–5.65 (m, 1H), 5.58 (d, <i>J</i> = 13.6 Hz, 2H), 5.38 (s, 1H), 4.28–4.16 (m, 2H), 3.74 (d, <i>J</i> = 8.9 Hz, 1H), 3.10 (d, <i>J</i> = 7.7 Hz, 1H), 2.43 (dd, <i>J</i> = 16.9, 7.8 Hz, 1H), 2.06 (t, <i>J</i> = 8.0 Hz, 1H), 1.92 (s, 4H), 1.87–1.81 (m, 1H), 1.68 (dd, <i>J</i> = 19.5, 9.9 Hz, 3H), 0.97 (d, <i>J</i> = 3.2 Hz, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 202.8, 199.9, 170.0, 147.6, 128.7, 123.6, 118.8, 82.7, 75.6, 72.1, 65.2, 56.4, 51.4, 50.3, 42.2, 39.6, 30.4, 30.1, 22.9, 21.0, 17.8; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>27</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 371.1853; found, 371.1851.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl Cyclopropanecarboxylate (<b>31</b>)</h4><div class="NLM_p last">To a solution of compound <b>20</b> (50 mg, 0.15 mmol) in 10 mL of anhydrous dichloromethane were added 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (EDCI; 30 mg, 0.16 mmol), DMAP (catalytic amount), and cyclopropanecarboxylic acid (17 mg, 0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v), and <b>31</b> was obtained as a white solid (25 mg, 41%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 6.13 (s, 1H), 5.80 (ddd, <i>J</i> = 10.2, 5.9, 1.9 Hz, 1H), 5.72–5.60 (m, 2H), 5.46 (s, 1H), 4.32 (s, 1H), 4.27 (d, <i>J</i> = 9.1 Hz, 1H), 3.81 (d, <i>J</i> = 9.2 Hz, 1H), 3.19 (d, <i>J</i> = 7.3 Hz, 1H), 2.56–2.40 (m, 1H), 2.13 (t, <i>J</i> = 8.1 Hz, 1H), 2.07–1.85 (m, 3H), 1.79 (d, <i>J</i> = 4.9 Hz, 1H), 1.77–1.68 (m, 2H), 1.55 (ddd, <i>J</i> = 12.7, 8.1, 4.6 Hz, 1H), 1.04 (d, <i>J</i> = 4.1 Hz, 6H), 0.99–0.76 (m, 4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 202.9, 199.7, 173.8, 147.6, 128.7, 123.6, 118.74, 82.7, 75.5, 72.1, 65.2, 56.5, 51.5, 50.4, 42.2, 39.6, 30.4, 30.0, 22.9, 17.7, 13.1, 9.0, 8.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>29</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 397.2010; found, 397.2013.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl Cyclohexanecarboxylate (<b>32</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and cyclohexanecarboxylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>32</b> was prepared from compound <b>20</b> as a white solid (yield 42%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 6.16 (s, 1H), 5.84 (ddd, <i>J</i> = 10.0, 5.8, 1.9 Hz, 1H), 5.76–5.61 (m, 2H), 5.48 (s, 1H), 4.41–4.25 (m, 2H), 3.85 (d, <i>J</i> = 9.1 Hz, 1H), 3.19 (d, <i>J</i> = 7.2 Hz, 1H), 2.61–2.45 (m, 1H), 2.31–2.16 (m, 2H), 1.97 (dd, <i>J</i> = 15.2, 9.4 Hz, 3H), 1.88–1.68 (m, 8H), 1.40–1.26 (m, 5H), 1.08 (d, <i>J</i> = 2.8 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.9, 199.8, 175.0, 147.5, 128.7, 123.6, 118.6, 82.8, 75.3, 72.1, 65.3, 56.7, 51.5, 50.4, 42.8, 42.3, 39.6, 30.4, 30.0, 28.6, 25.6, 25.3, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>27</sub>H<sub>35</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 439.2479; found, 439.2478.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl 3-Methylbut-2-enoate (<b>33</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and 3-methylbut-2-enoic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>33</b> was prepared from compound <b>20</b> as a white solid (yield 35%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 6.11 (s, 1H), 5.86–5.75 (m, 1H), 5.74–5.57 (m, 3H), 5.43 (s, 1H), 4.29 (d, <i>J</i> = 9.6 Hz, 2H), 3.82 (d, <i>J</i> = 9.0 Hz, 1H), 3.18 (d, <i>J</i> = 7.2 Hz, 1H), 2.49 (d, <i>J</i> = 8.2 Hz, 1H), 2.32 (d, <i>J</i> = 7.6 Hz, 1H), 2.12 (d, <i>J</i> = 7.8 Hz, 3H), 1.94 (d, <i>J</i> = 13.2 Hz, 2H), 1.77 (d, <i>J</i> = 16.2 Hz, 3H), 1.26 (d, <i>J</i> = 8.5 Hz, 4H), 1.03 (s, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 203.0, 199.9, 165.2, 158.6, 147.6, 128.7, 123.6, 118.7, 115.5, 82.8, 75.0, 72.2, 65.4, 56.7, 51.5, 50.4, 42.4, 39.6, 30.4, 30.0, 29.7, 27.5, 22.9, 20.4, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>31</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 411.2166; found, 411.2166.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl Benzoate (<b>34</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and benzoic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>34</b> was prepared from compound <b>20</b> as a white solid (yield 78%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.97 (d, <i>J</i> = 8.2 Hz, 2H), 7.52 (t, <i>J</i> = 7.3 Hz, 1H), 7.38 (t, <i>J</i> = 7.5 Hz, 2H), 6.14 (s, 1H), 5.89–5.76 (m, 2H), 5.67 (d, <i>J</i> = 10.4 Hz, 1H), 5.44 (s, 1H), 4.31 (d, <i>J</i> = 7.5 Hz, 2H), 3.83 (d, <i>J</i> = 9.1 Hz, 1H), 3.36 (d, <i>J</i> = 7.1 Hz, 1H), 2.56 (dd, <i>J</i> = 16.7, 8.5 Hz, 1H), 2.19 (t, <i>J</i> = 8.0 Hz, 1H), 2.07–1.86 (m, 3H), 1.83–1.70 (m, 3H), 1.03 (d, <i>J</i> = 3.2 Hz, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 203.0, 199.6, 165.4, 147.4, 133.3, 130.2, 130.0, 128.8, 128.4, 123.5, 118.9, 82.8, 72.2, 65.4, 56.8, 51.6, 50.6, 42.3, 39.6, 30.4, 30.1, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>27</sub>H<sub>29</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 433.2010; found, 433.2011.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl 4-Fluorobenzoate (<b>35</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and 4-fluorobenzoic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>35</b> was prepared from compound <b>20</b> as a white solid (yield 83%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.00 (dd, <i>J</i> = 8.7, 5.6 Hz, 2H), 7.07 (t, <i>J</i> = 8.6 Hz, 2H), 6.16 (s, 1H), 5.91–5.78 (m, 2H), 5.69 (dd, <i>J</i> = 10.3, 2.5 Hz, 1H), 5.47 (s, 1H), 4.32 (d, <i>J</i> = 8.2 Hz, 2H), 3.85 (d, <i>J</i> = 9.1 Hz, 1H), 3.37 (d, <i>J</i> = 7.3 Hz, 1H), 2.69–2.49 (m, 1H), 2.21 (t, <i>J</i> = 8.2 Hz, 1H), 2.09–1.96 (m, 2H), 1.95–1.76 (m, 4H), 1.06 (d, <i>J</i> = 5.1 Hz, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 202.8, 199.7, 166.0 (d, <i>J</i> = 254.3 Hz), 164.4, 147.4, 132.6 (d, <i>J</i> = 9.4 Hz), 128.8, 125.78 (d, <i>J</i> = 2.9 Hz), 123.5, 118.9, 115.5 (d, <i>J</i> = 22.2 Hz), 82.7, 72.2, 65.4, 56.7, 51.5, 50.5, 42.3, 39.6, 30.4, 30.4, 30.1, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>27</sub>H<sub>28</sub>FO<sub>5</sub> [M + H]<sup>+</sup>, 451.1915; found, 451.1910.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl 4-Chlorobenzoate (<b>36</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and 4-chlorobenzoic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>36</b> was prepared from compound <b>20</b> as a white solid (yield 88%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.78 (dd, <i>J</i> = 6.7, 1.8 Hz, 2H), 7.24 (dd, <i>J</i> = 6.8, 1.8 Hz, 2H), 6.03 (s, 1H), 5.78–5.59 (m, 2H), 5.55 (d, <i>J</i> = 10.2 Hz, 1H), 5.33 (s, 1H), 4.18 (d, <i>J</i> = 8.4 Hz, 2H), 3.72 (d, <i>J</i> = 9.1 Hz, 1H), 3.23 (d, <i>J</i> = 6.9 Hz, 1H), 2.54–2.31 (m, 1H), 2.13–1.98 (m, 1H), 1.93–1.80 (m, 2H), 1.76–1.61 (m, 3H), 1.50 (s, 1H), 0.92 (d, <i>J</i> = 5.5 Hz, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 202.8, 199.6, 164.5, 147.3, 139.8, 131.4, 128.9, 128.7, 128.0, 123.5, 119.0, 82.7, 72.2, 65.3, 56.6, 51.5, 50.5, 42.3, 39.6, 30.4, 30.1, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>27</sub>H<sub>28</sub>ClO<sub>5</sub> [M + H]<sup>+</sup>, 467.1620; found, 467.1619.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl 4-Methoxybenzoate (<b>37</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and 4-methoxybenzoic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>37</b> was prepared from compound <b>20</b> as a white solid (yield 72%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.82 (dd, <i>J</i> = 9.4, 2.5 Hz, 2H), 6.76 (dd, <i>J</i> = 9.4, 2.5 Hz, 2H), 6.03 (s, 1H), 5.80–5.65 (m, 2H), 5.64–5.51 (m, 1H), 5.32 (s, 1H), 4.20 (d, <i>J</i> = 7.2 Hz, 2H), 3.72 (d, <i>J</i> = 3.5 Hz, 4H), 3.25 (d, <i>J</i> = 6.9 Hz, 1H), 2.54–2.36 (m, 1H), 2.07 (dd, <i>J</i> = 19.0, 11.0 Hz, 1H), 1.99–1.85 (m, 2H), 1.83–1.71 (m, 2H), 1.70–1.57 (m, 2H), 0.93 (d, <i>J</i> = 4.6 Hz, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 203.1, 199.6, 165.1, 163.7, 147.5, 132.1, 128.8, 123.6, 122.0, 118.8, 113.6, 82.8, 76.3, 72.2, 65.4, 56.8, 55.4, 51.6, 50.6, 42.4, 39.6, 30.4, 30.1, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>31</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 463.2115; found, 463.2118.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl 4-(Methylsulfonyl)benzoate (<b>38</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and 4-(methylsulfonyl)benzoic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>38</b> was prepared from compound <b>20</b> as a white solid (yield 73%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.23–8.09 (m, 2H), 7.98 (d, <i>J</i> = 8.5 Hz, 2H), 6.18 (s, 1H), 5.89 (s, 1H), 5.86–5.76 (m, 1H), 5.68 (dd, <i>J</i> = 10.2, 2.4 Hz, 1H), 5.50 (s, 1H), 4.33 (d, <i>J</i> = 9.5 Hz, 2H), 3.85 (d, <i>J</i> = 9.1 Hz, 1H), 3.37 (d, <i>J</i> = 7.4 Hz, 1H), 3.05 (s, 3H), 2.68–2.52 (m, 1H), 2.22 (t, <i>J</i> = 8.3 Hz, 1H), 2.11–1.96 (m, 2H), 1.94–1.75 (m, 4H), 1.04 (d, <i>J</i> = 3.9 Hz, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 202.5, 199.8, 163.7, 147.2, 144.5, 134.3, 130.9, 128.9, 127.5, 123.4, 119.2, 82.6, 72.1, 65.2, 56.4, 51.5, 50.4, 44.3, 42.2, 39.6, 30.4, 30.1, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>31</sub>O<sub>7</sub>S [M + H]<sup>+</sup>, 511.1785; found, 511.1789.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl Isonicotinate (<b>39</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and isonicotinic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:4, v/v). Compound <b>39</b> was prepared from compound <b>20</b> as a white solid (yield 69%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.73 (d, <i>J</i> = 4.4 Hz, 2H), 7.78 (d, <i>J</i> = 4.4 Hz, 2H), 6.17 (s, 1H), 5.93–5.75 (m, 2H), 5.67 (d, <i>J</i> = 10.3 Hz, 1H), 5.48 (s, 1H), 4.31 (d, <i>J</i> = 7.3 Hz, 2H), 3.85 (d, <i>J</i> = 9.1 Hz, 1H), 3.35 (d, <i>J</i> = 7.0 Hz, 1H), 2.58 (dd, <i>J</i> = 17.2, 8.8 Hz, 1H), 2.21 (t, <i>J</i> = 7.8 Hz, 1H), 2.10–1.90 (m, 3H), 1.87–1.72 (m, 3H), 1.04 (d, <i>J</i> = 2.2 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.5, 199.6, 164.0, 150.6, 147.1, 136.6, 128.9, 123.4, 123.0, 119.2, 82.6, 77.2, 72.1, 65.2, 56.5, 51.5, 50.5, 42.2, 39.6, 30.4, 30.1, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>28</sub>NO<sub>5</sub> [M + H]<sup>+</sup>, 434.1962; found, 434.1961.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl Nicotinate (<b>40</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and nicotinic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:4, v/v). Compound <b>40</b> was prepared from compound <b>20</b> as a white solid (yield 65%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.66 (d, <i>J</i> = 35.1 Hz, 2H), 7.83 (d, <i>J</i> = 6.6 Hz, 1H), 7.64 (d, <i>J</i> = 16.0 Hz, 1H), 7.43–7.20 (m, 1H), 6.42 (dd, <i>J</i> = 16.1, 4.7 Hz, 1H), 6.16 (s, 1H), 5.79 (s, 2H), 5.68 (d, <i>J</i> = 7.8 Hz, 1H), 5.49 (s, 1H), 4.33 (d, <i>J</i> = 5.0 Hz, 2H), 3.85 (d, <i>J</i> = 8.7 Hz, 1H), 3.30 (d, <i>J</i> = 5.9 Hz, 1H), 2.55 (s, 1H), 2.17 (d, <i>J</i> = 5.7 Hz, 1H), 2.09–1.86 (m, 3H), 1.80 (dd, <i>J</i> = 16.0, 4.3 Hz, 2H), 1.39–0.98 (m, 7H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.8, 199.8, 165.0, 151.0, 149.9, 147.4, 142.2, 134.4, 128.8, 123.5, 119.6, 119.0, 82.7, 76.2, 72.1, 65.3, 56.5, 51.5, 50.4, 42.3, 39.6, 30.4, 30.1, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>28</sub>NO<sub>5</sub> [M + H]<sup>+</sup>, 434.1962; found, 434.1964.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl Picolinate (<b>41</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and picolinic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:4, v/v). Compound <b>41</b> was prepared from compound <b>20</b> as a white solid (yield 51%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.61 (d, <i>J</i> = 3.8 Hz, 1H), 7.66 (dd, <i>J</i> = 17.2, 11.6 Hz, 2H), 7.42 (d, <i>J</i> = 7.8 Hz, 1H), 6.82 (d, <i>J</i> = 15.7 Hz, 1H), 6.14 (s, 1H), 5.89–5.71 (m, 2H), 5.66 (d, <i>J</i> = 8.2 Hz, 1H), 5.45 (s, 1H), 4.31 (d, <i>J</i> = 10.1 Hz, 2H), 3.83 (d, <i>J</i> = 8.8 Hz, 1H), 3.28 (d, <i>J</i> = 7.1 Hz, 1H), 2.54 (dd, <i>J</i> = 16.5, 8.3 Hz, 1H), 2.22–2.12 (m, 1H), 2.03–1.89 (m, 2H), 1.76–1.59 (m, 2H), 1.30 (dd, <i>J</i> = 24.6, 10.2 Hz, 3H), 0.96 (d, <i>J</i> = 49.9 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.4, 199.1, 164.9, 152.3, 149.6, 147.0, 144.0, 136.1, 128.2, 123.8, 123.1, 121.1, 118.4, 82.2, 75.6, 64.8, 56.1, 51.0, 49.9, 41.8, 39.1, 29.9, 29.6, 22.4, 17.2; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>28</sub>NO<sub>5</sub> [M + H]<sup>+</sup>, 434.1962; found, 434.1963.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl Pyrazine-2-carboxylate (<b>42</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and pyrazine-2-carboxylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:2, v/v). Compound <b>42</b> was prepared from compound <b>20</b> as a white solid (yield 63%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 9.22 (d, <i>J</i> = 1.2 Hz, 1H), 8.80–8.68 (m, 2H), 6.18 (s, 1H), 5.94 (s, 1H), 5.83 (ddd, <i>J</i> = 10.1, 5.8, 1.8 Hz, 1H), 5.69 (dd, <i>J</i> = 10.4, 2.4 Hz, 1H), 5.50 (s, 1H), 4.33 (t, <i>J</i> = 4.5 Hz, 2H), 3.85 (d, <i>J</i> = 9.2 Hz, 1H), 3.44 (d, <i>J</i> = 7.6 Hz, 1H), 2.71–2.55 (m, 1H), 2.29–2.17 (m, 1H), 2.00 (ddd, <i>J</i> = 25.4, 10.9, 5.5 Hz, 3H), 1.88–1.75 (m, 3H), 1.05 (d, <i>J</i> = 4.6 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.5, 199.6, 162.5, 147.8, 146.9, 144.6, 128.9, 123.4, 119.5, 82.6, 72.1, 65.1, 56.3, 51.5, 50.4, 42.1, 39.5, 30.4, 30.0, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>27</sub>N<sub>2</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 435.1914; found, 435.1916.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl Pyrimidine-4-carboxylate (<b>43</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and pyrimidine-4-carboxylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>43</b> was prepared from compound <b>20</b> as a white solid (yield 47%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 9.39 (d, <i>J</i> = 1.2 Hz, 1H), 8.95 (d, <i>J</i> = 5.0 Hz, 1H), 7.95 (dd, <i>J</i> = 5.0, 1.4 Hz, 1H), 6.17 (s, 1H), 5.91–5.78 (m, 2H), 5.68 (dd, <i>J</i> = 10.2, 2.6 Hz, 1H), 5.49 (s, 1H), 4.41–4.21 (m, 2H), 3.85 (d, <i>J</i> = 9.2 Hz, 1H), 3.44 (d, <i>J</i> = 7.6 Hz, 1H), 2.70–2.55 (m, 1H), 2.23 (t, <i>J</i> = 8.4 Hz, 1H), 2.10–1.91 (m, 3H), 1.88–1.77 (m, 3H), 1.05 (d, <i>J</i> = 6.0 Hz, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 202.4, 199.8, 162.2, 159.5, 159.3, 154.0, 146.8, 129.0, 123.3, 121.6, 119.6, 82.5, 78.1, 72.1, 65.0, 56.4, 51.5, 50.4, 42.0, 39.5, 30.4, 30.0, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>27</sub>N<sub>2</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 435.1914; found, 435.1914.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl Quinoline-6-carboxylate (<b>44</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and quinoline-6-carboxylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>44</b> was prepared from compound <b>20</b> as a white solid (yield 53%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.97 (dd, <i>J</i> = 4.2, 1.7 Hz, 1H), 8.51 (d, <i>J</i> = 1.7 Hz, 1H), 8.34–8.19 (m, 2H), 8.09 (d, <i>J</i> = 8.8 Hz, 1H), 7.44 (dd, <i>J</i> = 8.3, 4.3 Hz, 1H), 6.17 (s, 1H), 5.89 (s, 1H), 5.81 (ddd, <i>J</i> = 10.1, 5.9, 1.8 Hz, 1H), 5.67 (dd, <i>J</i> = 10.3, 2.3 Hz, 1H), 5.48 (s, 1H), 4.33 (t, <i>J</i> = 4.6 Hz, 2H), 3.84 (d, <i>J</i> = 9.0 Hz, 1H), 3.41 (d, <i>J</i> = 7.2 Hz, 1H), 2.69–2.50 (m, 1H), 2.21 (t, <i>J</i> = 7.9 Hz, 1H), 1.99 (s, 2H), 1.93–1.74 (m, 4H), 1.03 (d, <i>J</i> = 4.8 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.9, 199.8, 164.9, 152.6, 150.1, 147.3, 137.6, 131.6, 129.7, 129.1, 128.8, 127.4, 123.4, 121.7, 119.1, 82.7, 72.1, 65.3, 56.6, 51.5, 50.5, 42.3, 39.5, 30.4, 30.1, 22.9, 17.70; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>31</sub>O<sub>7</sub>S [M + H]<sup>+</sup>, 484.2118; found, 484.2119.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl 3-Phenylpropanoate (<b>45</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and 3-phenylpropanoic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>45</b> was prepared from compound <b>20</b> as a white solid (yield 78%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.33–7.23 (m, 3H), 7.19–7.16 (m, 2H), 6.11 (s, 1H), 5.82 (ddd, <i>J</i> = 10.2, 6.0, 2.0 Hz, 1H), 5.72–5.63 (m, 2H), 5.41 (s, 1H), 4.36–4.26 (m, 2H), 3.83 (dd, <i>J</i> = 9.1, 1.0 Hz, 1H), 3.11 (d, <i>J</i> = 7.5 Hz, 1H), 2.90 (t, <i>J</i> = 7.7 Hz, 2H), 2.67–2.45 (m, 3H), 2.19–2.11 (m, 1H), 2.05–1.86 (m, 3H), 1.82 (s, 1H), 1.72 (ddd, <i>J</i> = 13.2, 8.6, 2.6 Hz, 2H), 1.07 (d, <i>J</i> = 4.1 Hz, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 202.7, 199.7, 171.8, 147.5, 140.3, 128.6, 128.3, 128.3, 126.1, 123.6, 118.7, 82.6, 75.6, 72.0, 65.1, 56.3, 51.4, 50.3, 42.1, 39.6, 35.6, 30.4, 30.4, 30.0, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>29</sub>H<sub>33</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 461.2323; found, 461.2320.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl Cinnamate (<b>46</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and cinnamic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>46</b> was prepared from compound <b>20</b> as a white solid (yield 84%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.64 (d, <i>J</i> = 16.0 Hz, 1H), 7.48 (d, <i>J</i> = 2.9 Hz, 2H), 7.35 (s, 3H), 6.35 (d, <i>J</i> = 16.0 Hz, 1H), 6.14 (s, 1H), 5.84–5.72 (m, 2H), 5.66 (d, <i>J</i> = 10.3 Hz, 1H), 5.46 (s, 1H), 4.31 (d, <i>J</i> = 9.7 Hz, 2H), 3.82 (d, <i>J</i> = 9.0 Hz, 1H), 3.28 (d, <i>J</i> = 7.1 Hz, 1H), 2.54 (dd, <i>J</i> = 16.9, 8.7 Hz, 1H), 2.16 (t, <i>J</i> = 7.6 Hz, 1H), 1.95 (dd, <i>J</i> = 30.3, 11.5 Hz, 3H), 1.76 (dd, <i>J</i> = 15.1, 9.6 Hz, 3H), 1.04 (s, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.8, 199.6, 165.6, 147.5, 145.9, 134.2, 130.4, 128.8, 128.2, 123.6, 118.8, 117.3, 82.7, 75.9, 72.1, 65.3, 56.5, 51.5, 50.4, 42.3, 39.6, 30.4, 30.0, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>29</sub>H<sub>31</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 459.2166; found, 459.2165.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-Phenylbut-2-enoate (<b>47</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-phenylbut-2-enoic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>47</b> was prepared from compound <b>20</b> as a white solid (yield 73%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.41–7.34 (m, 2H), 7.30–7.24 (m, 3H), 6.07 (s, 1H), 5.99 (d, <i>J</i> = 1.2 Hz, 1H), 5.76–5.69 (m, 2H), 5.60 (dd, <i>J</i> = 10.4, 2.4 Hz, 1H), 5.39 (s, 1H), 4.25 (d, <i>J</i> = 8.9 Hz, 2H), 3.78 (d, <i>J</i> = 8.7 Hz, 1H), 3.18 (d, <i>J</i> = 7.2 Hz, 1H), 2.44 (t, <i>J</i> = 6.7 Hz, 4H), 2.14–2.02 (m, 1H), 1.86 (dd, <i>J</i> = 14.8, 8.9 Hz, 3H), 1.67 (ddd, <i>J</i> = 18.1, 10.0, 5.0 Hz, 3H), 0.97 (s, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 202.8, 199.7, 165.4, 147.6, 141.9, 129.1, 128.7, 128.4, 126.4, 123.6, 118.7, 116.4, 82.8, 75.4, 72.2, 65.4, 56.6, 51.5, 42.4, 39.6, 30.4, 30.1, 22.9, 18.1, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>30</sub>H<sub>33</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 473.2323; found, 473.2323.</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-(4-Fluorophenyl)acrylate (<b>48</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-(4-fluorophenyl)acrylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>48</b> was prepared from compound <b>20</b> as a white solid (yield 84%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.61 (d, <i>J</i> = 16.1 Hz, 1H), 7.54–7.43 (m, 2H), 7.05 (t, <i>J</i> = 8.6 Hz, 2H), 6.28 (d, <i>J</i> = 16.0 Hz, 1H), 6.15 (s, 1H), 5.87–5.73 (m, 2H), 5.67 (dd, <i>J</i> = 10.3, 2.5 Hz, 1H), 5.47 (s, 1H), 4.32 (d, <i>J</i> = 10.7 Hz, 2H), 3.84 (d, <i>J</i> = 9.0 Hz, 1H), 3.29 (d, <i>J</i> = 7.3 Hz, 1H), 2.61–2.47 (m, 1H), 2.18 (t, <i>J</i> = 8.2 Hz, 1H), 2.08–1.89 (m, 3H), 1.81–1.65 (m, 3H), 1.05 (d, <i>J</i> = 3.2 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.9, 199.8, 165.6, 162.3, 146.1 (d, <i>J</i> = 212.0 Hz), 130.5, 130.5, 130.2 (d, <i>J</i> = 8.6 Hz), 128.8, 123.6, 118.9, 117.2, 117.2, 116.0 (d, <i>J</i> = 21.9 Hz), 82.7, 76.0, 72.2, 65.4, 56.6, 51.5, 50.5, 42.3, 39.6, 30.4, 30.1, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>29</sub>H<sub>30</sub>FO<sub>5</sub> [M + H]<sup>+</sup>, 477.2072; found, 477.2075.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-(4-Chlorophenyl)acrylate (<b>49</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-(4-chlorophenyl)acrylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>49</b> was prepared from compound <b>20</b> as a white solid (yield 89%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.01 (d, <i>J</i> = 7.4 Hz, 2H), 7.56 (t, <i>J</i> = 7.4 Hz, 1H), 7.43 (t, <i>J</i> = 7.5 Hz, 2H), 6.19 (s, 1H), 5.92–5.80 (m, 2H), 5.71 (d, <i>J</i> = 10.2 Hz, 1H), 5.48 (s, 1H), 4.35 (d, <i>J</i> = 7.8 Hz, 2H), 3.88 (d, <i>J</i> = 9.1 Hz, 1H), 3.40 (d, <i>J</i> = 7.1 Hz, 1H), 2.61 (dd, <i>J</i> = 16.5, 8.5 Hz, 1H), 2.24 (t, <i>J</i> = 8.0 Hz, 1H), 2.11–1.92 (m, 3H), 1.89–1.68 (m, 4H), 1.08 (d, <i>J</i> = 3.3 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.9, 199.7, 165.3, 147.3, 133.2, 129.9, 129.4, 128.8, 128.3, 123.4, 118.9, 82.7, 72.1, 65.3, 56.7, 51.5, 50.5, 42.3, 39.6, 30.4, 30.0, 22.9, 17.6; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>29</sub>H<sub>30</sub>ClO<sub>5</sub> [M + H]<sup>+</sup>, 493.1776; found, 493.1776.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-(4-methoxyphenyl)acrylate (<b>50</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-(4-methoxyphenyl)acrylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>50</b> was prepared from compound <b>20</b> as a white solid (yield 70%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.59 (d, <i>J</i> = 15.9 Hz, 1H), 7.43 (d, <i>J</i> = 8.7 Hz, 2H), 6.85 (d, <i>J</i> = 8.8 Hz, 2H), 6.28–6.09 (m, 2H), 5.86–5.71 (m, 2H), 5.65 (dd, <i>J</i> = 10.4, 2.4 Hz, 1H), 5.45 (s, 1H), 4.30 (d, <i>J</i> = 10.5 Hz, 2H), 3.82 (d, <i>J</i> = 7.5 Hz, 4H), 3.27 (d, <i>J</i> = 7.1 Hz, 1H), 2.61–2.42 (m, 1H), 2.15 (t, <i>J</i> = 8.0 Hz, 1H), 2.02–1.90 (m, 2H), 1.80–1.70 (m, 2H), 1.03 (d, <i>J</i> = 3.0 Hz, 6H), 0.91 (dd, <i>J</i> = 9.8, 5.0 Hz, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 203.0, 199.8, 166.0, 161.4, 147.5, 145.7, 130.0, 128.7, 127.0, 123.6, 118.8, 114.8, 114.2, 82.7, 75.8, 72.1, 65.4, 56.6, 55.3, 51.5, 50.4, 42.3, 39.6, 30.4, 30.0, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>30</sub>H<sub>33</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 489.2272; found, 489.2270.</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-(Furan-3-yl)acrylate (<b>51</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-(furan-3-yl)acrylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>51</b> was prepared from compound <b>20</b> as a white solid (yield 67%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.41 (dd, <i>J</i> = 25.7, 8.6 Hz, 2H), 6.62 (d, <i>J</i> = 3.4 Hz, 1H), 6.44 (dd, <i>J</i> = 3.4, 1.8 Hz, 1H), 6.27–6.10 (m, 2H), 5.81 (ddd, <i>J</i> = 10.1, 5.8, 1.9 Hz, 1H), 5.74 (s, 1H), 5.67 (dd, <i>J</i> = 10.2, 2.5 Hz, 1H), 5.46 (s, 1H), 4.37–4.23 (m, 2H), 3.83 (d, <i>J</i> = 8.9 Hz, 1H), 3.28 (d, <i>J</i> = 7.3 Hz, 1H), 2.59–2.45 (m, 1H), 2.16 (t, <i>J</i> = 8.1 Hz, 1H), 2.06–1.88 (m, 3H), 1.84–1.72 (m, 3H), 1.04 (d, <i>J</i> = 3.1 Hz, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 203.0, 199.7, 165.6, 150.8, 147.4, 144.9, 132.1, 128.7, 123.5, 118.9, 115.3, 115.0, 112.3, 82.7, 75.9, 72.1, 65.3, 56.6, 51.5, 50.4, 42.2, 39.6, 30.4, 30.0, 22.9, 17.6; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>27</sub>H<sub>29</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 449.1959; found, 449.1956.</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-(Thiophen-3-yl)acrylate (<b>52</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-(thiophen-3-yl)acrylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>52</b> was prepared from compound <b>20</b> as a white solid (yield 79%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.41 (dd, <i>J</i> = 25.7, 8.6 Hz, 2H), 6.62 (d, <i>J</i> = 3.4 Hz, 1H), 6.44 (dd, <i>J</i> = 3.4, 1.8 Hz, 1H), 6.27–6.10 (m, 2H), 5.81 (ddd, <i>J</i> = 10.1, 5.8, 1.9 Hz, 1H), 5.74 (s, 1H), 5.67 (dd, <i>J</i> = 10.2, 2.5 Hz, 1H), 5.46 (s, 1H), 4.37–4.23 (m, 2H), 3.83 (d, <i>J</i> = 8.9 Hz, 1H), 3.28 (d, <i>J</i> = 7.3 Hz, 1H), 2.59–2.45 (m, 1H), 2.16 (t, <i>J</i> = 8.1 Hz, 1H), 2.06–1.88 (m, 3H), 1.84–1.72 (m, 3H), 1.04 (d, <i>J</i> = 3.1 Hz, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 203.0, 199.7, 165.6, 150.8, 147.4, 144.9, 132.1, 128.7, 123.5, 118.9, 115.3, 115.0, 112.3, 82.7, 75.9, 72.1, 65.3, 56.6, 51.5, 50.4, 42.2, 39.6, 30.4, 30.0, 22.9, 17.6; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>27</sub>H<sub>29</sub>O<sub>5</sub>S [M + H]<sup>+</sup>, 465.1730; found, 465.1731.</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-(Naphthalen-2-yl)acrylate (<b>53</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-(naphthalen-2-yl)acrylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>53</b> was prepared from compound <b>20</b> as a white solid (yield 77%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.83 (s, 1H), 7.79–7.67 (m, 4H), 7.54 (d, <i>J</i> = 8.6 Hz, 1H), 7.46–7.36 (m, 2H), 6.38 (d, <i>J</i> = 15.9 Hz, 1H), 6.08 (s, 1H), 5.73 (d, <i>J</i> = 12.1 Hz, 2H), 5.58 (d, <i>J</i> = 10.2 Hz, 1H), 5.39 (s, 1H), 4.25 (d, <i>J</i> = 13.9 Hz, 2H), 3.76 (d, <i>J</i> = 8.9 Hz, 1H), 3.23 (d, <i>J</i> = 7.0 Hz, 1H), 2.47 (dd, <i>J</i> = 16.8, 8.5 Hz, 1H), 2.10 (t, <i>J</i> = 7.8 Hz, 1H), 1.88 (dd, <i>J</i> = 31.3, 11.3 Hz, 3H), 1.77–1.64 (m, 3H), 0.96 (s, 6H); <sup>13</sup>C NMR (75 MHz): δ 202.7, 199.5, 165.5, 147.3, 145.8, 134.1, 133.0, 131.6, 130.1, 128.5, 128.4, 127.5, 127.0, 126.4, 123.4, 118.6, 117.3, 82.5, 75.8, 71.9, 65.2, 56.4, 51.3, 50.2, 42.1, 39.4, 30.2, 29.9, 22.7, 17.5; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>33</sub>H<sub>33</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 509.2323; found, 509.2324.</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-(Benzo[<i>d</i>][1,3]dioxol-5-yl)acrylate (<b>54</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-(benzo[<i>d</i>][1,3]dioxol-5-yl)acrylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>54</b> was prepared from compound <b>20</b> as a white solid (yield 56%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.55 (d, <i>J</i> = 15.9 Hz, 1H), 7.05–6.92 (m, 2H), 6.78 (d, <i>J</i> = 8.6 Hz, 1H), 6.17 (d, <i>J</i> = 15.8 Hz, 2H), 5.99 (d, <i>J</i> = 3.2 Hz, 2H), 5.86–5.72 (m, 2H), 5.67 (dd, <i>J</i> = 10.2, 2.6 Hz, 1H), 5.46 (s, 1H), 4.31 (d, <i>J</i> = 10.8 Hz, 2H), 3.84 (d, <i>J</i> = 9.1 Hz, 1H), 3.28 (d, <i>J</i> = 7.2 Hz, 1H), 2.63–2.44 (m, 1H), 2.17 (t, <i>J</i> = 8.2 Hz, 1H), 2.12–1.88 (m, 3H), 1.82–1.70 (m, 3H), 1.04 (d, <i>J</i> = 3.2 Hz, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 203.0, 199.8, 165.9, 149.7, 148.2, 147.5, 145.7, 128.7, 124.8, 123.6, 118.9, 115.2, 108.4, 106.6, 101.5, 82.7, 75.9, 72.1, 65.4, 56.6, 51.5, 50.4, 42.3, 39.6, 30.4, 30.0, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>30</sub>H<sub>31</sub>O<sub>7</sub> [M + H]<sup>+</sup>, 503.2064; found, 503.2062.</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-(Benzofuran-5-yl)acrylate (<b>55</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-(benzofuran-5-yl)acrylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>55</b> was prepared from compound <b>20</b> as a white solid (yield 58%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.89–7.74 (m, 2H), 7.68 (d, <i>J</i> = 2.2 Hz, 1H), 7.52 (d, <i>J</i> = 0.9 Hz, 2H), 6.82 (d, <i>J</i> = 2.2 Hz, 1H), 6.39 (d, <i>J</i> = 16.0 Hz, 1H), 6.21 (s, 1H), 5.93–5.80 (m, 2H), 5.76–5.66 (m, 1H), 5.52 (s, 1H), 4.37 (d, <i>J</i> = 11.1 Hz, 2H), 3.89 (d, <i>J</i> = 9.3 Hz, 1H), 3.35 (d, <i>J</i> = 7.2 Hz, 1H), 2.65–2.52 (m, 1H), 2.23 (t, <i>J</i> = 8.3 Hz, 1H), 2.02 (dt, <i>J</i> = 17.0, 7.4 Hz, 3H), 1.87–1.74 (m, 3H), 1.09 (d, <i>J</i> = 2.8 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 203.0, 199.8, 165.9, 156.1, 147.5, 146.4, 145.9, 129.3, 127.9, 124.4, 123.5, 122.0, 118.9, 116.1, 111.8, 106.8, 82.7, 75.9, 72.1, 65.4, 56.6, 51.5, 50.4, 42.3, 39.6, 30.4, 30.0, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>31</sub>H<sub>31</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 499.2115; found, 499.2113.</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-(Pyridin-4-yl)acrylate (<b>56</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-(pyridin-4-yl)acrylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:2, v/v). Compound <b>56</b> was prepared from compound <b>20</b> as a white solid (yield 62%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.65 (s, 1H), 7.65–7.44 (m, 1H), 7.29 (t, <i>J</i> = 16.5 Hz, 2H), 6.50 (dd, <i>J</i> = 15.9, 8.0 Hz, 1H), 6.15 (d, <i>J</i> = 7.7 Hz, 1H), 5.80 (d, <i>J</i> = 8.1 Hz, 2H), 5.67 (d, <i>J</i> = 7.7 Hz, 1H), 5.47 (d, <i>J</i> = 8.2 Hz, 1H), 4.31 (d, <i>J</i> = 10.6 Hz, 2H), 3.84 (d, <i>J</i> = 8.7 Hz, 1H), 3.29 (d, <i>J</i> = 7.2 Hz, 1H), 2.56 (d, <i>J</i> = 8.6 Hz, 1H), 2.17 (d, <i>J</i> = 7.7 Hz, 1H), 1.97 (dd, <i>J</i> = 29.3, 11.2 Hz, 4H), 1.81–1.71 (m, 2H), 1.29–1.00 (m, 7H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.7, 199.7, 164.7, 150.3, 147.3, 142.9, 141.5, 128.8, 123.4, 122.1, 119.1, 82.6, 76.4, 72.1, 65.2, 56.5, 51.5, 50.4, 42.2, 39.6, 30.4, 30.1, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>30</sub>NO<sub>5</sub> [M + H]<sup>+</sup>, 460.2118; found, 460.2120.</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-(Pyridin-3-yl)acrylate (<b>57</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-(pyridin-3-yl)acrylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:2, v/v). Compound <b>57</b> was prepared from compound <b>20</b> as a white solid (yield 58%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.66 (d, <i>J</i> = 35.1 Hz, 2H), 7.83 (d, <i>J</i> = 6.6 Hz, 1H), 7.64 (d, <i>J</i> = 16.0 Hz, 1H), 7.43–7.20 (m, 1H), 6.42 (dd, <i>J</i> = 16.1, 4.7 Hz, 1H), 6.16 (s, 1H), 5.79 (s, 2H), 5.68 (d, <i>J</i> = 7.8 Hz, 1H), 5.49 (s, 1H), 4.33 (d, <i>J</i> = 5.0 Hz, 2H), 3.85 (d, <i>J</i> = 8.7 Hz, 1H), 3.30 (d, <i>J</i> = 5.9 Hz, 1H), 2.55 (s, 1H), 2.17 (d, <i>J</i> = 5.7 Hz, 1H), 2.09–1.86 (m, 3H), 1.80 (dd, <i>J</i> = 16.0, 4.3 Hz, 2H), 1.39–0.98 (m, 7H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.7, 199.8, 165.0, 151.0, 149.8, 147.3, 142.2, 134.3, 128.7, 123.5, 119.6, 119.0, 82.6, 76.2, 72.1, 65.2, 56.5, 51.5, 50.4, 42.2, 39.5, 30.4, 30.0, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>30</sub>NO<sub>5</sub> [M + H]<sup>+</sup>, 460.2118; found, 460.2121.</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-(Pyridin-2-yl)acrylate (<b>58</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-(pyridin-2-yl)acrylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:2, v/v). Compound <b>58</b> was prepared from compound <b>20</b> as a white solid (yield 54%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.61 (d, <i>J</i> = 3.8 Hz, 1H), 7.66 (dd, <i>J</i> = 17.2, 11.6 Hz, 2H), 7.42 (d, <i>J</i> = 7.8 Hz, 1H), 6.82 (d, <i>J</i> = 15.7 Hz, 1H), 6.14 (s, 1H), 5.89–5.71 (m, 2H), 5.66 (d, <i>J</i> = 8.2 Hz, 1H), 5.45 (s, 1H), 4.31 (d, <i>J</i> = 10.1 Hz, 2H), 3.83 (d, <i>J</i> = 8.8 Hz, 1H), 3.28 (d, <i>J</i> = 7.1 Hz, 1H), 2.54 (dd, <i>J</i> = 16.5, 8.3 Hz, 1H), 2.22–2.12 (m, 1H), 2.03–1.89 (m, 2H), 1.76–1.59 (m, 2H), 1.30 (dd, <i>J</i> = 24.6, 10.2 Hz, 3H), 0.96 (d, <i>J</i> = 49.9 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.3, 199.0, 164.8, 152.3, 149.5, 147.0, 144.0, 136.1, 128.2, 123.7, 123.1, 121.1, 118.3, 82.2, 75.6, 64.8, 56.1, 51.0, 49.9, 41.8, 39.1, 29.9, 29.5, 22.4, 17.2; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>30</sub>NO<sub>5</sub> [M + H]<sup>+</sup>, 460.2118; found, 460.2117.</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-(Pyrimidin-5-yl)acrylate (<b>59</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-(pyrimidin-5-yl)acrylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:8, v/v). Compound <b>59</b> was prepared from compound <b>20</b> as a white solid (yield 51%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 9.18 (s, 1H), 8.85 (s, 1H), 7.66–7.44 (m, 1H), 7.23 (s, 1H), 6.57–6.38 (m, 1H), 6.15 (d, <i>J</i> = 11.9 Hz, 1H), 5.79 (s, 2H), 5.67 (d, <i>J</i> = 10.3 Hz, 1H), 5.48 (d, <i>J</i> = 11.7 Hz, 1H), 4.31 (d, <i>J</i> = 11.5 Hz, 2H), 3.85 (d, <i>J</i> = 8.7 Hz, 1H), 3.28 (s, 1H), 2.55 (s, 1H), 2.00 (s, 4H), 1.27 (d, <i>J</i> = 9.4 Hz, 3H), 0.98 (dd, <i>J</i> = 29.6, 10.9 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.6, 199.8, 164.3, 159.2, 155.7, 147.2, 138.4, 129.4, 128.8, 123.4, 121.5, 119.1, 82.6, 72.1, 65.2, 56.4, 51.4, 50.4, 42.2, 39.5, 31.5, 30.4, 30.1, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>27</sub>H<sub>29</sub>N<sub>2</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 461.2071; found, 461.2073.</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-(2-Fluoropyridin-4-yl)acrylate (<b>60</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-(2-fluoropyridin-4-yl)acrylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:2, v/v). Compound <b>60</b> was prepared from compound <b>20</b> as a white solid (yield 65%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.51 (d, <i>J</i> = 1.6 Hz, 1H), 8.43 (d, <i>J</i> = 5.0 Hz, 1H), 7.69 (d, <i>J</i> = 16.2 Hz, 1H), 7.39 (t, <i>J</i> = 5.6 Hz, 1H), 6.62 (d, <i>J</i> = 16.2 Hz, 1H), 6.16 (s, 1H), 5.89–5.75 (m, 2H), 5.67 (dd, <i>J</i> = 10.3, 2.1 Hz, 1H), 5.50 (s, 1H), 4.31 (d, <i>J</i> = 8.8 Hz, 2H), 3.84 (d, <i>J</i> = 9.2 Hz, 1H), 3.29 (d, <i>J</i> = 7.4 Hz, 1H), 2.57 (dt, <i>J</i> = 12.2, 7.6 Hz, 1H), 2.19 (t, <i>J</i> = 8.3 Hz, 1H), 2.04–1.91 (m, 3H), 1.87–1.72 (m, 3H), 1.05 (d, <i>J</i> = 2.7 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.6, 199.8, 164.5, 157.1 (d, <i>J</i> = 263.7 Hz), 146.6 (d, <i>J</i> = 95.6 Hz), 139.2 (d, <i>J</i> = 24.4 Hz), 135.7, 129.0, 128.7, 124.5, 123.4, 122.1, 119.1, 82.5, 72.0, 65.2, 56.3, 51.4, 50.3, 42.1, 39.5, 30.3, 30.0, 22.8, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>29</sub>FNO<sub>5</sub> [M + H]<sup>+</sup>, 478.2024; found, 478.2024.</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-(3-Fluoropyridin-4-yl)acrylate (<b>61</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-(3-fluoropyridin-4-yl)acrylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:2, v/v). Compound <b>61</b> was prepared from compound <b>20</b> as a white solid (yield 67%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.24 (d, <i>J</i> = 5.2 Hz, 1H), 7.54 (d, <i>J</i> = 16.1 Hz, 1H), 7.25 (s, 1H), 6.99 (s, 1H), 6.52 (d, <i>J</i> = 16.1 Hz, 1H), 6.17 (s, 1H), 5.85–5.77 (m, 2H), 5.67 (dd, <i>J</i> = 10.2, 2.6 Hz, 1H), 5.50 (s, 1H), 4.31 (d, <i>J</i> = 10.4 Hz, 2H), 3.85 (d, <i>J</i> = 9.0 Hz, 1H), 3.29 (d, <i>J</i> = 7.4 Hz, 1H), 2.64–2.47 (m, 1H), 2.19 (t, <i>J</i> = 8.1 Hz, 1H), 1.99 (d, <i>J</i> = 3.3 Hz, 1H), 1.92 (d, <i>J</i> = 6.1 Hz, 1H), 1.83 (s, 1H), 1.81–1.75 (m, 2H), 1.06 (t, <i>J</i> = 6.4 Hz, 7H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.6, 199.8, 164.4, 147.8 (d, <i>J</i> = 93.3), 147.7 (d, <i>J</i> = 92.3), 141.5, 128.8, 123.4, 119.5, 119.2, 108.1 (d, <i>J</i> = 38.5 Hz), 82.6, 72.1, 65.2, 56.4, 51.4, 50.4, 42.2, 39.5, 30.4, 30.0, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>29</sub>FNO<sub>5</sub> [M + H]<sup>+</sup>, 478.2024; found, 478.2026.</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-(2-Chloropyridin-4-yl)acrylate (<b>62</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-(2-chloropyridin-4-yl)acrylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:2, v/v). Compound <b>62</b> was prepared from compound <b>20</b> as a white solid (yield 79%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.61 (s, 1H), 8.46 (d, <i>J</i> = 5.1 Hz, 1H), 7.93 (d, <i>J</i> = 16.1 Hz, 1H), 7.42 (d, <i>J</i> = 5.1 Hz, 1H), 6.52 (d, <i>J</i> = 16.1 Hz, 1H), 6.14 (s, 1H), 5.80 (q, <i>J</i> = 4.0 Hz, 2H), 5.65 (dd, <i>J</i> = 10.2, 2.2 Hz, 1H), 5.48 (s, 1H), 4.30 (d, <i>J</i> = 8.3 Hz, 2H), 3.83 (d, <i>J</i> = 9.1 Hz, 1H), 3.27 (d, <i>J</i> = 7.4 Hz, 1H), 2.62–2.47 (m, 1H), 2.17 (t, <i>J</i> = 8.3 Hz, 1H), 2.00 (d, <i>J</i> = 17.5 Hz, 2H), 1.92–1.71 (m, 4H), 1.03 (d, <i>J</i> = 2.5 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.5, 199.7, 164.4, 150.4, 147.9, 147.3, 139.5, 138.8, 131.6, 128.7, 123.9, 123.4, 120.9, 119.0, 82.6, 72.1, 65.2, 56.4, 51.4, 50.3, 42.2, 39.5, 30.4, 30.0, 22.9, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>29</sub>ClNO<sub>5</sub> [M + H]<sup>+</sup>, 494.1729; found, 494.1733.</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-(2-Methoxypyridin-4-yl)acrylate (<b>63</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-(2-methoxypyridin-4-yl)acrylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:2, v/v). Compound <b>63</b> was prepared from compound <b>20</b> as a white solid (yield 58%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.20 (d, <i>J</i> = 5.3 Hz, 1H), 7.55 (d, <i>J</i> = 16.0 Hz, 1H), 7.00 (d, <i>J</i> = 5.3 Hz, 1H), 6.82 (s, 1H), 6.50 (d, <i>J</i> = 16.0 Hz, 1H), 6.21 (s, 1H), 5.94–5.77 (m, 2H), 5.71 (d, <i>J</i> = 9.9 Hz, 1H), 5.53 (s, 1H), 4.36 (d, <i>J</i> = 11.8 Hz, 2H), 3.98 (s, 3H), 3.89 (d, <i>J</i> = 9.2 Hz, 1H), 3.33 (d, <i>J</i> = 7.3 Hz, 1H), 2.60 (dd, <i>J</i> = 17.1, 8.5 Hz, 1H), 2.21 (d, <i>J</i> = 8.2 Hz, 1H), 2.03 (dd, <i>J</i> = 20.6, 15.7 Hz, 3H), 1.81 (dd, <i>J</i> = 9.4, 4.6 Hz, 3H), 1.09 (d, <i>J</i> = 3.6 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.6, 199.7, 164.5, 147.3, 145.9, 139.4, 139.0, 135.7, 128.7, 124.5, 123.4, 122.1, 119.1, 82.6, 72.0, 65.2, 56.3, 51.4, 50.3, 42.2, 39.5, 30.4, 30.0, 22.8, 17.7; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>29</sub>H<sub>32</sub>NO<sub>6</sub> [M + H]<sup>+</sup>, 490.2224; found, 490.2228.</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> (4<i>aR</i>,5<i>R</i>,6<i>aR</i>,9<i>S</i>,11<i>aS</i>,11<i>bR</i>,14<i>R</i>)-4,4-Dimethyl-8-methylene-6,7-dioxo-4,4<i>a</i>,5,6,7,8,9,10,11,11<i>a</i>-decahydro-3<i>H</i>-5,11<i>b</i>-(epoxymethano)-6<i>a</i>,9-methanocyclohepta[<i>a</i>]naphthalen-14-yl (<i>E</i>)-3-(3-Chloropyridin-4-yl)acrylate (<b>64</b>)</h4><div class="NLM_p last">It was prepared by following a similar procedure to the preparation of compound <b>31</b>. To a solution of compound <b>20</b> (0.15 mmol) in 10 mL of anhydrous dichloromethane were added EDCI (0.16 mmol), DMAP (catalytic amount), and (<i>E</i>)-3-(3-chloropyridin-4-yl)acrylic acid (0.20 mmol). The resulting solution was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was subjected to column chromatography (petroleum ether/EtOAc 1:2, v/v). Compound <b>64</b> was prepared from compound <b>20</b> as a white solid (yield 73%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.38 (d, <i>J</i> = 5.1 Hz, 1H), 7.48 (d, <i>J</i> = 16.0 Hz, 1H), 7.38 (s, 1H), 7.27 (d, <i>J</i> = 6.5 Hz, 1H), 6.50 (d, <i>J</i> = 16.1 Hz, 1H), 6.14 (s, 1H), 5.86–5.73 (m, 2H), 5.65 (d, <i>J</i> = 10.3 Hz, 1H), 5.48 (s, 1H), 4.29 (d, <i>J</i> = 9.3 Hz, 2H), 3.82 (d, <i>J</i> = 9.1 Hz, 1H), 3.27 (d, <i>J</i> = 7.1 Hz, 1H), 2.63–2.45 (m, 1H), 2.17 (t, <i>J</i> = 8.2 Hz, 1H), 1.98–1.68 (m, 6H), 1.03 (d, <i>J</i> = 3.4 Hz, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.5, 199.8, 164.3, 152.4, 150.2, 147.2, 144.6, 141.3, 128.8, 123.4, 123.3, 122.7, 120.4, 119.1, 82.6, 72.1, 65.2, 60.3, 56.4, 51.4, 50.3, 42.2, 39.5, 30.4, 30.0, 22.9, 17.7, 14.2; HR-MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>29</sub>ClNO<sub>5</sub> [M + H]<sup>+</sup>, 494.1729; found, 494.1731.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00408" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12240" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12240" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00408?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00408</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental methods for biological assays, figures, tables, NMR spectra, HPLC spectra, and MS spectra (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00408/suppl_file/jm0c00408_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00408/suppl_file/jm0c00408_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00408/suppl_file/jm0c00408_si_001.pdf">jm0c00408_si_001.pdf (3.4 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00408/suppl_file/jm0c00408_si_002.csv">jm0c00408_si_002.csv (8.62 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00408" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83302" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83302" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shengtao Xu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5705-6377" title="Orcid link">http://orcid.org/0000-0002-5705-6377</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#630013161b1017235255504d000c0e"><span class="__cf_email__" data-cfemail="a5c6d5d0ddd6d1e59493968bc6cac8">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinyi Xu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1961-0402" title="Orcid link">http://orcid.org/0000-0002-1961-0402</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e2888b8c9b8b9a97a2818a8b8c83cc818d8f"><span class="__cf_email__" data-cfemail="1c767572657564695c7f7475727d327f7371">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Yao</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shaowen Xie</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoqian Ma</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Junkai Liu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongyu Wu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aijun Lin</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5786-4537" title="Orcid link">http://orcid.org/0000-0001-5786-4537</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hequan Yao</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dahong Li</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drug Design & Discovery, Ministry
of Education, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6964-4619" title="Orcid link">http://orcid.org/0000-0002-6964-4619</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dong-Hua Yang</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Health Sciences, St. John’s
University, 8000 Utopia
Parkway, Queens, New York 11439, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhe-Sheng Chen</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Health Sciences, St. John’s
University, 8000 Utopia
Parkway, Queens, New York 11439, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8289-097X" title="Orcid link">http://orcid.org/0000-0002-8289-097X</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28643" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28643" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This study was supported by the National Natural Science Foundation of China (nos. 81673306, 81703348, 81874289, and 81903446), the Natural Science Foundation of Jiangsu Province (BK20190564), the China Postdoctoral Science Foundation Grant 2019M652037, and the “Double First-Class” University project CPU2018GY04, CPU2018GY35, China Pharmaceutical University. In additon, Hong Yao wants to thank Nan Yang for her continued support and accompany. And here are the words he has kept in heart for years: “Meeting you was fate, dating you was my choice, falling in love with you was beyond my control. Till all the scenery we saw, I'll beside you to see the time flow”.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">AIBN</td><td class="NLM_def"><p class="first last">azodiisobutyronitrile</p></td></tr><tr><td class="NLM_term">DAST</td><td class="NLM_def"><p class="first last">diethylaminosulfur trifluoride</p></td></tr><tr><td class="NLM_term">DCFH<sub>2</sub>-DA</td><td class="NLM_def"><p class="first last">2′,7′-dichlorodihydrofluorescein diacetate</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term">H&E</td><td class="NLM_def"><p class="first last">hematoxylin and eosin</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">MsCl</td><td class="NLM_def"><p class="first last">mesyl chloride</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2<i>H</i>-tetrazolium bromide</p></td></tr><tr><td class="NLM_term">NAC</td><td class="NLM_def"><p class="first last"><i>N</i>-acetly cysteine</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">propidium iodide</p></td></tr><tr><td class="NLM_term">PR</td><td class="NLM_def"><p class="first last">progesterone receptor</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">TBAB</td><td class="NLM_def"><p class="first last">tetrabutylammonium bromide</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple-negative breast cancer</p></td></tr><tr><td class="NLM_term">TsOH</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonic acid</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i85">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64623" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64623" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 46 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sachs, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Ligt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopper, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogola, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bounova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weeber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balgobind, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracanin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begthel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korving, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Boxtel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelieveld, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hoeck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blokzijl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijman, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoogstraat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Ven, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinzalla, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boj, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voest, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessels, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Diest, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vries, R. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuppen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clevers, H.</span></span> <span> </span><span class="NLM_article-title">A living biobank of breast cancer organoids captures disease heterogeneity</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.cell.2017.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=29224780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCisr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=373-386&author=N.+Sachsauthor=J.+de+Ligtauthor=O.+Kopperauthor=E.+Gogolaauthor=G.+Bounovaauthor=F.+Weeberauthor=A.+V.+Balgobindauthor=K.+Windauthor=A.+Gracaninauthor=H.+Begthelauthor=J.+Korvingauthor=R.+van+Boxtelauthor=A.+A.+Duarteauthor=D.+Lelieveldauthor=A.+van+Hoeckauthor=R.+F.+Ernstauthor=F.+Blokzijlauthor=I.+J.+Nijmanauthor=M.+Hoogstraatauthor=M.+van+de+Venauthor=D.+A.+Eganauthor=V.+Zinzallaauthor=J.+Mollauthor=S.+F.+Bojauthor=E.+E.+Voestauthor=L.+Wesselsauthor=P.+J.+van+Diestauthor=S.+Rottenbergauthor=R.+G.+J.+Vriesauthor=E.+Cuppenauthor=H.+Clevers&title=A+living+biobank+of+breast+cancer+organoids+captures+disease+heterogeneity&doi=10.1016%2Fj.cell.2017.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity</span></div><div class="casAuthors">Sachs, Norman; de Ligt, Joep; Kopper, Oded; Gogola, Ewa; Bounova, Gergana; Weeber, Fleur; Balgobind, Anjali Vanita; Wind, Karin; Gracanin, Ana; Begthel, Harry; Korving, Jeroen; van Boxtel, Ruben; Duarte, Alexandra Alves; Lelieveld, Daphne; van Hoeck, Arne; Ernst, Robert Frans; Blokzijl, Francis; Nijman, Isaac Johannes; Hoogstraat, Marlous; van de Ven, Marieke; Egan, David Anthony; Zinzalla, Vittoria; Moll, Jurgen; Boj, Sylvia Fernandez; Voest, Emile Eugene; Wessels, Lodewyk; van Diest, Paul Joannes; Rottenberg, Sven; Vries, Robert Gerhardus Jacob; Cuppen, Edwin; Clevers, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">373-386.e10</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Breast cancer (BC) comprises multiple distinct subtypes that differ genetically, pathol., and clin.  Here, we describe a robust protocol for long-term culturing of human mammary epithelial organoids.  Using this protocol, >100 primary and metastatic BC organoid lines were generated, broadly recapitulating the diversity of the disease.  BC organoid morphologies typically matched the histopathol., hormone receptor status, and HER2 status of the original tumor.  DNA copy no. variations as well as sequence changes were consistent within tumor-organoid pairs and largely retained even after extended passaging.  BC organoids furthermore populated all major gene-expression-based classification groups and allowed in vitro drug screens that were consistent with in vivo xeno-transplantations and patient response.  This study describes a representative collection of well-characterized BC organoids available for cancer research and drug development, as well as a strategy to assess in vitro drug response in a personalized fashion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzzY-AEzj4lLVg90H21EOLACvtfcHk0ljzzl-g9x5W-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCisr%252FJ&md5=7067744a8289c9d46e871a541221c1eb</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DSachs%26aufirst%3DN.%26aulast%3Dde%2BLigt%26aufirst%3DJ.%26aulast%3DKopper%26aufirst%3DO.%26aulast%3DGogola%26aufirst%3DE.%26aulast%3DBounova%26aufirst%3DG.%26aulast%3DWeeber%26aufirst%3DF.%26aulast%3DBalgobind%26aufirst%3DA.%2BV.%26aulast%3DWind%26aufirst%3DK.%26aulast%3DGracanin%26aufirst%3DA.%26aulast%3DBegthel%26aufirst%3DH.%26aulast%3DKorving%26aufirst%3DJ.%26aulast%3Dvan%2BBoxtel%26aufirst%3DR.%26aulast%3DDuarte%26aufirst%3DA.%2BA.%26aulast%3DLelieveld%26aufirst%3DD.%26aulast%3Dvan%2BHoeck%26aufirst%3DA.%26aulast%3DErnst%26aufirst%3DR.%2BF.%26aulast%3DBlokzijl%26aufirst%3DF.%26aulast%3DNijman%26aufirst%3DI.%2BJ.%26aulast%3DHoogstraat%26aufirst%3DM.%26aulast%3Dvan%2Bde%2BVen%26aufirst%3DM.%26aulast%3DEgan%26aufirst%3DD.%2BA.%26aulast%3DZinzalla%26aufirst%3DV.%26aulast%3DMoll%26aufirst%3DJ.%26aulast%3DBoj%26aufirst%3DS.%2BF.%26aulast%3DVoest%26aufirst%3DE.%2BE.%26aulast%3DWessels%26aufirst%3DL.%26aulast%3Dvan%2BDiest%26aufirst%3DP.%2BJ.%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DVries%26aufirst%3DR.%2BG.%2BJ.%26aulast%3DCuppen%26aufirst%3DE.%26aulast%3DClevers%26aufirst%3DH.%26atitle%3DA%2520living%2520biobank%2520of%2520breast%2520cancer%2520organoids%2520captures%2520disease%2520heterogeneity%26jtitle%3DCell%26date%3D2018%26volume%3D172%26spage%3D373%26epage%3D386%26doi%3D10.1016%2Fj.cell.2017.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sei, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatschek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosetto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foukakis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navin, N. E.</span></span> <span> </span><span class="NLM_article-title">Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">879</span>– <span class="NLM_lpage">893</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.03.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.cell.2018.03.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=29681456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFejt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2018&pages=879-893&author=C.+Kimauthor=R.+Gaoauthor=E.+Seiauthor=R.+Brandtauthor=J.+Hartmanauthor=T.+Hatschekauthor=N.+Crosettoauthor=T.+Foukakisauthor=N.+E.+Navin&title=Chemoresistance+evolution+in+triple-negative+breast+cancer+delineated+by+single-cell+sequencing&doi=10.1016%2Fj.cell.2018.03.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing</span></div><div class="casAuthors">Kim, Charissa; Gao, Ruli; Sei, Emi; Brandt, Rachel; Hartman, Johan; Hatschek, Thomas; Crosetto, Nicola; Foukakis, Theodoros; Navin, Nicholas E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">879-893.e13</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is an aggressive subtype that frequently develops resistance to chemotherapy.  An unresolved question is whether resistance is caused by the selection of rare pre-existing clones or alternatively through the acquisition of new genomic aberrations.  To investigate this question, we applied single-cell DNA and RNA sequencing in addn. to bulk exome sequencing to profile longitudinal samples from 20 TNBC patients during neoadjuvant chemotherapy (NAC).  Deep-exome sequencing identified 10 patients in which NAC led to clonal extinction and 10 patients in which clones persisted after treatment.  In 8 patients, we performed a more detailed study using single-cell DNA sequencing to analyze 900 cells and single-cell RNA sequencing to analyze 6,862 cells.  Our data showed that resistant genotypes were pre-existing and adaptively selected by NAC, while transcriptional profiles were acquired by reprogramming in response to chemotherapy in TNBC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUuZd0FqIR7rVg90H21EOLACvtfcHk0lioyYus_2GqWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFejt74%253D&md5=aa3c4ee70bd54c40403b5a2cf5ce2432</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.03.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.03.041%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DR.%26aulast%3DSei%26aufirst%3DE.%26aulast%3DBrandt%26aufirst%3DR.%26aulast%3DHartman%26aufirst%3DJ.%26aulast%3DHatschek%26aufirst%3DT.%26aulast%3DCrosetto%26aufirst%3DN.%26aulast%3DFoukakis%26aufirst%3DT.%26aulast%3DNavin%26aufirst%3DN.%2BE.%26atitle%3DChemoresistance%2520evolution%2520in%2520triple-negative%2520breast%2520cancer%2520delineated%2520by%2520single-cell%2520sequencing%26jtitle%3DCell%26date%3D2018%26volume%3D173%26spage%3D879%26epage%3D893%26doi%3D10.1016%2Fj.cell.2018.03.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovey, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheang, M. C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kernaghan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilburn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazinska, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett-Lee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper-Wynne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatton, M. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoadley, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roylance, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timms, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardley, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanchbury, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harries, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliss, J. M.</span></span> <span> </span><span class="NLM_article-title">Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">628</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0009-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1038%2Fs41591-018-0009-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=29713086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVWrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=628&author=A.+Tuttauthor=H.+Toveyauthor=M.+C.+U.+Cheangauthor=S.+Kernaghanauthor=L.+Kilburnauthor=P.+Gazinskaauthor=J.+Owenauthor=J.+Abrahamauthor=S.+Barrettauthor=P.+Barrett-Leeauthor=R.+Brownauthor=S.+Chanauthor=M.+Dowsettauthor=J.+M.+Flanaganauthor=L.+Foxauthor=A.+Grigoriadisauthor=A.+Gutinauthor=C.+Harper-Wynneauthor=M.+Q.+Hattonauthor=K.+A.+Hoadleyauthor=J.+Parikhauthor=P.+Parkerauthor=C.+M.+Perouauthor=R.+Roylanceauthor=V.+Shahauthor=A.+Shawauthor=I.+E.+Smithauthor=K.+M.+Timmsauthor=A.+M.+Wardleyauthor=G.+Wilsonauthor=C.+Gillettauthor=J.+S.+Lanchburyauthor=A.+Ashworthauthor=N.+Rahmanauthor=M.+Harriesauthor=P.+Ellisauthor=S.+E.+Pinderauthor=J.+M.+Bliss&title=Carboplatin+in+BRCA1%2F2-mutated+and+triple-negative+breast+cancer+BRCAness+subgroups%3A+the+TNT+Trial&doi=10.1038%2Fs41591-018-0009-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial</span></div><div class="casAuthors">Tutt, Andrew; Tovey, Holly; Cheang, Maggie Chon U.; Kernaghan, Sarah; Kilburn, Lucy; Gazinska, Patrycja; Owen, Julie; Abraham, Jacinta; Barrett, Sophie; Barrett-Lee, Peter; Brown, Robert; Chan, Stephen; Dowsett, Mitchell; Flanagan, James M.; Fox, Lisa; Grigoriadis, Anita; Gutin, Alexander; Harper-Wynne, Catherine; Hatton, Matthew Q.; Hoadley, Katherine A.; Parikh, Jyoti; Parker, Peter; Perou, Charles M.; Roylance, Rebecca; Shah, Vandna; Shaw, Adam; Smith, Ian E.; Timms, Kirsten M.; Wardley, Andrew M.; Wilson, Gregory; Gillett, Cheryl; Lanchbury, Jerry S.; Ashworth, Alan; Rahman, Nazneen; Harries, Mark; Ellis, Paul; Pinder, Sarah E.; Bliss, Judith M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">628-637</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability.  HR also repairs DNA lesions caused by platinum agents and PARP inhibitors.  Triple-neg. breast cancers (TNBCs) harbor subpopulations with BRCA1/2 mutations, hypothesized to be esp. platinum-sensitive.  Cancers in putative 'BRCAness' subgroups-tumors with BRCA1 methylation; low levels of BRCA1 mRNA (BRCA1 mRNA-low); or mutational signatures for HR deficiency and those with basal phenotypes-may also be sensitive to platinum.  We assessed the efficacy of carboplatin and another mechanistically distinct therapy, docetaxel, in a phase 3 trial in subjects with unselected advanced TNBC.  A prespecified protocol enabled biomarker-treatment interaction analyses in gBRCA-BC and BRCAness subgroups.  The primary endpoint was objective response rate (ORR).  In the unselected population (376 subjects; 188 carboplatin, 188 docetaxel), carboplatin was not more active than docetaxel (ORR, 31.4% vs. 34.0%, resp.; P = 0.66).  In contrast, in subjects with gBRCA-BC, carboplatin had double the ORR of docetaxel (68% vs. 33%, resp.; biomarker, treatment interaction P = 0.01).  Such benefit was not obsd. for subjects with BRCA1 methylation, BRCA1 mRNA-low tumors or a high score in a Myriad HRD assay.  Significant interaction between treatment and the basal-like subtype was driven by high docetaxel response in the nonbasal subgroup.  We conclude that patients with advanced TNBC benefit from characterization of BRCA1/2 mutations, but not BRCA1 methylation or Myriad HRD analyses, to inform choices on platinum-based chemotherapy.  Addnl., gene expression anal. of basal-like cancers may also influence treatment selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBgHORfBZE5rVg90H21EOLACvtfcHk0lioyYus_2GqWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVWrsrs%253D&md5=bc041981d526eb551165880c3d779b94</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0009-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0009-7%26sid%3Dliteratum%253Aachs%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DTovey%26aufirst%3DH.%26aulast%3DCheang%26aufirst%3DM.%2BC.%2BU.%26aulast%3DKernaghan%26aufirst%3DS.%26aulast%3DKilburn%26aufirst%3DL.%26aulast%3DGazinska%26aufirst%3DP.%26aulast%3DOwen%26aufirst%3DJ.%26aulast%3DAbraham%26aufirst%3DJ.%26aulast%3DBarrett%26aufirst%3DS.%26aulast%3DBarrett-Lee%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DR.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DDowsett%26aufirst%3DM.%26aulast%3DFlanagan%26aufirst%3DJ.%2BM.%26aulast%3DFox%26aufirst%3DL.%26aulast%3DGrigoriadis%26aufirst%3DA.%26aulast%3DGutin%26aufirst%3DA.%26aulast%3DHarper-Wynne%26aufirst%3DC.%26aulast%3DHatton%26aufirst%3DM.%2BQ.%26aulast%3DHoadley%26aufirst%3DK.%2BA.%26aulast%3DParikh%26aufirst%3DJ.%26aulast%3DParker%26aufirst%3DP.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DRoylance%26aufirst%3DR.%26aulast%3DShah%26aufirst%3DV.%26aulast%3DShaw%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DTimms%26aufirst%3DK.%2BM.%26aulast%3DWardley%26aufirst%3DA.%2BM.%26aulast%3DWilson%26aufirst%3DG.%26aulast%3DGillett%26aufirst%3DC.%26aulast%3DLanchbury%26aufirst%3DJ.%2BS.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DRahman%26aufirst%3DN.%26aulast%3DHarries%26aufirst%3DM.%26aulast%3DEllis%26aufirst%3DP.%26aulast%3DPinder%26aufirst%3DS.%2BE.%26aulast%3DBliss%26aufirst%3DJ.%2BM.%26atitle%3DCarboplatin%2520in%2520BRCA1%252F2-mutated%2520and%2520triple-negative%2520breast%2520cancer%2520BRCAness%2520subgroups%253A%2520the%2520TNT%2520Trial%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D628%26doi%3D10.1038%2Fs41591-018-0009-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholer-Dahirel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourachot, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirven, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magagna, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhrmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonneau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondratova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuperstein, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinovyev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Givel, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrini, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soumelis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent-Salomon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechta-Grigoriou, F.</span></span> <span> </span><span class="NLM_article-title">Fibroblast heterogeneity and immunosuppressive environment in human breast cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2018.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ccell.2018.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=29455927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFSisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=463-479&author=A.+Costaauthor=Y.+Kiefferauthor=A.+Scholer-Dahirelauthor=F.+Pelonauthor=B.+Bourachotauthor=M.+Cardonauthor=P.+Sirvenauthor=I.+Magagnaauthor=L.+Fuhrmannauthor=C.+Bernardauthor=C.+Bonneauauthor=M.+Kondratovaauthor=I.+Kupersteinauthor=A.+Zinovyevauthor=A.-M.+Givelauthor=M.-C.+Parriniauthor=V.+Soumelisauthor=A.+Vincent-Salomonauthor=F.+Mechta-Grigoriou&title=Fibroblast+heterogeneity+and+immunosuppressive+environment+in+human+breast+cancer&doi=10.1016%2Fj.ccell.2018.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer</span></div><div class="casAuthors">Costa, Ana; Kieffer, Yann; Scholer-Dahirel, Alix; Pelon, Floriane; Bourachot, Brigitte; Cardon, Melissa; Sirven, Philemon; Magagna, Ilaria; Fuhrmann, Laetitia; Bernard, Charles; Bonneau, Claire; Kondratova, Maria; Kuperstein, Inna; Zinovyev, Andrei; Givel, Anne-Marie; Parrini, Maria-Carla; Soumelis, Vassili; Vincent-Salomon, Anne; Mechta-Grigoriou, Fatima</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">463-479.e10</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Carcinoma-assocd. fibroblasts (CAF) are key players in the tumor microenvironment.  Here, we characterize four CAF subsets in breast cancer with distinct properties and levels of activation.  Two myofibroblastic subsets (CAF-S1, CAF-S4) accumulate differentially in triple-neg. breast cancers (TNBC).  CAF-S1 fibroblasts promote an immunosuppressive environment through a multi-step mechanism.  By secreting CXCL12, CAF-S1 attracts CD4+CD25+ T lymphocytes and retains them by OX40L, PD-L2, and JAM2.  Moreover, CAF-S1 increases T lymphocyte survival and promotes their differentiation into CD25HighFOXP3High, through B7H3, CD73, and DPP4.  Finally, in contrast to CAF-S4, CAF-S1 enhances the regulatory T cell capacity to inhibit T effector proliferation.  These data are consistent with FOXP3+ T lymphocyte accumulation in CAF-S1-enriched TNBC and show how a CAF subset contributes to immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIGZxeA-XyIbVg90H21EOLACvtfcHk0lioyYus_2GqWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFSisrk%253D&md5=01514c0cf88bd85fcdc93a60c0ab41cb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DCosta%26aufirst%3DA.%26aulast%3DKieffer%26aufirst%3DY.%26aulast%3DScholer-Dahirel%26aufirst%3DA.%26aulast%3DPelon%26aufirst%3DF.%26aulast%3DBourachot%26aufirst%3DB.%26aulast%3DCardon%26aufirst%3DM.%26aulast%3DSirven%26aufirst%3DP.%26aulast%3DMagagna%26aufirst%3DI.%26aulast%3DFuhrmann%26aufirst%3DL.%26aulast%3DBernard%26aufirst%3DC.%26aulast%3DBonneau%26aufirst%3DC.%26aulast%3DKondratova%26aufirst%3DM.%26aulast%3DKuperstein%26aufirst%3DI.%26aulast%3DZinovyev%26aufirst%3DA.%26aulast%3DGivel%26aufirst%3DA.-M.%26aulast%3DParrini%26aufirst%3DM.-C.%26aulast%3DSoumelis%26aufirst%3DV.%26aulast%3DVincent-Salomon%26aufirst%3DA.%26aulast%3DMechta-Grigoriou%26aufirst%3DF.%26atitle%3DFibroblast%2520heterogeneity%2520and%2520immunosuppressive%2520environment%2520in%2520human%2520breast%2520cancer%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D33%26spage%3D463%26epage%3D479%26doi%3D10.1016%2Fj.ccell.2018.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneeweiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diéras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henschel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chui, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emens, L. A.</span></span> <span> </span><span class="NLM_article-title">Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">2108</span>– <span class="NLM_lpage">2121</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1809615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1056%2Fnejmoa1809615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=30345906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisV2rsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=2108-2121&author=P.+Schmidauthor=S.+Adamsauthor=H.+S.+Rugoauthor=A.+Schneeweissauthor=C.+H.+Barriosauthor=H.+Iwataauthor=V.+Di%C3%A9rasauthor=R.+Heggauthor=S.-A.+Imauthor=G.+Shaw+Wrightauthor=V.+Henschelauthor=L.+Molineroauthor=S.+Y.+Chuiauthor=R.+Funkeauthor=A.+Husainauthor=E.+P.+Winerauthor=S.+Loiauthor=L.+A.+Emens&title=Atezolizumab+and+nab-paclitaxel+in+advanced+triple-negative+breast+cancer&doi=10.1056%2Fnejmoa1809615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer</span></div><div class="casAuthors">Schmid, P.; Adams, S.; Rugo, H. S.; Schneeweiss, A.; Barrios, C. H.; Iwata, H.; Dieras, V.; Hegg, R.; Im, S.-A.; Wright, G. Shaw; Henschel, V.; Molinero, L.; Chui, S. Y.; Funke, R.; Husain, A.; Winer, E. P.; Loi, S.; Emens, L. A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2108-2121</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Unresectable locally advanced or metastatic triple-neg. (hormone-receptor-neg. and human epidermal growth factor receptor 2 [HER2]-neg.) breast cancer is an aggressive disease with poor outcomes.  Nanoparticle albumin-bound (nab)- paclitaxel may enhance the anticancer activity of atezolizumab. methods In this phase 3 trial, we randomly assigned (in a 1:1 ratio) patients with untreated metastatic triple-neg. breast cancer to receive atezolizumab plus nab-paclitaxel or placebo plus nab-paclitaxel; patients continued the intervention until disease progression or an unacceptable level of toxic effects occurred.  Stratification factors were the receipt or nonreceipt of neoadjuvant or adjuvant taxane therapy, the presence or absence of liver metastases at baseline, and programmed death ligand 1 (PD-L1) expression at baseline (pos. vs. neg.).  The two primary end points were progression- free survival (in the intention-to-treat population and PD-L1-pos. subgroup) and overall survival (tested in the intention-to-treat population; if the finding was significant, then it would be tested in the PD-L1-pos. subgroup). results Each group included 451 patients (median follow-up, 12.9 mo).  In the intentionto- treat anal., the median progression-free survival was 7.2 mo with atezolizumab plus nab-paclitaxel, as compared with 5.5 mo with placebo plus nab-paclitaxel (hazard ratio for progression or death, 0.80; 95% confidence interval [CI], 0.69 to 0.92; P = 0.002); among patients with PD-L1-pos. tumors, the median progression- free survival was 7.5 mo and 5.0 mo, resp. (hazard ratio, 0.62; 95% CI, 0.49 to 0.78; P<0.001).  In the intention-to-treat anal., the median overall survival was 21.3 mo with atezolizumab plus nab-paclitaxel and 17.6 mo with placebo plus nab-paclitaxel (hazard ratio for death, 0.84; 95% CI, 0.69 to 1.02; P = 0.08); among patients with PD-L1-pos. tumors, the median overall survival was 25.0 mo and 15.5 mo, resp. (hazard ratio, 0.62; 95% CI, 0.45 to 0.86).  No new adverse effects were identified.  Adverse events that led to the discontinuation of any agent occurred in 15.9% of the patients who received atezolizumab plus nab-paclitaxel and in 8.2% of those who received placebo plus nab-paclitaxel. conclusions Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-neg. breast cancer in both the intention-to-treat population and the PD-L1-pos. subgroup.  Adverse events were consistent with the known safety profiles of each agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBVvU9eDM8srVg90H21EOLACvtfcHk0lhOPFcOY_PyMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisV2rsrrI&md5=cf178f2bb201763452df26d207638095</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1809615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1809615%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DSchneeweiss%26aufirst%3DA.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26aulast%3DHegg%26aufirst%3DR.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DShaw%2BWright%26aufirst%3DG.%26aulast%3DHenschel%26aufirst%3DV.%26aulast%3DMolinero%26aufirst%3DL.%26aulast%3DChui%26aufirst%3DS.%2BY.%26aulast%3DFunke%26aufirst%3DR.%26aulast%3DHusain%26aufirst%3DA.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DEmens%26aufirst%3DL.%2BA.%26atitle%3DAtezolizumab%2520and%2520nab-paclitaxel%2520in%2520advanced%2520triple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D2108%26epage%3D2121%26doi%3D10.1056%2Fnejmoa1809615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edrada-Ebel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, R. J.</span></span> <span> </span><span class="NLM_article-title">The re-emergence of natural products for drug discovery in the genomics era</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">111</span>, <span class="refDoi"> DOI: 10.1038/nrd4510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1038%2Fnrd4510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=25614221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVarsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=111&author=A.+L.+Harveyauthor=R.+Edrada-Ebelauthor=R.+J.+Quinn&title=The+re-emergence+of+natural+products+for+drug+discovery+in+the+genomics+era&doi=10.1038%2Fnrd4510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The re-emergence of natural products for drug discovery in the genomics era</span></div><div class="casAuthors">Harvey, Alan L.; Edrada-Ebel, RuAngelie; Quinn, Ronald J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-129</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Natural products have been a rich source of compds. for drug discovery.  However, their use has diminished in the past two decades, in part because of tech. barriers to screening natural products in high-throughput assays against mol. targets.  Here, we review strategies for natural product screening that harness the recent tech. advances that have reduced these barriers.  We also assess the use of genomic and metabolomic approaches to augment traditional methods of studying natural products, and highlight recent examples of natural products in antimicrobial drug discovery and as inhibitors of protein-protein interactions.  The growing appreciation of functional assays and phenotypic screens may further contribute to a revival of interest in natural products for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkQ8QarpZ6orVg90H21EOLACvtfcHk0lhOPFcOY_PyMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVarsbg%253D&md5=b871148315dc0623683498fa15205b14</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd4510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4510%26sid%3Dliteratum%253Aachs%26aulast%3DHarvey%26aufirst%3DA.%2BL.%26aulast%3DEdrada-Ebel%26aufirst%3DR.%26aulast%3DQuinn%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520re-emergence%2520of%2520natural%2520products%2520for%2520drug%2520discovery%2520in%2520the%2520genomics%2520era%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D111%26doi%3D10.1038%2Fnrd4510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">Counting on natural products for drug design</span>. <i>Nat. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">531</span>, <span class="refDoi"> DOI: 10.1038/nchem.2479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1038%2Fnchem.2479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=27219696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslSrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=531&author=T.+Rodriguesauthor=D.+Rekerauthor=P.+Schneiderauthor=G.+Schneider&title=Counting+on+natural+products+for+drug+design&doi=10.1038%2Fnchem.2479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Counting on natural products for drug design</span></div><div class="casAuthors">Rodrigues, Tiago; Reker, Daniel; Schneider, Petra; Schneider, Gisbert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">531-541</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Natural products and their mol. frameworks have a long tradition as valuable starting points for medicinal chem. and drug discovery.  Recently, there has been a revitalization of interest in the inclusion of these chemotypes in compd. collections for screening and achieving selective target modulation.  Here the authors discuss natural-product-inspired drug discovery with a focus on recent advances in the design of synthetically tractable small mols. that mimic nature's chem.  The authors highlight the potential of innovative computational tools in processing structurally complex natural products to predict their macromol. targets and attempt to forecast the role that natural-product-derived fragments and fragment-like natural products will play in next-generation drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNR16z66-NgLVg90H21EOLACvtfcHk0lhOPFcOY_PyMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslSrsbk%253D&md5=3f6391192d648de2a54524afafd6203a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnchem.2479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.2479%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigues%26aufirst%3DT.%26aulast%3DReker%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DCounting%2520on%2520natural%2520products%2520for%2520drug%2520design%26jtitle%3DNat.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D531%26doi%3D10.1038%2Fnchem.2479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atanasov, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waltenberger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferschy-Wenzig, E.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linder, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wawrosch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhrin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temml, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaiger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heiss, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollinger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bochkov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihovilovic, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirsch, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuppner, H.</span></span> <span> </span><span class="NLM_article-title">Discovery and resupply of pharmacologically active plant-derived natural products: A review</span>. <i>Biotechnol. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1582</span>– <span class="NLM_lpage">1614</span>, <span class="refDoi"> DOI: 10.1016/j.biotechadv.2015.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.biotechadv.2015.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=26281720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGjsbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1582-1614&author=A.+G.+Atanasovauthor=B.+Waltenbergerauthor=E.-M.+Pferschy-Wenzigauthor=T.+Linderauthor=C.+Wawroschauthor=P.+Uhrinauthor=V.+Temmlauthor=L.+Wangauthor=S.+Schwaigerauthor=E.+H.+Heissauthor=J.+M.+Rollingerauthor=D.+Schusterauthor=J.+M.+Breussauthor=V.+Bochkovauthor=M.+D.+Mihovilovicauthor=B.+Koppauthor=R.+Bauerauthor=V.+M.+Dirschauthor=H.+Stuppner&title=Discovery+and+resupply+of+pharmacologically+active+plant-derived+natural+products%3A+A+review&doi=10.1016%2Fj.biotechadv.2015.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and resupply of pharmacologically active plant-derived natural products: A review</span></div><div class="casAuthors">Atanasov, Atanas G.; Waltenberger, Birgit; Pferschy-Wenzig, Eva-Maria; Linder, Thomas; Wawrosch, Christoph; Uhrin, Pavel; Temml, Veronika; Wang, Limei; Schwaiger, Stefan; Heiss, Elke H.; Rollinger, Judith M.; Schuster, Daniela; Breuss, Johannes M.; Bochkov, Valery; Mihovilovic, Marko D.; Kopp, Brigitte; Bauer, Rudolf; Dirsch, Verena M.; Stuppner, Hermann</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology Advances</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1582-1614</span>CODEN:
                <span class="NLM_cas:coden">BIADDD</span>;
        ISSN:<span class="NLM_cas:issn">0734-9750</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Medicinal plants have historically proven their value as a source of mols. with therapeutic potential, and nowadays still represent an important pool for the identification of novel drug leads.  In the past decades, pharmaceutical industry focused mainly on libraries of synthetic compds. as drug discovery source.  They are comparably easy to produce and resupply, and demonstrate good compatibility with established high throughput screening (HTS) platforms.  However, at the same time there has been a declining trend in the no. of new drugs reaching the market, raising renewed scientific interest in drug discovery from natural sources, despite of its known challenges.  In this survey, a brief outline of historical development is provided together with a comprehensive overview of used approaches and recent developments relevant to plant-derived natural product drug discovery.  Assocd. challenges and major strengths of natural product-based drug discovery are critically discussed.  A snapshot of the advanced plant-derived natural products that are currently in actively recruiting clin. trials is also presented.  Importantly, the transition of a natural compd. from a "screening hit" through a "drug lead" to a "marketed drug" is assocd. with increasingly challenging demands for compd. amt., which often cannot be met by re-isolation from the resp. plant sources.  In this regard, existing alternatives for resupply are also discussed, including different biotechnol. approaches and total org. synthesis.  While the intrinsic complexity of natural product-based drug discovery necessitates highly integrated interdisciplinary approaches, the reviewed scientific developments, recent technol. advances, and research trends clearly indicate that natural products will be among the most important sources of new drugs also in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaFpQuOxEnNrVg90H21EOLACvtfcHk0lgPLKHhzA_iqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGjsbjJ&md5=e1f2296576f1f80b984d99adbf83a20d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.biotechadv.2015.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biotechadv.2015.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DAtanasov%26aufirst%3DA.%2BG.%26aulast%3DWaltenberger%26aufirst%3DB.%26aulast%3DPferschy-Wenzig%26aufirst%3DE.-M.%26aulast%3DLinder%26aufirst%3DT.%26aulast%3DWawrosch%26aufirst%3DC.%26aulast%3DUhrin%26aufirst%3DP.%26aulast%3DTemml%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSchwaiger%26aufirst%3DS.%26aulast%3DHeiss%26aufirst%3DE.%2BH.%26aulast%3DRollinger%26aufirst%3DJ.%2BM.%26aulast%3DSchuster%26aufirst%3DD.%26aulast%3DBreuss%26aufirst%3DJ.%2BM.%26aulast%3DBochkov%26aufirst%3DV.%26aulast%3DMihovilovic%26aufirst%3DM.%2BD.%26aulast%3DKopp%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DR.%26aulast%3DDirsch%26aufirst%3DV.%2BM.%26aulast%3DStuppner%26aufirst%3DH.%26atitle%3DDiscovery%2520and%2520resupply%2520of%2520pharmacologically%2520active%2520plant-derived%2520natural%2520products%253A%2520A%2520review%26jtitle%3DBiotechnol.%2520Adv.%26date%3D2015%26volume%3D33%26spage%3D1582%26epage%3D1614%26doi%3D10.1016%2Fj.biotechadv.2015.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patridge, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gareiss, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span> <span> </span><span class="NLM_article-title">An analysis of FDA-approved drugs: natural products and their derivatives</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.drudis.2015.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=25617672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1ejt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=204-207&author=E.+Patridgeauthor=P.+Gareissauthor=M.+S.+Kinchauthor=D.+Hoyer&title=An+analysis+of+FDA-approved+drugs%3A+natural+products+and+their+derivatives&doi=10.1016%2Fj.drudis.2015.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of FDA-approved drugs: natural products and their derivatives</span></div><div class="casAuthors">Patridge, Eric; Gareiss, Peter; Kinch, Michael S.; Hoyer, Denton</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">204-207</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Natural products contribute greatly to the history and landscape of new mol. entities (NMEs).  An assessment of all FDA-approved NMEs reveals that natural products and their derivs. represent over one-third of all NMEs.  Nearly one-half of these are derived from mammals, one-quarter from microbes and one-quarter from plants.  Since the 1930s, the total fraction of natural products has diminished, whereas semisynthetic and synthetic natural product derivs. have increased.  Over time, this fraction has also become enriched with microbial natural products, which represent a significant portion of approved antibiotics, including more than two-thirds of all antibacterial NMEs.  In recent years, the declining focus on natural products has impacted the pipeline of NMEs from specific classes, and this trend is likely to continue without specific investment in the pursuit of natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEdmXjG8extLVg90H21EOLACvtfcHk0lgPLKHhzA_iqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1ejt70%253D&md5=fbe216c17b12f1d6769543344f5a4dbe</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DPatridge%26aufirst%3DE.%26aulast%3DGareiss%26aufirst%3DP.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DHoyer%26aufirst%3DD.%26atitle%3DAn%2520analysis%2520of%2520FDA-approved%2520drugs%253A%2520natural%2520products%2520and%2520their%2520derivatives%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D204%26epage%3D207%26doi%3D10.1016%2Fj.drudis.2015.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Probing the anticancer action of oridonin with fluorescent analogues: visualizing subcellular localization to mitochondria</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5022</span>– <span class="NLM_lpage">5034</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00408</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtF2lt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5022-5034&author=S.+Xuauthor=S.+Luoauthor=H.+Yaoauthor=H.+Caiauthor=X.+Miaoauthor=F.+Wuauthor=D.-H.+Yangauthor=X.+Wuauthor=W.+Xieauthor=H.+Yaoauthor=Z.-S.+Chenauthor=J.+Xu&title=Probing+the+anticancer+action+of+oridonin+with+fluorescent+analogues%3A+visualizing+subcellular+localization+to+mitochondria&doi=10.1021%2Facs.jmedchem.6b00408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the Anticancer Action of Oridonin with Fluorescent Analogues: Visualizing Subcellular Localization to Mitochondria</span></div><div class="casAuthors">Xu, Shengtao; Luo, Shanshan; Yao, Hong; Cai, Hao; Miao, Xiaoming; Wu, Fang; Yang, Dong-Hua; Wu, Xiaoming; Xie, Weijia; Yao, Hequan; Chen, Zhe-Sheng; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5022-5034</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oridonin (1) is a complex ent-kaurane diterpenoid exhibiting remarkable antitumor activity.  However, the detailed mechanism or cellular target that underlies this activity has not yet been identified.  Herein, we report an efficient approach for exploring the anticancer mechanism of oridonin through development of the potent fluorescent analogs.  A series of novel fluorescent oridonin probes linked with coumarin moieties were designed, synthesized, and characterized.  Fluorescence microscopy and confocal imaging studies suggested that fluorescent oridonin probe 17d was rapidly taken up into tumor cells and the mitochondrion was the main site of its accumulation.  Moreover, we confirmed that cytochrome c played an important role in oridonin induced mitochondrion-mediated apoptosis and α,β-unsatd. ketone is the active moiety of oridonin, which is crucial to its uptake, localization, and cytotoxicity.  Our results provide new insights on the mol. mechanism of oridonin and would be useful for its further development into an antitumor agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQwh1mki12ZrVg90H21EOLACvtfcHk0ljkQslAjlgnng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtF2lt7s%253D&md5=8017b3f84342c5da185cb84c7effa0d4</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00408%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DMiao%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DD.-H.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.-S.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DProbing%2520the%2520anticancer%2520action%2520of%2520oridonin%2520with%2520fluorescent%2520analogues%253A%2520visualizing%2520subcellular%2520localization%2520to%2520mitochondria%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5022%26epage%3D5034%26doi%3D10.1021%2Facs.jmedchem.6b00408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.-H.</span></span> <span> </span><span class="NLM_article-title">Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells</span>. <i>Cell Death Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e2633</span> <span class="refDoi"> DOI: 10.1038/cddis.2017.35</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1038%2Fcddis.2017.35" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=28230866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsVShsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&author=Z.+Yaoauthor=F.+Xieauthor=M.+Liauthor=Z.+Liangauthor=W.+Xuauthor=J.+Yangauthor=C.+Liuauthor=H.+Liauthor=H.+Zhouauthor=L.-H.+Qu&title=Oridonin+induces+autophagy+via+inhibition+of+glucose+metabolism+in+p53-mutated+colorectal+cancer+cells&doi=10.1038%2Fcddis.2017.35"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells</span></div><div class="casAuthors">Yao, Zhuo; Xie, Fuhua; Li, Min; Liang, Zirui; Xu, Wenli; Yang, Jianhua; Liu, Chang; Li, Hongwangwang; Zhou, Hui; Qu, Liang-Hu</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e2633</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Warburg effect is an important characteristic of tumor cells, making it an attractive therapeutic target.  Current anticancer drug development strategies predominantly focus on inhibitors of the specific mol. effectors involved in tumor cell proliferation.  These drugs or natural compds., many of which target the Warburg effect and the underlying mechanisms, still need to be characterized.  To elucidate the anticancer effects of a natural diterpenoid, oridonin, we first demonstrated the anticancer activity of oridonin both in vitro and in vivo in colorectal cancer (CRC) cells.  Then miRNA profiling of SW480 cells revealed those intracellular signaling related to energy supply was affected by oridonin, suggesting that glucose metab. is a potential target for CRC therapy.  Moreover, our results indicated that oridonin induced metabolic imbalances by significantly inhibiting glucose uptake and reducing lactate export through significantly downregulating the protein levels of GLUT1 and MCT1 in vitro and vivo.  However, the ATP level in oridonin-treated CRC cells was not decreased when oridonin blocked the glucose supply, indicating that oridonin induced autophagy process, an important ATP source in cancer cells.  The observation was then supported by the results of LC3-II detection and transmission electron microscopy anal., which confirmed the presence of autophagy.  Furthermore, p-AMPK was rapidly deactivated following oridonin treatment, resulting in downregulation of GLUT1 and induction of autophagy in the cancer cells.  Thus our finding helped to clarify the anticancer mechanisms of oridonin and suggested it could be applied as a glucose metab.-targeting agent for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovouxwql3G1rVg90H21EOLACvtfcHk0ljkQslAjlgnng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsVShsb4%253D&md5=f88961c8d675e3d1f433364f9161fc49</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2017.35&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2017.35%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DQu%26aufirst%3DL.-H.%26atitle%3DOridonin%2520induces%2520autophagy%2520via%2520inhibition%2520of%2520glucose%2520metabolism%2520in%2520p53-mutated%2520colorectal%2520cancer%2520cells%26jtitle%3DCell%2520Death%2520Discovery%26date%3D2017%26volume%3D8%26doi%3D10.1038%2Fcddis.2017.35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span> <span> </span><span class="NLM_article-title">Oridonin triggers chaperon-mediated proteasomal degradation of BCR-ABL in leukemia</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41525</span>, <span class="refDoi"> DOI: 10.1038/srep41525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1038%2Fsrep41525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=28128329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVOrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=41525&author=H.+Huangauthor=H.+Wengauthor=B.+Dongauthor=P.+Zhaoauthor=H.+Zhouauthor=L.+Qu&title=Oridonin+triggers+chaperon-mediated+proteasomal+degradation+of+BCR-ABL+in+leukemia&doi=10.1038%2Fsrep41525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia</span></div><div class="casAuthors">Huang, Huilin; Weng, Hengyou; Dong, Bowen; Zhao, Panpan; Zhou, Hui; Qu, Lianghu</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41525</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inducing degrdn. of oncoproteins by small mol. compds. has the potential to avoid drug resistance and therefore deserves to be exploited for new therapies.  Oridonin is a natural compd. with promising antitumor efficacy that can trigger the degrdn. of oncoproteins; however, the direct cellular targets and underlying mechanisms remain unclear.  Here we report that oridonin depletes BCR-ABL through chaperon-mediated proteasomal degrdn. in leukemia.  Mechanistically, oridonin poses oxidative stress in cancer cells and directly binds to cysteines of HSF1, leading to the activation of this master regulator of the chaperone system.  The resulting induction of HSP70 and ubiquitin proteins and the enhanced binding to CHIP E3 ligase hence target BCR-ABL for ubiquitin-proteasome degrdn.  Both wild-type and mutant forms of BCR-ABL can be efficiently degraded by oridonin, supporting its efficacy obsd. in cultured cells as well as mouse tumor xenograft assays with either imatinib-sensitive or -resistant cells.  Collectively, our results identify a novel mechanism by which oridonin induces rapid degrdn. of BCR-ABL as well as a novel pharmaceutical activator of HSF1 that represents a promising treatment for leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozBGpY9acRgbVg90H21EOLACvtfcHk0lixpPRQtHRQaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVOrsLg%253D&md5=5c2a35a6f46726ecdfaf6f49e62de577</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fsrep41525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep41525%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DWeng%26aufirst%3DH.%26aulast%3DDong%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DQu%26aufirst%3DL.%26atitle%3DOridonin%2520triggers%2520chaperon-mediated%2520proteasomal%2520degradation%2520of%2520BCR-ABL%2520in%2520leukemia%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D41525%26doi%3D10.1038%2Fsrep41525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of natural product oridonin-inspired anticancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2016.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=27344488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKnsL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2016&pages=102-117&author=Y.+Dingauthor=C.+Dingauthor=N.+Yeauthor=Z.+Liuauthor=E.+A.+Woldauthor=H.+Chenauthor=C.+Wildauthor=Q.+Shenauthor=J.+Zhou&title=Discovery+and+development+of+natural+product+oridonin-inspired+anticancer+agents&doi=10.1016%2Fj.ejmech.2016.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of natural product oridonin-inspired anticancer agents</span></div><div class="casAuthors">Ding, Ye; Ding, Chunyong; Ye, Na; Liu, Zhiqing; Wold, Eric A.; Chen, Haiying; Wild, Christopher; Shen, Qiang; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">102-117</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Natural products have historically been, and continue to be, an invaluable source for the discovery of various therapeutic agents.  Oridonin, a natural diterpenoid widely applied in traditional Chinese medicines, exhibits a broad range of biol. effects including anticancer and anti-inflammatory activities.  To further improve its potency, aq. soly. and bioavailability, the oridonin template serves as an exciting platform for drug discovery to yield better candidates with unique targets and enhanced drug properties.  A no. of oridonin derivs. (e.g. HAO472) have been designed and synthesized, and have contributed to substantial progress in the identification of new agents and relevant mol. mechanistic studies toward the treatment of human cancers and other diseases.  This review summarizes the recent advances in medicinal chem. on the explorations of novel oridonin analogs as potential anticancer therapeutics, and provides a detailed discussion of future directions for the development and progression of this class of mols. into the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv6x0p1uhEt7Vg90H21EOLACvtfcHk0lixpPRQtHRQaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKnsL3E&md5=0cce14ee999e3e59fe48cf6a1249d90b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DYe%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWild%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520development%2520of%2520natural%2520product%2520oridonin-inspired%2520anticancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D122%26spage%3D102%26epage%3D117%26doi%3D10.1016%2Fj.ejmech.2016.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, R.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.-M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel Jiyuan Oridonin A-1, 2, 3-triazole-azole derivatives as antiproliferative agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">1263</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2018.08.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=30193221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1OmsL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=1249-1263&author=Y.+Keauthor=J.-J.+Liangauthor=R.-J.+Houauthor=M.-M.+Liauthor=L.-F.+Zhaoauthor=W.+Wangauthor=Y.+Liuauthor=H.+Xieauthor=R.-H.+Yangauthor=T.-X.+Huauthor=J.-Y.+Wangauthor=H.-M.+Liu&title=Synthesis+and+biological+evaluation+of+novel+Jiyuan+Oridonin+A-1%2C+2%2C+3-triazole-azole+derivatives+as+antiproliferative+agents&doi=10.1016%2Fj.ejmech.2018.08.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel Jiyuan Oridonin A-1,2,3-triazole-azole derivatives as antiproliferative agents</span></div><div class="casAuthors">Ke, Yu; Liang, Jian-Jia; Hou, Rui-Juan; Li, Ming-Ming; Zhao, Long-Fei; Wang, Wang; Liu, Ying; Xie, Hang; Yang, Rui-Hua; Hu, Tian-Xing; Wang, Jin-Yi; Liu, Hong-Min</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1249-1263</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">As a continuation of our research on developing potent and potentially safe anti-proliferative agents, two series of novel Jiyuan Oridonin A-1,2,3-triazole-azole hybrids were designed, synthesized and evaluated for their anti-proliferative activity against four selected cancer cell lines (MGC-803, MCF-7, PC-3, Eca-109).  Some compds. with better growth inhibitory effects were chosen to carry out further studies in A549 and SMMC-7721.  Most of the synthesized compds. exhibited moderate to good activity against all the cancer cell lines selected.  Particularly, the most active agent I showed high potency against human cancer cells with IC50 ranging from 0.2 ± 0.0 to 5.0 ± 0.9 μM.  Cellular mechanism studies elucidated compd. I arrests cell cycle at G1 phase and induce a strong apoptotic response in SMMC-7721 cells.  Furthermore, I could inhibit the colony formation and migration via Wnt signaling pathway in SMMC-7721 cells.  For all these reasons, compd. I holds promising potential as anti-proliferative agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo99lG7Gj981bVg90H21EOLACvtfcHk0lixpPRQtHRQaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1OmsL3F&md5=b36aebfc2935c6f6754f48cb97406554</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.056%26sid%3Dliteratum%253Aachs%26aulast%3DKe%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DJ.-J.%26aulast%3DHou%26aufirst%3DR.-J.%26aulast%3DLi%26aufirst%3DM.-M.%26aulast%3DZhao%26aufirst%3DL.-F.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DR.-H.%26aulast%3DHu%26aufirst%3DT.-X.%26aulast%3DWang%26aufirst%3DJ.-Y.%26aulast%3DLiu%26aufirst%3DH.-M.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520Jiyuan%2520Oridonin%2520A-1%252C%25202%252C%25203-triazole-azole%2520derivatives%2520as%2520antiproliferative%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D1249%26epage%3D1263%26doi%3D10.1016%2Fj.ejmech.2018.08.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span> <span> </span><span class="NLM_article-title">Effective enmein-type mimics of clinical candidate HAO472: Design, synthesis and biological evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.03.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2019.03.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=30921757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtFGktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2019&pages=169-179&author=X.+Huauthor=Z.+Baiauthor=J.+Qiaoauthor=H.+Liauthor=S.+Xuauthor=X.+Wangauthor=Y.+Xuauthor=J.+Xuauthor=H.+Huaauthor=D.+Li&title=Effective+enmein-type+mimics+of+clinical+candidate+HAO472%3A+Design%2C+synthesis+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2019.03.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Effective enmein-type mimics of clinical candidate HAO472: Design, synthesis and biological evaluation</span></div><div class="casAuthors">Hu, Xu; Bai, Ziyi; Qiao, Jian; Li, Haonan; Xu, Shengtao; Wang, Xianhua; Xu, Yongnan; Xu, Jinyi; Hua, Huiming; Li, Dahong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">169-179</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of enmein-type diterpenoid amino acid ester derivs., e.g. I, were designed and synthesized according to L-alanine-(14-oridonin) ester trifluoroacetate (clin. candidate HAO472).  Their antiproliferative activities were tested against SGC-7901, Bel-7402, HL-60, PC-3, A549 and K562 cancer cell lines and L-02 normal liver cells.  The results showed that I possessed the most potent cytotoxicity with IC50 s at sub-micromolar level against human hepatoma Bel-7402 and chronic myelogenous leukemia K562 cells and more potent than L-alanine-(14-oridonin) ester.  More importantly, I displayed 70-fold less cytotoxicity than parent II (IC50 = 25.47 μM) against L-02 cells, which exhibited certain selectivity.  Further mechanism study in Bel-7402 cells revealed that I could induce apoptosis, G1 phase cell cycle arrest and mitochondrial dysfunction.  Western blot results of caspase-3, Bax and cytochrome C up-regulation and pro-caspase-3, Bcl-2 and Bcl-xL down-regulation confirmed the intrinsic pathways.  Overall, these data collectively demonstrated the high efficiency and selectivity of I, L-phenylalanine-enmein-type diterpenoid ester, which inspires further and effective application as a potential antitumor candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKI4-bKkcdNbVg90H21EOLACvtfcHk0lixpPRQtHRQaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtFGktrk%253D&md5=eed8d737389d712a6ff470b3e8e89f41</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.03.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.03.046%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DZ.%26aulast%3DQiao%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DHua%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DD.%26atitle%3DEffective%2520enmein-type%2520mimics%2520of%2520clinical%2520candidate%2520HAO472%253A%2520Design%252C%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D171%26spage%3D169%26epage%3D179%26doi%3D10.1016%2Fj.ejmech.2019.03.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span> <span> </span><span class="NLM_article-title">Novel enmein-type diterpenoid hybrids coupled with nitrogen mustards: Synthesis of promising candidates for anticancer therapeutics</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">598</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2018.01.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=29407983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFehsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2018&pages=588-598&author=X.+Gaoauthor=J.+Liauthor=M.+Wangauthor=S.+Xuauthor=W.+Liuauthor=L.+Zangauthor=Z.+Liauthor=H.+Huaauthor=J.+Xuauthor=D.+Li&title=Novel+enmein-type+diterpenoid+hybrids+coupled+with+nitrogen+mustards%3A+Synthesis+of+promising+candidates+for+anticancer+therapeutics&doi=10.1016%2Fj.ejmech.2018.01.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Novel enmein-type diterpenoid hybrids coupled with nitrogen mustards: Synthesis of promising candidates for anticancer therapeutics</span></div><div class="casAuthors">Gao, Xiang; Li, Jia; Wang, Mingying; Xu, Shengtao; Liu, Weiwei; Zang, Linghe; Li, Zhanlin; Hua, Huiming; Xu, Jinyi; Li, Dahong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">588-598</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Natural derived enmein-type diterpenoids exert cytotoxicity against a wide range of human cancer cells.  Yet their medicinal applications are hindered by insufficient potency for chemotherapy.  Hence, a series of novel enmein-type diterpenoid hybrids coupled with nitrogen mustards were designed and synthesized to increase antitumor efficacy while reducing systemic toxicity.  Most conjugates exhibited stronger antiproliferative activities than parent diterpenoids and nitrogen mustards, esp. for multidrug-resistant tumor cell line Bel-7402/5-FU.  Among them, compd. I showed the most potent inhibitory activities in human leukemia HL-60 cells, human prostate cancer PC-3 cells, human liver cancer Bel-7402 cells and drug-resistant human liver cancer Bel-7402/5-FU cells with IC50 values of 7.83 μM, 3.97 μM, 0.77 μM and 2.07 μM, resp.  Addnl., high selectivity with selectivity index over 130 was also obsd. from cytotoxic evaluation between L-02 human normal liver cells and Bel-7402 malignant liver cells.  Further studies on mechanism of action indicated that I induced both apoptosis and G1 phase cell cycle arrest in Bel-7402 hepatoma cells.  Moreover, the dysfunction in mitochondrial pathway was also involved in I initiated apoptotic activation, which entailed the loss of mitochondrial membrane potential followed by upregulating the bax/bcl-2 ratio and increasing the expression of cytochrome c, p53, caspase-3 and -9.  Overall, I has the potential to emerge as a promising drug candidate for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobX_nRPa9xVbVg90H21EOLACvtfcHk0lj9Jjp5Rwfmgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFehsbo%253D&md5=6f238158d7604aa8a1465c7c33fb61c0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.069%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DHua%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DD.%26atitle%3DNovel%2520enmein-type%2520diterpenoid%2520hybrids%2520coupled%2520with%2520nitrogen%2520mustards%253A%2520Synthesis%2520of%2520promising%2520candidates%2520for%2520anticancer%2520therapeutics%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D146%26spage%3D588%26epage%3D598%26doi%3D10.1016%2Fj.ejmech.2018.01.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, Z.-S.</span></span> <span> </span><span class="NLM_article-title">Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: A novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2019.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=30981113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVSns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2019&pages=15-31&author=Q.-K.+Shenauthor=H.+Dengauthor=S.-B.+Wangauthor=Y.-S.+Tianauthor=Z.-S.+Quan&title=Synthesis%2C+and+evaluation+of+in+vitro+and+in+vivo+anticancer+activity+of+14-substituted+oridonin+analogs%3A+A+novel+and+potent+cell+cycle+arrest+and+apoptosis+inducer+through+the+p53-MDM2+pathway&doi=10.1016%2Fj.ejmech.2019.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: A novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway</span></div><div class="casAuthors">Shen, Qing-Kun; Deng, Hao; Wang, Shi-Ben; Tian, Yu-Shun; Quan, Zhen-Shan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-31</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel oridonin derivs. bearing various substituents on the 14-OH position, e.g., I [R = H, 5-Cl, 5-MeO, 6-F, 6-Cl, 6-Br, 6-MeO, 5,6-(MeO)2, 4,5,6-(MeO)3], were designed and synthesized.  Their antitumor activity was evaluated in vitro against three human cancer cell lines (HCT116, BEL7402, and MCF7).  Most tested derivs. showed improved anti-proliferative activity compared to the lead compd. oridonin and the pos. control drug 5-fluorouracil (5-Fu).  Among them, compd. I (R = 6-MeO) (II) (IC50 = 0.16 μM) exhibited the most potent anti-proliferative activity against HCT116 cells; it was about 43- and 155-fold more efficacious than that of oridonin (IC50 = 6.84 μM) and 5-Fu (IC50 = 24.80 μM) in HCT116 cancer cells.  Interestingly, the IC50 value of compd. II in HCT116 cells was 23.6-fold higher than that in L02 normal cells; it exhibited better selective anti-proliferative activity and specificity than oridonin and 5-Fu.  Furthermore, compd. II possibly induced cell cycle arrest and apoptosis by regulating the p53-MDM2 signaling pathway.  Notably, II displayed more significant suppression of tumor growth than oridonin in colon tumor xenograft models where the tumor growth inhibition rate was 85.82%.  Therefore, compd. II could be a potential lead compd. for the development of a novel antitumor agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Cxov2WQyEbVg90H21EOLACvtfcHk0lj9Jjp5Rwfmgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVSns7g%253D&md5=c225f3228e796acdf20ac9e15570a0af</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DQ.-K.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.-B.%26aulast%3DTian%26aufirst%3DY.-S.%26aulast%3DQuan%26aufirst%3DZ.-S.%26atitle%3DSynthesis%252C%2520and%2520evaluation%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520anticancer%2520activity%2520of%252014-substituted%2520oridonin%2520analogs%253A%2520A%2520novel%2520and%2520potent%2520cell%2520cycle%2520arrest%2520and%2520apoptosis%2520inducer%2520through%2520the%2520p53-MDM2%2520pathway%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D173%26spage%3D15%26epage%3D31%26doi%3D10.1016%2Fj.ejmech.2019.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.-M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological mechanisms research on 1, 2, 3-triazole derivatives of Jiyuan Oridonin A</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4761</span>– <span class="NLM_lpage">4773</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.bmc.2017.11.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=4761-4773&author=Y.+Keauthor=W.+Wangauthor=L.-F.+Zhaoauthor=J.-J.+Liangauthor=Y.+Liuauthor=X.+Zhangauthor=K.+Fengauthor=H.-M.+Liu&title=Design%2C+synthesis+and+biological+mechanisms+research+on+1%2C+2%2C+3-triazole+derivatives+of+Jiyuan+Oridonin+A&doi=10.1016%2Fj.bmc.2017.11.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DKe%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DL.-F.%26aulast%3DLiang%26aufirst%3DJ.-J.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DH.-M.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520mechanisms%2520research%2520on%25201%252C%25202%252C%25203-triazole%2520derivatives%2520of%2520Jiyuan%2520Oridonin%2520A%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D4761%26epage%3D4773%26doi%3D10.1016%2Fj.bmc.2017.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, S.</span></span> <span> </span><span class="NLM_article-title">Oridonin derivatives as potential anticancer drug candidates triggering apoptosis through mitochondrial pathway in the liver cancer cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">379</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2019.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=31200238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKqsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=365-379&author=D.+Luoauthor=Y.+Yiauthor=K.+Pengauthor=T.+Liuauthor=J.+Yangauthor=S.+Liuauthor=W.+Zhaoauthor=X.+Quauthor=W.+Yuauthor=Y.+Guauthor=S.+Wan&title=Oridonin+derivatives+as+potential+anticancer+drug+candidates+triggering+apoptosis+through+mitochondrial+pathway+in+the+liver+cancer+cells&doi=10.1016%2Fj.ejmech.2019.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Oridonin derivatives as potential anticancer drug candidates triggering apoptosis through mitochondrial pathway in the liver cancer cells</span></div><div class="casAuthors">Luo, Dongdong; Yi, Yujiao; Peng, Kai; Liu, Tangrong; Yang, Jiayu; Liu, Shan; Zhao, Wanzhou; Qu, Xianjun; Yu, Wengong; Gu, Yuchao; Wan, Shengbiao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">365-379</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The biol. function of the natural ent-kaurene diterpenoid isolated from genus Isodon, oridonin, has been intensively studied.  However, its mechanism studies and clin. applications were hampered by its moderate biol. activities.  In order to enlarge the applied range of oridonin and explore its mechanism of action, a series of derivs. were designed and synthesized based on the structure of oridonin.  Some of the derivs. were significantly more potent than oridonin against four cancer cell lines.  Esp., the most potent compd. 20 markedly inhibited the proliferation of well differentiated HepG2 and poorly differentiated PLC/PRF/5 cells, with IC50 values as low as 1.36 μM and 0.78 μM resp., while the IC50 values of oridonin are 8.12 μM and 7.41 μM.  We found that compd. 20 inhibited liver cancer cell proliferation via arresting cell cycle at G1 phase.  Moreover, it induced liver cancer cell apoptosis by decreasing the mitochondrial membrane potential, increasing intracellular reactive oxygen species level and inducing the expression of apoptosis-related proteins.  Furthermore, compd. 20 significantly inhibited growth of PLC/PRF/5 xenograft tumors in nude mice and had no observable toxic effect.  Altogether, these results indicated that compd. 20 is a promising lead for liver cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYfm_zSvHvr7Vg90H21EOLACvtfcHk0ljiijBiR-COZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKqsL3L&md5=b1577a59e12dbfa28bcdec3643c801e1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DYi%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DS.%26atitle%3DOridonin%2520derivatives%2520as%2520potential%2520anticancer%2520drug%2520candidates%2520triggering%2520apoptosis%2520through%2520mitochondrial%2520pathway%2520in%2520the%2520liver%2520cancer%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D178%26spage%3D365%26epage%3D379%26doi%3D10.1016%2Fj.ejmech.2019.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, T.</span></span> <span> </span><span class="NLM_article-title">Total Synthesis of (−)-Oridonin: An Interrupted-Nazarov Approach</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">20048</span>– <span class="NLM_lpage">20052</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b12034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b12034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlWkt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=20048-20052&author=L.+Kongauthor=F.+Suauthor=H.+Yuauthor=Z.+Jiangauthor=Y.+Luauthor=T.+Luo&title=Total+Synthesis+of+%28%E2%88%92%29-Oridonin%3A+An+Interrupted-Nazarov+Approach&doi=10.1021%2Fjacs.9b12034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Total Synthesis of (-)-Oridonin: An Interrupted Nazarov Approach</span></div><div class="casAuthors">Kong, Lingran; Su, Fan; Yu, Hang; Jiang, Zhe; Lu, Yandong; Luo, Tuoping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">20048-20052</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An enantioselective total synthesis of (-)-oridonin (I) is accomplished based on a key interrupted Nazarov reaction.  The stereochem. of the Nazarov/Hosomi-Sakurai cascade was first explored to forge a tetracyclic skeleton with challenging quaternary carbons.  A delicate sequence of two ring-rearrangements and late-stage redox manipulations was carried out to achieve the de novo synthesis of this highly oxidized ent-kauranoid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPvxDRyPJoorVg90H21EOLACvtfcHk0ljiijBiR-COZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlWkt77J&md5=099682884a3156fdb9442d623465ad3d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b12034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b12034%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DT.%26atitle%3DTotal%2520Synthesis%2520of%2520%2528%25E2%2588%2592%2529-Oridonin%253A%2520An%2520Interrupted-Nazarov%2520Approach%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D20048%26epage%3D20052%26doi%3D10.1021%2Fjacs.9b12034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Oridonin induces apoptosis, inhibits migration and invasion on highly-metastatic human breast cancer cells</span>. <i>Am. J. Chin. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1142/s0192415x13500134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1142%2Fs0192415x13500134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=23336515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=177-196&author=S.+Wangauthor=Z.+Zhongauthor=J.+Wanauthor=W.+Tanauthor=G.+Wuauthor=M.+Chenauthor=Y.+Wang&title=Oridonin+induces+apoptosis%2C+inhibits+migration+and+invasion+on+highly-metastatic+human+breast+cancer+cells&doi=10.1142%2Fs0192415x13500134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Oridonin Induces Apoptosis, Inhibits Migration and Invasion on Highly-Metastatic Human Breast Cancer Cells</span></div><div class="casAuthors">Wang, Shengpeng; Zhong, Zhangfeng; Wan, Jianbo; Tan, Wen; Wu, Guosheng; Chen, Meiwan; Wang, Yitao</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Chinese Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">177-196</span>CODEN:
                <span class="NLM_cas:coden">AJCMBA</span>;
        ISSN:<span class="NLM_cas:issn">0192-415X</span>.
    
            (<span class="NLM_cas:orgname">World Scientific Publishing Co. Pte. Ltd.</span>)
        </div><div class="casAbstract">Oridonin, a natural tetracycline diterpenoid isolated from Chinese herb Rabdosia rubescens, has been reported to be a potent cytotoxic agent against a wide variety of tumors.  However, its effect on highly metastatic breast cancer cells has not been addressed.  In this study, we investigated the effects of oridonin on growth, migration and invasion of highly-metastatic human breast cancer cells.  Our results showed that oridonin induced potent growth inhibition on human breast cancer cells MCF-7 and MDA-MB-231 in a time- and dose-dependent manner.  According to the flow cytometric anal., oridonin suppressed MCF-7 cell growth by cell cycle arrest at the G2/M phase and caused accumulation of MDA-MB-231 cells in the Sub-G1 phase.  The induced apoptotic effect of oridonin was further confirmed by a morphol. characteristics assay and TUNEL assay.  Oridonin triggered the redn. of Bcl-2/Bax ratio, caspase-8, NF-κB (p65), IKKα, IKKβ, phospho-mTOR, and increased expression level of cleaved PARP, Fas and PPARγ in a time-dependent manner.  Immunofluorescent anal. showed that γH2AX-contg. nuclear foci were significant in oridonin-treated MDA-MB-231 cells.  Meanwhile, oridonin significantly suppressed MDA-MB-231 cell migration and invasion, decreased MMP-2/MMP-9 activation and inhibited the expression of Integrin β1 and FAK.  In conclusion, oridonin inhibited the growth and induced apoptosis in breast cancer cells, which might be related to DNA damage and activation of intrinsic or extrinsic apoptotic pathways.  Moreover, oridonin also inhibited tumor invasion and metastasis in vitro possibly via decreasing the expression of MMPs and regulating the Integrin β1/FAK pathway in MDA-MB-231 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgWa5C-bFw1LVg90H21EOLACvtfcHk0ljiijBiR-COZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWktbY%253D&md5=29748b2273c09072683ce0e58813200f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1142%2Fs0192415x13500134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1142%252Fs0192415x13500134%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DZhong%26aufirst%3DZ.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DOridonin%2520induces%2520apoptosis%252C%2520inhibits%2520migration%2520and%2520invasion%2520on%2520highly-metastatic%2520human%2520breast%2520cancer%2520cells%26jtitle%3DAm.%2520J.%2520Chin.%2520Med.%26date%3D2013%26volume%3D41%26spage%3D177%26epage%3D196%26doi%3D10.1142%2Fs0192415x13500134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span> <span> </span><span class="NLM_article-title">Oridonin phosphate-induced autophagy effectively enhances cell apoptosis of human breast cancer cells</span>. <i>Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">365</span>, <span class="refDoi"> DOI: 10.1007/s12032-014-0365-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1007%2Fs12032-014-0365-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=25491140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A280%3ADC%252BC2MzmvFegtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=365&author=Y.+Liauthor=Y.+Wangauthor=S.+Wangauthor=Y.+Gaoauthor=X.+Zhangauthor=C.+Lu&title=Oridonin+phosphate-induced+autophagy+effectively+enhances+cell+apoptosis+of+human+breast+cancer+cells&doi=10.1007%2Fs12032-014-0365-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Oridonin phosphate-induced autophagy effectively enhances cell apoptosis of human breast cancer cells</span></div><div class="casAuthors">Li Yue; Wang Ying; Wang Suihai; Gao Yanjun; Zhang Xuefeng; Lu Chunhua</div><div class="citationInfo"><span class="NLM_cas:title">Medical oncology (Northwood, London, England)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">365</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Oridonin is an active diterpenoid, which was extracted from traditional Chinese herbs and had been widely used in clinical treatment nowadays.  Oridonin phosphate is one of the derivatives of oridonin.  In the present study, we explored its anti-tumor effect and investigated the molecular mechanism of oridonin phosphate in breast cancer cell lines.  Firstly, cell viability was analyzed by MTT assay.  The breast cancer cells were treated with increasing concentrations of oridonin phosphate for 24, 48 and 72 h, respectively.  The results demonstrated that oridonin phosphate inhibited the proliferation of MDA-MB-436 and MDA-MB-231 cells in a dose- and time-dependent manner.  Next, cell apoptosis rate was detected in oridonin phosphate-treated breast cancer cells by Annexin V-FITC/PI dual staining analysis and the data demonstrated that oridonin phosphate induced cell apoptosis of breast cancer cells in time- and dose-dependent manner.  Moreover, apoptosis-related proteins were detected by Western blotting analysis.  The results showed that the expression level of Bax was up-regulated and the expression level of Bcl-2 was down-regulated.  Meanwhile, the level of cleaved caspase-9 was significantly increased when the cells were treated with 40 μM of oridonin phosphate for 48 h, although the expression level of pro-caspase-9 was not obviously changed.  All of the data revealed that mitochondrial apoptosis pathway may be involved in the cell apoptosis induced by oridonin phosphate in breast cancer cells.  Importantly, the expression levels of autophagy-related protein beclin-1 and LC3-II were significantly higher in oridonin phosphate-treated breast cancer cell lines MDA-MB-436 and MDA-MB-231 for 48 h.  Additionally, we further explored the relationship between apoptosis and autophagy specifically induced by oridonin phosphate in breast cancer cells.  The result showed that inhibition of autophagy suppressed the cell apoptosis in oridonin phosphate-treated MDA-MB-436 cells.  Taken together, the compound of oridonin phosphate simultaneously induced cell apoptosis and autophagy in breast cancer cells.  Inhibition oridonin phosphate-induced cell autophagy suppressed the progression of cell apoptosis, which revealed that oridonin phosphate-induced autophagy participated in up-regulation of apoptosis in human breast cancer cells.  It would provide some new clues for the therapy of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxuey5f2gs6LJzI8owOhpDfW6udTcc2eZjaVoALzMiXLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzmvFegtQ%253D%253D&md5=1fcc603503c057f62e1782358c3c4079</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs12032-014-0365-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12032-014-0365-1%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DC.%26atitle%3DOridonin%2520phosphate-induced%2520autophagy%2520effectively%2520enhances%2520cell%2520apoptosis%2520of%2520human%2520breast%2520cancer%2520cells%26jtitle%3DMed.%2520Oncol.%26date%3D2015%26volume%3D32%26spage%3D365%26doi%3D10.1007%2Fs12032-014-0365-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ester, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Oridonin ring A-based diverse constructions of enone functionality: identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8814</span>– <span class="NLM_lpage">8825</span>, <span class="refDoi"> DOI: 10.1021/jm401248x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401248x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1aht7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8814-8825&author=C.+Dingauthor=Y.+Zhangauthor=H.+Chenauthor=Z.+Yangauthor=C.+Wildauthor=N.+Yeauthor=C.+D.+Esterauthor=A.+Xiongauthor=M.+A.+Whiteauthor=Q.+Shenauthor=J.+Zhou&title=Oridonin+ring+A-based+diverse+constructions+of+enone+functionality%3A+identification+of+novel+dienone+analogues+effective+for+highly+aggressive+breast+cancer+by+inducing+apoptosis&doi=10.1021%2Fjm401248x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Oridonin Ring A Based Diverse Constructions of Enone Functionality: Identification of Novel Dienone Analogues Effective for Highly Aggressive Breast Cancer by Inducing Apoptosis</span></div><div class="casAuthors">Ding, Chunyong; Zhang, Yusong; Chen, Haijun; Yang, Zhengduo; Wild, Christopher; Ye, Na; Ester, Corbin D.; Xiong, Ailian; White, Mark A.; Shen, Qiang; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8814-8825</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oridonin (I) has attracted considerable attention in recent years because of its unique and safe anticancer pharmacol. profile.  Nevertheless, it exhibits moderate to poor effects against highly aggressive cancers including triple-neg. and drug-resistant breast cancer cells.  Herein, we report the rational design and synthesis of novel dienone derivs. with an addnl. α,β-unsatd. ketone system diversely installed in the A-ring based on this class of natural scaffold that features dense functionalities and stereochem.-rich frameworks.  Efficient and regioselective enone construction strategies have been established.  Meanwhile, a unique 3,7-rearrangement reaction was identified to furnish an unprecedented dienone scaffold.  Intriguingly, these new analogs have been demonstrated to significantly induce apoptosis and inhibit colony formation with superior antitumor effects against aggressive and drug-resistant breast cancer cells in vitro and in vivo while also exhibiting comparable or lower toxicity to normal human mammary epithelial cells in comparison with I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp42KnrzHKFwbVg90H21EOLACvtfcHk0liMNX6OzrbLQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1aht7nJ&md5=467a07903a1d9f8c4df11c5dfa15bfc5</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm401248x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401248x%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWild%26aufirst%3DC.%26aulast%3DYe%26aufirst%3DN.%26aulast%3DEster%26aufirst%3DC.%2BD.%26aulast%3DXiong%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DM.%2BA.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DOridonin%2520ring%2520A-based%2520diverse%2520constructions%2520of%2520enone%2520functionality%253A%2520identification%2520of%2520novel%2520dienone%2520analogues%2520effective%2520for%2520highly%2520aggressive%2520breast%2520cancer%2520by%2520inducing%2520apoptosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8814%26epage%3D8825%26doi%3D10.1021%2Fjm401248x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5048</span>– <span class="NLM_lpage">5058</span>, <span class="refDoi"> DOI: 10.1021/jm400367n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400367n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVeqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5048-5058&author=C.+Dingauthor=Y.+Zhangauthor=H.+Chenauthor=Z.+Yangauthor=C.+Wildauthor=L.+Chuauthor=H.+Liuauthor=Q.+Shenauthor=J.+Zhou&title=Novel+nitrogen-enriched+oridonin+analogues+with+thiazole-fused+A-ring%3A+protecting+group-free+synthesis%2C+enhanced+anticancer+profile%2C+and+improved+aqueous+solubility&doi=10.1021%2Fjm400367n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Nitrogen-Enriched Oridonin Analogues with Thiazole-Fused A-Ring: Protecting Group-Free Synthesis, Enhanced Anticancer Profile, and Improved Aqueous Solubility</span></div><div class="casAuthors">Ding, Chunyong; Zhang, Yusong; Chen, Haijun; Yang, Zhengduo; Wild, Christopher; Chu, Lili; Liu, Huiling; Shen, Qiang; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5048-5058</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oridonin (I), a complex ent-kaurane diterpenoid isolated from the traditional Chinese herb Isodon rubescens, has demonstrated great potential in the treatment of various human cancers due to its unique and safe anticancer pharmacol. profile.  Nevertheless, the clin. development of oridonin for cancer therapy has been hampered by its relatively moderate potency, limited aq. soly., and poor bioavailability.  Herein, we report the concise synthesis of a series of novel nitrogen-enriched oridonin derivs. with thiazole-fused A-ring through an efficient protecting group-free synthetic strategy.  Most of them, including compds. II [R = Me; R = NR1R2, R1 = Me, CHMe2, n-Bu, cyclohexyl, 2-(piperidin-1-yl)ethyl, allyl], exhibited potent antiproliferative effects against breast, pancreatic, and prostate cancer cells with low micromolar to submicromolar IC50 values as well as markedly enhanced aq. soly.  These new analogs obtained by rationally modifying the natural product have been shown not only to significantly induce the apoptosis and suppress growth of triple-neg. MDA-MB-231 breast cancer both in vitro and in vivo but are also effective against drug-resistant ER-pos. MCF-7 clones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfnEskkayfSLVg90H21EOLACvtfcHk0liMNX6OzrbLQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVeqtL0%253D&md5=b7ec95c47f40492b7aea80159cbbe9bb</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm400367n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400367n%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWild%26aufirst%3DC.%26aulast%3DChu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DNovel%2520nitrogen-enriched%2520oridonin%2520analogues%2520with%2520thiazole-fused%2520A-ring%253A%2520protecting%2520group-free%2520synthesis%252C%2520enhanced%2520anticancer%2520profile%252C%2520and%2520improved%2520aqueous%2520solubility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5048%26epage%3D5058%26doi%3D10.1021%2Fjm400367n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span> <span> </span><span class="NLM_article-title">A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.06.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.canlet.2016.06.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=27387452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFant7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2016&pages=393-402&author=J.+Wuauthor=Y.+Dingauthor=C.-H.+Chenauthor=Z.+Zhouauthor=C.+Dingauthor=H.+Chenauthor=J.+Zhouauthor=C.+Chen&title=A+new+oridonin+analog+suppresses+triple-negative+breast+cancer+cells+and+tumor+growth+via+the+induction+of+death+receptor+5&doi=10.1016%2Fj.canlet.2016.06.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5</span></div><div class="casAuthors">Wu, Jing; Ding, Ye; Chen, Chuan-Huizhi; Zhou, Zhongmei; Ding, Chunyong; Chen, Haiying; Zhou, Jia; Chen, Ceshi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">393-402</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) remains the leading cause of death among women with breast cancer worldwide.  Oridonin is a natural anti-cancer compd. that is isolated from the traditional Chinese herb Rabdosia rubescens.  However, the antitumor efficacies of oridonin in the treatments of TNBC and other cancers are far from ideal.  In this study, we investigated a series of newly designed oridonin analogs in terms of their actions against HCC1806 and HCC1937 TNBC cell lines and identified CYD-6-28, which significantly inhibits cancer cell proliferation and induces G2/M-phase cell cycle arrest and apoptosis.  CYD-6-28 induces the expression of p21 and the cleavage of caspase-3, -7, -8 and PARP and inhibits the expression levels of Cyclin D1, FLIPL and XIAP.  CYD-6-28 also inhibits the activations of STAT3 and AKT and induces the activation of ERK.  We demonstrated that CYD-6-28 induces apoptosis at least partially by inducing the expression of death receptor 5 (DR5).  Finally, CYD-6-28 significantly suppresses HCC1806 xenograft tumor growth in nude mice at 5 mg/kg without affecting body wt.  Taken together, these results indicate that CYD-6-28 has the potential to be developed as a therapeutic agent to treat TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwRKWDYjI09bVg90H21EOLACvtfcHk0ljOzwTi_xhLaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFant7%252FO&md5=b550f5511d3bec8d73774cecf290aa81</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DA%2520new%2520oridonin%2520analog%2520suppresses%2520triple-negative%2520breast%2520cancer%2520cells%2520and%2520tumor%2520growth%2520via%2520the%2520induction%2520of%2520death%2520receptor%25205%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D380%26spage%3D393%26epage%3D402%26doi%3D10.1016%2Fj.canlet.2016.06.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Overcoming synthetic challenges of oridonin A-ring structural diversification: regio-and stereoselective installation of azides and 1, 2, 3-triazoles at the C-1, C-2, or C-3 position</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3718</span>– <span class="NLM_lpage">3721</span>, <span class="refDoi"> DOI: 10.1021/ol4015865</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol4015865" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKqtL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=3718-3721&author=C.+Dingauthor=Y.+Zhangauthor=H.+Chenauthor=C.+Wildauthor=T.+Wangauthor=M.+A.+Whiteauthor=Q.+Shenauthor=J.+Zhou&title=Overcoming+synthetic+challenges+of+oridonin+A-ring+structural+diversification%3A+regio-and+stereoselective+installation+of+azides+and+1%2C+2%2C+3-triazoles+at+the+C-1%2C+C-2%2C+or+C-3+position&doi=10.1021%2Fol4015865"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming Synthetic Challenges of Oridonin A-Ring Structural Diversification: Regio- and Stereoselective Installation of Azides and 1,2,3-Triazoles at the C-1, C-2, or C-3 Position</span></div><div class="casAuthors">Ding, Chunyong; Zhang, Yusong; Chen, Haijun; Wild, Christopher; Wang, Tianzhi; White, Mark A.; Shen, Qiang; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3718-3721</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Efficient and concise synthetic approaches have been developed for the rapid and diverse installation of azide functionalities at the C-1, C-2, or C-3 positions of oridonin with highly controlled regio- and stereoselectivity, while keeping key reactive pharmacophores intact by utilizing unique preactivation strategies based on the common synthon I.  Further functionalization of these azides through click chem. yielding triazole derivs. successfully provides access to an expanded natural scaffold-based compd. library for potential anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1L_ezFF5FhrVg90H21EOLACvtfcHk0ljOzwTi_xhLaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKqtL%252FN&md5=3471ade39c5ccc1631d2d3cec830414e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fol4015865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol4015865%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWild%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DM.%2BA.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DOvercoming%2520synthetic%2520challenges%2520of%2520oridonin%2520A-ring%2520structural%2520diversification%253A%2520regio-and%2520stereoselective%2520installation%2520of%2520azides%2520and%25201%252C%25202%252C%25203-triazoles%2520at%2520the%2520C-1%252C%2520C-2%252C%2520or%2520C-3%2520position%26jtitle%3DOrg.%2520Lett.%26date%3D2013%26volume%3D15%26spage%3D3718%26epage%3D3721%26doi%3D10.1021%2Fol4015865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Regio-and stereospecific synthesis of oridonin D-ring aziridinated analogues for the treatment of triple-negative breast cancer via mediated irreversible covalent warheads</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2737</span>– <span class="NLM_lpage">2752</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGjur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2737-2752&author=Y.+Dingauthor=D.+Liauthor=C.+Dingauthor=P.+Wangauthor=Z.+Liuauthor=E.+A.+Woldauthor=N.+Yeauthor=H.+Chenauthor=M.+A.+Whiteauthor=Q.+Shenauthor=J.+Zhou&title=Regio-and+stereospecific+synthesis+of+oridonin+D-ring+aziridinated+analogues+for+the+treatment+of+triple-negative+breast+cancer+via+mediated+irreversible+covalent+warheads&doi=10.1021%2Facs.jmedchem.7b01514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Regio- and Stereospecific Synthesis of Oridonin D-Ring Aziridinated Analogues for the Treatment of Triple-Negative Breast Cancer via Mediated Irreversible Covalent Warheads</span></div><div class="casAuthors">Ding, Ye; Li, Dengfeng; Ding, Chunyong; Wang, Pingyuan; Liu, Zhiqing; Wold, Eric A.; Ye, Na; Chen, Haiying; White, Mark A.; Shen, Qiang; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2737-2752</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Covalent drug discovery has undergone a resurgence in recent years due to comprehensive optimization of the structure-activity relationship (SAR) and the structure-reactivity relationship (SRR) for covalent drug candidates.  The natural product oridonin maintains an impressive pharmacol. profile through its covalent enone warhead on the D-ring and has attracted substantial SAR studies to characterize its potential in the development of new mol. entities for the treatment of various human cancers and inflammation.  Herein, for the first time, we report the excessive reactivity of this covalent warhead and mediation of the covalent binding capability through a Rh2(esp)2-catalyzed mild and concise regio- and stereospecific aziridination approach.  Importantly, aziridonin I (YD0514), with a more-druglike irreversible covalent warhead, has been identified to significantly induce apoptosis and inhibit colony formation against triple-neg. breast cancer with enhanced antitumor effects in vitro and in vivo while displaying lower toxicity to normal human mammary epithelial cells in comparison to oridonin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-HLJjmpeUUbVg90H21EOLACvtfcHk0ljOzwTi_xhLaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGjur8%253D&md5=97c421639ae1f21bf3b0e349ba07212d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01514%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DYe%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWhite%26aufirst%3DM.%2BA.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DRegio-and%2520stereospecific%2520synthesis%2520of%2520oridonin%2520D-ring%2520aziridinated%2520analogues%2520for%2520the%2520treatment%2520of%2520triple-negative%2520breast%2520cancer%2520via%2520mediated%2520irreversible%2520covalent%2520warheads%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2737%26epage%3D2752%26doi%3D10.1021%2Facs.jmedchem.7b01514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span> <span> </span><span class="NLM_article-title">Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>424</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2018.03.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.canlet.2018.03.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=29580806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXms1Ghsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=424&publication_year=2018&pages=97-108&author=D.+Liauthor=H.+Wangauthor=Y.+Dingauthor=Z.+Zhangauthor=Z.+Zhengauthor=J.+Dongauthor=H.+Kimauthor=X.+Mengauthor=Q.+Zhouauthor=J.+Zhouauthor=L.+Fangauthor=Q.+Shen&title=Targeting+the+NRF-2%2FRHOA%2FROCK+signaling+pathway+with+a+novel+aziridonin%2C+YD0514%2C+to+suppress+breast+cancer+progression+and+lung+metastasis&doi=10.1016%2Fj.canlet.2018.03.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis</span></div><div class="casAuthors">Li, Dengfeng; Wang, Hong; Ding, Ye; Zhang, Ziwei; Zheng, Zhi; Dong, Jiabin; Kim, Hyejin; Meng, Xiaojing; Zhou, Qianjun; Zhou, Jia; Fang, Lin; Shen, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">424</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">97-108</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Metastasis is a major cause of breast cancer-assocd. mortality.  Natural products extd. from herbs provide rich bioactive compds. with anticancer efficacy but may have limited or moderate potency and considerable toxicity.  We developed a novel aziridonin, YD0514, by aziridinating oridonin, a natural product of the medicinal herb Rabdosia rubescens.  In this study, we found that YD0514 significantly inhibited proliferation, motility, and adhesion of metastatic breast cancer cell lines MDA-MB-231, GI101, GILM2, and GILM3.  YD0514 also decreased the protein expression of matrix metalloproteinases 2 and 9 (MMP2 and MMP9), focal adhesion kinase (FAK), and integrin family members.  Importantly, YD0514 suppressed the growth of metastatic breast cancer xenograft tumors and significantly inhibited lung metastasis in vivo.  Lastly, we showed that YD0514's anti-metastatic effect on highly aggressive breast cancer is mediated via regulating the NRF-2/RHOA/ROCK signaling pathway.  These results demonstrate that YD0514, the first active analog based on an oridonin D-ring modification, has the potential to be developed as an anti-metastasis therapy for patients with metastatic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoql0Gzj4yj_bVg90H21EOLACvtfcHk0lgCnhJHGvo7Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXms1Ghsb8%253D&md5=eb619b17e9b1d81f625baf721fdc71a6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2018.03.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2018.03.029%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DQ.%26atitle%3DTargeting%2520the%2520NRF-2%252FRHOA%252FROCK%2520signaling%2520pathway%2520with%2520a%2520novel%2520aziridonin%252C%2520YD0514%252C%2520to%2520suppress%2520breast%2520cancer%2520progression%2520and%2520lung%2520metastasis%26jtitle%3DCancer%2520Lett.%26date%3D2018%26volume%3D424%26spage%3D97%26epage%3D108%26doi%3D10.1016%2Fj.canlet.2018.03.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">A novel potent anticancer compound optimized from a natural oridonin scaffold induces apoptosis and cell cycle arrest through the mitochondrial pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1449</span>– <span class="NLM_lpage">1468</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01652</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01652" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFWiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1449-1468&author=S.+Xuauthor=H.+Yaoauthor=S.+Luoauthor=Y.-K.+Zhangauthor=D.-H.+Yangauthor=D.+Liauthor=G.+Wangauthor=M.+Huauthor=Y.+Qiuauthor=X.+Wuauthor=H.+Yaoauthor=W.+Xieauthor=Z.-S.+Chenauthor=J.+Xu&title=A+novel+potent+anticancer+compound+optimized+from+a+natural+oridonin+scaffold+induces+apoptosis+and+cell+cycle+arrest+through+the+mitochondrial+pathway&doi=10.1021%2Facs.jmedchem.6b01652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway</span></div><div class="casAuthors">Xu, Shengtao; Yao, Hong; Luo, Shanshan; Zhang, Yun-Kai; Yang, Dong-Hua; Li, Dahong; Wang, Guangyu; Hu, Mei; Qiu, Yangyi; Wu, Xiaoming; Yao, Hequan; Xie, Weijia; Chen, Zhe-Sheng; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1449-1468</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The cytotoxicity of the natural ent-kaurene diterpenoid, oridonin, has been extensively studied.  However, the application of oridonin for cancer therapy was hampered primarily by its moderate potency.  In this study, a series of oridonin A-ring modified analogs, and their derivs. bearing various substituents on 14-OH position, were designed, synthesized and evaluated for anticancer efficacy.  Some of the derivs. were significantly more potent than oridonin against both drug-sensitive and drug-resistant cancer cells.  The most potent compd., I, was 200-fold more efficacious than oridonin in MCF-7 cancer cells.  Furthermore, I induced apoptosis and cell cycle arrest at the G2/M phase.  A decrease in mitochondrial membrane potential and increased Bax/Bcl-2 ratio, accompanied by activated caspase-3 cleavage, were obsd. in MCF-7 cells after treatment with I, suggesting that the mitochondrial pathway was involved in the I-mediated apoptosis.  Moreover, I significantly inhibited tumor growth in mouse xenograft models and had no observable toxic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpho5HBZ5sjAbVg90H21EOLACvtfcHk0lgCnhJHGvo7Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFWiur0%253D&md5=41ea3cb2bb52b27e4eea18ee90e60fd0</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01652%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.-K.%26aulast%3DYang%26aufirst%3DD.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DZ.-S.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DA%2520novel%2520potent%2520anticancer%2520compound%2520optimized%2520from%2520a%2520natural%2520oridonin%2520scaffold%2520induces%2520apoptosis%2520and%2520cell%2520cycle%2520arrest%2520through%2520the%2520mitochondrial%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1449%26epage%3D1468%26doi%3D10.1021%2Facs.jmedchem.6b01652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sager, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, B.</span></span> <span> </span><span class="NLM_article-title">Hydroxyl Groups in Synthetic and Natural Product Derived Therapeutics–A Perspective on a Common Functional Group</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8915</span>– <span class="NLM_lpage">8930</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00179</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00179" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlOjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8915-8930&author=J.+Cramerauthor=C.+P.+Sagerauthor=B.+Ernst&title=Hydroxyl+Groups+in+Synthetic+and+Natural+Product+Derived+Therapeutics%E2%80%93A+Perspective+on+a+Common+Functional+Group&doi=10.1021%2Facs.jmedchem.9b00179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxyl Groups in Synthetic and Natural-Product-Derived Therapeutics: A Perspective on a Common Functional Group</span></div><div class="casAuthors">Cramer, Jonathan; Sager, Christoph P.; Ernst, Beat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8915-8930</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  By forming extended hydrogen bond networks, the contribution of hydroxyl groups to affinity can reach several orders of magnitude.  However, because of the high directionality of their interactions, a maximal affinity gain can only be achieved when the ligand scaffold allows a perfect spatial fit with the binding site.  In contrast to the broad potential of hydroxyl groups for mol. recognition is their exceptionally high desolvation penalty, which can equally reduce binding affinity.  As a consequence, alcs. are rarely present in synthetic drugs, but predominantly found in therapeutics derived directly or inspired from natural products, which were shaped under evolutionary pressure.  In this perspective, advantages as well as drawbacks influencing the use of OH groups in medicinal chem. are discussed and illustrated with four exemplary case studies.  Addnl., guidelines for drug design are derived from common features found in existing therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Ay8IcfLbF7Vg90H21EOLACvtfcHk0lgCnhJHGvo7Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlOjsLY%253D&md5=5fff184a72d160ae211d4bc3d8dfba47</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00179%26sid%3Dliteratum%253Aachs%26aulast%3DCramer%26aufirst%3DJ.%26aulast%3DSager%26aufirst%3DC.%2BP.%26aulast%3DErnst%26aufirst%3DB.%26atitle%3DHydroxyl%2520Groups%2520in%2520Synthetic%2520and%2520Natural%2520Product%2520Derived%2520Therapeutics%25E2%2580%2593A%2520Perspective%2520on%2520a%2520Common%2520Functional%2520Group%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8915%26epage%3D8930%26doi%3D10.1021%2Facs.jmedchem.9b00179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">The structural modification of natural products for novel drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1272757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1080%2F17460441.2016.1272757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=28006993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2sXivVek" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=121-140&author=H.+Yaoauthor=J.+Liuauthor=S.+Xuauthor=Z.+Zhuauthor=J.+Xu&title=The+structural+modification+of+natural+products+for+novel+drug+discovery&doi=10.1080%2F17460441.2016.1272757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The structural modification of natural products for novel drug discovery</span></div><div class="casAuthors">Yao, Hong; Liu, Junkai; Xu, Shengtao; Zhu, Zheying; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-140</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Throughout history, natural products (NPs) have provided a rich source of compds. that have wide applications in the fields of medicine, health sciences, pharmacy and biol.  Although naturally active substances are good lead compds. for the discovery of new drugs, most of them suffer from various deficiencies or shortcomings, such as complex structures, poor stability and soly.  Therefore, structural modification of NPs is needed to develop novel compds. with specific properties.: This article presents an overview on the structural modifications of NPs in drug development.  The application of multiple classes of NPs to the treatment of conditions such as cancers, infection, Alzheimer's and diabetes are discussed.  This article also reveals that modification of NPs is a versatile approach to explore their mode of actions, which may lead to the discovery of novel drugs.: NPs are usually described by structural diversity and complexity.  The use of isolated NPs as scaffolds for modification is a good approach to drug discovery and development.  Despite many limitations assocd. with NPs, the total synthesis, semisynthetic modification, SAR-based modification, sometimes even a single atom alteration, may lead to the discovery of a novel drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6S_a4H8DIPLVg90H21EOLACvtfcHk0ljKSpoy29xxoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXivVek&md5=46b49696429d04c7982c315339a2c9bb</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1272757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1272757%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DThe%2520structural%2520modification%2520of%2520natural%2520products%2520for%2520novel%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2017%26volume%3D12%26spage%3D121%26epage%3D140%26doi%3D10.1080%2F17460441.2016.1272757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Structural simplification of natural products</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">4180</span>– <span class="NLM_lpage">4220</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.8b00504</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.8b00504" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFGntrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2019&pages=4180-4220&author=S.+Wangauthor=G.+Dongauthor=C.+Sheng&title=Structural+simplification+of+natural+products&doi=10.1021%2Facs.chemrev.8b00504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Simplification of Natural Products</span></div><div class="casAuthors">Wang, Shengzheng; Dong, Guoqiang; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">4180-4220</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Natural products (NPs) are important sources of clin. drugs due to their structural diversity and biol. prevalidation.  However, the structural complexity of NPs leads to synthetic difficulties, unfavorable pharmacokinetic profiles, and poor drug-likeness.  Structural simplification by truncating unnecessary substructures is a powerful strategy for overcoming these limitations and improving the efficiency and success rate of NP-based drug development.  Herein, we will provide a comprehensive review of the structural simplification of NPs with a focus on design strategies, case studies, and new technologies.  In particular, a no. of successful examples leading to marketed drugs or drug candidates will be discussed in detail to illustrate how structural simplification is applied in lead optimization of NPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3XsYo2dUwabVg90H21EOLACvtfcHk0ljKSpoy29xxoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFGntrw%253D&md5=7cec4ad3ab49a40e82c72447524f5523</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.8b00504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.8b00504%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DStructural%2520simplification%2520of%2520natural%2520products%26jtitle%3DChem.%2520Rev.%26date%3D2019%26volume%3D119%26spage%3D4180%26epage%3D4220%26doi%3D10.1021%2Facs.chemrev.8b00504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Novel anticancer oridonin derivatives possessing a diazen-1-ium-1, 2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2795</span>– <span class="NLM_lpage">2800</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.04.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.bmcl.2016.04.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=27158140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnt1Ohsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2795-2800&author=S.+Xuauthor=G.+Wangauthor=Y.+Linauthor=Y.+Zhangauthor=L.+Peiauthor=H.+Yaoauthor=M.+Huauthor=Y.+Qiuauthor=Z.+Huangauthor=Y.+Zhangauthor=J.+Xu&title=Novel+anticancer+oridonin+derivatives+possessing+a+diazen-1-ium-1%2C+2-diolate+nitric+oxide+donor+moiety%3A+Design%2C+synthesis%2C+biological+evaluation+and+nitric+oxide+release+studies&doi=10.1016%2Fj.bmcl.2016.04.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies</span></div><div class="casAuthors">Xu, Shengtao; Wang, Guangyu; Lin, Yan; Zhang, Yanju; Pei, Lingling; Yao, Hong; Hu, Mei; Qiu, Yangyi; Huang, Zhangjian; Zhang, Yihua; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2795-2800</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Oridonin (I) is a complex ent-kaurane diterpenoid with unique antitumor profile, which is isolated from Isodon rubescens.  In order to develop novel derivs. of oridonin with improved potency, a series of nitric oxide (NO)-releasing oridonin derivs. were synthesized by coupling diazeniumdiolates with oridonin and its semisynthesized analogs.  Their in vitro antiproliferative activity, nitric oxide release ability, and preliminary anticancer mechanism were further evaluated.  The results displayed that all the target compds. exhibited potent antiproliferative activities, with IC50 values ranging from 1.84 to 17.01 μM.  Besides, it was obsd. that in most cases, the antiproliferative activity correlated well with levels of intracellular NO release.  More interestingly, preliminary mechanism studies revealed that the most potent compd. II induced apoptosis and arrested the cell cycle at the S phase in Bel-7402 cells, which is different from parent compd. oridonin.  Together, the above promising results warrant the further development of oridonin/NO hybrids as potential antitumor leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXhYN12V1_WbVg90H21EOLACvtfcHk0ljKSpoy29xxoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnt1Ohsr8%253D&md5=220727c1cafb5a7f059c4812b4f243f8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.04.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.04.068%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DNovel%2520anticancer%2520oridonin%2520derivatives%2520possessing%2520a%2520diazen-1-ium-1%252C%25202-diolate%2520nitric%2520oxide%2520donor%2520moiety%253A%2520Design%252C%2520synthesis%252C%2520biological%2520evaluation%2520and%2520nitric%2520oxide%2520release%2520studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2795%26epage%3D2800%26doi%3D10.1016%2Fj.bmcl.2016.04.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">310</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.03.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2017.03.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=28395199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVCrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2017&pages=310-321&author=S.+Xuauthor=H.+Yaoauthor=L.+Peiauthor=M.+Huauthor=D.+Liauthor=Y.+Qiuauthor=G.+Wangauthor=L.+Wuauthor=H.+Yaoauthor=Z.+Zhuauthor=J.+Xu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+NAD%28P%29H%3A+Quinone+oxidoreductase+%28NQO1%29-targeted+oridonin+prodrugs+possessing+indolequinone+moiety+for+hypoxia-selective+activation&doi=10.1016%2Fj.ejmech.2017.03.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation</span></div><div class="casAuthors">Xu, Shengtao; Yao, Hong; Pei, Lingling; Hu, Mei; Li, Dahong; Qiu, Yangyi; Wang, Guangyu; Wu, Liang; Yao, Hequan; Zhu, Zheying; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">310-321</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The enzyme NQO1 is a potential target for selective cancer therapy due to its overexpression in certain hypoxic tumors.  A series of prodrugs possessing a variety of cytotoxic diterpenoids (oridonin and its analogs) as the leaving groups activated by NQO1 were synthesized by functionalization of 3-(hydroxymethyl)indolequinone, which is a good substrate of NQO1.  The target compds. exhibited relatively higher antiproliferative activities against NQO1-rich human colon carcinoma cells (HT-29) and human lung carcinoma (A549) cells (IC50 = 0.263-2.904 μM), while NQO1-deficient lung adenosquamous carcinoma cells (H596) were less sensitive to these compds., among which, compd. I exhibited the most potent antiproliferative activity against both A549 and HT-29 cells, with IC50 values of 0.386 and 0.263 μM, resp.  Further HPLC and docking studies demonstrated that I is a good substrate of NQO1.  Moreover, the investigation of anticancer mechanism showed that the representative compd. I affected cell cycle and induced NQO1 dependent apoptosis through an oxidative stress triggered mitochondria-related pathway in A549 cells.  Besides, the antitumor activity of I was also verified in a liver cancer xenograft mouse model.  Biol. evaluation of these compds. concludes that there is a strong correlation between NQO1 enzyme and induction of cancer cell death.  Thus, this suggests that some of the target compds. activated by NQO1 are novel prodrug candidates potential for selective anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUnJI_Q_X6ErVg90H21EOLACvtfcHk0liYVwSZbVZYTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVCrurc%253D&md5=5436e872c6b9f388096a8c76488f9767</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.03.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.03.055%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DPei%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520NAD%2528P%2529H%253A%2520Quinone%2520oxidoreductase%2520%2528NQO1%2529-targeted%2520oridonin%2520prodrugs%2520possessing%2520indolequinone%2520moiety%2520for%2520hypoxia-selective%2520activation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D132%26spage%3D310%26epage%3D321%26doi%3D10.1016%2Fj.ejmech.2017.03.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">6, 7-Seco-ent-kauranoids derived from oridonin as potential anticancer agents</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">2391</span>– <span class="NLM_lpage">2398</span>, <span class="refDoi"> DOI: 10.1021/acs.jnatprod.7b00057</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jnatprod.7b00057" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVOju7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2017&pages=2391-2398&author=S.+Xuauthor=H.+Yaoauthor=M.+Huauthor=D.+Liauthor=Z.+Zhuauthor=W.+Xieauthor=H.+Yaoauthor=L.+Wuauthor=Z.-S.+Chenauthor=J.+Xu&title=6%2C+7-Seco-ent-kauranoids+derived+from+oridonin+as+potential+anticancer+agents&doi=10.1021%2Facs.jnatprod.7b00057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">6,7-Seco-ent-Kauranoids Derived from Oridonin as Potential Anticancer Agents</span></div><div class="casAuthors">Xu, Shengtao; Yao, Hong; Hu, Mei; Li, Dahong; Zhu, Zheying; Xie, Weijia; Yao, Hequan; Wu, Liang; Chen, Zhe-Sheng; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2391-2398</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">Structurally unique 6,7-seco-ent-kaurenes, which are widely distributed in the genus Isodon, have attracted considerable attention because of their antitumor activities.  Previously, a convenient conversion of com. available oridonin to 6,7-seco-ent-kaurenes was developed.  Herein, several novel spiro-lactone-type ent-kaurene derivs. bearing various substituents at the C-1 and C-14 positions were further designed and synthesized from the natural product oridonin.  Moreover, a no. of seven-membered C-ring-expanded 6,7-seco-ent-kaurenes were also identified for the first time.  It was obsd. that most of the spiro-lactone-type ent-kaurenes tested markedly inhibited the proliferation of cancer cells, with an IC50 value as low as 0.55 μM.  An investigation on its mechanism of action showed that the representative compd. 7b (ent-6,7,15-trioxo-7,20-epoxy(14β-O-p-floroienzoyl)-1-alkene-6,7-seco-16-kaurene) affected the cell cycle and induced apoptosis at a low micromolar level in MCF-7 human breast cancer cells.  Furthermore, compd. 7b inhibited liver tumor growth in an in vivo mouse model and exhibited no observable toxic effects.  Collectively, the results warrant further preclin. investigations of these spiro-lactone-type ent-kaurenes as potential novel anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVPu7Z3RMnSbVg90H21EOLACvtfcHk0liYVwSZbVZYTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVOju7rM&md5=31e2ffa92a5cf1abcb84941e2eca4d7d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jnatprod.7b00057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jnatprod.7b00057%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DZ.-S.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3D6%252C%25207-Seco-ent-kauranoids%2520derived%2520from%2520oridonin%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2017%26volume%3D80%26spage%3D2391%26epage%3D2398%26doi%3D10.1021%2Facs.jnatprod.7b00057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">797</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.1021/ml500141f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500141f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1WqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=797-802&author=S.+Xuauthor=L.+Peiauthor=C.+Wangauthor=Y.-K.+Zhangauthor=D.+Liauthor=H.+Yaoauthor=X.+Wuauthor=Z.-S.+Chenauthor=Y.+Sunauthor=J.+Xu&title=Novel+hybrids+of+natural+oridonin-bearing+nitrogen+mustards+as+potential+anticancer+drug+candidates&doi=10.1021%2Fml500141f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Hybrids of Natural Oridonin-Bearing Nitrogen Mustards as Potential Anticancer Drug Candidates</span></div><div class="casAuthors">Xu, Shengtao; Pei, Lingling; Wang, Chengqian; Zhang, Yun-Kai; Li, Dahong; Yao, Hequan; Wu, Xiaoming; Chen, Zhe-Sheng; Sun, Yijun; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">797-802</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel hybrids from natural product oridonin and nitrogen mustards were designed and synthesized to obtain more efficacious and less toxic antitumor agents.  The antiproliferative evaluation showed that most conjugates were more potent than their parent compds. oridonin and clin. used nitrogen mustards against four human cancer cell lines (K562, MCF-7, Bel-7402, and MGC-803).  Furthermore, some compds. exhibited antiproliferative activities against the multidrug resistant cell lines (SW620/AD300 and NCI-H460/MX20).  It was shown that the most effective compd. I possesses a strong inhibitory activity with an IC50 value 21-fold lower than that of oridonin in MCF-7 cells and also exhibits selective cytotoxicity toward the cancer cells.  Intriguingly, compd. I has been demonstrated to significantly induce apoptosis and affect cell cycle progression in human hepatoma Bel-7402 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWN_rVEgplcLVg90H21EOLACvtfcHk0liYVwSZbVZYTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1WqtLw%253D&md5=a07e486f15a5e587e074ac957b319c6c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fml500141f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500141f%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DPei%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.-K.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.-S.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DNovel%2520hybrids%2520of%2520natural%2520oridonin-bearing%2520nitrogen%2520mustards%2520as%2520potential%2520anticancer%2520drug%2520candidates%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D797%26epage%3D802%26doi%3D10.1021%2Fml500141f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: Synthesis and biological evaluation of ent-6, 7-seco-oridonin derivatives as novel potential anticancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">242</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.03.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2012.03.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=22483090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtlSksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=242-250&author=L.+Wangauthor=D.+Liauthor=S.+Xuauthor=H.+Caiauthor=H.+Yaoauthor=Y.+Zhangauthor=J.+Jiangauthor=J.+Xu&title=The+conversion+of+oridonin+to+spirolactone-type+or+enmein-type+diterpenoid%3A+Synthesis+and+biological+evaluation+of+ent-6%2C+7-seco-oridonin+derivatives+as+novel+potential+anticancer+agents&doi=10.1016%2Fj.ejmech.2012.03.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: Synthesis and biological evaluation of ent-6,7-seco-oridonin derivatives as novel potential anticancer agents</span></div><div class="casAuthors">Wang, Lei; Li, Dahong; Xu, Shengtao; Cai, Hao; Yao, Hequan; Zhang, Yihua; Jiang, Jieyun; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">242-250</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Starting from com. available natural product oridonin (I), a practical synthesis of ent-6,7-seco-oridonin derivs., e.g., II and III, was accomplished and their biol. activities were evaluated.  The conversion of spirolactone-type diterpenoid to enmein-type was first completed.  The results demonstrated that all synthesized ent-6,7-seco-oridonin derivs. could markedly inhibit the proliferation of cancer cells.  Compared with Taxol, the most cytotoxic compd. II has similar potency in A549 cell and slightly less cytotoxicity in Bel-7402 cell.  II was also more potent than parent compd. oridonin in mice with MGC-803 gastric cancer in vivo.  Then a series of novel 14-O-derivs. of II were further designed and synthesized, which showed better activity than II and similar activity as Taxol in vitro.  The structure-activity relationships of oridonin derivs. were also discussed in the present investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2rgdU2mwym7Vg90H21EOLACvtfcHk0liArtQ6KDcIfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtlSksrw%253D&md5=0cb57a6483e63f89885807a8cf5b5da0</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.03.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.03.024%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DThe%2520conversion%2520of%2520oridonin%2520to%2520spirolactone-type%2520or%2520enmein-type%2520diterpenoid%253A%2520Synthesis%2520and%2520biological%2520evaluation%2520of%2520ent-6%252C%25207-seco-oridonin%2520derivatives%2520as%2520novel%2520potential%2520anticancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D52%26spage%3D242%26epage%3D250%26doi%3D10.1016%2Fj.ejmech.2012.03.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Enmein-type diterpenoid analogs from natural kaurene-type oridonin: Synthesis and their antitumor biological evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2013.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=23644204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFOmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=215-221&author=D.+Liauthor=S.+Xuauthor=H.+Caiauthor=L.+Peiauthor=H.+Zhangauthor=L.+Wangauthor=H.+Yaoauthor=X.+Wuauthor=J.+Jiangauthor=Y.+Sunauthor=J.+Xu&title=Enmein-type+diterpenoid+analogs+from+natural+kaurene-type+oridonin%3A+Synthesis+and+their+antitumor+biological+evaluation&doi=10.1016%2Fj.ejmech.2013.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Enmein-type diterpenoid analogs from natural kaurene-type oridonin: Synthesis and their antitumor biological evaluation</span></div><div class="casAuthors">Li, Dahong; Xu, Shengtao; Cai, Hao; Pei, Lingling; Zhang, Hengyuan; Wang, Lei; Yao, Hequan; Wu, Xiaoming; Jiang, Jieyun; Sun, Yijun; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">215-221</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of enmein-type diterpenoid analogs derived from natural kaurene-type diterpenoid oridonin were synthesized and biol. evaluated.  All target compds. showed improved anti-proliferative activities against four human cancer cell lines compared with natural oridonin and the parent compd.  Some compds. were more potent than pos. control Taxol.  Furthermore, mechanistic investigation showed that the representative compd. I affected cell cycle and induced apoptosis at low micro-molar level in human hepatoma Bel-7402 cells, via an oxidative stress triggered mitochondria-related caspase-dependent pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq08za9z5IyLVg90H21EOLACvtfcHk0liArtQ6KDcIfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFOmtL8%253D&md5=fe2faf2585f4da95c9b2c130a41bd015</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DPei%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DEnmein-type%2520diterpenoid%2520analogs%2520from%2520natural%2520kaurene-type%2520oridonin%253A%2520Synthesis%2520and%2520their%2520antitumor%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D64%26spage%3D215%26epage%3D221%26doi%3D10.1016%2Fj.ejmech.2013.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and antimycobacterial activity evaluation of natural oridonin derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2811</span>– <span class="NLM_lpage">2814</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.04.119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.bmcl.2014.04.119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=24835198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFGlsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2811-2814&author=S.+Xuauthor=D.+Liauthor=L.+Peiauthor=H.+Yaoauthor=C.+Wangauthor=H.+Caiauthor=H.+Yaoauthor=X.+Wuauthor=J.+Xu&title=Design%2C+synthesis+and+antimycobacterial+activity+evaluation+of+natural+oridonin+derivatives&doi=10.1016%2Fj.bmcl.2014.04.119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and antimycobacterial activity evaluation of natural oridonin derivatives</span></div><div class="casAuthors">Xu, Shengtao; Li, Dahong; Pei, Lingling; Yao, Hong; Wang, Chengqian; Cai, Hao; Yao, Hequan; Wu, Xiaoming; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2811-2814</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In an effort to develop novel potent antitubercular drugs, thirty-one oridonin derivs. were designed and prepd.  All the compds. obtained were screened for their in vitro activities against Mycobacterium phlei, Mycobacterium smegmatis and Mycobacterium marinum.  Among them, thirteen compds. showed significant inhibitory activity against M. phlei with MICs less than 2 μg/mL.  I, II and III (R = H, F) contg. trans-cinnamic acid moiety were the most potent (MIC = 0.5 μg/mL), comparable to the well-known antitubercular drug streptomycin.  The preliminary structure-activity relationships (SARs) were also analyzed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgZ3jyzlwXnbVg90H21EOLACvtfcHk0liArtQ6KDcIfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFGlsro%253D&md5=dc86b69534096ace890c588bc3f5e787</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.04.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.04.119%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DPei%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520antimycobacterial%2520activity%2520evaluation%2520of%2520natural%2520oridonin%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2811%26epage%3D2814%26doi%3D10.1016%2Fj.bmcl.2014.04.119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of spirolactone-type diterpenoid derivatives from kaurene-type oridonin with improved antiproliferative effects and their apoptosis-inducing activity in human hepatoma Bel-7402 cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2012.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=23274570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CnsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2013&pages=322-328&author=D.+Liauthor=H.+Caiauthor=B.+Jiangauthor=G.+Liuauthor=Y.+Wangauthor=L.+Wangauthor=H.+Yaoauthor=X.+Wuauthor=Y.+Sunauthor=J.+Xu&title=Synthesis+of+spirolactone-type+diterpenoid+derivatives+from+kaurene-type+oridonin+with+improved+antiproliferative+effects+and+their+apoptosis-inducing+activity+in+human+hepatoma+Bel-7402+cells&doi=10.1016%2Fj.ejmech.2012.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of spirolactone-type diterpenoid derivatives from kaurene-type oridonin with improved antiproliferative effects and their apoptosis-inducing activity in human hepatoma Bel-7402 cells</span></div><div class="casAuthors">Li, Dahong; Cai, Hao; Jiang, Bowen; Liu, Guyue; Wang, Yuetong; Wang, Lei; Yao, Hequan; Wu, Xiaoming; Sun, Yijun; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">322-328</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel spirolactone-type diterpenoid derivs. I (R = Me, Et, Bu, Ph, C6H4R'-4, C6H4Cl-2; R' = Me, OMe, CF3, NO2, Cl) of oridonin (II) were designed and synthesized.  All the target compds. showed improved anti-proliferative activity against a panel of human cancer cell lines and the most effective compd. I (R = C6H4Cl-2) was more potent than pos. control Taxol in K562 and Bel-7402 cells with IC50 values of 0.39 μM and 1.39 μM, resp.  The cellular mechanisms showed that compd. I (R = C6H4Cl-2) induced apoptosis at low micromolar concns. in human hepatoma Bel-7402 cells.  These results demonstrate that the spirolactone-type diterpenoid derivs. of oridonin (II) have optimized growth inhibitory activity against cancer cells and interesting apoptosis-inducing ability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaxRr56kGxoLVg90H21EOLACvtfcHk0lhWJbiaqdmJLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CnsLY%253D&md5=383c580be734fe21c83e745fb8a989ee</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DSynthesis%2520of%2520spirolactone-type%2520diterpenoid%2520derivatives%2520from%2520kaurene-type%2520oridonin%2520with%2520improved%2520antiproliferative%2520effects%2520and%2520their%2520apoptosis-inducing%2520activity%2520in%2520human%2520hepatoma%2520Bel-7402%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D59%26spage%3D322%26epage%3D328%26doi%3D10.1016%2Fj.ejmech.2012.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Library Construction and Biological Evaluation of Enmein-Type Diterpenoid Analogues as Potential Anticancer Agents</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">812</span>– <span class="NLM_lpage">818</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1002%2Fcmdc.201200559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=23520191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkt1Kmu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=812-818&author=D.+Liauthor=S.+Xuauthor=H.+Caiauthor=L.+Peiauthor=L.+Wangauthor=X.+Wuauthor=H.+Yaoauthor=J.+Jiangauthor=Y.+Sunauthor=J.+Xu&title=Library+Construction+and+Biological+Evaluation+of+Enmein-Type+Diterpenoid+Analogues+as+Potential+Anticancer+Agents&doi=10.1002%2Fcmdc.201200559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Library Construction and Biological Evaluation of Enmein-Type Diterpenoid Analogs as Potential Anticancer Agents</span></div><div class="casAuthors">Li, Dahong; Xu, Shengtao; Cai, Hao; Pei, Lingling; Wang, Lei; Wu, Xiaoming; Yao, Hequan; Jiang, Jieyun; Sun, Yijun; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">812-818</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A library of promising enmein-type 14-O-diterpenoid derivs. was constructed from a com. available kaurene-type oridonin by practical and efficient synthetic methods.  These synthetic derivs. were evaluated for their antiproliferative activities against a set of four human cancer cell lines.  The IC50 values are similar to or improved over those of the parent mol. and paclitaxel, the latter of which was used as a pos. control.  One compd. was further investigated for its apoptotic properties against human hepatocarcinoma Bel-7402 cells to better understand its mode of action.  Moreover, said compd. was shown to have potent antitumor activity in vivo in studies with a murine model of gastric cancer (MGC-803 mice).  These results warrant further preclin. investigations of these diterpenoid-based analogs as potential novel anticancer chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDgo7iZxPz27Vg90H21EOLACvtfcHk0lhWJbiaqdmJLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkt1Kmu7Y%253D&md5=badf4285fabc9c75b77e5d600a551d63</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200559%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DPei%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DLibrary%2520Construction%2520and%2520Biological%2520Evaluation%2520of%2520Enmein-Type%2520Diterpenoid%2520Analogues%2520as%2520Potential%2520Anticancer%2520Agents%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D812%26epage%3D818%26doi%3D10.1002%2Fcmdc.201200559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarthy, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shyr, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietenpol, J. A.</span></span> <span> </span><span class="NLM_article-title">Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">2750</span>– <span class="NLM_lpage">2767</span>, <span class="refDoi"> DOI: 10.1172/jci45014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1172%2Fjci45014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=21633166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVKgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=2750-2767&author=B.+D.+Lehmannauthor=J.+A.+Bauerauthor=X.+Chenauthor=M.+E.+Sandersauthor=A.+B.+Chakravarthyauthor=Y.+Shyrauthor=J.+A.+Pietenpol&title=Identification+of+human+triple-negative+breast+cancer+subtypes+and+preclinical+models+for+selection+of+targeted+therapies&doi=10.1172%2Fjci45014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</span></div><div class="casAuthors">Lehmann, Brian D.; Bauer, Joshua A.; Chen, Xi; Sanders, Melinda E.; Chakravarthy, A. Bapsi; Shyr, Yu; Pietenpol, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2750-2767</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a highly diverse group of cancers, and subtyping is necessary to better identify mol.-based therapies.  In this study, we analyzed gene expression (GE) profiles from 21 breast cancer data sets and identified 587 TNBC cases.  Cluster anal. identified 6 TNBC subtypes displaying unique GE and ontologies, including 2 basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR) subtype.  Further, GE anal. allowed us to identify TNBC cell line models representative of these subtypes.  Predicted "driver" signaling pathways were pharmacol. targeted in these cell line models as proof of concept that anal. of distinct GE signatures can inform therapy selection.  BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines preferentially responded to cisplatin.  M and MSL subtypes were enriched in GE for epithelial-mesenchymal transition, and growth factor pathways and cell models responded to NVP-BEZ235 (a PI3K/mTOR inhibitor) and dasatinib (an abl/src inhibitor).  The LAR subtype includes patients with decreased relapse-free survival and was characterized by androgen receptor (AR) signaling.  LAR cell lines were uniquely sensitive to bicalutamide (an AR antagonist).  These data may be useful in biomarker selection, drug discovery, and clin. trial design that will enable alignment of TNBC patients to appropriate targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbhoQQUFogW7Vg90H21EOLACvtfcHk0lhWJbiaqdmJLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVKgu78%253D&md5=c3681c79e0b972f16f6d5a5ecdc99fec</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1172%2Fjci45014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci45014%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DBauer%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSanders%26aufirst%3DM.%2BE.%26aulast%3DChakravarthy%26aufirst%3DA.%2BB.%26aulast%3DShyr%26aufirst%3DY.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DIdentification%2520of%2520human%2520triple-negative%2520breast%2520cancer%2520subtypes%2520and%2520preclinical%2520models%2520for%2520selection%2520of%2520targeted%2520therapies%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D2750%26epage%3D2767%26doi%3D10.1172%2Fjci45014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buolamwini, J.</span></span> <span> </span><span class="NLM_article-title">Cell cycle molecular targets in novel anticancer drug discovery</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">392</span>, <span class="refDoi"> DOI: 10.2174/1381612003400948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.2174%2F1381612003400948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10788588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjt1Cltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=379-392&author=J.+Buolamwini&title=Cell+cycle+molecular+targets+in+novel+anticancer+drug+discovery&doi=10.2174%2F1381612003400948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle molecular targets in novel anticancer drug discovery</span></div><div class="casAuthors">Buolamwini, John K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">379-392</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review with 79 refs.  A no. of potential mol. targets for novel anticancer drug discovery have been identified in cell cycle control mechanisms.  Prominent among these are the regulatory proteins, cyclins and their effector counterparts the cyclin dependent kinases (CDKs).  Aberrant expression of these proteins, particularly cyclins involved in the G1 phase of the cell cycle, namely the D and E cyclins, has been assocd. with a variety of human cancers, including breast and colorectal cancer, B-lymphoma, prostate and non-small cell lung cancer.  Inhibition of CDK kinase activity has turned out to be the most productive strategy for the discovery and design novel anticancer agents specifically targeting the cell cycle.  Other potentially useful cell cycle areas for exploration include cyclin-CDK interactions, Cdc25 activation of cyclin-CDK complexes, ubiquitin-mediated proteolysis of cyclins, cell cycle check point kinases like Chk1, and recently identified oncogenic cell cycle-related aurora and polo-like kinases.  Potent specific inhibitors have been identified that bind to the ATP site of CDKs, mainly cyclin B-CDK1, cyclin A-CDK2, and cyclin D-CDK4 complexes, and inhibit kinase activity.  X-ray crystallog. data of CDKs, and their complexes with inhibitors have played a major role in the success of drug discovery efforts.  Combinatorial chem., high-throughput screening, functional genomics and informatics have also contributed.  CDK inhibitors currently under investigation include flavopiridol, olomoucine, roscovitine, puvalanol B, the dihydroindolo[3,2-d][1]benzazepinone kenpaullone, indirubin-3'-monoxime and novel diaminothiazoles such as AG12275.  The anticancer therapeutic potential of CDK inhibitors has been demonstrated in preclin. studies, and Phases I and II clin. trials in cancer patients are currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqehW2hdiN9mrVg90H21EOLACvtfcHk0lhWJbiaqdmJLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjt1Cltb8%253D&md5=9a480b0daaa4559e9f0d6c36f0586732</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F1381612003400948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612003400948%26sid%3Dliteratum%253Aachs%26aulast%3DBuolamwini%26aufirst%3DJ.%26atitle%3DCell%2520cycle%2520molecular%2520targets%2520in%2520novel%2520anticancer%2520drug%2520discovery%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2000%26volume%3D6%26spage%3D379%26epage%3D392%26doi%3D10.2174%2F1381612003400948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tristão, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessoa, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamichi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batista, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durão Junior, M. d. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monte, J. C. M.</span></span> <span> </span><span class="NLM_article-title">Synergistic effect of apoptosis and necroptosis inhibitors in cisplatin-induced nephrotoxicity</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1007/s10495-015-1190-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1007%2Fs10495-015-1190-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=26519037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOgtb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=51-59&author=V.+R.+Trist%C3%A3oauthor=E.+A.+Pessoaauthor=R.+Nakamichiauthor=L.+A.+Reisauthor=M.+C.+Batistaauthor=M.+d.+S.+Dur%C3%A3o+Juniorauthor=J.+C.+M.+Monte&title=Synergistic+effect+of+apoptosis+and+necroptosis+inhibitors+in+cisplatin-induced+nephrotoxicity&doi=10.1007%2Fs10495-015-1190-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic effect of apoptosis and necroptosis inhibitors in cisplatin-induced nephrotoxicity</span></div><div class="casAuthors">Tristao, Vivian Regina; Pessoa, Edson A.; Nakamichi, Renata; Reis, Luciana A.; Batista, Marcelo Costa; Junior, Marcelino de Souza Durao; Monte, Julio Cesar Martins</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-59</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Necroptosis is a nonapoptotic cell death pathway.  We aim to study the effect of necrostatin-1 (a specific necroptosis inhibitor) in cisplatin-induced injury.  We analyzed the effect of the combined use of inhibitors of apoptosis (z-vad) and necroptosis (necrostatin-1) in acute kidney injury by cisplatin in human proximal tubule cells.  Our results showed moderate effectiveness in cytoprotection after treatment with z-vad.  But the concomitant use of inhibitors (z-vad and necrostatin-1) presented synergistic and additive protection.  The present study analyzed the caspase-3 activity and we obsd. a significant decrease in the group treated with z-vad and cisplatin.  However we did not observe changes in the group treated with both inhibitors (z-vad and necrostatin-1) and cisplatin.  Thus, demonstrating that necroptosis is a caspase-independent mechanism.  We also analyzed the effect of necrostatin-1 in vivo model.  C57BL/6 mice were treated with cisplatin and/or inhibitors.  The concomitant use of inhibitors (z-vad and necrostatin-1) recovered renal function and decreased levels of urinary Ngal.  Addnl., we analyzed the expression of RIP-1, a specific marker for necroptosis.  In animals treated with cisplatin and z-VAD levels of RIP-1 were higher.  This result reinforces that necroptosis occurs only in conditions where apoptosis was blocked.  However, the use of both inhibitors (z-vad and necrostatin-1) provided addnl. protection.  In conclusion, our study has a significant potential to show in vitro and in vivo protection obtained by necrostatin-1.  Therefore, our results suggest that necroptosis may be an important mechanism of cell death after kidney injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrusb22tWWXS7Vg90H21EOLACvtfcHk0lgHLQ0l6iYF3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOgtb3L&md5=ddb2974b419a811fd21d76cb0ef8cb28</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs10495-015-1190-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-015-1190-5%26sid%3Dliteratum%253Aachs%26aulast%3DTrist%25C3%25A3o%26aufirst%3DV.%2BR.%26aulast%3DPessoa%26aufirst%3DE.%2BA.%26aulast%3DNakamichi%26aufirst%3DR.%26aulast%3DReis%26aufirst%3DL.%2BA.%26aulast%3DBatista%26aufirst%3DM.%2BC.%26aulast%3DDur%25C3%25A3o%2BJunior%26aufirst%3DM.%2Bd.%2BS.%26aulast%3DMonte%26aufirst%3DJ.%2BC.%2BM.%26atitle%3DSynergistic%2520effect%2520of%2520apoptosis%2520and%2520necroptosis%2520inhibitors%2520in%2520cisplatin-induced%2520nephrotoxicity%26jtitle%3DApoptosis%26date%3D2016%26volume%3D21%26spage%3D51%26epage%3D59%26doi%3D10.1007%2Fs10495-015-1190-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, P.</span></span> <span> </span><span class="NLM_article-title">Formal synthesis of semiaquilegin A</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1123</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2009.12.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.tetlet.2009.12.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Wrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=1121-1123&author=J.+Liauthor=Y.+Jiangauthor=Q.+Liauthor=Q.+Xiaoauthor=Y.+Jiaauthor=P.+Tu&title=Formal+synthesis+of+semiaquilegin+A&doi=10.1016%2Fj.tetlet.2009.12.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Formal synthesis of semiaquilegin A</span></div><div class="casAuthors">Li, Jing; Jiang, Yong; Li, Qingjiang; Xiao, Qiang; Jia, Yanxing; Tu, Pengfei</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1121-1123</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A formal synthesis of semiaquilegin A is achieved starting from readily available oridonin in 19 linear steps, providing I.  The abs. configuration of the natural product has been established.  A variety of useful analogs were prepd. through this synthetic route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobSkDSV0ejm7Vg90H21EOLACvtfcHk0lgHLQ0l6iYF3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Wrug%253D%253D&md5=a3faa991827a40a4f8ffb167856b48a5</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2009.12.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2009.12.118%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DXiao%26aufirst%3DQ.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DP.%26atitle%3DFormal%2520synthesis%2520of%2520semiaquilegin%2520A%26jtitle%3DTetrahedron%2520Lett.%26date%3D2010%26volume%3D51%26spage%3D1121%26epage%3D1123%26doi%3D10.1016%2Fj.tetlet.2009.12.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piyachaturawat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saengsawang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, S.-B.</span></span> <span> </span><span class="NLM_article-title">Structural modification of oridonin via DAST induced rearrangement</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">29548</span>– <span class="NLM_lpage">29554</span>, <span class="refDoi"> DOI: 10.1039/c8ra05728a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1039%2Fc8ra05728a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFCjtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=29548-29554&author=D.-D.+Luoauthor=K.+Pengauthor=J.-Y.+Yangauthor=P.+Piyachaturawatauthor=W.+Saengsawangauthor=L.+Aoauthor=W.-Z.+Zhaoauthor=Y.+Tangauthor=S.-B.+Wan&title=Structural+modification+of+oridonin+via+DAST+induced+rearrangement&doi=10.1039%2Fc8ra05728a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Structural modification of oridonin via DAST induced rearrangement</span></div><div class="casAuthors">Luo, Dong-Dong; Peng, Kai; Yang, Jia-Yu; Piyachaturawat, Pawinee; Saengsawang, Witchuda; Ao, Lei; Zhao, Wan-Zhou; Tang, Yu; Wan, Sheng-Biao</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">29548-29554</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A simple and efficient protocol was developed for the syntheses of oridonin analogs, e.g., I, i.e. 6,20-epoxy ent-kaurane diterpenoid analogs from oridonin via diethylaminosulfur trifluoride (DAST) promoted rearrangement, most of which exhibited superior anticancer activities compared with their precursor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqF5w8CqsFA7Vg90H21EOLACvtfcHk0lgHLQ0l6iYF3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFCjtrzK&md5=4da877324bfba65093341626302c3fe8</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1039%2Fc8ra05728a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc8ra05728a%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DD.-D.%26aulast%3DPeng%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DJ.-Y.%26aulast%3DPiyachaturawat%26aufirst%3DP.%26aulast%3DSaengsawang%26aufirst%3DW.%26aulast%3DAo%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DW.-Z.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DS.-B.%26atitle%3DStructural%2520modification%2520of%2520oridonin%2520via%2520DAST%2520induced%2520rearrangement%26jtitle%3DRSC%2520Adv.%26date%3D2018%26volume%3D8%26spage%3D29548%26epage%3D29554%26doi%3D10.1039%2Fc8ra05728a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Run-Zhu Fan, Lin Chen, Tong Su, Wei Li, Jia-Luo Huang, Jun Sang, Gui-Hua Tang, <span class="NLM_string-name hlFld-ContribAuthor">Sheng Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 8,9-seco-ent-Kaurane Diterpenoids as Potential Leads for the Treatment of Triple-Negative Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (14)
                                     , 9926-9942. <a href="https://doi.org/10.1021/acs.jmedchem.1c00166" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00166</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00166%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B8%25252C9-seco-ent-Kaurane%252BDiterpenoids%252Bas%252BPotential%252BLeads%252Bfor%252Bthe%252BTreatment%252Bof%252BTriple-Negative%252BBreast%252BCancer%26aulast%3DFan%26aufirst%3DRun-Zhu%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D28012021%26date%3D08072021%26volume%3D64%26issue%3D14%26spage%3D9926%26epage%3D9942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yue  Zhao</span>, <span class="hlFld-ContribAuthor ">Weiwei  Xiao</span>, <span class="hlFld-ContribAuthor ">Wanqing  Peng</span>, <span class="hlFld-ContribAuthor ">Qinghua  Huang</span>, <span class="hlFld-ContribAuthor ">Kunru  Wu</span>, <span class="hlFld-ContribAuthor ">Colin E.  Evans</span>, <span class="hlFld-ContribAuthor ">Xinguang  Liu</span>, <span class="hlFld-ContribAuthor ">Hua  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Oridonin-Loaded Nanoparticles Inhibit Breast Cancer Progression Through Regulation of ROS-Related Nrf2 Signaling Pathway. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Bioengineering and Biotechnology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fbioe.2021.600579" title="DOI URL">https://doi.org/10.3389/fbioe.2021.600579</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fbioe.2021.600579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffbioe.2021.600579%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Bioengineering%2520and%2520Biotechnology%26atitle%3DOridonin-Loaded%252BNanoparticles%252BInhibit%252BBreast%252BCancer%252BProgression%252BThrough%252BRegulation%252Bof%252BROS-Related%252BNrf2%252BSignaling%252BPathway%26aulast%3DZhao%26aufirst%3DYue%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Structural Modification of Oridonin Yields A More Potent Anticancer Agent. </span><span class="cited-content_cbyCitation_journal-name">Synfacts</span><span> <strong>2020,</strong>,, 1228. <a href="https://doi.org/10.1055/s-0040-1705904" title="DOI URL">https://doi.org/10.1055/s-0040-1705904</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0040-1705904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0040-1705904%26sid%3Dliteratum%253Aachs%26jtitle%3DSynfacts%26atitle%3DStructural%252BModification%252Bof%252BOridonin%252BYields%252BA%252BMore%252BPotent%252BAnticancer%252BAgent%26date%3D2020%26date%3D2020%26volume%3D16%26issue%3D10%26spage%3D1228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of oridonin and some representative oridonin analogues reported to be effective against breast cancer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>14</b> and <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TsOH, MeCH(OMe)<sub>2</sub>, dry acetone, reflux, 10 min, 95%; (b) 30% H<sub>2</sub>O<sub>2</sub> (water solution), 6 N NaOH, MeOH, 0 °C, 88%; (c) pyridine, DMAP, PhOC(S)Cl, dichloromethane, 0 °C-rt, 75%; (d) AIBN, <i>n</i>-Bu<sub>3</sub>SnH, toluene, reflux, 85%; (e) MsCl, Et<sub>3</sub>N, dichloromethane, rt, overnight; (f) LiBr, Li<sub>2</sub>CO<sub>3</sub>, DMF, 110 °C, 2 h; (g) 10% HCl, THF (v/v, 1:1), rt, 0.5 h, 55% from <b>11</b>; and (h) DAST, dichloromethane, −20 °C, 41% from <b>11</b>.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>18</b>, <b>19</b>, and <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) MsCl, TEA, 0 °C, 2 h; (b) LiBr, Li<sub>2</sub>CO<sub>3</sub>, DMF, 110 °C, 0.5 h; (c) 10% HCl, THF (v/v, 1:1), rt, 0.5 h, 54% from <b>8</b>; (d) acetic anhydride, TsOH, 40 °C, 84%; and (e) DAST, dichloromethane, −20 °C, 75%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>25</b> and <b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, CS<sub>2</sub>, MeI, imidazole, THF, 0 °C-rt, 88%; (b) AIBN, <i>n</i>-Bu<sub>3</sub>SnH, toluene, reflux, 85%; (c) MsCl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight; (d) LiBr, Li<sub>2</sub>CO<sub>3</sub>, DMF, 110 °C, 2 h; (e) 10% HCl, THF (v/v, 1:1), rt, 0.5 h, 58% from <b>22</b>; and (f) acetic anhydride, TsOH, 40 °C, 83%.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) trifluoroacetic anhydride, DMAP, rt, 2 h, 90%; (b) DAST, dichloromethane, −20 °C, 70%; and (c) 0.5 N NaOH, TBAB, 75%.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>30–64</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) corresponding acids, DMAP, EDCI, dichloromethane, rt, 2–72 h, 35–89%.</p></p></figure><figure data-id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>56</b>-induced G2/M arrest in HCC1806 cancer cells. HCC1806 cells were incubated with different concentrations of <b>56</b> (0, 50, 100, and 200 nM) for 48 h. (a) Cells were harvested and stained with PI and then analyzed by flow cytometry. (b) Histograms display the cell cycle distribution percentages. (c) Western blot analysis of the G2/M-related protein. Cells were harvested and lysed for the detection of p-cdc25c, cdc2, and cyclin B1. (d) Histograms display the density ratios of cdc2, cdc25c, and cyclin B1 to GAPDH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>56</b>-induced apoptosis in HCC1806 cancer cells. (a) Flow cytometry analysis of apoptotic HCC1806 breast cancer cells induced by <b>56</b> at different concentrations (48 h). (b) Apoptotic ratio of different concentrations of <b>56</b> in HCC1806 breast cancer cells. The values are the means ± SD of at least three independent experiments. ***<i>p</i> < 0.001 compared to the vehicle control group (DMSO, vehicle control). (c) Western blot analysis of biomarkers for apoptosis induced by <b>56</b> in HCC1806 cells at different concentrations (48 h). (d,e) Histograms display the density ratios of Bad, Bax, Bcl-2, PI3K, p-PI3K, Akt, p-Akt, mTOR, and p-mTOR to GAPDH. Data are represented as the mean ± SD of three independent experiments. ***<i>p</i> < 0.001 compared to control cells. (f) Protective effects of necrostatin-1 and z-VAD in HCC1806 cells. HCC1806 cells were pretreated with vehicle or 50 μM z-VAD or/and necrostatin-1 for 2 h and then was incubated with 200 nM compound <b>56</b> for 72 h. The values are the means ± SD of at least three independent experiments. ***<i>p</i> < 0.001 vs the control group; <sup>###</sup><i>p</i> < 0.001 vs the compound <b>56</b>-treated group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Accumulation of ROS production in HCC1806 cells induced by <b>56</b> (48 h). (a) Generation of ROS was measured using the ROS-detecting fluorescent dye DCFH<sub>2</sub>-DA in combination with FACScan flow cytometry. (b) Corresponding histograms of FACScan flow cytometry are shown. ***<i>p</i> < 0.001 compared to control cells. <sup>###</sup><i>p</i> < 0.001, 200 nM <b>56</b>-treated cells compared with NAC and 200 nM <b>56</b>-treated cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of <b>56</b> on metastasis, invasion, and adhesion of HCC1806 cells. (a,b) Scratches of HCC1806 cell colonies were generated with pipette tips (200 μL). After 24 or 48 h of incubation with 0, 50, 100, and 200 nM compound <b>56</b>, representative images were captured using phase contrast microscopy. *<i>p</i> < 0.05 and ***<i>p</i> < 0.001 vs the control group. (c,d) HCC1806 cells were seeded onto chambers and incubated with <b>56</b> (0, 50, 100, and 200 nM) for 24 h. Cells that migrated through the chambers were stained with crystal violet, and representative images were captured. ***<i>p</i> < 0.001 vs the control group. (e,f) HCC1806 cells were incubated with <b>56</b> (0, 50, 100, and 200 nM) in 96-well plates for 24 h, and the nonadherent cells were washed away with phosphate-buffered saline, while the adhesive cells were counted using phase contrast microscopy. ***<i>p</i> < 0.001 vs the control group. (g) Western blot analysis of biomarkers for migration in HCC1806 cells treated with different concentrations of <b>56</b> (48 h). (h) Histograms display the density ratios of MMP-2, MMP-9, integrin β1, FAK, p-FAK, and EGFR to GAPDH. Data are represented as the mean ± SD of three independent experiments. ***<i>p</i> < 0.001; control compared with <b>56</b>-treated cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>56</b> suppressed TNBC cell xenograft growth <i>in vivo</i>. (a) Bioluminescence images of tumor growth in luciferase-based HCC1806 xenograft nude mice from day 0 to day 21. (b) Normal HCC1806 cell xenograft tumor volume changes during treatment. ***<i>p</i> < 0.001 vs the control group. (c) Images of normal HCC1806 tumors from mice 23 days after initiation of treatment. After administering vehicle, paclitaxel (6 mg/kg per 2 days), <b>56</b> (12.5 mg/kg per day), and <b>56</b> (25 mg/kg per day) for 23 days, the mice were sacrificed, and the tumors were weighed. (d) Weight of the excised tumors of each group. ***<i>p</i> < 0.001 vs the control group; <sup>#</sup><i>p</i> < 0.05 vs the paclitaxel group. (e) Body weight changes of mice during treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. H&E, Ki67, and TUNEL immunohistochemical staining of tumors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/medium/jm0c00408_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. H&E staining of the heart, liver, spleen, lung, and kidney of mice. No abnormalities in these organs were observed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00408/20200806/images/large/jm0c00408_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00408&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i85">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52501" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52501" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 46 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sachs, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Ligt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopper, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogola, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bounova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weeber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balgobind, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracanin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begthel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korving, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Boxtel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelieveld, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hoeck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blokzijl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijman, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoogstraat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Ven, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinzalla, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boj, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voest, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessels, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Diest, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vries, R. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuppen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clevers, H.</span></span> <span> </span><span class="NLM_article-title">A living biobank of breast cancer organoids captures disease heterogeneity</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.cell.2017.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=29224780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCisr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=373-386&author=N.+Sachsauthor=J.+de+Ligtauthor=O.+Kopperauthor=E.+Gogolaauthor=G.+Bounovaauthor=F.+Weeberauthor=A.+V.+Balgobindauthor=K.+Windauthor=A.+Gracaninauthor=H.+Begthelauthor=J.+Korvingauthor=R.+van+Boxtelauthor=A.+A.+Duarteauthor=D.+Lelieveldauthor=A.+van+Hoeckauthor=R.+F.+Ernstauthor=F.+Blokzijlauthor=I.+J.+Nijmanauthor=M.+Hoogstraatauthor=M.+van+de+Venauthor=D.+A.+Eganauthor=V.+Zinzallaauthor=J.+Mollauthor=S.+F.+Bojauthor=E.+E.+Voestauthor=L.+Wesselsauthor=P.+J.+van+Diestauthor=S.+Rottenbergauthor=R.+G.+J.+Vriesauthor=E.+Cuppenauthor=H.+Clevers&title=A+living+biobank+of+breast+cancer+organoids+captures+disease+heterogeneity&doi=10.1016%2Fj.cell.2017.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity</span></div><div class="casAuthors">Sachs, Norman; de Ligt, Joep; Kopper, Oded; Gogola, Ewa; Bounova, Gergana; Weeber, Fleur; Balgobind, Anjali Vanita; Wind, Karin; Gracanin, Ana; Begthel, Harry; Korving, Jeroen; van Boxtel, Ruben; Duarte, Alexandra Alves; Lelieveld, Daphne; van Hoeck, Arne; Ernst, Robert Frans; Blokzijl, Francis; Nijman, Isaac Johannes; Hoogstraat, Marlous; van de Ven, Marieke; Egan, David Anthony; Zinzalla, Vittoria; Moll, Jurgen; Boj, Sylvia Fernandez; Voest, Emile Eugene; Wessels, Lodewyk; van Diest, Paul Joannes; Rottenberg, Sven; Vries, Robert Gerhardus Jacob; Cuppen, Edwin; Clevers, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">373-386.e10</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Breast cancer (BC) comprises multiple distinct subtypes that differ genetically, pathol., and clin.  Here, we describe a robust protocol for long-term culturing of human mammary epithelial organoids.  Using this protocol, >100 primary and metastatic BC organoid lines were generated, broadly recapitulating the diversity of the disease.  BC organoid morphologies typically matched the histopathol., hormone receptor status, and HER2 status of the original tumor.  DNA copy no. variations as well as sequence changes were consistent within tumor-organoid pairs and largely retained even after extended passaging.  BC organoids furthermore populated all major gene-expression-based classification groups and allowed in vitro drug screens that were consistent with in vivo xeno-transplantations and patient response.  This study describes a representative collection of well-characterized BC organoids available for cancer research and drug development, as well as a strategy to assess in vitro drug response in a personalized fashion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzzY-AEzj4lLVg90H21EOLACvtfcHk0liKygIUPTlZOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCisr%252FJ&md5=7067744a8289c9d46e871a541221c1eb</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DSachs%26aufirst%3DN.%26aulast%3Dde%2BLigt%26aufirst%3DJ.%26aulast%3DKopper%26aufirst%3DO.%26aulast%3DGogola%26aufirst%3DE.%26aulast%3DBounova%26aufirst%3DG.%26aulast%3DWeeber%26aufirst%3DF.%26aulast%3DBalgobind%26aufirst%3DA.%2BV.%26aulast%3DWind%26aufirst%3DK.%26aulast%3DGracanin%26aufirst%3DA.%26aulast%3DBegthel%26aufirst%3DH.%26aulast%3DKorving%26aufirst%3DJ.%26aulast%3Dvan%2BBoxtel%26aufirst%3DR.%26aulast%3DDuarte%26aufirst%3DA.%2BA.%26aulast%3DLelieveld%26aufirst%3DD.%26aulast%3Dvan%2BHoeck%26aufirst%3DA.%26aulast%3DErnst%26aufirst%3DR.%2BF.%26aulast%3DBlokzijl%26aufirst%3DF.%26aulast%3DNijman%26aufirst%3DI.%2BJ.%26aulast%3DHoogstraat%26aufirst%3DM.%26aulast%3Dvan%2Bde%2BVen%26aufirst%3DM.%26aulast%3DEgan%26aufirst%3DD.%2BA.%26aulast%3DZinzalla%26aufirst%3DV.%26aulast%3DMoll%26aufirst%3DJ.%26aulast%3DBoj%26aufirst%3DS.%2BF.%26aulast%3DVoest%26aufirst%3DE.%2BE.%26aulast%3DWessels%26aufirst%3DL.%26aulast%3Dvan%2BDiest%26aufirst%3DP.%2BJ.%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DVries%26aufirst%3DR.%2BG.%2BJ.%26aulast%3DCuppen%26aufirst%3DE.%26aulast%3DClevers%26aufirst%3DH.%26atitle%3DA%2520living%2520biobank%2520of%2520breast%2520cancer%2520organoids%2520captures%2520disease%2520heterogeneity%26jtitle%3DCell%26date%3D2018%26volume%3D172%26spage%3D373%26epage%3D386%26doi%3D10.1016%2Fj.cell.2017.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sei, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatschek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosetto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foukakis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navin, N. E.</span></span> <span> </span><span class="NLM_article-title">Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">879</span>– <span class="NLM_lpage">893</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.03.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.cell.2018.03.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=29681456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFejt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2018&pages=879-893&author=C.+Kimauthor=R.+Gaoauthor=E.+Seiauthor=R.+Brandtauthor=J.+Hartmanauthor=T.+Hatschekauthor=N.+Crosettoauthor=T.+Foukakisauthor=N.+E.+Navin&title=Chemoresistance+evolution+in+triple-negative+breast+cancer+delineated+by+single-cell+sequencing&doi=10.1016%2Fj.cell.2018.03.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing</span></div><div class="casAuthors">Kim, Charissa; Gao, Ruli; Sei, Emi; Brandt, Rachel; Hartman, Johan; Hatschek, Thomas; Crosetto, Nicola; Foukakis, Theodoros; Navin, Nicholas E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">879-893.e13</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is an aggressive subtype that frequently develops resistance to chemotherapy.  An unresolved question is whether resistance is caused by the selection of rare pre-existing clones or alternatively through the acquisition of new genomic aberrations.  To investigate this question, we applied single-cell DNA and RNA sequencing in addn. to bulk exome sequencing to profile longitudinal samples from 20 TNBC patients during neoadjuvant chemotherapy (NAC).  Deep-exome sequencing identified 10 patients in which NAC led to clonal extinction and 10 patients in which clones persisted after treatment.  In 8 patients, we performed a more detailed study using single-cell DNA sequencing to analyze 900 cells and single-cell RNA sequencing to analyze 6,862 cells.  Our data showed that resistant genotypes were pre-existing and adaptively selected by NAC, while transcriptional profiles were acquired by reprogramming in response to chemotherapy in TNBC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUuZd0FqIR7rVg90H21EOLACvtfcHk0liKygIUPTlZOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFejt74%253D&md5=aa3c4ee70bd54c40403b5a2cf5ce2432</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.03.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.03.041%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DR.%26aulast%3DSei%26aufirst%3DE.%26aulast%3DBrandt%26aufirst%3DR.%26aulast%3DHartman%26aufirst%3DJ.%26aulast%3DHatschek%26aufirst%3DT.%26aulast%3DCrosetto%26aufirst%3DN.%26aulast%3DFoukakis%26aufirst%3DT.%26aulast%3DNavin%26aufirst%3DN.%2BE.%26atitle%3DChemoresistance%2520evolution%2520in%2520triple-negative%2520breast%2520cancer%2520delineated%2520by%2520single-cell%2520sequencing%26jtitle%3DCell%26date%3D2018%26volume%3D173%26spage%3D879%26epage%3D893%26doi%3D10.1016%2Fj.cell.2018.03.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovey, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheang, M. C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kernaghan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilburn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazinska, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett-Lee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper-Wynne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatton, M. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoadley, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roylance, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timms, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardley, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanchbury, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harries, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliss, J. M.</span></span> <span> </span><span class="NLM_article-title">Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">628</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0009-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1038%2Fs41591-018-0009-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=29713086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVWrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=628&author=A.+Tuttauthor=H.+Toveyauthor=M.+C.+U.+Cheangauthor=S.+Kernaghanauthor=L.+Kilburnauthor=P.+Gazinskaauthor=J.+Owenauthor=J.+Abrahamauthor=S.+Barrettauthor=P.+Barrett-Leeauthor=R.+Brownauthor=S.+Chanauthor=M.+Dowsettauthor=J.+M.+Flanaganauthor=L.+Foxauthor=A.+Grigoriadisauthor=A.+Gutinauthor=C.+Harper-Wynneauthor=M.+Q.+Hattonauthor=K.+A.+Hoadleyauthor=J.+Parikhauthor=P.+Parkerauthor=C.+M.+Perouauthor=R.+Roylanceauthor=V.+Shahauthor=A.+Shawauthor=I.+E.+Smithauthor=K.+M.+Timmsauthor=A.+M.+Wardleyauthor=G.+Wilsonauthor=C.+Gillettauthor=J.+S.+Lanchburyauthor=A.+Ashworthauthor=N.+Rahmanauthor=M.+Harriesauthor=P.+Ellisauthor=S.+E.+Pinderauthor=J.+M.+Bliss&title=Carboplatin+in+BRCA1%2F2-mutated+and+triple-negative+breast+cancer+BRCAness+subgroups%3A+the+TNT+Trial&doi=10.1038%2Fs41591-018-0009-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial</span></div><div class="casAuthors">Tutt, Andrew; Tovey, Holly; Cheang, Maggie Chon U.; Kernaghan, Sarah; Kilburn, Lucy; Gazinska, Patrycja; Owen, Julie; Abraham, Jacinta; Barrett, Sophie; Barrett-Lee, Peter; Brown, Robert; Chan, Stephen; Dowsett, Mitchell; Flanagan, James M.; Fox, Lisa; Grigoriadis, Anita; Gutin, Alexander; Harper-Wynne, Catherine; Hatton, Matthew Q.; Hoadley, Katherine A.; Parikh, Jyoti; Parker, Peter; Perou, Charles M.; Roylance, Rebecca; Shah, Vandna; Shaw, Adam; Smith, Ian E.; Timms, Kirsten M.; Wardley, Andrew M.; Wilson, Gregory; Gillett, Cheryl; Lanchbury, Jerry S.; Ashworth, Alan; Rahman, Nazneen; Harries, Mark; Ellis, Paul; Pinder, Sarah E.; Bliss, Judith M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">628-637</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability.  HR also repairs DNA lesions caused by platinum agents and PARP inhibitors.  Triple-neg. breast cancers (TNBCs) harbor subpopulations with BRCA1/2 mutations, hypothesized to be esp. platinum-sensitive.  Cancers in putative 'BRCAness' subgroups-tumors with BRCA1 methylation; low levels of BRCA1 mRNA (BRCA1 mRNA-low); or mutational signatures for HR deficiency and those with basal phenotypes-may also be sensitive to platinum.  We assessed the efficacy of carboplatin and another mechanistically distinct therapy, docetaxel, in a phase 3 trial in subjects with unselected advanced TNBC.  A prespecified protocol enabled biomarker-treatment interaction analyses in gBRCA-BC and BRCAness subgroups.  The primary endpoint was objective response rate (ORR).  In the unselected population (376 subjects; 188 carboplatin, 188 docetaxel), carboplatin was not more active than docetaxel (ORR, 31.4% vs. 34.0%, resp.; P = 0.66).  In contrast, in subjects with gBRCA-BC, carboplatin had double the ORR of docetaxel (68% vs. 33%, resp.; biomarker, treatment interaction P = 0.01).  Such benefit was not obsd. for subjects with BRCA1 methylation, BRCA1 mRNA-low tumors or a high score in a Myriad HRD assay.  Significant interaction between treatment and the basal-like subtype was driven by high docetaxel response in the nonbasal subgroup.  We conclude that patients with advanced TNBC benefit from characterization of BRCA1/2 mutations, but not BRCA1 methylation or Myriad HRD analyses, to inform choices on platinum-based chemotherapy.  Addnl., gene expression anal. of basal-like cancers may also influence treatment selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBgHORfBZE5rVg90H21EOLACvtfcHk0lgRGxYr5-tzAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVWrsrs%253D&md5=bc041981d526eb551165880c3d779b94</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0009-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0009-7%26sid%3Dliteratum%253Aachs%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DTovey%26aufirst%3DH.%26aulast%3DCheang%26aufirst%3DM.%2BC.%2BU.%26aulast%3DKernaghan%26aufirst%3DS.%26aulast%3DKilburn%26aufirst%3DL.%26aulast%3DGazinska%26aufirst%3DP.%26aulast%3DOwen%26aufirst%3DJ.%26aulast%3DAbraham%26aufirst%3DJ.%26aulast%3DBarrett%26aufirst%3DS.%26aulast%3DBarrett-Lee%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DR.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DDowsett%26aufirst%3DM.%26aulast%3DFlanagan%26aufirst%3DJ.%2BM.%26aulast%3DFox%26aufirst%3DL.%26aulast%3DGrigoriadis%26aufirst%3DA.%26aulast%3DGutin%26aufirst%3DA.%26aulast%3DHarper-Wynne%26aufirst%3DC.%26aulast%3DHatton%26aufirst%3DM.%2BQ.%26aulast%3DHoadley%26aufirst%3DK.%2BA.%26aulast%3DParikh%26aufirst%3DJ.%26aulast%3DParker%26aufirst%3DP.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DRoylance%26aufirst%3DR.%26aulast%3DShah%26aufirst%3DV.%26aulast%3DShaw%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DTimms%26aufirst%3DK.%2BM.%26aulast%3DWardley%26aufirst%3DA.%2BM.%26aulast%3DWilson%26aufirst%3DG.%26aulast%3DGillett%26aufirst%3DC.%26aulast%3DLanchbury%26aufirst%3DJ.%2BS.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DRahman%26aufirst%3DN.%26aulast%3DHarries%26aufirst%3DM.%26aulast%3DEllis%26aufirst%3DP.%26aulast%3DPinder%26aufirst%3DS.%2BE.%26aulast%3DBliss%26aufirst%3DJ.%2BM.%26atitle%3DCarboplatin%2520in%2520BRCA1%252F2-mutated%2520and%2520triple-negative%2520breast%2520cancer%2520BRCAness%2520subgroups%253A%2520the%2520TNT%2520Trial%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D628%26doi%3D10.1038%2Fs41591-018-0009-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholer-Dahirel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourachot, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirven, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magagna, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhrmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonneau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondratova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuperstein, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinovyev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Givel, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrini, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soumelis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent-Salomon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechta-Grigoriou, F.</span></span> <span> </span><span class="NLM_article-title">Fibroblast heterogeneity and immunosuppressive environment in human breast cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2018.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ccell.2018.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=29455927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFSisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=463-479&author=A.+Costaauthor=Y.+Kiefferauthor=A.+Scholer-Dahirelauthor=F.+Pelonauthor=B.+Bourachotauthor=M.+Cardonauthor=P.+Sirvenauthor=I.+Magagnaauthor=L.+Fuhrmannauthor=C.+Bernardauthor=C.+Bonneauauthor=M.+Kondratovaauthor=I.+Kupersteinauthor=A.+Zinovyevauthor=A.-M.+Givelauthor=M.-C.+Parriniauthor=V.+Soumelisauthor=A.+Vincent-Salomonauthor=F.+Mechta-Grigoriou&title=Fibroblast+heterogeneity+and+immunosuppressive+environment+in+human+breast+cancer&doi=10.1016%2Fj.ccell.2018.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer</span></div><div class="casAuthors">Costa, Ana; Kieffer, Yann; Scholer-Dahirel, Alix; Pelon, Floriane; Bourachot, Brigitte; Cardon, Melissa; Sirven, Philemon; Magagna, Ilaria; Fuhrmann, Laetitia; Bernard, Charles; Bonneau, Claire; Kondratova, Maria; Kuperstein, Inna; Zinovyev, Andrei; Givel, Anne-Marie; Parrini, Maria-Carla; Soumelis, Vassili; Vincent-Salomon, Anne; Mechta-Grigoriou, Fatima</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">463-479.e10</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Carcinoma-assocd. fibroblasts (CAF) are key players in the tumor microenvironment.  Here, we characterize four CAF subsets in breast cancer with distinct properties and levels of activation.  Two myofibroblastic subsets (CAF-S1, CAF-S4) accumulate differentially in triple-neg. breast cancers (TNBC).  CAF-S1 fibroblasts promote an immunosuppressive environment through a multi-step mechanism.  By secreting CXCL12, CAF-S1 attracts CD4+CD25+ T lymphocytes and retains them by OX40L, PD-L2, and JAM2.  Moreover, CAF-S1 increases T lymphocyte survival and promotes their differentiation into CD25HighFOXP3High, through B7H3, CD73, and DPP4.  Finally, in contrast to CAF-S4, CAF-S1 enhances the regulatory T cell capacity to inhibit T effector proliferation.  These data are consistent with FOXP3+ T lymphocyte accumulation in CAF-S1-enriched TNBC and show how a CAF subset contributes to immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIGZxeA-XyIbVg90H21EOLACvtfcHk0ljVF9qwQMUS8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFSisrk%253D&md5=01514c0cf88bd85fcdc93a60c0ab41cb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DCosta%26aufirst%3DA.%26aulast%3DKieffer%26aufirst%3DY.%26aulast%3DScholer-Dahirel%26aufirst%3DA.%26aulast%3DPelon%26aufirst%3DF.%26aulast%3DBourachot%26aufirst%3DB.%26aulast%3DCardon%26aufirst%3DM.%26aulast%3DSirven%26aufirst%3DP.%26aulast%3DMagagna%26aufirst%3DI.%26aulast%3DFuhrmann%26aufirst%3DL.%26aulast%3DBernard%26aufirst%3DC.%26aulast%3DBonneau%26aufirst%3DC.%26aulast%3DKondratova%26aufirst%3DM.%26aulast%3DKuperstein%26aufirst%3DI.%26aulast%3DZinovyev%26aufirst%3DA.%26aulast%3DGivel%26aufirst%3DA.-M.%26aulast%3DParrini%26aufirst%3DM.-C.%26aulast%3DSoumelis%26aufirst%3DV.%26aulast%3DVincent-Salomon%26aufirst%3DA.%26aulast%3DMechta-Grigoriou%26aufirst%3DF.%26atitle%3DFibroblast%2520heterogeneity%2520and%2520immunosuppressive%2520environment%2520in%2520human%2520breast%2520cancer%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D33%26spage%3D463%26epage%3D479%26doi%3D10.1016%2Fj.ccell.2018.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneeweiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diéras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henschel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chui, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emens, L. A.</span></span> <span> </span><span class="NLM_article-title">Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">2108</span>– <span class="NLM_lpage">2121</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1809615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1056%2Fnejmoa1809615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=30345906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisV2rsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=2108-2121&author=P.+Schmidauthor=S.+Adamsauthor=H.+S.+Rugoauthor=A.+Schneeweissauthor=C.+H.+Barriosauthor=H.+Iwataauthor=V.+Di%C3%A9rasauthor=R.+Heggauthor=S.-A.+Imauthor=G.+Shaw+Wrightauthor=V.+Henschelauthor=L.+Molineroauthor=S.+Y.+Chuiauthor=R.+Funkeauthor=A.+Husainauthor=E.+P.+Winerauthor=S.+Loiauthor=L.+A.+Emens&title=Atezolizumab+and+nab-paclitaxel+in+advanced+triple-negative+breast+cancer&doi=10.1056%2Fnejmoa1809615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer</span></div><div class="casAuthors">Schmid, P.; Adams, S.; Rugo, H. S.; Schneeweiss, A.; Barrios, C. H.; Iwata, H.; Dieras, V.; Hegg, R.; Im, S.-A.; Wright, G. Shaw; Henschel, V.; Molinero, L.; Chui, S. Y.; Funke, R.; Husain, A.; Winer, E. P.; Loi, S.; Emens, L. A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2108-2121</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Unresectable locally advanced or metastatic triple-neg. (hormone-receptor-neg. and human epidermal growth factor receptor 2 [HER2]-neg.) breast cancer is an aggressive disease with poor outcomes.  Nanoparticle albumin-bound (nab)- paclitaxel may enhance the anticancer activity of atezolizumab. methods In this phase 3 trial, we randomly assigned (in a 1:1 ratio) patients with untreated metastatic triple-neg. breast cancer to receive atezolizumab plus nab-paclitaxel or placebo plus nab-paclitaxel; patients continued the intervention until disease progression or an unacceptable level of toxic effects occurred.  Stratification factors were the receipt or nonreceipt of neoadjuvant or adjuvant taxane therapy, the presence or absence of liver metastases at baseline, and programmed death ligand 1 (PD-L1) expression at baseline (pos. vs. neg.).  The two primary end points were progression- free survival (in the intention-to-treat population and PD-L1-pos. subgroup) and overall survival (tested in the intention-to-treat population; if the finding was significant, then it would be tested in the PD-L1-pos. subgroup). results Each group included 451 patients (median follow-up, 12.9 mo).  In the intentionto- treat anal., the median progression-free survival was 7.2 mo with atezolizumab plus nab-paclitaxel, as compared with 5.5 mo with placebo plus nab-paclitaxel (hazard ratio for progression or death, 0.80; 95% confidence interval [CI], 0.69 to 0.92; P = 0.002); among patients with PD-L1-pos. tumors, the median progression- free survival was 7.5 mo and 5.0 mo, resp. (hazard ratio, 0.62; 95% CI, 0.49 to 0.78; P<0.001).  In the intention-to-treat anal., the median overall survival was 21.3 mo with atezolizumab plus nab-paclitaxel and 17.6 mo with placebo plus nab-paclitaxel (hazard ratio for death, 0.84; 95% CI, 0.69 to 1.02; P = 0.08); among patients with PD-L1-pos. tumors, the median overall survival was 25.0 mo and 15.5 mo, resp. (hazard ratio, 0.62; 95% CI, 0.45 to 0.86).  No new adverse effects were identified.  Adverse events that led to the discontinuation of any agent occurred in 15.9% of the patients who received atezolizumab plus nab-paclitaxel and in 8.2% of those who received placebo plus nab-paclitaxel. conclusions Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-neg. breast cancer in both the intention-to-treat population and the PD-L1-pos. subgroup.  Adverse events were consistent with the known safety profiles of each agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBVvU9eDM8srVg90H21EOLACvtfcHk0ljVF9qwQMUS8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisV2rsrrI&md5=cf178f2bb201763452df26d207638095</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1809615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1809615%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DSchneeweiss%26aufirst%3DA.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26aulast%3DHegg%26aufirst%3DR.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DShaw%2BWright%26aufirst%3DG.%26aulast%3DHenschel%26aufirst%3DV.%26aulast%3DMolinero%26aufirst%3DL.%26aulast%3DChui%26aufirst%3DS.%2BY.%26aulast%3DFunke%26aufirst%3DR.%26aulast%3DHusain%26aufirst%3DA.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DEmens%26aufirst%3DL.%2BA.%26atitle%3DAtezolizumab%2520and%2520nab-paclitaxel%2520in%2520advanced%2520triple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D2108%26epage%3D2121%26doi%3D10.1056%2Fnejmoa1809615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edrada-Ebel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, R. J.</span></span> <span> </span><span class="NLM_article-title">The re-emergence of natural products for drug discovery in the genomics era</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">111</span>, <span class="refDoi"> DOI: 10.1038/nrd4510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1038%2Fnrd4510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=25614221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVarsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=111&author=A.+L.+Harveyauthor=R.+Edrada-Ebelauthor=R.+J.+Quinn&title=The+re-emergence+of+natural+products+for+drug+discovery+in+the+genomics+era&doi=10.1038%2Fnrd4510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The re-emergence of natural products for drug discovery in the genomics era</span></div><div class="casAuthors">Harvey, Alan L.; Edrada-Ebel, RuAngelie; Quinn, Ronald J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-129</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Natural products have been a rich source of compds. for drug discovery.  However, their use has diminished in the past two decades, in part because of tech. barriers to screening natural products in high-throughput assays against mol. targets.  Here, we review strategies for natural product screening that harness the recent tech. advances that have reduced these barriers.  We also assess the use of genomic and metabolomic approaches to augment traditional methods of studying natural products, and highlight recent examples of natural products in antimicrobial drug discovery and as inhibitors of protein-protein interactions.  The growing appreciation of functional assays and phenotypic screens may further contribute to a revival of interest in natural products for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkQ8QarpZ6orVg90H21EOLACvtfcHk0ljVF9qwQMUS8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVarsbg%253D&md5=b871148315dc0623683498fa15205b14</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd4510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4510%26sid%3Dliteratum%253Aachs%26aulast%3DHarvey%26aufirst%3DA.%2BL.%26aulast%3DEdrada-Ebel%26aufirst%3DR.%26aulast%3DQuinn%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520re-emergence%2520of%2520natural%2520products%2520for%2520drug%2520discovery%2520in%2520the%2520genomics%2520era%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D111%26doi%3D10.1038%2Fnrd4510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">Counting on natural products for drug design</span>. <i>Nat. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">531</span>, <span class="refDoi"> DOI: 10.1038/nchem.2479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1038%2Fnchem.2479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=27219696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslSrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=531&author=T.+Rodriguesauthor=D.+Rekerauthor=P.+Schneiderauthor=G.+Schneider&title=Counting+on+natural+products+for+drug+design&doi=10.1038%2Fnchem.2479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Counting on natural products for drug design</span></div><div class="casAuthors">Rodrigues, Tiago; Reker, Daniel; Schneider, Petra; Schneider, Gisbert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">531-541</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Natural products and their mol. frameworks have a long tradition as valuable starting points for medicinal chem. and drug discovery.  Recently, there has been a revitalization of interest in the inclusion of these chemotypes in compd. collections for screening and achieving selective target modulation.  Here the authors discuss natural-product-inspired drug discovery with a focus on recent advances in the design of synthetically tractable small mols. that mimic nature's chem.  The authors highlight the potential of innovative computational tools in processing structurally complex natural products to predict their macromol. targets and attempt to forecast the role that natural-product-derived fragments and fragment-like natural products will play in next-generation drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNR16z66-NgLVg90H21EOLACvtfcHk0lh6oKEzSUzdpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslSrsbk%253D&md5=3f6391192d648de2a54524afafd6203a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnchem.2479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.2479%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigues%26aufirst%3DT.%26aulast%3DReker%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DCounting%2520on%2520natural%2520products%2520for%2520drug%2520design%26jtitle%3DNat.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D531%26doi%3D10.1038%2Fnchem.2479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atanasov, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waltenberger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferschy-Wenzig, E.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linder, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wawrosch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhrin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temml, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaiger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heiss, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollinger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bochkov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihovilovic, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirsch, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuppner, H.</span></span> <span> </span><span class="NLM_article-title">Discovery and resupply of pharmacologically active plant-derived natural products: A review</span>. <i>Biotechnol. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1582</span>– <span class="NLM_lpage">1614</span>, <span class="refDoi"> DOI: 10.1016/j.biotechadv.2015.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.biotechadv.2015.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=26281720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGjsbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1582-1614&author=A.+G.+Atanasovauthor=B.+Waltenbergerauthor=E.-M.+Pferschy-Wenzigauthor=T.+Linderauthor=C.+Wawroschauthor=P.+Uhrinauthor=V.+Temmlauthor=L.+Wangauthor=S.+Schwaigerauthor=E.+H.+Heissauthor=J.+M.+Rollingerauthor=D.+Schusterauthor=J.+M.+Breussauthor=V.+Bochkovauthor=M.+D.+Mihovilovicauthor=B.+Koppauthor=R.+Bauerauthor=V.+M.+Dirschauthor=H.+Stuppner&title=Discovery+and+resupply+of+pharmacologically+active+plant-derived+natural+products%3A+A+review&doi=10.1016%2Fj.biotechadv.2015.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and resupply of pharmacologically active plant-derived natural products: A review</span></div><div class="casAuthors">Atanasov, Atanas G.; Waltenberger, Birgit; Pferschy-Wenzig, Eva-Maria; Linder, Thomas; Wawrosch, Christoph; Uhrin, Pavel; Temml, Veronika; Wang, Limei; Schwaiger, Stefan; Heiss, Elke H.; Rollinger, Judith M.; Schuster, Daniela; Breuss, Johannes M.; Bochkov, Valery; Mihovilovic, Marko D.; Kopp, Brigitte; Bauer, Rudolf; Dirsch, Verena M.; Stuppner, Hermann</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology Advances</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1582-1614</span>CODEN:
                <span class="NLM_cas:coden">BIADDD</span>;
        ISSN:<span class="NLM_cas:issn">0734-9750</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Medicinal plants have historically proven their value as a source of mols. with therapeutic potential, and nowadays still represent an important pool for the identification of novel drug leads.  In the past decades, pharmaceutical industry focused mainly on libraries of synthetic compds. as drug discovery source.  They are comparably easy to produce and resupply, and demonstrate good compatibility with established high throughput screening (HTS) platforms.  However, at the same time there has been a declining trend in the no. of new drugs reaching the market, raising renewed scientific interest in drug discovery from natural sources, despite of its known challenges.  In this survey, a brief outline of historical development is provided together with a comprehensive overview of used approaches and recent developments relevant to plant-derived natural product drug discovery.  Assocd. challenges and major strengths of natural product-based drug discovery are critically discussed.  A snapshot of the advanced plant-derived natural products that are currently in actively recruiting clin. trials is also presented.  Importantly, the transition of a natural compd. from a "screening hit" through a "drug lead" to a "marketed drug" is assocd. with increasingly challenging demands for compd. amt., which often cannot be met by re-isolation from the resp. plant sources.  In this regard, existing alternatives for resupply are also discussed, including different biotechnol. approaches and total org. synthesis.  While the intrinsic complexity of natural product-based drug discovery necessitates highly integrated interdisciplinary approaches, the reviewed scientific developments, recent technol. advances, and research trends clearly indicate that natural products will be among the most important sources of new drugs also in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaFpQuOxEnNrVg90H21EOLACvtfcHk0lh6oKEzSUzdpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGjsbjJ&md5=e1f2296576f1f80b984d99adbf83a20d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.biotechadv.2015.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biotechadv.2015.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DAtanasov%26aufirst%3DA.%2BG.%26aulast%3DWaltenberger%26aufirst%3DB.%26aulast%3DPferschy-Wenzig%26aufirst%3DE.-M.%26aulast%3DLinder%26aufirst%3DT.%26aulast%3DWawrosch%26aufirst%3DC.%26aulast%3DUhrin%26aufirst%3DP.%26aulast%3DTemml%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSchwaiger%26aufirst%3DS.%26aulast%3DHeiss%26aufirst%3DE.%2BH.%26aulast%3DRollinger%26aufirst%3DJ.%2BM.%26aulast%3DSchuster%26aufirst%3DD.%26aulast%3DBreuss%26aufirst%3DJ.%2BM.%26aulast%3DBochkov%26aufirst%3DV.%26aulast%3DMihovilovic%26aufirst%3DM.%2BD.%26aulast%3DKopp%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DR.%26aulast%3DDirsch%26aufirst%3DV.%2BM.%26aulast%3DStuppner%26aufirst%3DH.%26atitle%3DDiscovery%2520and%2520resupply%2520of%2520pharmacologically%2520active%2520plant-derived%2520natural%2520products%253A%2520A%2520review%26jtitle%3DBiotechnol.%2520Adv.%26date%3D2015%26volume%3D33%26spage%3D1582%26epage%3D1614%26doi%3D10.1016%2Fj.biotechadv.2015.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patridge, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gareiss, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span> <span> </span><span class="NLM_article-title">An analysis of FDA-approved drugs: natural products and their derivatives</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.drudis.2015.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=25617672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1ejt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=204-207&author=E.+Patridgeauthor=P.+Gareissauthor=M.+S.+Kinchauthor=D.+Hoyer&title=An+analysis+of+FDA-approved+drugs%3A+natural+products+and+their+derivatives&doi=10.1016%2Fj.drudis.2015.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of FDA-approved drugs: natural products and their derivatives</span></div><div class="casAuthors">Patridge, Eric; Gareiss, Peter; Kinch, Michael S.; Hoyer, Denton</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">204-207</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Natural products contribute greatly to the history and landscape of new mol. entities (NMEs).  An assessment of all FDA-approved NMEs reveals that natural products and their derivs. represent over one-third of all NMEs.  Nearly one-half of these are derived from mammals, one-quarter from microbes and one-quarter from plants.  Since the 1930s, the total fraction of natural products has diminished, whereas semisynthetic and synthetic natural product derivs. have increased.  Over time, this fraction has also become enriched with microbial natural products, which represent a significant portion of approved antibiotics, including more than two-thirds of all antibacterial NMEs.  In recent years, the declining focus on natural products has impacted the pipeline of NMEs from specific classes, and this trend is likely to continue without specific investment in the pursuit of natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEdmXjG8extLVg90H21EOLACvtfcHk0lh6oKEzSUzdpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1ejt70%253D&md5=fbe216c17b12f1d6769543344f5a4dbe</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DPatridge%26aufirst%3DE.%26aulast%3DGareiss%26aufirst%3DP.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DHoyer%26aufirst%3DD.%26atitle%3DAn%2520analysis%2520of%2520FDA-approved%2520drugs%253A%2520natural%2520products%2520and%2520their%2520derivatives%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D204%26epage%3D207%26doi%3D10.1016%2Fj.drudis.2015.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Probing the anticancer action of oridonin with fluorescent analogues: visualizing subcellular localization to mitochondria</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5022</span>– <span class="NLM_lpage">5034</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00408</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtF2lt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5022-5034&author=S.+Xuauthor=S.+Luoauthor=H.+Yaoauthor=H.+Caiauthor=X.+Miaoauthor=F.+Wuauthor=D.-H.+Yangauthor=X.+Wuauthor=W.+Xieauthor=H.+Yaoauthor=Z.-S.+Chenauthor=J.+Xu&title=Probing+the+anticancer+action+of+oridonin+with+fluorescent+analogues%3A+visualizing+subcellular+localization+to+mitochondria&doi=10.1021%2Facs.jmedchem.6b00408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the Anticancer Action of Oridonin with Fluorescent Analogues: Visualizing Subcellular Localization to Mitochondria</span></div><div class="casAuthors">Xu, Shengtao; Luo, Shanshan; Yao, Hong; Cai, Hao; Miao, Xiaoming; Wu, Fang; Yang, Dong-Hua; Wu, Xiaoming; Xie, Weijia; Yao, Hequan; Chen, Zhe-Sheng; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5022-5034</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oridonin (1) is a complex ent-kaurane diterpenoid exhibiting remarkable antitumor activity.  However, the detailed mechanism or cellular target that underlies this activity has not yet been identified.  Herein, we report an efficient approach for exploring the anticancer mechanism of oridonin through development of the potent fluorescent analogs.  A series of novel fluorescent oridonin probes linked with coumarin moieties were designed, synthesized, and characterized.  Fluorescence microscopy and confocal imaging studies suggested that fluorescent oridonin probe 17d was rapidly taken up into tumor cells and the mitochondrion was the main site of its accumulation.  Moreover, we confirmed that cytochrome c played an important role in oridonin induced mitochondrion-mediated apoptosis and α,β-unsatd. ketone is the active moiety of oridonin, which is crucial to its uptake, localization, and cytotoxicity.  Our results provide new insights on the mol. mechanism of oridonin and would be useful for its further development into an antitumor agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQwh1mki12ZrVg90H21EOLACvtfcHk0lgWdMGpg8oCZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtF2lt7s%253D&md5=8017b3f84342c5da185cb84c7effa0d4</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00408%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DMiao%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DD.-H.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.-S.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DProbing%2520the%2520anticancer%2520action%2520of%2520oridonin%2520with%2520fluorescent%2520analogues%253A%2520visualizing%2520subcellular%2520localization%2520to%2520mitochondria%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5022%26epage%3D5034%26doi%3D10.1021%2Facs.jmedchem.6b00408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.-H.</span></span> <span> </span><span class="NLM_article-title">Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells</span>. <i>Cell Death Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e2633</span> <span class="refDoi"> DOI: 10.1038/cddis.2017.35</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1038%2Fcddis.2017.35" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=28230866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsVShsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&author=Z.+Yaoauthor=F.+Xieauthor=M.+Liauthor=Z.+Liangauthor=W.+Xuauthor=J.+Yangauthor=C.+Liuauthor=H.+Liauthor=H.+Zhouauthor=L.-H.+Qu&title=Oridonin+induces+autophagy+via+inhibition+of+glucose+metabolism+in+p53-mutated+colorectal+cancer+cells&doi=10.1038%2Fcddis.2017.35"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells</span></div><div class="casAuthors">Yao, Zhuo; Xie, Fuhua; Li, Min; Liang, Zirui; Xu, Wenli; Yang, Jianhua; Liu, Chang; Li, Hongwangwang; Zhou, Hui; Qu, Liang-Hu</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e2633</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Warburg effect is an important characteristic of tumor cells, making it an attractive therapeutic target.  Current anticancer drug development strategies predominantly focus on inhibitors of the specific mol. effectors involved in tumor cell proliferation.  These drugs or natural compds., many of which target the Warburg effect and the underlying mechanisms, still need to be characterized.  To elucidate the anticancer effects of a natural diterpenoid, oridonin, we first demonstrated the anticancer activity of oridonin both in vitro and in vivo in colorectal cancer (CRC) cells.  Then miRNA profiling of SW480 cells revealed those intracellular signaling related to energy supply was affected by oridonin, suggesting that glucose metab. is a potential target for CRC therapy.  Moreover, our results indicated that oridonin induced metabolic imbalances by significantly inhibiting glucose uptake and reducing lactate export through significantly downregulating the protein levels of GLUT1 and MCT1 in vitro and vivo.  However, the ATP level in oridonin-treated CRC cells was not decreased when oridonin blocked the glucose supply, indicating that oridonin induced autophagy process, an important ATP source in cancer cells.  The observation was then supported by the results of LC3-II detection and transmission electron microscopy anal., which confirmed the presence of autophagy.  Furthermore, p-AMPK was rapidly deactivated following oridonin treatment, resulting in downregulation of GLUT1 and induction of autophagy in the cancer cells.  Thus our finding helped to clarify the anticancer mechanisms of oridonin and suggested it could be applied as a glucose metab.-targeting agent for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovouxwql3G1rVg90H21EOLACvtfcHk0lgWdMGpg8oCZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsVShsb4%253D&md5=f88961c8d675e3d1f433364f9161fc49</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2017.35&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2017.35%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DQu%26aufirst%3DL.-H.%26atitle%3DOridonin%2520induces%2520autophagy%2520via%2520inhibition%2520of%2520glucose%2520metabolism%2520in%2520p53-mutated%2520colorectal%2520cancer%2520cells%26jtitle%3DCell%2520Death%2520Discovery%26date%3D2017%26volume%3D8%26doi%3D10.1038%2Fcddis.2017.35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span> <span> </span><span class="NLM_article-title">Oridonin triggers chaperon-mediated proteasomal degradation of BCR-ABL in leukemia</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41525</span>, <span class="refDoi"> DOI: 10.1038/srep41525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1038%2Fsrep41525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=28128329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVOrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=41525&author=H.+Huangauthor=H.+Wengauthor=B.+Dongauthor=P.+Zhaoauthor=H.+Zhouauthor=L.+Qu&title=Oridonin+triggers+chaperon-mediated+proteasomal+degradation+of+BCR-ABL+in+leukemia&doi=10.1038%2Fsrep41525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia</span></div><div class="casAuthors">Huang, Huilin; Weng, Hengyou; Dong, Bowen; Zhao, Panpan; Zhou, Hui; Qu, Lianghu</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41525</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inducing degrdn. of oncoproteins by small mol. compds. has the potential to avoid drug resistance and therefore deserves to be exploited for new therapies.  Oridonin is a natural compd. with promising antitumor efficacy that can trigger the degrdn. of oncoproteins; however, the direct cellular targets and underlying mechanisms remain unclear.  Here we report that oridonin depletes BCR-ABL through chaperon-mediated proteasomal degrdn. in leukemia.  Mechanistically, oridonin poses oxidative stress in cancer cells and directly binds to cysteines of HSF1, leading to the activation of this master regulator of the chaperone system.  The resulting induction of HSP70 and ubiquitin proteins and the enhanced binding to CHIP E3 ligase hence target BCR-ABL for ubiquitin-proteasome degrdn.  Both wild-type and mutant forms of BCR-ABL can be efficiently degraded by oridonin, supporting its efficacy obsd. in cultured cells as well as mouse tumor xenograft assays with either imatinib-sensitive or -resistant cells.  Collectively, our results identify a novel mechanism by which oridonin induces rapid degrdn. of BCR-ABL as well as a novel pharmaceutical activator of HSF1 that represents a promising treatment for leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozBGpY9acRgbVg90H21EOLACvtfcHk0lgWdMGpg8oCZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVOrsLg%253D&md5=5c2a35a6f46726ecdfaf6f49e62de577</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fsrep41525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep41525%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DWeng%26aufirst%3DH.%26aulast%3DDong%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DQu%26aufirst%3DL.%26atitle%3DOridonin%2520triggers%2520chaperon-mediated%2520proteasomal%2520degradation%2520of%2520BCR-ABL%2520in%2520leukemia%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D41525%26doi%3D10.1038%2Fsrep41525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of natural product oridonin-inspired anticancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2016.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=27344488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKnsL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2016&pages=102-117&author=Y.+Dingauthor=C.+Dingauthor=N.+Yeauthor=Z.+Liuauthor=E.+A.+Woldauthor=H.+Chenauthor=C.+Wildauthor=Q.+Shenauthor=J.+Zhou&title=Discovery+and+development+of+natural+product+oridonin-inspired+anticancer+agents&doi=10.1016%2Fj.ejmech.2016.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of natural product oridonin-inspired anticancer agents</span></div><div class="casAuthors">Ding, Ye; Ding, Chunyong; Ye, Na; Liu, Zhiqing; Wold, Eric A.; Chen, Haiying; Wild, Christopher; Shen, Qiang; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">102-117</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Natural products have historically been, and continue to be, an invaluable source for the discovery of various therapeutic agents.  Oridonin, a natural diterpenoid widely applied in traditional Chinese medicines, exhibits a broad range of biol. effects including anticancer and anti-inflammatory activities.  To further improve its potency, aq. soly. and bioavailability, the oridonin template serves as an exciting platform for drug discovery to yield better candidates with unique targets and enhanced drug properties.  A no. of oridonin derivs. (e.g. HAO472) have been designed and synthesized, and have contributed to substantial progress in the identification of new agents and relevant mol. mechanistic studies toward the treatment of human cancers and other diseases.  This review summarizes the recent advances in medicinal chem. on the explorations of novel oridonin analogs as potential anticancer therapeutics, and provides a detailed discussion of future directions for the development and progression of this class of mols. into the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv6x0p1uhEt7Vg90H21EOLACvtfcHk0lgA7I2jZH3VSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKnsL3E&md5=0cce14ee999e3e59fe48cf6a1249d90b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DYe%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWild%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520development%2520of%2520natural%2520product%2520oridonin-inspired%2520anticancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D122%26spage%3D102%26epage%3D117%26doi%3D10.1016%2Fj.ejmech.2016.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, R.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.-M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel Jiyuan Oridonin A-1, 2, 3-triazole-azole derivatives as antiproliferative agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">1263</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2018.08.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=30193221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1OmsL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=1249-1263&author=Y.+Keauthor=J.-J.+Liangauthor=R.-J.+Houauthor=M.-M.+Liauthor=L.-F.+Zhaoauthor=W.+Wangauthor=Y.+Liuauthor=H.+Xieauthor=R.-H.+Yangauthor=T.-X.+Huauthor=J.-Y.+Wangauthor=H.-M.+Liu&title=Synthesis+and+biological+evaluation+of+novel+Jiyuan+Oridonin+A-1%2C+2%2C+3-triazole-azole+derivatives+as+antiproliferative+agents&doi=10.1016%2Fj.ejmech.2018.08.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel Jiyuan Oridonin A-1,2,3-triazole-azole derivatives as antiproliferative agents</span></div><div class="casAuthors">Ke, Yu; Liang, Jian-Jia; Hou, Rui-Juan; Li, Ming-Ming; Zhao, Long-Fei; Wang, Wang; Liu, Ying; Xie, Hang; Yang, Rui-Hua; Hu, Tian-Xing; Wang, Jin-Yi; Liu, Hong-Min</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1249-1263</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">As a continuation of our research on developing potent and potentially safe anti-proliferative agents, two series of novel Jiyuan Oridonin A-1,2,3-triazole-azole hybrids were designed, synthesized and evaluated for their anti-proliferative activity against four selected cancer cell lines (MGC-803, MCF-7, PC-3, Eca-109).  Some compds. with better growth inhibitory effects were chosen to carry out further studies in A549 and SMMC-7721.  Most of the synthesized compds. exhibited moderate to good activity against all the cancer cell lines selected.  Particularly, the most active agent I showed high potency against human cancer cells with IC50 ranging from 0.2 ± 0.0 to 5.0 ± 0.9 μM.  Cellular mechanism studies elucidated compd. I arrests cell cycle at G1 phase and induce a strong apoptotic response in SMMC-7721 cells.  Furthermore, I could inhibit the colony formation and migration via Wnt signaling pathway in SMMC-7721 cells.  For all these reasons, compd. I holds promising potential as anti-proliferative agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo99lG7Gj981bVg90H21EOLACvtfcHk0lgA7I2jZH3VSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1OmsL3F&md5=b36aebfc2935c6f6754f48cb97406554</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.056%26sid%3Dliteratum%253Aachs%26aulast%3DKe%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DJ.-J.%26aulast%3DHou%26aufirst%3DR.-J.%26aulast%3DLi%26aufirst%3DM.-M.%26aulast%3DZhao%26aufirst%3DL.-F.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DR.-H.%26aulast%3DHu%26aufirst%3DT.-X.%26aulast%3DWang%26aufirst%3DJ.-Y.%26aulast%3DLiu%26aufirst%3DH.-M.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520Jiyuan%2520Oridonin%2520A-1%252C%25202%252C%25203-triazole-azole%2520derivatives%2520as%2520antiproliferative%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D1249%26epage%3D1263%26doi%3D10.1016%2Fj.ejmech.2018.08.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span> <span> </span><span class="NLM_article-title">Effective enmein-type mimics of clinical candidate HAO472: Design, synthesis and biological evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.03.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2019.03.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=30921757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtFGktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2019&pages=169-179&author=X.+Huauthor=Z.+Baiauthor=J.+Qiaoauthor=H.+Liauthor=S.+Xuauthor=X.+Wangauthor=Y.+Xuauthor=J.+Xuauthor=H.+Huaauthor=D.+Li&title=Effective+enmein-type+mimics+of+clinical+candidate+HAO472%3A+Design%2C+synthesis+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2019.03.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Effective enmein-type mimics of clinical candidate HAO472: Design, synthesis and biological evaluation</span></div><div class="casAuthors">Hu, Xu; Bai, Ziyi; Qiao, Jian; Li, Haonan; Xu, Shengtao; Wang, Xianhua; Xu, Yongnan; Xu, Jinyi; Hua, Huiming; Li, Dahong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">169-179</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of enmein-type diterpenoid amino acid ester derivs., e.g. I, were designed and synthesized according to L-alanine-(14-oridonin) ester trifluoroacetate (clin. candidate HAO472).  Their antiproliferative activities were tested against SGC-7901, Bel-7402, HL-60, PC-3, A549 and K562 cancer cell lines and L-02 normal liver cells.  The results showed that I possessed the most potent cytotoxicity with IC50 s at sub-micromolar level against human hepatoma Bel-7402 and chronic myelogenous leukemia K562 cells and more potent than L-alanine-(14-oridonin) ester.  More importantly, I displayed 70-fold less cytotoxicity than parent II (IC50 = 25.47 μM) against L-02 cells, which exhibited certain selectivity.  Further mechanism study in Bel-7402 cells revealed that I could induce apoptosis, G1 phase cell cycle arrest and mitochondrial dysfunction.  Western blot results of caspase-3, Bax and cytochrome C up-regulation and pro-caspase-3, Bcl-2 and Bcl-xL down-regulation confirmed the intrinsic pathways.  Overall, these data collectively demonstrated the high efficiency and selectivity of I, L-phenylalanine-enmein-type diterpenoid ester, which inspires further and effective application as a potential antitumor candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKI4-bKkcdNbVg90H21EOLACvtfcHk0lgA7I2jZH3VSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtFGktrk%253D&md5=eed8d737389d712a6ff470b3e8e89f41</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.03.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.03.046%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DZ.%26aulast%3DQiao%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DHua%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DD.%26atitle%3DEffective%2520enmein-type%2520mimics%2520of%2520clinical%2520candidate%2520HAO472%253A%2520Design%252C%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D171%26spage%3D169%26epage%3D179%26doi%3D10.1016%2Fj.ejmech.2019.03.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span> <span> </span><span class="NLM_article-title">Novel enmein-type diterpenoid hybrids coupled with nitrogen mustards: Synthesis of promising candidates for anticancer therapeutics</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">598</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2018.01.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=29407983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFehsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2018&pages=588-598&author=X.+Gaoauthor=J.+Liauthor=M.+Wangauthor=S.+Xuauthor=W.+Liuauthor=L.+Zangauthor=Z.+Liauthor=H.+Huaauthor=J.+Xuauthor=D.+Li&title=Novel+enmein-type+diterpenoid+hybrids+coupled+with+nitrogen+mustards%3A+Synthesis+of+promising+candidates+for+anticancer+therapeutics&doi=10.1016%2Fj.ejmech.2018.01.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Novel enmein-type diterpenoid hybrids coupled with nitrogen mustards: Synthesis of promising candidates for anticancer therapeutics</span></div><div class="casAuthors">Gao, Xiang; Li, Jia; Wang, Mingying; Xu, Shengtao; Liu, Weiwei; Zang, Linghe; Li, Zhanlin; Hua, Huiming; Xu, Jinyi; Li, Dahong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">588-598</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Natural derived enmein-type diterpenoids exert cytotoxicity against a wide range of human cancer cells.  Yet their medicinal applications are hindered by insufficient potency for chemotherapy.  Hence, a series of novel enmein-type diterpenoid hybrids coupled with nitrogen mustards were designed and synthesized to increase antitumor efficacy while reducing systemic toxicity.  Most conjugates exhibited stronger antiproliferative activities than parent diterpenoids and nitrogen mustards, esp. for multidrug-resistant tumor cell line Bel-7402/5-FU.  Among them, compd. I showed the most potent inhibitory activities in human leukemia HL-60 cells, human prostate cancer PC-3 cells, human liver cancer Bel-7402 cells and drug-resistant human liver cancer Bel-7402/5-FU cells with IC50 values of 7.83 μM, 3.97 μM, 0.77 μM and 2.07 μM, resp.  Addnl., high selectivity with selectivity index over 130 was also obsd. from cytotoxic evaluation between L-02 human normal liver cells and Bel-7402 malignant liver cells.  Further studies on mechanism of action indicated that I induced both apoptosis and G1 phase cell cycle arrest in Bel-7402 hepatoma cells.  Moreover, the dysfunction in mitochondrial pathway was also involved in I initiated apoptotic activation, which entailed the loss of mitochondrial membrane potential followed by upregulating the bax/bcl-2 ratio and increasing the expression of cytochrome c, p53, caspase-3 and -9.  Overall, I has the potential to emerge as a promising drug candidate for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobX_nRPa9xVbVg90H21EOLACvtfcHk0lgzKjkdf13ZLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFehsbo%253D&md5=6f238158d7604aa8a1465c7c33fb61c0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.069%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DHua%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DD.%26atitle%3DNovel%2520enmein-type%2520diterpenoid%2520hybrids%2520coupled%2520with%2520nitrogen%2520mustards%253A%2520Synthesis%2520of%2520promising%2520candidates%2520for%2520anticancer%2520therapeutics%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D146%26spage%3D588%26epage%3D598%26doi%3D10.1016%2Fj.ejmech.2018.01.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, Z.-S.</span></span> <span> </span><span class="NLM_article-title">Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: A novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2019.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=30981113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVSns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2019&pages=15-31&author=Q.-K.+Shenauthor=H.+Dengauthor=S.-B.+Wangauthor=Y.-S.+Tianauthor=Z.-S.+Quan&title=Synthesis%2C+and+evaluation+of+in+vitro+and+in+vivo+anticancer+activity+of+14-substituted+oridonin+analogs%3A+A+novel+and+potent+cell+cycle+arrest+and+apoptosis+inducer+through+the+p53-MDM2+pathway&doi=10.1016%2Fj.ejmech.2019.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: A novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway</span></div><div class="casAuthors">Shen, Qing-Kun; Deng, Hao; Wang, Shi-Ben; Tian, Yu-Shun; Quan, Zhen-Shan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-31</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel oridonin derivs. bearing various substituents on the 14-OH position, e.g., I [R = H, 5-Cl, 5-MeO, 6-F, 6-Cl, 6-Br, 6-MeO, 5,6-(MeO)2, 4,5,6-(MeO)3], were designed and synthesized.  Their antitumor activity was evaluated in vitro against three human cancer cell lines (HCT116, BEL7402, and MCF7).  Most tested derivs. showed improved anti-proliferative activity compared to the lead compd. oridonin and the pos. control drug 5-fluorouracil (5-Fu).  Among them, compd. I (R = 6-MeO) (II) (IC50 = 0.16 μM) exhibited the most potent anti-proliferative activity against HCT116 cells; it was about 43- and 155-fold more efficacious than that of oridonin (IC50 = 6.84 μM) and 5-Fu (IC50 = 24.80 μM) in HCT116 cancer cells.  Interestingly, the IC50 value of compd. II in HCT116 cells was 23.6-fold higher than that in L02 normal cells; it exhibited better selective anti-proliferative activity and specificity than oridonin and 5-Fu.  Furthermore, compd. II possibly induced cell cycle arrest and apoptosis by regulating the p53-MDM2 signaling pathway.  Notably, II displayed more significant suppression of tumor growth than oridonin in colon tumor xenograft models where the tumor growth inhibition rate was 85.82%.  Therefore, compd. II could be a potential lead compd. for the development of a novel antitumor agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Cxov2WQyEbVg90H21EOLACvtfcHk0lgzKjkdf13ZLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVSns7g%253D&md5=c225f3228e796acdf20ac9e15570a0af</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DQ.-K.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.-B.%26aulast%3DTian%26aufirst%3DY.-S.%26aulast%3DQuan%26aufirst%3DZ.-S.%26atitle%3DSynthesis%252C%2520and%2520evaluation%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520anticancer%2520activity%2520of%252014-substituted%2520oridonin%2520analogs%253A%2520A%2520novel%2520and%2520potent%2520cell%2520cycle%2520arrest%2520and%2520apoptosis%2520inducer%2520through%2520the%2520p53-MDM2%2520pathway%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D173%26spage%3D15%26epage%3D31%26doi%3D10.1016%2Fj.ejmech.2019.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.-M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological mechanisms research on 1, 2, 3-triazole derivatives of Jiyuan Oridonin A</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4761</span>– <span class="NLM_lpage">4773</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.bmc.2017.11.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=4761-4773&author=Y.+Keauthor=W.+Wangauthor=L.-F.+Zhaoauthor=J.-J.+Liangauthor=Y.+Liuauthor=X.+Zhangauthor=K.+Fengauthor=H.-M.+Liu&title=Design%2C+synthesis+and+biological+mechanisms+research+on+1%2C+2%2C+3-triazole+derivatives+of+Jiyuan+Oridonin+A&doi=10.1016%2Fj.bmc.2017.11.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DKe%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DL.-F.%26aulast%3DLiang%26aufirst%3DJ.-J.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DH.-M.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520mechanisms%2520research%2520on%25201%252C%25202%252C%25203-triazole%2520derivatives%2520of%2520Jiyuan%2520Oridonin%2520A%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D4761%26epage%3D4773%26doi%3D10.1016%2Fj.bmc.2017.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, S.</span></span> <span> </span><span class="NLM_article-title">Oridonin derivatives as potential anticancer drug candidates triggering apoptosis through mitochondrial pathway in the liver cancer cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">379</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2019.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=31200238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKqsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=365-379&author=D.+Luoauthor=Y.+Yiauthor=K.+Pengauthor=T.+Liuauthor=J.+Yangauthor=S.+Liuauthor=W.+Zhaoauthor=X.+Quauthor=W.+Yuauthor=Y.+Guauthor=S.+Wan&title=Oridonin+derivatives+as+potential+anticancer+drug+candidates+triggering+apoptosis+through+mitochondrial+pathway+in+the+liver+cancer+cells&doi=10.1016%2Fj.ejmech.2019.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Oridonin derivatives as potential anticancer drug candidates triggering apoptosis through mitochondrial pathway in the liver cancer cells</span></div><div class="casAuthors">Luo, Dongdong; Yi, Yujiao; Peng, Kai; Liu, Tangrong; Yang, Jiayu; Liu, Shan; Zhao, Wanzhou; Qu, Xianjun; Yu, Wengong; Gu, Yuchao; Wan, Shengbiao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">365-379</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The biol. function of the natural ent-kaurene diterpenoid isolated from genus Isodon, oridonin, has been intensively studied.  However, its mechanism studies and clin. applications were hampered by its moderate biol. activities.  In order to enlarge the applied range of oridonin and explore its mechanism of action, a series of derivs. were designed and synthesized based on the structure of oridonin.  Some of the derivs. were significantly more potent than oridonin against four cancer cell lines.  Esp., the most potent compd. 20 markedly inhibited the proliferation of well differentiated HepG2 and poorly differentiated PLC/PRF/5 cells, with IC50 values as low as 1.36 μM and 0.78 μM resp., while the IC50 values of oridonin are 8.12 μM and 7.41 μM.  We found that compd. 20 inhibited liver cancer cell proliferation via arresting cell cycle at G1 phase.  Moreover, it induced liver cancer cell apoptosis by decreasing the mitochondrial membrane potential, increasing intracellular reactive oxygen species level and inducing the expression of apoptosis-related proteins.  Furthermore, compd. 20 significantly inhibited growth of PLC/PRF/5 xenograft tumors in nude mice and had no observable toxic effect.  Altogether, these results indicated that compd. 20 is a promising lead for liver cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYfm_zSvHvr7Vg90H21EOLACvtfcHk0lgzKjkdf13ZLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKqsL3L&md5=b1577a59e12dbfa28bcdec3643c801e1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DYi%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DS.%26atitle%3DOridonin%2520derivatives%2520as%2520potential%2520anticancer%2520drug%2520candidates%2520triggering%2520apoptosis%2520through%2520mitochondrial%2520pathway%2520in%2520the%2520liver%2520cancer%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D178%26spage%3D365%26epage%3D379%26doi%3D10.1016%2Fj.ejmech.2019.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, T.</span></span> <span> </span><span class="NLM_article-title">Total Synthesis of (−)-Oridonin: An Interrupted-Nazarov Approach</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">20048</span>– <span class="NLM_lpage">20052</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b12034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b12034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlWkt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=20048-20052&author=L.+Kongauthor=F.+Suauthor=H.+Yuauthor=Z.+Jiangauthor=Y.+Luauthor=T.+Luo&title=Total+Synthesis+of+%28%E2%88%92%29-Oridonin%3A+An+Interrupted-Nazarov+Approach&doi=10.1021%2Fjacs.9b12034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Total Synthesis of (-)-Oridonin: An Interrupted Nazarov Approach</span></div><div class="casAuthors">Kong, Lingran; Su, Fan; Yu, Hang; Jiang, Zhe; Lu, Yandong; Luo, Tuoping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">20048-20052</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An enantioselective total synthesis of (-)-oridonin (I) is accomplished based on a key interrupted Nazarov reaction.  The stereochem. of the Nazarov/Hosomi-Sakurai cascade was first explored to forge a tetracyclic skeleton with challenging quaternary carbons.  A delicate sequence of two ring-rearrangements and late-stage redox manipulations was carried out to achieve the de novo synthesis of this highly oxidized ent-kauranoid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPvxDRyPJoorVg90H21EOLACvtfcHk0lhUHJs7TymPPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlWkt77J&md5=099682884a3156fdb9442d623465ad3d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b12034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b12034%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DT.%26atitle%3DTotal%2520Synthesis%2520of%2520%2528%25E2%2588%2592%2529-Oridonin%253A%2520An%2520Interrupted-Nazarov%2520Approach%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D20048%26epage%3D20052%26doi%3D10.1021%2Fjacs.9b12034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Oridonin induces apoptosis, inhibits migration and invasion on highly-metastatic human breast cancer cells</span>. <i>Am. J. Chin. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1142/s0192415x13500134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1142%2Fs0192415x13500134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=23336515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=177-196&author=S.+Wangauthor=Z.+Zhongauthor=J.+Wanauthor=W.+Tanauthor=G.+Wuauthor=M.+Chenauthor=Y.+Wang&title=Oridonin+induces+apoptosis%2C+inhibits+migration+and+invasion+on+highly-metastatic+human+breast+cancer+cells&doi=10.1142%2Fs0192415x13500134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Oridonin Induces Apoptosis, Inhibits Migration and Invasion on Highly-Metastatic Human Breast Cancer Cells</span></div><div class="casAuthors">Wang, Shengpeng; Zhong, Zhangfeng; Wan, Jianbo; Tan, Wen; Wu, Guosheng; Chen, Meiwan; Wang, Yitao</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Chinese Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">177-196</span>CODEN:
                <span class="NLM_cas:coden">AJCMBA</span>;
        ISSN:<span class="NLM_cas:issn">0192-415X</span>.
    
            (<span class="NLM_cas:orgname">World Scientific Publishing Co. Pte. Ltd.</span>)
        </div><div class="casAbstract">Oridonin, a natural tetracycline diterpenoid isolated from Chinese herb Rabdosia rubescens, has been reported to be a potent cytotoxic agent against a wide variety of tumors.  However, its effect on highly metastatic breast cancer cells has not been addressed.  In this study, we investigated the effects of oridonin on growth, migration and invasion of highly-metastatic human breast cancer cells.  Our results showed that oridonin induced potent growth inhibition on human breast cancer cells MCF-7 and MDA-MB-231 in a time- and dose-dependent manner.  According to the flow cytometric anal., oridonin suppressed MCF-7 cell growth by cell cycle arrest at the G2/M phase and caused accumulation of MDA-MB-231 cells in the Sub-G1 phase.  The induced apoptotic effect of oridonin was further confirmed by a morphol. characteristics assay and TUNEL assay.  Oridonin triggered the redn. of Bcl-2/Bax ratio, caspase-8, NF-κB (p65), IKKα, IKKβ, phospho-mTOR, and increased expression level of cleaved PARP, Fas and PPARγ in a time-dependent manner.  Immunofluorescent anal. showed that γH2AX-contg. nuclear foci were significant in oridonin-treated MDA-MB-231 cells.  Meanwhile, oridonin significantly suppressed MDA-MB-231 cell migration and invasion, decreased MMP-2/MMP-9 activation and inhibited the expression of Integrin β1 and FAK.  In conclusion, oridonin inhibited the growth and induced apoptosis in breast cancer cells, which might be related to DNA damage and activation of intrinsic or extrinsic apoptotic pathways.  Moreover, oridonin also inhibited tumor invasion and metastasis in vitro possibly via decreasing the expression of MMPs and regulating the Integrin β1/FAK pathway in MDA-MB-231 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgWa5C-bFw1LVg90H21EOLACvtfcHk0lhUHJs7TymPPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWktbY%253D&md5=29748b2273c09072683ce0e58813200f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1142%2Fs0192415x13500134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1142%252Fs0192415x13500134%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DZhong%26aufirst%3DZ.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DOridonin%2520induces%2520apoptosis%252C%2520inhibits%2520migration%2520and%2520invasion%2520on%2520highly-metastatic%2520human%2520breast%2520cancer%2520cells%26jtitle%3DAm.%2520J.%2520Chin.%2520Med.%26date%3D2013%26volume%3D41%26spage%3D177%26epage%3D196%26doi%3D10.1142%2Fs0192415x13500134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span> <span> </span><span class="NLM_article-title">Oridonin phosphate-induced autophagy effectively enhances cell apoptosis of human breast cancer cells</span>. <i>Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">365</span>, <span class="refDoi"> DOI: 10.1007/s12032-014-0365-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1007%2Fs12032-014-0365-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=25491140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A280%3ADC%252BC2MzmvFegtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=365&author=Y.+Liauthor=Y.+Wangauthor=S.+Wangauthor=Y.+Gaoauthor=X.+Zhangauthor=C.+Lu&title=Oridonin+phosphate-induced+autophagy+effectively+enhances+cell+apoptosis+of+human+breast+cancer+cells&doi=10.1007%2Fs12032-014-0365-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Oridonin phosphate-induced autophagy effectively enhances cell apoptosis of human breast cancer cells</span></div><div class="casAuthors">Li Yue; Wang Ying; Wang Suihai; Gao Yanjun; Zhang Xuefeng; Lu Chunhua</div><div class="citationInfo"><span class="NLM_cas:title">Medical oncology (Northwood, London, England)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">365</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Oridonin is an active diterpenoid, which was extracted from traditional Chinese herbs and had been widely used in clinical treatment nowadays.  Oridonin phosphate is one of the derivatives of oridonin.  In the present study, we explored its anti-tumor effect and investigated the molecular mechanism of oridonin phosphate in breast cancer cell lines.  Firstly, cell viability was analyzed by MTT assay.  The breast cancer cells were treated with increasing concentrations of oridonin phosphate for 24, 48 and 72 h, respectively.  The results demonstrated that oridonin phosphate inhibited the proliferation of MDA-MB-436 and MDA-MB-231 cells in a dose- and time-dependent manner.  Next, cell apoptosis rate was detected in oridonin phosphate-treated breast cancer cells by Annexin V-FITC/PI dual staining analysis and the data demonstrated that oridonin phosphate induced cell apoptosis of breast cancer cells in time- and dose-dependent manner.  Moreover, apoptosis-related proteins were detected by Western blotting analysis.  The results showed that the expression level of Bax was up-regulated and the expression level of Bcl-2 was down-regulated.  Meanwhile, the level of cleaved caspase-9 was significantly increased when the cells were treated with 40 μM of oridonin phosphate for 48 h, although the expression level of pro-caspase-9 was not obviously changed.  All of the data revealed that mitochondrial apoptosis pathway may be involved in the cell apoptosis induced by oridonin phosphate in breast cancer cells.  Importantly, the expression levels of autophagy-related protein beclin-1 and LC3-II were significantly higher in oridonin phosphate-treated breast cancer cell lines MDA-MB-436 and MDA-MB-231 for 48 h.  Additionally, we further explored the relationship between apoptosis and autophagy specifically induced by oridonin phosphate in breast cancer cells.  The result showed that inhibition of autophagy suppressed the cell apoptosis in oridonin phosphate-treated MDA-MB-436 cells.  Taken together, the compound of oridonin phosphate simultaneously induced cell apoptosis and autophagy in breast cancer cells.  Inhibition oridonin phosphate-induced cell autophagy suppressed the progression of cell apoptosis, which revealed that oridonin phosphate-induced autophagy participated in up-regulation of apoptosis in human breast cancer cells.  It would provide some new clues for the therapy of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxuey5f2gs6LJzI8owOhpDfW6udTcc2eZYO5jovtMOL7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzmvFegtQ%253D%253D&md5=1fcc603503c057f62e1782358c3c4079</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs12032-014-0365-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12032-014-0365-1%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DC.%26atitle%3DOridonin%2520phosphate-induced%2520autophagy%2520effectively%2520enhances%2520cell%2520apoptosis%2520of%2520human%2520breast%2520cancer%2520cells%26jtitle%3DMed.%2520Oncol.%26date%3D2015%26volume%3D32%26spage%3D365%26doi%3D10.1007%2Fs12032-014-0365-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ester, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Oridonin ring A-based diverse constructions of enone functionality: identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8814</span>– <span class="NLM_lpage">8825</span>, <span class="refDoi"> DOI: 10.1021/jm401248x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401248x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1aht7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8814-8825&author=C.+Dingauthor=Y.+Zhangauthor=H.+Chenauthor=Z.+Yangauthor=C.+Wildauthor=N.+Yeauthor=C.+D.+Esterauthor=A.+Xiongauthor=M.+A.+Whiteauthor=Q.+Shenauthor=J.+Zhou&title=Oridonin+ring+A-based+diverse+constructions+of+enone+functionality%3A+identification+of+novel+dienone+analogues+effective+for+highly+aggressive+breast+cancer+by+inducing+apoptosis&doi=10.1021%2Fjm401248x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Oridonin Ring A Based Diverse Constructions of Enone Functionality: Identification of Novel Dienone Analogues Effective for Highly Aggressive Breast Cancer by Inducing Apoptosis</span></div><div class="casAuthors">Ding, Chunyong; Zhang, Yusong; Chen, Haijun; Yang, Zhengduo; Wild, Christopher; Ye, Na; Ester, Corbin D.; Xiong, Ailian; White, Mark A.; Shen, Qiang; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8814-8825</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oridonin (I) has attracted considerable attention in recent years because of its unique and safe anticancer pharmacol. profile.  Nevertheless, it exhibits moderate to poor effects against highly aggressive cancers including triple-neg. and drug-resistant breast cancer cells.  Herein, we report the rational design and synthesis of novel dienone derivs. with an addnl. α,β-unsatd. ketone system diversely installed in the A-ring based on this class of natural scaffold that features dense functionalities and stereochem.-rich frameworks.  Efficient and regioselective enone construction strategies have been established.  Meanwhile, a unique 3,7-rearrangement reaction was identified to furnish an unprecedented dienone scaffold.  Intriguingly, these new analogs have been demonstrated to significantly induce apoptosis and inhibit colony formation with superior antitumor effects against aggressive and drug-resistant breast cancer cells in vitro and in vivo while also exhibiting comparable or lower toxicity to normal human mammary epithelial cells in comparison with I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp42KnrzHKFwbVg90H21EOLACvtfcHk0lhLxYrVflYq-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1aht7nJ&md5=467a07903a1d9f8c4df11c5dfa15bfc5</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm401248x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401248x%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWild%26aufirst%3DC.%26aulast%3DYe%26aufirst%3DN.%26aulast%3DEster%26aufirst%3DC.%2BD.%26aulast%3DXiong%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DM.%2BA.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DOridonin%2520ring%2520A-based%2520diverse%2520constructions%2520of%2520enone%2520functionality%253A%2520identification%2520of%2520novel%2520dienone%2520analogues%2520effective%2520for%2520highly%2520aggressive%2520breast%2520cancer%2520by%2520inducing%2520apoptosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8814%26epage%3D8825%26doi%3D10.1021%2Fjm401248x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5048</span>– <span class="NLM_lpage">5058</span>, <span class="refDoi"> DOI: 10.1021/jm400367n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400367n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVeqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5048-5058&author=C.+Dingauthor=Y.+Zhangauthor=H.+Chenauthor=Z.+Yangauthor=C.+Wildauthor=L.+Chuauthor=H.+Liuauthor=Q.+Shenauthor=J.+Zhou&title=Novel+nitrogen-enriched+oridonin+analogues+with+thiazole-fused+A-ring%3A+protecting+group-free+synthesis%2C+enhanced+anticancer+profile%2C+and+improved+aqueous+solubility&doi=10.1021%2Fjm400367n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Nitrogen-Enriched Oridonin Analogues with Thiazole-Fused A-Ring: Protecting Group-Free Synthesis, Enhanced Anticancer Profile, and Improved Aqueous Solubility</span></div><div class="casAuthors">Ding, Chunyong; Zhang, Yusong; Chen, Haijun; Yang, Zhengduo; Wild, Christopher; Chu, Lili; Liu, Huiling; Shen, Qiang; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5048-5058</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oridonin (I), a complex ent-kaurane diterpenoid isolated from the traditional Chinese herb Isodon rubescens, has demonstrated great potential in the treatment of various human cancers due to its unique and safe anticancer pharmacol. profile.  Nevertheless, the clin. development of oridonin for cancer therapy has been hampered by its relatively moderate potency, limited aq. soly., and poor bioavailability.  Herein, we report the concise synthesis of a series of novel nitrogen-enriched oridonin derivs. with thiazole-fused A-ring through an efficient protecting group-free synthetic strategy.  Most of them, including compds. II [R = Me; R = NR1R2, R1 = Me, CHMe2, n-Bu, cyclohexyl, 2-(piperidin-1-yl)ethyl, allyl], exhibited potent antiproliferative effects against breast, pancreatic, and prostate cancer cells with low micromolar to submicromolar IC50 values as well as markedly enhanced aq. soly.  These new analogs obtained by rationally modifying the natural product have been shown not only to significantly induce the apoptosis and suppress growth of triple-neg. MDA-MB-231 breast cancer both in vitro and in vivo but are also effective against drug-resistant ER-pos. MCF-7 clones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfnEskkayfSLVg90H21EOLACvtfcHk0lhLxYrVflYq-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVeqtL0%253D&md5=b7ec95c47f40492b7aea80159cbbe9bb</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm400367n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400367n%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWild%26aufirst%3DC.%26aulast%3DChu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DNovel%2520nitrogen-enriched%2520oridonin%2520analogues%2520with%2520thiazole-fused%2520A-ring%253A%2520protecting%2520group-free%2520synthesis%252C%2520enhanced%2520anticancer%2520profile%252C%2520and%2520improved%2520aqueous%2520solubility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5048%26epage%3D5058%26doi%3D10.1021%2Fjm400367n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span> <span> </span><span class="NLM_article-title">A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.06.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.canlet.2016.06.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=27387452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFant7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2016&pages=393-402&author=J.+Wuauthor=Y.+Dingauthor=C.-H.+Chenauthor=Z.+Zhouauthor=C.+Dingauthor=H.+Chenauthor=J.+Zhouauthor=C.+Chen&title=A+new+oridonin+analog+suppresses+triple-negative+breast+cancer+cells+and+tumor+growth+via+the+induction+of+death+receptor+5&doi=10.1016%2Fj.canlet.2016.06.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5</span></div><div class="casAuthors">Wu, Jing; Ding, Ye; Chen, Chuan-Huizhi; Zhou, Zhongmei; Ding, Chunyong; Chen, Haiying; Zhou, Jia; Chen, Ceshi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">393-402</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) remains the leading cause of death among women with breast cancer worldwide.  Oridonin is a natural anti-cancer compd. that is isolated from the traditional Chinese herb Rabdosia rubescens.  However, the antitumor efficacies of oridonin in the treatments of TNBC and other cancers are far from ideal.  In this study, we investigated a series of newly designed oridonin analogs in terms of their actions against HCC1806 and HCC1937 TNBC cell lines and identified CYD-6-28, which significantly inhibits cancer cell proliferation and induces G2/M-phase cell cycle arrest and apoptosis.  CYD-6-28 induces the expression of p21 and the cleavage of caspase-3, -7, -8 and PARP and inhibits the expression levels of Cyclin D1, FLIPL and XIAP.  CYD-6-28 also inhibits the activations of STAT3 and AKT and induces the activation of ERK.  We demonstrated that CYD-6-28 induces apoptosis at least partially by inducing the expression of death receptor 5 (DR5).  Finally, CYD-6-28 significantly suppresses HCC1806 xenograft tumor growth in nude mice at 5 mg/kg without affecting body wt.  Taken together, these results indicate that CYD-6-28 has the potential to be developed as a therapeutic agent to treat TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwRKWDYjI09bVg90H21EOLACvtfcHk0liqd7HSPZU2Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFant7%252FO&md5=b550f5511d3bec8d73774cecf290aa81</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DA%2520new%2520oridonin%2520analog%2520suppresses%2520triple-negative%2520breast%2520cancer%2520cells%2520and%2520tumor%2520growth%2520via%2520the%2520induction%2520of%2520death%2520receptor%25205%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D380%26spage%3D393%26epage%3D402%26doi%3D10.1016%2Fj.canlet.2016.06.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Overcoming synthetic challenges of oridonin A-ring structural diversification: regio-and stereoselective installation of azides and 1, 2, 3-triazoles at the C-1, C-2, or C-3 position</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3718</span>– <span class="NLM_lpage">3721</span>, <span class="refDoi"> DOI: 10.1021/ol4015865</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol4015865" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKqtL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=3718-3721&author=C.+Dingauthor=Y.+Zhangauthor=H.+Chenauthor=C.+Wildauthor=T.+Wangauthor=M.+A.+Whiteauthor=Q.+Shenauthor=J.+Zhou&title=Overcoming+synthetic+challenges+of+oridonin+A-ring+structural+diversification%3A+regio-and+stereoselective+installation+of+azides+and+1%2C+2%2C+3-triazoles+at+the+C-1%2C+C-2%2C+or+C-3+position&doi=10.1021%2Fol4015865"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming Synthetic Challenges of Oridonin A-Ring Structural Diversification: Regio- and Stereoselective Installation of Azides and 1,2,3-Triazoles at the C-1, C-2, or C-3 Position</span></div><div class="casAuthors">Ding, Chunyong; Zhang, Yusong; Chen, Haijun; Wild, Christopher; Wang, Tianzhi; White, Mark A.; Shen, Qiang; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3718-3721</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Efficient and concise synthetic approaches have been developed for the rapid and diverse installation of azide functionalities at the C-1, C-2, or C-3 positions of oridonin with highly controlled regio- and stereoselectivity, while keeping key reactive pharmacophores intact by utilizing unique preactivation strategies based on the common synthon I.  Further functionalization of these azides through click chem. yielding triazole derivs. successfully provides access to an expanded natural scaffold-based compd. library for potential anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1L_ezFF5FhrVg90H21EOLACvtfcHk0liqd7HSPZU2Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKqtL%252FN&md5=3471ade39c5ccc1631d2d3cec830414e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fol4015865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol4015865%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWild%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DM.%2BA.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DOvercoming%2520synthetic%2520challenges%2520of%2520oridonin%2520A-ring%2520structural%2520diversification%253A%2520regio-and%2520stereoselective%2520installation%2520of%2520azides%2520and%25201%252C%25202%252C%25203-triazoles%2520at%2520the%2520C-1%252C%2520C-2%252C%2520or%2520C-3%2520position%26jtitle%3DOrg.%2520Lett.%26date%3D2013%26volume%3D15%26spage%3D3718%26epage%3D3721%26doi%3D10.1021%2Fol4015865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Regio-and stereospecific synthesis of oridonin D-ring aziridinated analogues for the treatment of triple-negative breast cancer via mediated irreversible covalent warheads</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2737</span>– <span class="NLM_lpage">2752</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGjur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2737-2752&author=Y.+Dingauthor=D.+Liauthor=C.+Dingauthor=P.+Wangauthor=Z.+Liuauthor=E.+A.+Woldauthor=N.+Yeauthor=H.+Chenauthor=M.+A.+Whiteauthor=Q.+Shenauthor=J.+Zhou&title=Regio-and+stereospecific+synthesis+of+oridonin+D-ring+aziridinated+analogues+for+the+treatment+of+triple-negative+breast+cancer+via+mediated+irreversible+covalent+warheads&doi=10.1021%2Facs.jmedchem.7b01514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Regio- and Stereospecific Synthesis of Oridonin D-Ring Aziridinated Analogues for the Treatment of Triple-Negative Breast Cancer via Mediated Irreversible Covalent Warheads</span></div><div class="casAuthors">Ding, Ye; Li, Dengfeng; Ding, Chunyong; Wang, Pingyuan; Liu, Zhiqing; Wold, Eric A.; Ye, Na; Chen, Haiying; White, Mark A.; Shen, Qiang; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2737-2752</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Covalent drug discovery has undergone a resurgence in recent years due to comprehensive optimization of the structure-activity relationship (SAR) and the structure-reactivity relationship (SRR) for covalent drug candidates.  The natural product oridonin maintains an impressive pharmacol. profile through its covalent enone warhead on the D-ring and has attracted substantial SAR studies to characterize its potential in the development of new mol. entities for the treatment of various human cancers and inflammation.  Herein, for the first time, we report the excessive reactivity of this covalent warhead and mediation of the covalent binding capability through a Rh2(esp)2-catalyzed mild and concise regio- and stereospecific aziridination approach.  Importantly, aziridonin I (YD0514), with a more-druglike irreversible covalent warhead, has been identified to significantly induce apoptosis and inhibit colony formation against triple-neg. breast cancer with enhanced antitumor effects in vitro and in vivo while displaying lower toxicity to normal human mammary epithelial cells in comparison to oridonin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-HLJjmpeUUbVg90H21EOLACvtfcHk0liqd7HSPZU2Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGjur8%253D&md5=97c421639ae1f21bf3b0e349ba07212d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01514%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DYe%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWhite%26aufirst%3DM.%2BA.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DRegio-and%2520stereospecific%2520synthesis%2520of%2520oridonin%2520D-ring%2520aziridinated%2520analogues%2520for%2520the%2520treatment%2520of%2520triple-negative%2520breast%2520cancer%2520via%2520mediated%2520irreversible%2520covalent%2520warheads%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2737%26epage%3D2752%26doi%3D10.1021%2Facs.jmedchem.7b01514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span> <span> </span><span class="NLM_article-title">Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>424</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2018.03.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.canlet.2018.03.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=29580806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXms1Ghsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=424&publication_year=2018&pages=97-108&author=D.+Liauthor=H.+Wangauthor=Y.+Dingauthor=Z.+Zhangauthor=Z.+Zhengauthor=J.+Dongauthor=H.+Kimauthor=X.+Mengauthor=Q.+Zhouauthor=J.+Zhouauthor=L.+Fangauthor=Q.+Shen&title=Targeting+the+NRF-2%2FRHOA%2FROCK+signaling+pathway+with+a+novel+aziridonin%2C+YD0514%2C+to+suppress+breast+cancer+progression+and+lung+metastasis&doi=10.1016%2Fj.canlet.2018.03.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis</span></div><div class="casAuthors">Li, Dengfeng; Wang, Hong; Ding, Ye; Zhang, Ziwei; Zheng, Zhi; Dong, Jiabin; Kim, Hyejin; Meng, Xiaojing; Zhou, Qianjun; Zhou, Jia; Fang, Lin; Shen, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">424</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">97-108</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Metastasis is a major cause of breast cancer-assocd. mortality.  Natural products extd. from herbs provide rich bioactive compds. with anticancer efficacy but may have limited or moderate potency and considerable toxicity.  We developed a novel aziridonin, YD0514, by aziridinating oridonin, a natural product of the medicinal herb Rabdosia rubescens.  In this study, we found that YD0514 significantly inhibited proliferation, motility, and adhesion of metastatic breast cancer cell lines MDA-MB-231, GI101, GILM2, and GILM3.  YD0514 also decreased the protein expression of matrix metalloproteinases 2 and 9 (MMP2 and MMP9), focal adhesion kinase (FAK), and integrin family members.  Importantly, YD0514 suppressed the growth of metastatic breast cancer xenograft tumors and significantly inhibited lung metastasis in vivo.  Lastly, we showed that YD0514's anti-metastatic effect on highly aggressive breast cancer is mediated via regulating the NRF-2/RHOA/ROCK signaling pathway.  These results demonstrate that YD0514, the first active analog based on an oridonin D-ring modification, has the potential to be developed as an anti-metastasis therapy for patients with metastatic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoql0Gzj4yj_bVg90H21EOLACvtfcHk0lhaKtZ4rR432Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXms1Ghsb8%253D&md5=eb619b17e9b1d81f625baf721fdc71a6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2018.03.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2018.03.029%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DQ.%26atitle%3DTargeting%2520the%2520NRF-2%252FRHOA%252FROCK%2520signaling%2520pathway%2520with%2520a%2520novel%2520aziridonin%252C%2520YD0514%252C%2520to%2520suppress%2520breast%2520cancer%2520progression%2520and%2520lung%2520metastasis%26jtitle%3DCancer%2520Lett.%26date%3D2018%26volume%3D424%26spage%3D97%26epage%3D108%26doi%3D10.1016%2Fj.canlet.2018.03.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">A novel potent anticancer compound optimized from a natural oridonin scaffold induces apoptosis and cell cycle arrest through the mitochondrial pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1449</span>– <span class="NLM_lpage">1468</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01652</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01652" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFWiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1449-1468&author=S.+Xuauthor=H.+Yaoauthor=S.+Luoauthor=Y.-K.+Zhangauthor=D.-H.+Yangauthor=D.+Liauthor=G.+Wangauthor=M.+Huauthor=Y.+Qiuauthor=X.+Wuauthor=H.+Yaoauthor=W.+Xieauthor=Z.-S.+Chenauthor=J.+Xu&title=A+novel+potent+anticancer+compound+optimized+from+a+natural+oridonin+scaffold+induces+apoptosis+and+cell+cycle+arrest+through+the+mitochondrial+pathway&doi=10.1021%2Facs.jmedchem.6b01652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway</span></div><div class="casAuthors">Xu, Shengtao; Yao, Hong; Luo, Shanshan; Zhang, Yun-Kai; Yang, Dong-Hua; Li, Dahong; Wang, Guangyu; Hu, Mei; Qiu, Yangyi; Wu, Xiaoming; Yao, Hequan; Xie, Weijia; Chen, Zhe-Sheng; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1449-1468</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The cytotoxicity of the natural ent-kaurene diterpenoid, oridonin, has been extensively studied.  However, the application of oridonin for cancer therapy was hampered primarily by its moderate potency.  In this study, a series of oridonin A-ring modified analogs, and their derivs. bearing various substituents on 14-OH position, were designed, synthesized and evaluated for anticancer efficacy.  Some of the derivs. were significantly more potent than oridonin against both drug-sensitive and drug-resistant cancer cells.  The most potent compd., I, was 200-fold more efficacious than oridonin in MCF-7 cancer cells.  Furthermore, I induced apoptosis and cell cycle arrest at the G2/M phase.  A decrease in mitochondrial membrane potential and increased Bax/Bcl-2 ratio, accompanied by activated caspase-3 cleavage, were obsd. in MCF-7 cells after treatment with I, suggesting that the mitochondrial pathway was involved in the I-mediated apoptosis.  Moreover, I significantly inhibited tumor growth in mouse xenograft models and had no observable toxic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpho5HBZ5sjAbVg90H21EOLACvtfcHk0lhaKtZ4rR432Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFWiur0%253D&md5=41ea3cb2bb52b27e4eea18ee90e60fd0</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01652%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.-K.%26aulast%3DYang%26aufirst%3DD.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DZ.-S.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DA%2520novel%2520potent%2520anticancer%2520compound%2520optimized%2520from%2520a%2520natural%2520oridonin%2520scaffold%2520induces%2520apoptosis%2520and%2520cell%2520cycle%2520arrest%2520through%2520the%2520mitochondrial%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1449%26epage%3D1468%26doi%3D10.1021%2Facs.jmedchem.6b01652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sager, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, B.</span></span> <span> </span><span class="NLM_article-title">Hydroxyl Groups in Synthetic and Natural Product Derived Therapeutics–A Perspective on a Common Functional Group</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8915</span>– <span class="NLM_lpage">8930</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00179</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00179" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlOjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8915-8930&author=J.+Cramerauthor=C.+P.+Sagerauthor=B.+Ernst&title=Hydroxyl+Groups+in+Synthetic+and+Natural+Product+Derived+Therapeutics%E2%80%93A+Perspective+on+a+Common+Functional+Group&doi=10.1021%2Facs.jmedchem.9b00179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxyl Groups in Synthetic and Natural-Product-Derived Therapeutics: A Perspective on a Common Functional Group</span></div><div class="casAuthors">Cramer, Jonathan; Sager, Christoph P.; Ernst, Beat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8915-8930</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  By forming extended hydrogen bond networks, the contribution of hydroxyl groups to affinity can reach several orders of magnitude.  However, because of the high directionality of their interactions, a maximal affinity gain can only be achieved when the ligand scaffold allows a perfect spatial fit with the binding site.  In contrast to the broad potential of hydroxyl groups for mol. recognition is their exceptionally high desolvation penalty, which can equally reduce binding affinity.  As a consequence, alcs. are rarely present in synthetic drugs, but predominantly found in therapeutics derived directly or inspired from natural products, which were shaped under evolutionary pressure.  In this perspective, advantages as well as drawbacks influencing the use of OH groups in medicinal chem. are discussed and illustrated with four exemplary case studies.  Addnl., guidelines for drug design are derived from common features found in existing therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Ay8IcfLbF7Vg90H21EOLACvtfcHk0lhaKtZ4rR432Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlOjsLY%253D&md5=5fff184a72d160ae211d4bc3d8dfba47</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00179%26sid%3Dliteratum%253Aachs%26aulast%3DCramer%26aufirst%3DJ.%26aulast%3DSager%26aufirst%3DC.%2BP.%26aulast%3DErnst%26aufirst%3DB.%26atitle%3DHydroxyl%2520Groups%2520in%2520Synthetic%2520and%2520Natural%2520Product%2520Derived%2520Therapeutics%25E2%2580%2593A%2520Perspective%2520on%2520a%2520Common%2520Functional%2520Group%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8915%26epage%3D8930%26doi%3D10.1021%2Facs.jmedchem.9b00179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">The structural modification of natural products for novel drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1272757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1080%2F17460441.2016.1272757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=28006993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2sXivVek" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=121-140&author=H.+Yaoauthor=J.+Liuauthor=S.+Xuauthor=Z.+Zhuauthor=J.+Xu&title=The+structural+modification+of+natural+products+for+novel+drug+discovery&doi=10.1080%2F17460441.2016.1272757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The structural modification of natural products for novel drug discovery</span></div><div class="casAuthors">Yao, Hong; Liu, Junkai; Xu, Shengtao; Zhu, Zheying; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-140</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Throughout history, natural products (NPs) have provided a rich source of compds. that have wide applications in the fields of medicine, health sciences, pharmacy and biol.  Although naturally active substances are good lead compds. for the discovery of new drugs, most of them suffer from various deficiencies or shortcomings, such as complex structures, poor stability and soly.  Therefore, structural modification of NPs is needed to develop novel compds. with specific properties.: This article presents an overview on the structural modifications of NPs in drug development.  The application of multiple classes of NPs to the treatment of conditions such as cancers, infection, Alzheimer's and diabetes are discussed.  This article also reveals that modification of NPs is a versatile approach to explore their mode of actions, which may lead to the discovery of novel drugs.: NPs are usually described by structural diversity and complexity.  The use of isolated NPs as scaffolds for modification is a good approach to drug discovery and development.  Despite many limitations assocd. with NPs, the total synthesis, semisynthetic modification, SAR-based modification, sometimes even a single atom alteration, may lead to the discovery of a novel drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6S_a4H8DIPLVg90H21EOLACvtfcHk0lgJ0T8IadHdtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXivVek&md5=46b49696429d04c7982c315339a2c9bb</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1272757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1272757%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DThe%2520structural%2520modification%2520of%2520natural%2520products%2520for%2520novel%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2017%26volume%3D12%26spage%3D121%26epage%3D140%26doi%3D10.1080%2F17460441.2016.1272757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Structural simplification of natural products</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">4180</span>– <span class="NLM_lpage">4220</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.8b00504</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.8b00504" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFGntrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2019&pages=4180-4220&author=S.+Wangauthor=G.+Dongauthor=C.+Sheng&title=Structural+simplification+of+natural+products&doi=10.1021%2Facs.chemrev.8b00504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Simplification of Natural Products</span></div><div class="casAuthors">Wang, Shengzheng; Dong, Guoqiang; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">4180-4220</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Natural products (NPs) are important sources of clin. drugs due to their structural diversity and biol. prevalidation.  However, the structural complexity of NPs leads to synthetic difficulties, unfavorable pharmacokinetic profiles, and poor drug-likeness.  Structural simplification by truncating unnecessary substructures is a powerful strategy for overcoming these limitations and improving the efficiency and success rate of NP-based drug development.  Herein, we will provide a comprehensive review of the structural simplification of NPs with a focus on design strategies, case studies, and new technologies.  In particular, a no. of successful examples leading to marketed drugs or drug candidates will be discussed in detail to illustrate how structural simplification is applied in lead optimization of NPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3XsYo2dUwabVg90H21EOLACvtfcHk0lgJ0T8IadHdtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFGntrw%253D&md5=7cec4ad3ab49a40e82c72447524f5523</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.8b00504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.8b00504%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DStructural%2520simplification%2520of%2520natural%2520products%26jtitle%3DChem.%2520Rev.%26date%3D2019%26volume%3D119%26spage%3D4180%26epage%3D4220%26doi%3D10.1021%2Facs.chemrev.8b00504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Novel anticancer oridonin derivatives possessing a diazen-1-ium-1, 2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2795</span>– <span class="NLM_lpage">2800</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.04.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.bmcl.2016.04.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=27158140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnt1Ohsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2795-2800&author=S.+Xuauthor=G.+Wangauthor=Y.+Linauthor=Y.+Zhangauthor=L.+Peiauthor=H.+Yaoauthor=M.+Huauthor=Y.+Qiuauthor=Z.+Huangauthor=Y.+Zhangauthor=J.+Xu&title=Novel+anticancer+oridonin+derivatives+possessing+a+diazen-1-ium-1%2C+2-diolate+nitric+oxide+donor+moiety%3A+Design%2C+synthesis%2C+biological+evaluation+and+nitric+oxide+release+studies&doi=10.1016%2Fj.bmcl.2016.04.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies</span></div><div class="casAuthors">Xu, Shengtao; Wang, Guangyu; Lin, Yan; Zhang, Yanju; Pei, Lingling; Yao, Hong; Hu, Mei; Qiu, Yangyi; Huang, Zhangjian; Zhang, Yihua; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2795-2800</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Oridonin (I) is a complex ent-kaurane diterpenoid with unique antitumor profile, which is isolated from Isodon rubescens.  In order to develop novel derivs. of oridonin with improved potency, a series of nitric oxide (NO)-releasing oridonin derivs. were synthesized by coupling diazeniumdiolates with oridonin and its semisynthesized analogs.  Their in vitro antiproliferative activity, nitric oxide release ability, and preliminary anticancer mechanism were further evaluated.  The results displayed that all the target compds. exhibited potent antiproliferative activities, with IC50 values ranging from 1.84 to 17.01 μM.  Besides, it was obsd. that in most cases, the antiproliferative activity correlated well with levels of intracellular NO release.  More interestingly, preliminary mechanism studies revealed that the most potent compd. II induced apoptosis and arrested the cell cycle at the S phase in Bel-7402 cells, which is different from parent compd. oridonin.  Together, the above promising results warrant the further development of oridonin/NO hybrids as potential antitumor leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXhYN12V1_WbVg90H21EOLACvtfcHk0lgJ0T8IadHdtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnt1Ohsr8%253D&md5=220727c1cafb5a7f059c4812b4f243f8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.04.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.04.068%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DNovel%2520anticancer%2520oridonin%2520derivatives%2520possessing%2520a%2520diazen-1-ium-1%252C%25202-diolate%2520nitric%2520oxide%2520donor%2520moiety%253A%2520Design%252C%2520synthesis%252C%2520biological%2520evaluation%2520and%2520nitric%2520oxide%2520release%2520studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2795%26epage%3D2800%26doi%3D10.1016%2Fj.bmcl.2016.04.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">310</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.03.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2017.03.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=28395199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVCrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2017&pages=310-321&author=S.+Xuauthor=H.+Yaoauthor=L.+Peiauthor=M.+Huauthor=D.+Liauthor=Y.+Qiuauthor=G.+Wangauthor=L.+Wuauthor=H.+Yaoauthor=Z.+Zhuauthor=J.+Xu&title=Design%2C+synthesis%2C+and+biological+evaluation+of+NAD%28P%29H%3A+Quinone+oxidoreductase+%28NQO1%29-targeted+oridonin+prodrugs+possessing+indolequinone+moiety+for+hypoxia-selective+activation&doi=10.1016%2Fj.ejmech.2017.03.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation</span></div><div class="casAuthors">Xu, Shengtao; Yao, Hong; Pei, Lingling; Hu, Mei; Li, Dahong; Qiu, Yangyi; Wang, Guangyu; Wu, Liang; Yao, Hequan; Zhu, Zheying; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">310-321</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The enzyme NQO1 is a potential target for selective cancer therapy due to its overexpression in certain hypoxic tumors.  A series of prodrugs possessing a variety of cytotoxic diterpenoids (oridonin and its analogs) as the leaving groups activated by NQO1 were synthesized by functionalization of 3-(hydroxymethyl)indolequinone, which is a good substrate of NQO1.  The target compds. exhibited relatively higher antiproliferative activities against NQO1-rich human colon carcinoma cells (HT-29) and human lung carcinoma (A549) cells (IC50 = 0.263-2.904 μM), while NQO1-deficient lung adenosquamous carcinoma cells (H596) were less sensitive to these compds., among which, compd. I exhibited the most potent antiproliferative activity against both A549 and HT-29 cells, with IC50 values of 0.386 and 0.263 μM, resp.  Further HPLC and docking studies demonstrated that I is a good substrate of NQO1.  Moreover, the investigation of anticancer mechanism showed that the representative compd. I affected cell cycle and induced NQO1 dependent apoptosis through an oxidative stress triggered mitochondria-related pathway in A549 cells.  Besides, the antitumor activity of I was also verified in a liver cancer xenograft mouse model.  Biol. evaluation of these compds. concludes that there is a strong correlation between NQO1 enzyme and induction of cancer cell death.  Thus, this suggests that some of the target compds. activated by NQO1 are novel prodrug candidates potential for selective anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUnJI_Q_X6ErVg90H21EOLACvtfcHk0lhaWif7lZOB-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVCrurc%253D&md5=5436e872c6b9f388096a8c76488f9767</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.03.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.03.055%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DPei%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520NAD%2528P%2529H%253A%2520Quinone%2520oxidoreductase%2520%2528NQO1%2529-targeted%2520oridonin%2520prodrugs%2520possessing%2520indolequinone%2520moiety%2520for%2520hypoxia-selective%2520activation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D132%26spage%3D310%26epage%3D321%26doi%3D10.1016%2Fj.ejmech.2017.03.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">6, 7-Seco-ent-kauranoids derived from oridonin as potential anticancer agents</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">2391</span>– <span class="NLM_lpage">2398</span>, <span class="refDoi"> DOI: 10.1021/acs.jnatprod.7b00057</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jnatprod.7b00057" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVOju7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2017&pages=2391-2398&author=S.+Xuauthor=H.+Yaoauthor=M.+Huauthor=D.+Liauthor=Z.+Zhuauthor=W.+Xieauthor=H.+Yaoauthor=L.+Wuauthor=Z.-S.+Chenauthor=J.+Xu&title=6%2C+7-Seco-ent-kauranoids+derived+from+oridonin+as+potential+anticancer+agents&doi=10.1021%2Facs.jnatprod.7b00057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">6,7-Seco-ent-Kauranoids Derived from Oridonin as Potential Anticancer Agents</span></div><div class="casAuthors">Xu, Shengtao; Yao, Hong; Hu, Mei; Li, Dahong; Zhu, Zheying; Xie, Weijia; Yao, Hequan; Wu, Liang; Chen, Zhe-Sheng; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2391-2398</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">Structurally unique 6,7-seco-ent-kaurenes, which are widely distributed in the genus Isodon, have attracted considerable attention because of their antitumor activities.  Previously, a convenient conversion of com. available oridonin to 6,7-seco-ent-kaurenes was developed.  Herein, several novel spiro-lactone-type ent-kaurene derivs. bearing various substituents at the C-1 and C-14 positions were further designed and synthesized from the natural product oridonin.  Moreover, a no. of seven-membered C-ring-expanded 6,7-seco-ent-kaurenes were also identified for the first time.  It was obsd. that most of the spiro-lactone-type ent-kaurenes tested markedly inhibited the proliferation of cancer cells, with an IC50 value as low as 0.55 μM.  An investigation on its mechanism of action showed that the representative compd. 7b (ent-6,7,15-trioxo-7,20-epoxy(14β-O-p-floroienzoyl)-1-alkene-6,7-seco-16-kaurene) affected the cell cycle and induced apoptosis at a low micromolar level in MCF-7 human breast cancer cells.  Furthermore, compd. 7b inhibited liver tumor growth in an in vivo mouse model and exhibited no observable toxic effects.  Collectively, the results warrant further preclin. investigations of these spiro-lactone-type ent-kaurenes as potential novel anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVPu7Z3RMnSbVg90H21EOLACvtfcHk0lhaWif7lZOB-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVOju7rM&md5=31e2ffa92a5cf1abcb84941e2eca4d7d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jnatprod.7b00057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jnatprod.7b00057%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DZ.-S.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3D6%252C%25207-Seco-ent-kauranoids%2520derived%2520from%2520oridonin%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2017%26volume%3D80%26spage%3D2391%26epage%3D2398%26doi%3D10.1021%2Facs.jnatprod.7b00057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">797</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.1021/ml500141f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500141f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1WqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=797-802&author=S.+Xuauthor=L.+Peiauthor=C.+Wangauthor=Y.-K.+Zhangauthor=D.+Liauthor=H.+Yaoauthor=X.+Wuauthor=Z.-S.+Chenauthor=Y.+Sunauthor=J.+Xu&title=Novel+hybrids+of+natural+oridonin-bearing+nitrogen+mustards+as+potential+anticancer+drug+candidates&doi=10.1021%2Fml500141f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Hybrids of Natural Oridonin-Bearing Nitrogen Mustards as Potential Anticancer Drug Candidates</span></div><div class="casAuthors">Xu, Shengtao; Pei, Lingling; Wang, Chengqian; Zhang, Yun-Kai; Li, Dahong; Yao, Hequan; Wu, Xiaoming; Chen, Zhe-Sheng; Sun, Yijun; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">797-802</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel hybrids from natural product oridonin and nitrogen mustards were designed and synthesized to obtain more efficacious and less toxic antitumor agents.  The antiproliferative evaluation showed that most conjugates were more potent than their parent compds. oridonin and clin. used nitrogen mustards against four human cancer cell lines (K562, MCF-7, Bel-7402, and MGC-803).  Furthermore, some compds. exhibited antiproliferative activities against the multidrug resistant cell lines (SW620/AD300 and NCI-H460/MX20).  It was shown that the most effective compd. I possesses a strong inhibitory activity with an IC50 value 21-fold lower than that of oridonin in MCF-7 cells and also exhibits selective cytotoxicity toward the cancer cells.  Intriguingly, compd. I has been demonstrated to significantly induce apoptosis and affect cell cycle progression in human hepatoma Bel-7402 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWN_rVEgplcLVg90H21EOLACvtfcHk0lhaWif7lZOB-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1WqtLw%253D&md5=a07e486f15a5e587e074ac957b319c6c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fml500141f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500141f%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DPei%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.-K.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.-S.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DNovel%2520hybrids%2520of%2520natural%2520oridonin-bearing%2520nitrogen%2520mustards%2520as%2520potential%2520anticancer%2520drug%2520candidates%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D797%26epage%3D802%26doi%3D10.1021%2Fml500141f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: Synthesis and biological evaluation of ent-6, 7-seco-oridonin derivatives as novel potential anticancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">242</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.03.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2012.03.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=22483090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtlSksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=242-250&author=L.+Wangauthor=D.+Liauthor=S.+Xuauthor=H.+Caiauthor=H.+Yaoauthor=Y.+Zhangauthor=J.+Jiangauthor=J.+Xu&title=The+conversion+of+oridonin+to+spirolactone-type+or+enmein-type+diterpenoid%3A+Synthesis+and+biological+evaluation+of+ent-6%2C+7-seco-oridonin+derivatives+as+novel+potential+anticancer+agents&doi=10.1016%2Fj.ejmech.2012.03.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: Synthesis and biological evaluation of ent-6,7-seco-oridonin derivatives as novel potential anticancer agents</span></div><div class="casAuthors">Wang, Lei; Li, Dahong; Xu, Shengtao; Cai, Hao; Yao, Hequan; Zhang, Yihua; Jiang, Jieyun; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">242-250</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Starting from com. available natural product oridonin (I), a practical synthesis of ent-6,7-seco-oridonin derivs., e.g., II and III, was accomplished and their biol. activities were evaluated.  The conversion of spirolactone-type diterpenoid to enmein-type was first completed.  The results demonstrated that all synthesized ent-6,7-seco-oridonin derivs. could markedly inhibit the proliferation of cancer cells.  Compared with Taxol, the most cytotoxic compd. II has similar potency in A549 cell and slightly less cytotoxicity in Bel-7402 cell.  II was also more potent than parent compd. oridonin in mice with MGC-803 gastric cancer in vivo.  Then a series of novel 14-O-derivs. of II were further designed and synthesized, which showed better activity than II and similar activity as Taxol in vitro.  The structure-activity relationships of oridonin derivs. were also discussed in the present investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2rgdU2mwym7Vg90H21EOLACvtfcHk0lhhuSFvxQ-3FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtlSksrw%253D&md5=0cb57a6483e63f89885807a8cf5b5da0</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.03.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.03.024%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DThe%2520conversion%2520of%2520oridonin%2520to%2520spirolactone-type%2520or%2520enmein-type%2520diterpenoid%253A%2520Synthesis%2520and%2520biological%2520evaluation%2520of%2520ent-6%252C%25207-seco-oridonin%2520derivatives%2520as%2520novel%2520potential%2520anticancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D52%26spage%3D242%26epage%3D250%26doi%3D10.1016%2Fj.ejmech.2012.03.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Enmein-type diterpenoid analogs from natural kaurene-type oridonin: Synthesis and their antitumor biological evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2013.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=23644204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFOmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=215-221&author=D.+Liauthor=S.+Xuauthor=H.+Caiauthor=L.+Peiauthor=H.+Zhangauthor=L.+Wangauthor=H.+Yaoauthor=X.+Wuauthor=J.+Jiangauthor=Y.+Sunauthor=J.+Xu&title=Enmein-type+diterpenoid+analogs+from+natural+kaurene-type+oridonin%3A+Synthesis+and+their+antitumor+biological+evaluation&doi=10.1016%2Fj.ejmech.2013.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Enmein-type diterpenoid analogs from natural kaurene-type oridonin: Synthesis and their antitumor biological evaluation</span></div><div class="casAuthors">Li, Dahong; Xu, Shengtao; Cai, Hao; Pei, Lingling; Zhang, Hengyuan; Wang, Lei; Yao, Hequan; Wu, Xiaoming; Jiang, Jieyun; Sun, Yijun; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">215-221</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of enmein-type diterpenoid analogs derived from natural kaurene-type diterpenoid oridonin were synthesized and biol. evaluated.  All target compds. showed improved anti-proliferative activities against four human cancer cell lines compared with natural oridonin and the parent compd.  Some compds. were more potent than pos. control Taxol.  Furthermore, mechanistic investigation showed that the representative compd. I affected cell cycle and induced apoptosis at low micro-molar level in human hepatoma Bel-7402 cells, via an oxidative stress triggered mitochondria-related caspase-dependent pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq08za9z5IyLVg90H21EOLACvtfcHk0lhhuSFvxQ-3FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFOmtL8%253D&md5=fe2faf2585f4da95c9b2c130a41bd015</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DPei%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DEnmein-type%2520diterpenoid%2520analogs%2520from%2520natural%2520kaurene-type%2520oridonin%253A%2520Synthesis%2520and%2520their%2520antitumor%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D64%26spage%3D215%26epage%3D221%26doi%3D10.1016%2Fj.ejmech.2013.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and antimycobacterial activity evaluation of natural oridonin derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2811</span>– <span class="NLM_lpage">2814</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.04.119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.bmcl.2014.04.119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=24835198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFGlsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2811-2814&author=S.+Xuauthor=D.+Liauthor=L.+Peiauthor=H.+Yaoauthor=C.+Wangauthor=H.+Caiauthor=H.+Yaoauthor=X.+Wuauthor=J.+Xu&title=Design%2C+synthesis+and+antimycobacterial+activity+evaluation+of+natural+oridonin+derivatives&doi=10.1016%2Fj.bmcl.2014.04.119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and antimycobacterial activity evaluation of natural oridonin derivatives</span></div><div class="casAuthors">Xu, Shengtao; Li, Dahong; Pei, Lingling; Yao, Hong; Wang, Chengqian; Cai, Hao; Yao, Hequan; Wu, Xiaoming; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2811-2814</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In an effort to develop novel potent antitubercular drugs, thirty-one oridonin derivs. were designed and prepd.  All the compds. obtained were screened for their in vitro activities against Mycobacterium phlei, Mycobacterium smegmatis and Mycobacterium marinum.  Among them, thirteen compds. showed significant inhibitory activity against M. phlei with MICs less than 2 μg/mL.  I, II and III (R = H, F) contg. trans-cinnamic acid moiety were the most potent (MIC = 0.5 μg/mL), comparable to the well-known antitubercular drug streptomycin.  The preliminary structure-activity relationships (SARs) were also analyzed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgZ3jyzlwXnbVg90H21EOLACvtfcHk0lhhuSFvxQ-3FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFGlsro%253D&md5=dc86b69534096ace890c588bc3f5e787</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.04.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.04.119%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DPei%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520antimycobacterial%2520activity%2520evaluation%2520of%2520natural%2520oridonin%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2811%26epage%3D2814%26doi%3D10.1016%2Fj.bmcl.2014.04.119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of spirolactone-type diterpenoid derivatives from kaurene-type oridonin with improved antiproliferative effects and their apoptosis-inducing activity in human hepatoma Bel-7402 cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.ejmech.2012.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=23274570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CnsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2013&pages=322-328&author=D.+Liauthor=H.+Caiauthor=B.+Jiangauthor=G.+Liuauthor=Y.+Wangauthor=L.+Wangauthor=H.+Yaoauthor=X.+Wuauthor=Y.+Sunauthor=J.+Xu&title=Synthesis+of+spirolactone-type+diterpenoid+derivatives+from+kaurene-type+oridonin+with+improved+antiproliferative+effects+and+their+apoptosis-inducing+activity+in+human+hepatoma+Bel-7402+cells&doi=10.1016%2Fj.ejmech.2012.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of spirolactone-type diterpenoid derivatives from kaurene-type oridonin with improved antiproliferative effects and their apoptosis-inducing activity in human hepatoma Bel-7402 cells</span></div><div class="casAuthors">Li, Dahong; Cai, Hao; Jiang, Bowen; Liu, Guyue; Wang, Yuetong; Wang, Lei; Yao, Hequan; Wu, Xiaoming; Sun, Yijun; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">322-328</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel spirolactone-type diterpenoid derivs. I (R = Me, Et, Bu, Ph, C6H4R'-4, C6H4Cl-2; R' = Me, OMe, CF3, NO2, Cl) of oridonin (II) were designed and synthesized.  All the target compds. showed improved anti-proliferative activity against a panel of human cancer cell lines and the most effective compd. I (R = C6H4Cl-2) was more potent than pos. control Taxol in K562 and Bel-7402 cells with IC50 values of 0.39 μM and 1.39 μM, resp.  The cellular mechanisms showed that compd. I (R = C6H4Cl-2) induced apoptosis at low micromolar concns. in human hepatoma Bel-7402 cells.  These results demonstrate that the spirolactone-type diterpenoid derivs. of oridonin (II) have optimized growth inhibitory activity against cancer cells and interesting apoptosis-inducing ability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaxRr56kGxoLVg90H21EOLACvtfcHk0lhTsxGI96IA0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CnsLY%253D&md5=383c580be734fe21c83e745fb8a989ee</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DSynthesis%2520of%2520spirolactone-type%2520diterpenoid%2520derivatives%2520from%2520kaurene-type%2520oridonin%2520with%2520improved%2520antiproliferative%2520effects%2520and%2520their%2520apoptosis-inducing%2520activity%2520in%2520human%2520hepatoma%2520Bel-7402%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D59%26spage%3D322%26epage%3D328%26doi%3D10.1016%2Fj.ejmech.2012.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Library Construction and Biological Evaluation of Enmein-Type Diterpenoid Analogues as Potential Anticancer Agents</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">812</span>– <span class="NLM_lpage">818</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1002%2Fcmdc.201200559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=23520191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkt1Kmu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=812-818&author=D.+Liauthor=S.+Xuauthor=H.+Caiauthor=L.+Peiauthor=L.+Wangauthor=X.+Wuauthor=H.+Yaoauthor=J.+Jiangauthor=Y.+Sunauthor=J.+Xu&title=Library+Construction+and+Biological+Evaluation+of+Enmein-Type+Diterpenoid+Analogues+as+Potential+Anticancer+Agents&doi=10.1002%2Fcmdc.201200559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Library Construction and Biological Evaluation of Enmein-Type Diterpenoid Analogs as Potential Anticancer Agents</span></div><div class="casAuthors">Li, Dahong; Xu, Shengtao; Cai, Hao; Pei, Lingling; Wang, Lei; Wu, Xiaoming; Yao, Hequan; Jiang, Jieyun; Sun, Yijun; Xu, Jinyi</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">812-818</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A library of promising enmein-type 14-O-diterpenoid derivs. was constructed from a com. available kaurene-type oridonin by practical and efficient synthetic methods.  These synthetic derivs. were evaluated for their antiproliferative activities against a set of four human cancer cell lines.  The IC50 values are similar to or improved over those of the parent mol. and paclitaxel, the latter of which was used as a pos. control.  One compd. was further investigated for its apoptotic properties against human hepatocarcinoma Bel-7402 cells to better understand its mode of action.  Moreover, said compd. was shown to have potent antitumor activity in vivo in studies with a murine model of gastric cancer (MGC-803 mice).  These results warrant further preclin. investigations of these diterpenoid-based analogs as potential novel anticancer chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDgo7iZxPz27Vg90H21EOLACvtfcHk0lhTsxGI96IA0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkt1Kmu7Y%253D&md5=badf4285fabc9c75b77e5d600a551d63</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200559%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DPei%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DLibrary%2520Construction%2520and%2520Biological%2520Evaluation%2520of%2520Enmein-Type%2520Diterpenoid%2520Analogues%2520as%2520Potential%2520Anticancer%2520Agents%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D812%26epage%3D818%26doi%3D10.1002%2Fcmdc.201200559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarthy, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shyr, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietenpol, J. A.</span></span> <span> </span><span class="NLM_article-title">Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">2750</span>– <span class="NLM_lpage">2767</span>, <span class="refDoi"> DOI: 10.1172/jci45014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1172%2Fjci45014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=21633166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVKgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=2750-2767&author=B.+D.+Lehmannauthor=J.+A.+Bauerauthor=X.+Chenauthor=M.+E.+Sandersauthor=A.+B.+Chakravarthyauthor=Y.+Shyrauthor=J.+A.+Pietenpol&title=Identification+of+human+triple-negative+breast+cancer+subtypes+and+preclinical+models+for+selection+of+targeted+therapies&doi=10.1172%2Fjci45014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</span></div><div class="casAuthors">Lehmann, Brian D.; Bauer, Joshua A.; Chen, Xi; Sanders, Melinda E.; Chakravarthy, A. Bapsi; Shyr, Yu; Pietenpol, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2750-2767</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a highly diverse group of cancers, and subtyping is necessary to better identify mol.-based therapies.  In this study, we analyzed gene expression (GE) profiles from 21 breast cancer data sets and identified 587 TNBC cases.  Cluster anal. identified 6 TNBC subtypes displaying unique GE and ontologies, including 2 basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR) subtype.  Further, GE anal. allowed us to identify TNBC cell line models representative of these subtypes.  Predicted "driver" signaling pathways were pharmacol. targeted in these cell line models as proof of concept that anal. of distinct GE signatures can inform therapy selection.  BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines preferentially responded to cisplatin.  M and MSL subtypes were enriched in GE for epithelial-mesenchymal transition, and growth factor pathways and cell models responded to NVP-BEZ235 (a PI3K/mTOR inhibitor) and dasatinib (an abl/src inhibitor).  The LAR subtype includes patients with decreased relapse-free survival and was characterized by androgen receptor (AR) signaling.  LAR cell lines were uniquely sensitive to bicalutamide (an AR antagonist).  These data may be useful in biomarker selection, drug discovery, and clin. trial design that will enable alignment of TNBC patients to appropriate targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbhoQQUFogW7Vg90H21EOLACvtfcHk0lhTsxGI96IA0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVKgu78%253D&md5=c3681c79e0b972f16f6d5a5ecdc99fec</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1172%2Fjci45014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci45014%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DBauer%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSanders%26aufirst%3DM.%2BE.%26aulast%3DChakravarthy%26aufirst%3DA.%2BB.%26aulast%3DShyr%26aufirst%3DY.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DIdentification%2520of%2520human%2520triple-negative%2520breast%2520cancer%2520subtypes%2520and%2520preclinical%2520models%2520for%2520selection%2520of%2520targeted%2520therapies%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D2750%26epage%3D2767%26doi%3D10.1172%2Fjci45014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buolamwini, J.</span></span> <span> </span><span class="NLM_article-title">Cell cycle molecular targets in novel anticancer drug discovery</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">392</span>, <span class="refDoi"> DOI: 10.2174/1381612003400948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.2174%2F1381612003400948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10788588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjt1Cltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=379-392&author=J.+Buolamwini&title=Cell+cycle+molecular+targets+in+novel+anticancer+drug+discovery&doi=10.2174%2F1381612003400948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle molecular targets in novel anticancer drug discovery</span></div><div class="casAuthors">Buolamwini, John K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">379-392</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review with 79 refs.  A no. of potential mol. targets for novel anticancer drug discovery have been identified in cell cycle control mechanisms.  Prominent among these are the regulatory proteins, cyclins and their effector counterparts the cyclin dependent kinases (CDKs).  Aberrant expression of these proteins, particularly cyclins involved in the G1 phase of the cell cycle, namely the D and E cyclins, has been assocd. with a variety of human cancers, including breast and colorectal cancer, B-lymphoma, prostate and non-small cell lung cancer.  Inhibition of CDK kinase activity has turned out to be the most productive strategy for the discovery and design novel anticancer agents specifically targeting the cell cycle.  Other potentially useful cell cycle areas for exploration include cyclin-CDK interactions, Cdc25 activation of cyclin-CDK complexes, ubiquitin-mediated proteolysis of cyclins, cell cycle check point kinases like Chk1, and recently identified oncogenic cell cycle-related aurora and polo-like kinases.  Potent specific inhibitors have been identified that bind to the ATP site of CDKs, mainly cyclin B-CDK1, cyclin A-CDK2, and cyclin D-CDK4 complexes, and inhibit kinase activity.  X-ray crystallog. data of CDKs, and their complexes with inhibitors have played a major role in the success of drug discovery efforts.  Combinatorial chem., high-throughput screening, functional genomics and informatics have also contributed.  CDK inhibitors currently under investigation include flavopiridol, olomoucine, roscovitine, puvalanol B, the dihydroindolo[3,2-d][1]benzazepinone kenpaullone, indirubin-3'-monoxime and novel diaminothiazoles such as AG12275.  The anticancer therapeutic potential of CDK inhibitors has been demonstrated in preclin. studies, and Phases I and II clin. trials in cancer patients are currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqehW2hdiN9mrVg90H21EOLACvtfcHk0lhTsxGI96IA0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjt1Cltb8%253D&md5=9a480b0daaa4559e9f0d6c36f0586732</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F1381612003400948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612003400948%26sid%3Dliteratum%253Aachs%26aulast%3DBuolamwini%26aufirst%3DJ.%26atitle%3DCell%2520cycle%2520molecular%2520targets%2520in%2520novel%2520anticancer%2520drug%2520discovery%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2000%26volume%3D6%26spage%3D379%26epage%3D392%26doi%3D10.2174%2F1381612003400948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tristão, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessoa, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamichi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batista, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durão Junior, M. d. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monte, J. C. M.</span></span> <span> </span><span class="NLM_article-title">Synergistic effect of apoptosis and necroptosis inhibitors in cisplatin-induced nephrotoxicity</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1007/s10495-015-1190-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1007%2Fs10495-015-1190-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=26519037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOgtb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=51-59&author=V.+R.+Trist%C3%A3oauthor=E.+A.+Pessoaauthor=R.+Nakamichiauthor=L.+A.+Reisauthor=M.+C.+Batistaauthor=M.+d.+S.+Dur%C3%A3o+Juniorauthor=J.+C.+M.+Monte&title=Synergistic+effect+of+apoptosis+and+necroptosis+inhibitors+in+cisplatin-induced+nephrotoxicity&doi=10.1007%2Fs10495-015-1190-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic effect of apoptosis and necroptosis inhibitors in cisplatin-induced nephrotoxicity</span></div><div class="casAuthors">Tristao, Vivian Regina; Pessoa, Edson A.; Nakamichi, Renata; Reis, Luciana A.; Batista, Marcelo Costa; Junior, Marcelino de Souza Durao; Monte, Julio Cesar Martins</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-59</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Necroptosis is a nonapoptotic cell death pathway.  We aim to study the effect of necrostatin-1 (a specific necroptosis inhibitor) in cisplatin-induced injury.  We analyzed the effect of the combined use of inhibitors of apoptosis (z-vad) and necroptosis (necrostatin-1) in acute kidney injury by cisplatin in human proximal tubule cells.  Our results showed moderate effectiveness in cytoprotection after treatment with z-vad.  But the concomitant use of inhibitors (z-vad and necrostatin-1) presented synergistic and additive protection.  The present study analyzed the caspase-3 activity and we obsd. a significant decrease in the group treated with z-vad and cisplatin.  However we did not observe changes in the group treated with both inhibitors (z-vad and necrostatin-1) and cisplatin.  Thus, demonstrating that necroptosis is a caspase-independent mechanism.  We also analyzed the effect of necrostatin-1 in vivo model.  C57BL/6 mice were treated with cisplatin and/or inhibitors.  The concomitant use of inhibitors (z-vad and necrostatin-1) recovered renal function and decreased levels of urinary Ngal.  Addnl., we analyzed the expression of RIP-1, a specific marker for necroptosis.  In animals treated with cisplatin and z-VAD levels of RIP-1 were higher.  This result reinforces that necroptosis occurs only in conditions where apoptosis was blocked.  However, the use of both inhibitors (z-vad and necrostatin-1) provided addnl. protection.  In conclusion, our study has a significant potential to show in vitro and in vivo protection obtained by necrostatin-1.  Therefore, our results suggest that necroptosis may be an important mechanism of cell death after kidney injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrusb22tWWXS7Vg90H21EOLACvtfcHk0ljjUkXOgPeNMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOgtb3L&md5=ddb2974b419a811fd21d76cb0ef8cb28</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs10495-015-1190-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-015-1190-5%26sid%3Dliteratum%253Aachs%26aulast%3DTrist%25C3%25A3o%26aufirst%3DV.%2BR.%26aulast%3DPessoa%26aufirst%3DE.%2BA.%26aulast%3DNakamichi%26aufirst%3DR.%26aulast%3DReis%26aufirst%3DL.%2BA.%26aulast%3DBatista%26aufirst%3DM.%2BC.%26aulast%3DDur%25C3%25A3o%2BJunior%26aufirst%3DM.%2Bd.%2BS.%26aulast%3DMonte%26aufirst%3DJ.%2BC.%2BM.%26atitle%3DSynergistic%2520effect%2520of%2520apoptosis%2520and%2520necroptosis%2520inhibitors%2520in%2520cisplatin-induced%2520nephrotoxicity%26jtitle%3DApoptosis%26date%3D2016%26volume%3D21%26spage%3D51%26epage%3D59%26doi%3D10.1007%2Fs10495-015-1190-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, P.</span></span> <span> </span><span class="NLM_article-title">Formal synthesis of semiaquilegin A</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1123</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2009.12.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1016%2Fj.tetlet.2009.12.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Wrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=1121-1123&author=J.+Liauthor=Y.+Jiangauthor=Q.+Liauthor=Q.+Xiaoauthor=Y.+Jiaauthor=P.+Tu&title=Formal+synthesis+of+semiaquilegin+A&doi=10.1016%2Fj.tetlet.2009.12.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Formal synthesis of semiaquilegin A</span></div><div class="casAuthors">Li, Jing; Jiang, Yong; Li, Qingjiang; Xiao, Qiang; Jia, Yanxing; Tu, Pengfei</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1121-1123</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A formal synthesis of semiaquilegin A is achieved starting from readily available oridonin in 19 linear steps, providing I.  The abs. configuration of the natural product has been established.  A variety of useful analogs were prepd. through this synthetic route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobSkDSV0ejm7Vg90H21EOLACvtfcHk0ljjUkXOgPeNMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Wrug%253D%253D&md5=a3faa991827a40a4f8ffb167856b48a5</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2009.12.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2009.12.118%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DXiao%26aufirst%3DQ.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DP.%26atitle%3DFormal%2520synthesis%2520of%2520semiaquilegin%2520A%26jtitle%3DTetrahedron%2520Lett.%26date%3D2010%26volume%3D51%26spage%3D1121%26epage%3D1123%26doi%3D10.1016%2Fj.tetlet.2009.12.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piyachaturawat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saengsawang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, S.-B.</span></span> <span> </span><span class="NLM_article-title">Structural modification of oridonin via DAST induced rearrangement</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">29548</span>– <span class="NLM_lpage">29554</span>, <span class="refDoi"> DOI: 10.1039/c8ra05728a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=10.1039%2Fc8ra05728a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFCjtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=29548-29554&author=D.-D.+Luoauthor=K.+Pengauthor=J.-Y.+Yangauthor=P.+Piyachaturawatauthor=W.+Saengsawangauthor=L.+Aoauthor=W.-Z.+Zhaoauthor=Y.+Tangauthor=S.-B.+Wan&title=Structural+modification+of+oridonin+via+DAST+induced+rearrangement&doi=10.1039%2Fc8ra05728a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Structural modification of oridonin via DAST induced rearrangement</span></div><div class="casAuthors">Luo, Dong-Dong; Peng, Kai; Yang, Jia-Yu; Piyachaturawat, Pawinee; Saengsawang, Witchuda; Ao, Lei; Zhao, Wan-Zhou; Tang, Yu; Wan, Sheng-Biao</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">29548-29554</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A simple and efficient protocol was developed for the syntheses of oridonin analogs, e.g., I, i.e. 6,20-epoxy ent-kaurane diterpenoid analogs from oridonin via diethylaminosulfur trifluoride (DAST) promoted rearrangement, most of which exhibited superior anticancer activities compared with their precursor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqF5w8CqsFA7Vg90H21EOLACvtfcHk0ljjUkXOgPeNMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFCjtrzK&md5=4da877324bfba65093341626302c3fe8</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1039%2Fc8ra05728a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc8ra05728a%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DD.-D.%26aulast%3DPeng%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DJ.-Y.%26aulast%3DPiyachaturawat%26aufirst%3DP.%26aulast%3DSaengsawang%26aufirst%3DW.%26aulast%3DAo%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DW.-Z.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DS.-B.%26atitle%3DStructural%2520modification%2520of%2520oridonin%2520via%2520DAST%2520induced%2520rearrangement%26jtitle%3DRSC%2520Adv.%26date%3D2018%26volume%3D8%26spage%3D29548%26epage%3D29554%26doi%3D10.1039%2Fc8ra05728a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i81"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00408">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_23487"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00408?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00408</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental methods for biological assays, figures, tables, NMR spectra, HPLC spectra, and MS spectra (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00408/suppl_file/jm0c00408_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00408/suppl_file/jm0c00408_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00408/suppl_file/jm0c00408_si_001.pdf">jm0c00408_si_001.pdf (3.4 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00408/suppl_file/jm0c00408_si_002.csv">jm0c00408_si_002.csv (8.62 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00408&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-15%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00408%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00408" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                12MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679950f0ec183ca6","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
